[go: up one dir, main page]

WO2000051991A1 - 4-AMINO-QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANsSDUCTION MEDIATED BY TYROSINE KINASES - Google Patents

4-AMINO-QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANsSDUCTION MEDIATED BY TYROSINE KINASES Download PDF

Info

Publication number
WO2000051991A1
WO2000051991A1 PCT/EP2000/001496 EP0001496W WO0051991A1 WO 2000051991 A1 WO2000051991 A1 WO 2000051991A1 EP 0001496 W EP0001496 W EP 0001496W WO 0051991 A1 WO0051991 A1 WO 0051991A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
alkyl
substituted
oxo
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/001496
Other languages
French (fr)
Inventor
Frank Himmelsbach
Elke Langkopf
Birgit Jung
Thomas Metz
Flavio Solca
Stefan Blech
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999108567 external-priority patent/DE19908567A1/en
Priority claimed from DE1999111366 external-priority patent/DE19911366A1/en
Priority claimed from DE1999128306 external-priority patent/DE19928306A1/en
Priority claimed from DE19954816A external-priority patent/DE19954816A1/en
Priority to EEP200100449A priority Critical patent/EE200100449A/en
Priority to AU32816/00A priority patent/AU3281600A/en
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to BR0008524-3A priority patent/BR0008524A/en
Priority to JP2000602218A priority patent/JP3751201B2/en
Priority to US09/914,323 priority patent/US6972288B1/en
Priority to HU0301132A priority patent/HUP0301132A3/en
Priority to HR20010617A priority patent/HRP20010617A2/en
Priority to EP00910695A priority patent/EP1157011A1/en
Priority to CA002361174A priority patent/CA2361174C/en
Priority to SK1211-2001A priority patent/SK12112001A3/en
Priority to EA200100830A priority patent/EA200100830A1/en
Priority to KR1020017010981A priority patent/KR20020068261A/en
Priority to IL14414300A priority patent/IL144143A0/en
Priority to PL00351619A priority patent/PL351619A1/en
Publication of WO2000051991A1 publication Critical patent/WO2000051991A1/en
Priority to BG105765A priority patent/BG105765A/en
Priority to NO20014114A priority patent/NO20014114L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to bicyclic heterocycles of general formula
  • R a denotes a hydrogen atom or a Ci- 4 -alkyl group
  • R b denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups R-_ to R 3 , whilst
  • R-_ and R 2 which may be identical or different, in each case denote a hydrogen, fluorine, chlorine, bromine or iodine atom, a Cj . , 4 -alkyl, hydroxy, C- ⁇ -alkoxy, C 3 _ 6 -cycloalkyl, C 4 . 6 -cycloalkoxy, C 2 . 5 -alkenyl or C 2 . 5 -alkynyl group,
  • CA 4 -alkylsulphenyl C 1 _ 4 -alkylsulphinyl, C-__ 4 -al- kylsulphonyl, C 1 . 4 -alkylsulphonyloxy, trifluoromethyl- sulphenyl, trifluoromethylsulphinyl or trifluoromethyl- sulphonyl group,
  • R 3 denotes a hydrogen, fluorine, chlorine or bromine atom
  • R c and R d which may be identical or different, in each case denote a hydrogen, fluorine or chlorine atom, a methoxy group or a methyl group optionally substituted by a methoxy, dime- thylamino, diethylamino, pyrrolidino, piperidino or morpholino group , X denotes a methine group substituted by a cyano group or a nitrogen atom,
  • A denotes an oxygen atom or an imino group optionally substituted by a C- ⁇ -alkyl group
  • B denotes a carbonyl or sulphonyl group
  • C denotes a 1, 3-allenylene, 1,1- or 1,2-vinylene group which may be substituted in each case by one or two methyl groups or by a trifluoromethyl group,
  • D denotes an alkylene, -CO-alkylene or -S0 2 -alkylene group wherein the alkylene moiety in each case contains 1 to 8 carbon atoms and additionally 1 to 4 hydrogen atoms in the alkylene moiety may be replaced by fluorine atoms, whilst the linking of the -CO-alkylene and -S0 2 -alkylene group to the adjacent group C in each case must take place via the carbonyl or sulphonyl group,
  • R 4 denotes a hydrogen atom or a C-__ 4 -alkyl group
  • E denotes an R 6 0-CO-alkylene-NR s , (R 7 0-PO-OR 8 ) -alkylene-NR 5 or (R 7 0-PO-R 9 ) -alkylene-NR 5 -group wherein in each case the alkylene moiety, which is straight-chained and contains 1 to ⁇ carbon atoms, may additionally be substituted by one or two C ⁇ -alkyl groups or by an R s O-CO or group, wherein
  • R 5 denotes a hydrogen atom
  • a C 1 . 4 -alkyl group which may be substituted by an R 6 0-CO, (R 7 0-PO-OR 8 ) or (R 7 0-PO-R 9 ) group,
  • an ethyl or propyl group optionally substituted by one or two methyl or ethyl groups, which may be terminally substituted in each case by a CAg-alkylcarbonylsulphenyl, C 3 . 7 -cycloalkylcarbonylsulphenyl, C 3 _ 7 -cycloalkyl-C 1 . 3 -alkyl- carbonylsulphenyl, arylcarbonylsulphenyl or aryl-C 1 _ 3 -al- kylcarbonylsulphenyl group,
  • an ethyl or propyl group optionally substituted by one or two methyl or ethyl groups which may be terminally substituted in each case by a C 3.7 -cyc- loalkylcarbonyloxy, C 3 _ 7 -cycloalkyl-C ⁇ -alkylcarbonyloxy, arylcarbonyloxy or aryl-C- ⁇ ⁇ -alkylcarbonyloxy group,
  • an ethyl or propyl group optionally substituted by one or two methyl or ethyl groups, each of which may be terminally substituted by a hydroxy, C- ⁇ -alkoxy, amino, C ⁇ -alkylamino or di- (Ci- 4 -alkyl) -amino group or by a 4- to 7-membered al- kyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups a methylene group in the 4 position may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, imino or N- (C 1 . 4 -alkyl) -imino group,
  • R g , R 7 and R 8 which may be identical or different, in each case denote a hydrogen atom
  • CAg-alkyl group which may be substituted by a hydroxy, C- ⁇ -alkoxy, amino, C ⁇ -alkylamino or di- (C ⁇ -alkyl) -amino group or by a 4- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, imino or N- (C ⁇ -alkyl) -imino group,
  • R e and R f which may be identical or different, in each case denote a hydrogen atom or a CA 4 -alkyl group and
  • R g denotes a C- ⁇ -alkyl, C 3 . 7 -cycloalkyl, C ⁇ -alkoxy or C 5 _ 7 -cycloalkoxy group,
  • R 9 denotes a C ⁇ -alkyl, aryl or aryl-C ⁇ -alkyl group
  • R 6 0-CO a 4- to 7-membered alkyleneimino group which may be substituted by an R 6 0-CO, (R 7 0-PO-OR 8 ) , (R 7 0-PO-R 9 ) , R 6 0-CO-C 1 . 4 -alkyl , bis- (RgO-CO) -C ⁇ -alkyl, (R 7 0-PO-OR 8 ) -C- ⁇ -alkyl or (R 7 0-PO-R 9 ) -C ⁇ -alkyl group wherein R 6 to R 9 are as hereinbefore defined,
  • R 10 a piperazino or homopiperazino group which is substituted in the 4 position by the group R 10 and is additionally substituted at a cyclic carbon atom by an R s O-CO, (R 7 0-P0-OR 8 ) , (R 7 0-PO-R 9 ) , or (R 7 0-P0-R 9 ) -Ci- 4 -alkyl group wherein R 6 to R 9 are as hereinbefore defined and
  • R 10 denotes a hydrogen atom, a G ⁇ .,-alkyl, formyl, C 1 . 4 -alkylcarbonyl or C 1 . 4 -alkylsulphonyl group,
  • R 6 0-CO-C 1 . 4 -alkyl bis- (RgO-CO) -C 1 _ 4 -alkyl, (R 7 0-PO-OR 8 ) -C x . 4 -alkyl or (R 7 0-PO-R 9 ) - C._- 4 -alkyl group wherein R 6 to R 9 are as hereinbefore defined,
  • R 6 0-CO-C 1 . 4 -alkyl bis- (R 6 0-CO) -C ⁇ -alkyl , (R 7 0-PO-OR 8 ) -C- . _ 4 -alkyl or (R 7 0-PO-R 9 ) -C 1 . 4 -alkyl group and is additionally substituted at cyclic carbon atoms by one or two RgO-CO or RgO-CO-C 1 . 4 -alkyl groups or by an R 6 0-CO-group and an R 6 0-CO-C 1 . 4 -alkyl group wherein R 6 to R 9 are as hereinbefore defined,
  • R 6 0-CO a morpholino or homomorpholino group which is substituted in each case by an R 6 0-CO, (R 7 0-PO-OR 8 ) , (R 7 0-PO-R 9 ) , kyl, bis- (R s O-CO) -C 1 _ admir-alkyl, (R 7 0-P0-0R 8 ) -C ⁇ -alkyl or (R 7 0-PO-R 9 ) -C 1 . 4 -alkyl group wherein R 6 to R 9 are as hereinbefore defined, a morpholino or homomorpholino group which is substituted by two RgO-CO or groups or by an R 6 0-CO-group and an RgO-CO-C 1 . 4 -alkyl group wherein R s is as hereinbefore defined,
  • a 2-oxo-morpholino group which may be substituted by 1 to 4 C- ⁇ -alkyl groups
  • a 2-oxo-thiomor holino group which may be substituted by 1 to 4 C j .- j -alkyl groups
  • a C 1 . 4 -alkyl-NR 5 -group wherein the C ⁇ -alkyl moiety, which is straight-chained and may additionally be substituted by one or two methyl groups, is in each case terminally substituted by a di- (C.__ 4 -alkoxy) -methyl or tri- (C 1 _ 4 -alkoxy) -methyl group, whilst R s is as hereinbefore defined,
  • C 1 . 4 -alkyl-NR 5 -group wherein the C 1 . 4 -alkyl moiety, which is straight-chained and may additionally be substituted by one or two methyl groups, is in each case terminally substituted by a 1, 3-dioxolan-2-yl or 1, 3-dioxan-2-yl group optionally substituted by one or two methyl groups, while R s is as hereinbefore defined,
  • R X1 denotes a 2-oxo-tetrahydrofuran-3 -yl , 2-oxo-tetrahy- drofuran-4-yl, 2-oxo-tetrahydropyran-3 -yl , 2-oxo-tetrahy- dropyran-4-yl, 2-oxo-tetrahydropyran-5-yl , 2-oxo-tetrahy- drothiophen-3-yl, 2-oxo-tetrahydrothiophen-4-yl, 2-oxo- tetrahydrothiopyran-3-yl, 2-oxo-tetrahydrothiopyran-4-yl or 2-oxo-tetrahydrothiopyran-5-yl group optionally substituted by one or two methyl groups,
  • an amino group or an amino group optionally substituted by 1 or 2 C ⁇ ,,-alkyl groups wherein the alkyl groups may be identical or different and each alkyl moiety may be substituted from position 2 by a hydroxy, C 1 . 4 -alkoxy, amino, C 1 _ 4 -alkylamino or di- (C ⁇ -alkyl) -amino group or by a 4- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulphur atom, or by a sulphi- nyl, sulphonyl, imino or N- (C-__ 4 -alkyl) -imino group,
  • a 6- to 7-membered alkyleneimino group optionally substituted by 1 or 2 methyl groups wherein in each case a methylene group in the 4 position is replaced by an oxygen or sulphur atom, by an imino group substituted by the group R 10 , by a sulphinyl or sulphonyl group, whilst R 10 is as hereinbefore defined,
  • F denotes a group, whilst the alkylene moiety is linked to the group G, or an oxygen atom, whilst the latter may not be linked to a nitrogen atom of the group G, and
  • G denotes an R s O-CO-alkylene-NR s , (R 7 0-PO-OR 8 ) -alkylene-NR 5 or (R 7 0-PO-R 9 ) -alkylene-NR s -group wherein in each case the alkylene moiety, which is straight -chained and contains 1 to 6 carbon atoms, may additionally be substituted by one or two C ⁇ -alkyl groups or by an R s O-CO or group, wherein R 5 to R 9 are as hereinbefore defined,
  • RgO-CO RgO-CO
  • R 7 0-PO-OR 8 R 7 0-PO-OR 8
  • R 7 0-PO-R 9 a 4- to 7-membered alkyleneimino group which is substituted by an RgO-CO, (R 7 0-PO-OR 8 ) , (R 7 0-PO-R 9 ) , , bis- (RgO-CO) -C- ⁇ -alkyl, (R 7 0-PO-OR 8 ) -C- . . 4 -alkyl or (R 7 0-PO-R 9 ) - Ci- 4 -alkyl group wherein R s to R 9 are as hereinbefore defined,
  • R 6 0-CO-C 1 . 4 -alkyl bis- (R 6 0-CO) -C-_. 4 -alkyl, (R 7 0-PO-OR s ) -C 1 . 4 -alkyl or (R 7 0-PO-R 9 ) -C 1 . 4 -alkyl group and is additionally substituted at cyclic carbon atoms by one or two RgO-CO or R 6 0-CO-C 1 . 4 -alkyl groups or by an R 6 0-CO-group and an group wherein R s to R 9 are as hereinbefore defined,
  • R s O-CO a morpholino or homomorpholino group which is substituted in each case by an R s O-CO, (R 7 0-PO-OR 8 ) , (R 7 0-PO-R 9 ) , R 6 0-CO- C ⁇ -alkyl, bis- (R s O-CO) -C ⁇ -alkyl, (R 7 0-PO-OR 8 ) -C ⁇ -alkyl or (R 7 0-PO-R 9 ) -0 ⁇ 4 -alkyl group wherein R s to R 9 are as hereinbefore defined,
  • R 6 0-CO-C 1 . 4 -alkyl bis- (R 6 0-CO) - Ci- 4 -alkyl, (R 7 0-PO-OR 8 ) -C ⁇ -alkyl or (R 7 0-PO-R 9 ) -C ⁇ -alkyl group wherein R 6 to R 9 are as hereinbefore defined,
  • R 6 0-CO-C.__ 4 -alkyl bis- (R 6 0-CO) - 0 ⁇ 4 -alkyl, (R 7 0-PO-OR 8 ) -C 1 _ 4 -alkyl or (R 7 0-PO-R 9 ) -C-_.
  • a 2-oxo-morpholinyl group which is substituted in the 4 position by a hydrogen atom, by a C ⁇ -alkyl, R 6 0-CO-C 1 _ 4 -alkyl , (R 7 0-PO-OR 8 ) -C- . . 4 -alkyl or (R 7 0-PO-R 9 ) -C- ⁇ -alkyl group, while R 6 to R 9 are as hereinbefore defined and the abovementioned 2-oxo- morpholinyl groups are in each case linked to a carbon atom of the group F,
  • a morpholino or thiomorpholino group which is substituted in the 2 and 6 position by a C 1 . 4 -alkoxy group, a Ci- 4 -alkyl-NR S -group wherein the C-__ 4 -alkyl moiety, which is straight-chained and may additionally be substituted by one or two methyl groups, is in each case terminally substituted by a di- (C ⁇ -alkoxy) -methyl or tri- (C 1 . 4 -alkoxy) -methyl group, whilst R 5 is as hereinbefore defined,
  • R h NR s -group wherein R s is as hereinbefore defined and R h denotes a 2-oxo-tetrahydrofuran-3-yl , 2-oxo-tetrahydrofuran- 4-yl, 2-oxo-tetrahydropyran-3-yl, 2-oxo-tetrahydropyran-4-yl or 2-oxo-tetrahydropyran-5-yl group optionally substituted by one or two methyl groups,
  • alkyl groups wherein the alkyl groups may be identical or different and each alkyl moiety may be substituted from position 2 by a hydroxy, C- ⁇ -alkoxy, amino, C ⁇ -alkylamino or di- (Ci.
  • a 6- to 7-membered alkyleneimino group optionally substituted by 1 or 2 methyl groups wherein in each case a methylene group in the 4 position is replaced by an oxygen or sulphur atom, by an imino group substituted by the group R 10 , a by a sulphinyl or sulphonyl group, wherein R 10 is as hereinbefore defined, an imidazolyl group optionally substituted by 1 to 3 methyl groups ,
  • F and G together denote a hydrogen, fluorine or chlorine atom
  • R 6 0-CO R 7 0-P0- OR 8
  • R 7 0-PO-R 9 R s to R 9
  • a 5- to 7-membered alkyleneimino group wherein in the above- mentioned 6- to 7-membered alkyleneimino groups a methylene group in the 4 position may be replaced in each case by an oxygen or sulphur atom, by an imino group substituted by the group R 10 , or by a sulphinyl or sulphonyl group, wherein R 10 is as hereinbefore defined,
  • At least one of the groups E, G or F together with G contains an R 6 0-CO, (R 7 0-PO-OR 8 ) or (R 7 0-PO-R 9 ) - group or
  • D together with E contains an R g CO-0- (R e CR f ) -O-CO, (R 7 0-PO-OR 8 ) or (R 7 0-PO-R 9 ) -group or
  • E or G contains an optionally substituted 2-oxo-morpholinyl group, a morpholino or thiomorpholino group substituted in the 2 position or in the 2 and 6 positions by a C ⁇ -alkoxy group,
  • E contains an optionally substituted 2-oxo-thiomorpholino group or an optionally substituted 2-oxo-tetrahydrothio- phen-3-yl, 2-oxo-tetrahydrothiophen-4-yl, 2-oxo-tetrahy- drothiopyran-3 -yl , 2-oxo-tetrahydrothiopyran-4-yl or 2-oxo-tetrahydrothiopyran-5-yl group.
  • aryl moieties mentioned in the definitions of the abovementioned groups is meant a phenyl group which in each case may be monosubstituted by R 12 , mono-, di- or trisubsti- tuted by R 13 or monosubstituted by R 12 and additionally mono- or disubstituted by R 13 , whilst the substituents may be identical or different and
  • R 12 denotes a cyano, carboxy, C 1 . 4 -alkoxycarbonyl , aminocarbonyl, C 1 _ 4 -alkylaminocarbonyl, di- (C ⁇ -alkyl) -aminocarbonyl , C ⁇ -alkylsulphenyl, C 1 . 4 -alkylsulphinyl , C 1 _ 4 -alkylsulphonyl , hydroxy, C- ⁇ -alkylsulphonyloxy, trifluoromethyloxy, nitro, amino, C- ⁇ -alkylamino, di- (C ⁇ -alkyl) -amino, C x .
  • R 13 denotes a fluorine, chlorine, bromine or iodine atom, a C x _ 4 -alkyl, trifluoromethyl or C x _ 4 -alkoxy group or
  • heteroaryl groups mentioned in the definitions of the abovementioned groups also include a 5-membered heteroaromatic group which contains an imino group, an oxygen or sulphur atom or an imino group, an oxygen or sulphur atom and one or two nitrogen atoms, or
  • the abovementioned 5-membered heteroaromatic groups may be substituted in each case by 1 or 2 methyl or ethyl groups and the abovementioned 6-membered heteroaromatic groups may be substituted in each case by 1 or 2 methyl or ethyl groups or by a fluorine, chlorine, bromine or iodine atom, or by a tri- fluoromethyl , hydroxy, methoxy or ethoxy group.
  • R a denotes a hydrogen atom or a C- ⁇ -alkyl group
  • R b denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups R x to R 3 , wherein
  • R x and R 2 which may be identical or different, each denote a hydrogen, fluorine, chlorine, bromine or iodine atom, a G ⁇ -alkyl, hydroxy, C 1 . 4 -alkoxy, C 3 . 6 -cycloalkyl, C 4 .g-cycloalkoxy, C 2 . 5 -alkenyl or C 2 . 5 -alkynyl group,
  • Ci- 4 -alkylsulphenyl C x . 4 -alkylsulphinyl, C ⁇ -alkyl- sulphonyl, C- ⁇ -alkylsulphonyloxy, trifluoromethylsulphenyl, trifluoromethylsulphinyl or trifluoromethylsulphonyl group,
  • R 3 denotes a hydrogen, fluorine, chlorine or bromine atom
  • R c and R d which may be identical or different, each denote a hydrogen, fluorine or chlorine atom, a methoxy group or a methyl group optionally substituted by a methoxy, dimethylamino, diethylamino, pyrrolidino, piperidino or morpholino group,
  • X denotes a methine group substituted by a cyano group or a nitrogen atom
  • A denotes an oxygen atom or an imino group optionally substituted by a C-__ 4 -alkyl group
  • B denotes a carbonyl or sulphonyl group
  • C denotes a 1, 3-allenylene, 1,1- or 1,2-vinylene group, which may be substituted in each case by one or two methyl groups or by a trifluoromethyl group
  • D denotes an alkylene, -CO-alkylene or -S0 2 -alkylene group wherein the alkylene moiety contains 1 to 8 carbon atoms in each case and additionally 1 to 4 hydrogen atoms in the alkylene moiety may be replaced by fluorine atoms, while the linking of the -CO-alkylene or -S0 2 -alkylene group to the adjacent group C must take place via the carbonyl or sulphonyl group,
  • R 4 denotes a hydrogen atom or a C 1 . i -alkyl group
  • D is bound to a nitrogen atom of the group E, it may also denote a carbonyl or sulphonyl group,
  • E denotes an R s O-CO-alkylene-NR 5 , (R 7 0-PO-OR 8 ) -alkylene-NR 5 or (R 7 0-PO-R 9 ) -alkylene-NR 5 group wherein in each case the alkylene moiety, which is straight -chained and contains 1 to 6 carbon atoms, may additionally be substituted by one or two C ⁇ -alkyl groups or by an R 6 0-CO or R 6 0-CO-C x . 2 -alkyl group, while
  • R 5 denotes a hydrogen atom, a C x . 4 -alkyl group which may be substituted by a hydroxy, Ci- 4 -alkoxy, carboxy, R s O-CO, (R 7 0-PO-OR 8 ) , (R 7 0-PO-R 9 ) , ami- no, C-_. 4 -alkylaiT.in0 or di- (C x .
  • R 6 , R 7 and R 8 which may be identical or different, in each case denote a hydrogen atom
  • a C-_. ⁇ -alkyl group which may be substituted by a hydroxy, C 1 . 4 -alkoxy, amino, C 1 . 4 -alkylamino or di- (C 1 . 4 -alkyl) -amino group or by a 4- to 7-membered alkyleneimino group, while in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, imino or N- (C x _ 4 -alkyl) -imino group,
  • R e and R f which may be identical or different, in each case denote a hydrogen atom or a C x . 4 -alkyl group and
  • R g denotes a C-__ 4 -alkyl, C 3 _ 7 -cycloalkyl , C 1 . 4 -alkoxy or C s _ 7 -cycloalkoxy group
  • R 9 denotes a C x _ 4 -alkyl, aryl or aryl-C x _ 4 -alkyl group
  • R 10 denotes a hydrogen atom, a C x _ 4 -alkyl, formyl, C x _ 4 -al- kylcarbonyl or C___ 4 -alkylsulphonyl group,
  • R 10 a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group R 10 , while the above- mentioned 5- to 7-membered rings in each case are additionally substituted at a carbon atom by an R s O-CO, (R 7 0-PO-OR 8 ) , (R 7 0- PO-R 9 ) , R 6 0-CO-C-_ 4 -alkyl, (R 7 0-PO-OR 8 ) -C-. 4 -alkyl or (R 7 0-P0-R 9 ) - C 1 . 4 -alkyl group wherein R 6 to R 10 are as hereinbefore defined,
  • R 6 0-CO-C x _ 4 -alkyl substituted in the 1 position by an R 6 0-CO-C x _ 4 -alkyl , (R 7 0-PO-OR 8 ) - C-__ 4 -alkyl or (R 7 0-PO-R 9 ) -C x _ 4 -alkyl group wherein R 6 to R 9 are as hereinbefore defined,
  • a 6- to 7-membered alkyleneimino group optionally substituted by 1 or 2 methyl groups, wherein in each case a methylene group in the 4 position is replaced by an oxygen or sulphur atom, by an imino group substituted by the group R xo , by a sulphinyl or sulphonyl group, while R x0 is as hereinbefore defined,
  • a C s . 7 -cycloalkyl group wherein a methylene group is replaced by an oxygen or sulphur atom, by an imino group substituted by the group R 10 , or by a sulphinyl or sulphonyl group, while R x0 is as hereinbefore defined,
  • R 9 group wherein R e to R g and R 7 to R 9 are as hereinbefore defined,
  • F denotes a C x -. s - lkylene group, an -0-C x _ s -alkylene group, wherein the alkylene moiety is linked to the group G, or an oxygen atom, which may not be linked to a nitrogen atom of the group G, and
  • G denotes an R 6 0-CO-alkylene-NR S , (R 7 0-PO-OR 8 ) -alkylene-NR s or (R 7 0-PO-R 9 ) -alkylene-NR 5 group wherein in each case the alkylene moiety, which is straight-chained and contains 1 to 6 carbon atoms, may additionally be substituted by one or two C x _ 2 -alkyl groups or by an R 6 0-CO or R 6 0-CO-C x _ 2 -alkyl group, wherein R 5 to R 9 are as hereinbefore defined,
  • R 6 0-CO a 4- to 7-membered alkyleneimino group, which is substituted by an R 6 0-CO, (R 7 0-PO-OR 8 ) , (R 7 0-PO-R 9 ) , R s O-CO-C x.4 -alkyl , (R 7 0-PO-OR 8 ) -C x . 4 -alkyl or (R 7 0-PO-R 9 ) -C x . 4 -alkyl group wherein R 6 to R 9 are as hereinbefore defined,
  • R 6 0-CO a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group R x0 , while the abovementioned 5- to 7-membered rings in each case are additionally substituted at a carbon atom by an R 6 0-CO, (R 7 0-PO-OR 8 ) , (R 7 0- P0-R 9 ) , R 6 0-CO-C x . 4 -alkyl, (R 7 0-P0-0R 8 ) -C x . 4 -alkyl or (R 7 0-PO-R 9 ) - C x . 4 -alkyl group wherein R 6 to R 10 are as hereinbefore defined,
  • R 6 0-CO-C x . 4 -alkyl substituted in the 1 position by an R 6 0-CO-C x . 4 -alkyl , (R 7 0-PO-OR 8 ) - C x . 4 -alkyl or (R 7 0-PO-R 9 ) -C x . 4 -alkyl group wherein R s to R 9 are as hereinbefore defined,
  • a 6- to 7-membered alkyleneimino group optionally substituted by 1 or 2 methyl groups wherein in each case a methylene group in the 4 position is replaced by an oxygen or sulphur atom, by an imino group substituted by the group R 10 , by a sulphinyl or sulphonyl group, while R xo is as hereinbefore defined, an imidazolyl group optionally substituted by 1 to 3 methyl groups ,
  • F and G together denote a hydrogen, fluorine or chlorine atom
  • a 5- to 7-membered alkyleneimino group while in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulphur atom, by an imino group substituted by the group R x0 , or by a sulphinyl or sulphonyl group, while R xo is as hereinbefore defined,
  • At least one of the groups E, G or F together with G contains an R s O-CO, (R 7 0-PO-OR 8 ) or (R 7 0-PO-R 9 ) group or
  • D together with E contains an R g CO-0- (R e CR f ) -O-CO, (R 7 0-PO-OR 8 ) or (R 7 0-PO-R 9 ) group, and also the compounds of the abovementioned general formula I wherein R a to R d , A to G and X are as hereinbefore defined, but additionally
  • the piperazino and homopiperazino groups substituted by R 10 are each additionally substituted at a cyclic carbon atom by a bis- (R 6 0-CO) -C x . 4 -alkyl group and the piperazino, homopiperazino, pyrrolidinyl, piperidinyl and hexahydroazepinyl group mentioned above in the definition of the groups E and G are each substituted at the nitrogen atom by a bis- (R 6 0-CO) -C x . 4 -alkyl group,
  • R x and R 2 which may be identical or different, denote aryl, - aryloxy, arylmethyl or arylmethoxy groups or
  • E denotes a 2-oxo-morpholino group which may be substituted by 1 or 2 methyl groups ,
  • G denotes a 2-oxo-morpholino group which may be substituted by 1 or 2 methyl groups, or
  • a 2-oxo-morpholinyl group which is substituted in the 4 position by a hydrogen atom, by a C x . 4 -alkyl, R 6 0-CO-C x _ 4 -alkyl , (R 7 0-PO-OR 8 ) -C x . 4 -alkyl or (R 7 0-PO-R 9 ) -C x . 4 -alkyl group, while R 6 to R 9 are as hereinbefore defined and the abovementioned 2-oxo- morpholinyl groups in each case are linked to a carbon atom of the group F, and/or
  • F and G together may denote a C 3 . 7 -cycloalkyl-C x . 4 -alkoxy group, with the proviso that
  • At least one of the groups E, G or F together with G contains an RgO-CO, (R 7 0-PO-OR 8 ) or (R 7 0-PO-R 9 ) group or D together with E contains an R g CO-0- (R e CR f ) -O-CO, (R 7 0-PO-OR 8 ) or (R 7 0-PO-R 9 ) group or
  • E or G contains an optionally substituted 2-oxo-morpholinyl group
  • R 5 denotes an ethyl or propyl group optionally substituted by one or two methyl groups, which is terminally substituted in each case by a C x . 6 -alkylcarbonylsulphenyl , C 3 . 7 -cycloalkylcarbo- nylsulphenyl, C 3 . 7 -cycloalkyl-C x . 3 -alkylcarbonylsulphenyl, aryl- carbonylsulphenyl or aryl-C x . 3 -alkylcarbonylsulphenyl group,
  • E denotes a morpholino or homomorpholino group, which is substituted in each case by an R 6 0-CO, (R 7 0-PO-OR 8 ) , (R 7 0-PO-R 9 ) , RgO-CO-C x . 4 -alkyl, bis- (RgO-CO) -C._ 4 -alkyl, (R 7 0-PO-OR 8 ) -C x . 4 -alkyl or (R 7 0-PO-R 9 ) -C- . - 4 -alkyl group wherein R 6 to R 9 are as hereinbefore defined,
  • a morpholino group which is substituted in the 2- and 6 -positions in each case by a C x . 4 -alkoxy group, a C x _ 4 -alkyl-NR 5 group wherein the C x _ 4 -alkyl moiety, which is straight-chained and may additionally be substituted by one or two methyl groups, is terminally substituted in each case by a di- (C x . 4 -alkoxy) -methyl or tri- (C x _ 4 -alkoxy) -methyl group, while R 5 is as hereinbefore defined,
  • C x _ 4 -alkyl-NR 5 group wherein the C x . 4 -alkyl moiety, which is straight-chained and may additionally be substituted by one or two methyl groups, is terminally substituted in each case by a 1, 3-dioxolan-2-yl or 1, 3-dioxan-2-yl group optionally substituted by one or two methyl groups, while R 5 is as hereinbefore defined, or
  • R 1X NR 5 group wherein R 5 is as hereinbefore defined and
  • R 1X denotes a 2-oxo-tetrahydrofuran-3-yl , 2-oxo-tetrahy- drofuran-4-yl , 2-oxo-tetrahydropyran-3-yl, 2-oxo-tetrahy- dropyran-4-yl , 2-oxo-tetrahydropyran-5-yl, 2-oxo-tetrahy- drothiophen-3-yl, 2-oxo-tetrahydrothiophen-4-yl, 2-oxo- tetrahydrothiopyran-3-yl, 2-oxo-tetrahydrothiopyran-4-yl or 2-oxo-tetrahydrothiopyran-5-yl group optionally substituted by one or two methyl groups,
  • C x _ 4 -alkyl-NR 5 group wherein the C x . 4 -alkyl moiety, which is straight-chained and may additionally be substituted by one or two methyl groups, is terminally substituted in each case by a 1, 3-dioxolan-2-yl or 1, 3-dioxan-2-yl group optionally substituted by one or two methyl groups, while R s is as hereinbefore defined, or
  • R h denotes a 2-oxo-tetrahydrofuran-3-yl, 2-oxo-tetrahy- drofuran-4-yl, 2-oxo-tetrahydropyran-3-yl , 2-oxo-tetrahy- dropyran-4-yl or 2-oxo-tetrahydropyran-5-yl group optionally substituted by one or two methyl groups,
  • At least one of the groups E, G or F together with G contains an RgO-CO, (R 7 0-PO-OR 8 ) or (R 7 0-PO-R 9 ) group or
  • D together with E contains an R g CO-0- (R e CR f ) -O-CO, (R 7 0-PO-OR a ) or (R 7 0-PO-R 9 ) group or
  • E or G contains an optionally substituted 2-oxo-morpholinyl group
  • E contains an optionally substituted 2-oxo-thiomorpholino group or an optionally substituted 2-oxo-tetrahydrothiophen- 3-yl, 2-oxo-tetrahydrothiophen-4-yl, 2-oxo-tetrahydrothio- pyran-3-yl, 2-oxo-tetrahydrothiopyran-4-yl or 2-oxo-tetrahy- drothiopyran-5-yl group,
  • an ethyl or propyl group optionally substituted by one or two methyl or ethyl groups, which is terminally substituted in each case by a C x _ 6 -alkylcarbonyloxy, C 3 . 7 -cycloalkylcarbonyloxy, C 3 . 7 -cycloalkyl-C x . 3 -alkylcarbonyloxy, arylcarbonyloxy or aryl-C x _ 3 -alkylcarbonyloxy group ,
  • E denotes a 4- to 7-membered alkyleneimino group which is substituted by two RgOCO or R 6 OCO-C x _ 4 -alkyl groups or by an R 6 OCO group and an R 6 OCO-C x . 4 -alkyl group wherein R 6 is as hereinbefore defined,
  • R 6 0-CO-C x _ 4 -alkyl bis- (R 6 0-CO) - C x . 4 -alkyl, (R 7 0-PO-OR 3 ) -C x . 4 -alkyl or (R 7 0-PO-R 9 ) -C x _ 4 -alkyl group, while the abovementioned 5- to 7-membered rings in each case are additionally substituted at carbon atoms by one or two R g O- CO or R 6 0-CO-C x . 4 -alkyl groups or by an R 6 0-CO group and an R 6 0- CO-C x _ 4 -alkyl group wherein R 6 to R 9 are as hereinbefore defined,
  • G denotes a 4- to 7-membered alkyleneimino group which is substituted by two RgO-CO or R 6 0-CO-C x _ 4 -alkyl groups or by an RgO-CO group and an R 5 0-CO-C,_ 4 -alkyl group wherein R 6 is as hereinbefore defined, a piperazino or homopiperazino group which is substituted in the 4 position by the group R xo and is additionally substituted at cyclic carbon atoms by two R 6 0-CO or R s O-CO-C x _ 4 -alkyl groups or by an R 6 0-CO group and an R s O-CO-C x . 4 -alkyl group wherein R s and R 10 are as hereinbefore defined,
  • thiomorpholino group which is substituted in the 2 position by a C x _ 4 -alkoxy group, or a thiomorpholino group which is substituted in the 2 and 6 positions in each case by a C-__ 4 -alkoxy group,
  • At least one of the groups E, G or F together with G contains an RgO-CO, (R 7 0-PO-OR 8 ) or (R 7 0-PO-R 9 ) group or
  • D together with E contains an R g C0-0- (R e CR f ) -O-CO, (R 7 0-PO-OR 8 ) or (R 7 0-PO-R 9 ) group or
  • E or G contains an optionally substituted 2-oxo-morpholinyl group ,
  • E contains an optionally substituted 2-oxo-thiomorpholino group or an optionally substituted 2-oxo-tetrahydrothio- phen-3-yl, 2-oxo-tetrahydrothiophen-4-yl , 2-oxo-tetrahy- drothiopyran-3-yl , 2-oxo-tetrahydrothiopyran-4-yl or 2-oxo-tetrahydrothiopyran-5-yl group,
  • R a denotes a hydrogen atom
  • R b denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups R x to R 3 , wherein
  • R x and R 2 which may be identical or different, each denote a hydrogen, fluorine, chlorine, bromine or iodine atom,
  • R 3 denotes a hydrogen, fluorine, chlorine or bromine atom
  • R c and R d in each case denote a hydrogen atom
  • X denotes a methine group substituted by a cyano group or a nitrogen atom
  • A denotes an imino group optionally substituted by a methyl or ethyl group
  • B denotes a carbonyl group
  • C denotes a 1,1- or 1,2-vinylene group which is substituted in each case by one or two methyl groups or may be substituted by a trifluoromethyl group
  • D denotes an alkylene or -CO-alkylene group wherein the alkylene moiety in each case contains 1 to 4 carbon atoms, while the linking of the -CO-alkylene group to the adjacent group C in each case must take place via the carbonyl group,
  • R 4 denotes a hydrogen atom or a methyl or ethyl group
  • D is bound to a nitrogen atom of the group E, it may also denote a carbonyl or sulphonyl group,
  • E denotes an R 6 0-CO-alkylene-NR 5 , (R 7 0-PO-OR 8 ) -alkylene-NR s or (R 7 0-PO-R 9 ) -alkylene-NR 5 group wherein in each case the alkylene moiety, which is straight -chained and contains 1 to 4 carbon atoms, may additionally be substituted by one or two C x.2 -alkyl groups or by an R 6 0-CO or R 6 0-CO-C x . 2 -alkyl group, wherein
  • R 5 denotes a hydrogen atom
  • a C x . 4 -alkyl group which may be substituted by an R 6 0-CO group , an ethyl or propyl group optionally substituted by one or two methyl or ethyl groups which is terminally substituted in each case by a hydroxy, C x . 4 -alkoxy, di- (C x _ 4 -alkyl) amino, C x .g-alkylcarbonylsulphenyl , C 3 . 6 -cyclo- alkylcarbonylsulphenyl, C 3 .
  • an ethyl or propyl group optionally substituted by one or two methyl or ethyl groups which is terminally substituted in each case by a C x . s -alkylcarbonyloxy, C 3 .g-cycloalkyl- carbonyloxy, C 3 . 6 -cycloalkyl-C x . 3 -alkylcarbonyloxy, aryl- carbonyloxy or aryl -C x _ 3 -alkylcarbonyloxy group,
  • R 6 , R 7 and R 8 which may be identical or different, in each case denote a hydrogen atom
  • a C x . 8 -alkyl group which may be substituted by a hydroxy, C x _ 4 -alkoxy, or di- (C x _ 4 -alkyl) -amino group or by a 4- to 7-membered alkyleneimino group, while in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen atom or by an N- (C x . 2 -alkyl) -imino group,
  • R e and R f which may be identical or different, in each case denote a hydrogen atom or a C x . 4 -alkyl group and R g denotes a C x . 4 -alkyl, C 3 . 6 -cycloalkyl, C x . 4 -alkoxy or C 5 .g-cycloalkoxy group,
  • Rg denotes a C x . 4 -alkyl group
  • R 10 denotes a hydrogen atom, a methyl, ethyl, acetyl or methylsulfonyl group
  • R 6 0-CO-C x . 4 -alkyl bis- (RgO-CO) -C x . 4 -alkyl, (R 7 0-PO-OR 8 ) -C.. 4 -alkyl or (R 7 0-PO-R 9 ) - C x . 4 -alkyl group wherein R 6 to R 9 are as hereinbefore defined,
  • a 2-oxo-morpholino group which may be substituted by 1 to 4 C x _ 2 -alkyl groups
  • a 2-oxo-thiomorpholino group which may be substituted by 1 to 4 C x . 2 -alkyl groups
  • R xx denotes a 2-oxo-tetrahydrofuran-3-yl , 2-oxo-tetrahy- drofuran-4-yl, 2-oxo-tetrahydropyran-3-yl , 2-oxo-tetrahy- dropyran-4-yl, 2-oxo-tetrahydropyran-5-yl , 2-oxo-tetrahy- drothiophen-3-yl, 2-oxo-tetrahydrothiophen-4 -yl , 2-oxo- tetrahydrothiopyran-3-yl, 2-oxo-tetrahydrothiopyran-4-yl or 2-oxo-tetrahydrothiopyran-5-yl group optionally substituted by one or two methyl groups,
  • R g CO-0- (R e CR f ) -O-CO or (R 7 0-PO-OR 8 ) group wherein R e to R g and R 7 and R 8 are as hereinbefore defined,
  • F denotes an -0-C x , 4 -alkylene group, while the alkylene moiety is linked to the group G, or an oxygen atom, while this may not be linked to a nitrogen atom of the group G
  • G denotes an R s O-CO-alkylene-NR 5 , (R 7 0-PO-OR 8 ) -alkylene-NR s or (R 7 0-PO-R 9 ) -alkylene-NR 5 group wherein in each case the alkylene moiety, which is straight-chained and contains 1 to 4 carbon atoms, may additionally be substituted by one or two C x . 2 -alkyl groups or by an R s O-CO or R 6 0-CO-C x _ 2 -alkyl group, while R 5 to R 9 are as hereinbefore defined,
  • R 6 0-CO-C x . 4 -alkyl bis- (RgO-CO) -C x . 4 -alkyl, (R 7 0-PO-OR 8 ) -C x . 4 -alkyl or (R 7 0-PO-R 9 ) - C x . 4 -alkyl group wherein R 6 to R 9 are as hereinbefore defined,
  • a 2-oxo-morpholino group which may be substituted by 1 or 2 methyl groups
  • a 2-oxo-morpholinyl group which is substituted in the 4 position by a C x . 4 -alkyl or R 6 0-CO-C x . 4 -alkyl group
  • R s is as hereinbefore defined and the abovementioned 2-oxo-morpholinyl groups in each case are linked to a carbon atom of the group F,
  • R h NR 5 group wherein R 5 is as hereinbefore defined and R h denotes a substituted 2-oxo-tetrahydrofuran-3-yl, 2-oxo- tetrahydrofuran-4-yl, 2-oxo-tetrahydropyran-3-yl, 2-oxo- tetrahydropyran-4-yl or 2-oxo-tetrahydropyran-5-yl group optionally by one or two methyl groups, or
  • F and G together denote a hydrogen atom
  • D together with E contains an R g CO-0- (R e CR f ) -O-CO or (R 7 0-P0-0R 8 ) group or
  • E contains an optionally substituted 2-oxo-thiomorpholino group or an optionally substituted 2-oxo-tetrahydrothio- phen-3-yl, 2-oxo-tetrahydrothiophen-4-yl, 2-oxo-tetrahydro- thiopyran-3-yl, 2-oxo-tetrahydrothiopyran-4-yl or 2-oxo- tetrahydrothiopyran-5-yl group,
  • aryl moieties mentioned in the definition of the abovementioned groups denote a phenyl group which may in each case be monosubstituted by R 12 , mono- or disubstituted by R X3 or monosubstituted by R x2 and additionally mono or disubstituted by R X3 , while the substituents may be identical or different and
  • R x2 denotes a cyano, C x . 2 -alkoxycarbonyl , aminocarbonyl, C x . 2 -alkylaminocarbonyl, di- (C x _ 2 -alkyl) -aminocarbonyl, C x . 2 -alkylsulphenyl, C x . 2 -alkylsulphinyl, C x.2 -alkylsulphonyl , hydroxy, nitro, amino, C x . 2 -alkylamino or di- (C x _ 2 -alkyl) -amino group and
  • R x3 denotes a fluorine, chlorine, bromine or iodine atom, a C x . 2 -alkyl, trifluoromethyl or C x . 2 -alkoxy group or
  • R a denotes a hydrogen atom
  • R b denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups R x to R 3 , wherein
  • R x and R 2 which may be identical or different, each denote a hydrogen, fluorine, chlorine or bromine atom, or a methyl, trifluoromethyl , methoxy, ethynyl or cyano group,
  • R 3 denotes a hydrogen atom
  • R c and R d in each case denote a hydrogen atom
  • X denotes a methine group substituted by a cyano group, or a nitrogen atom
  • A denotes an imino group
  • C denotes a 1,1- or 1,2-vinylene group, an ethynylene group or
  • D denotes a C x . 4 -alkylene group
  • R 4 denotes a hydrogen atom
  • D is bound to a nitrogen atom of the group E, it may also denote a carbonyl group
  • E denotes an R 6 0-CO-alkylene-NR 5 , (R 7 0-PO-OR 8 ) -alkylene-NR 5 or (R 7 0-PO-R 9 ) -alkylene-NR 5 group wherein in each case the alkylene moiety, which is straight -chained and contains 1 to 4 carbon atoms, may additionally be substituted by one or two C x _ 2 -alkyl groups or by an R 6 0-CO or RgO-CO-C x . 2 -alkyl group, while
  • R 5 denotes a hydrogen atom
  • R s , R 7 and R 8 which may be identical or different, in each case denote a hydrogen atom
  • R e denotes a hydrogen atom or a C x _ 4 -alkyl group
  • R f denotes a hydrogen atom
  • R g denotes a C x . 4 -alkyl, cyclopentyl, cyclohexyl, C x . 4 -alk- oxy, cyclopentyloxy or cyclohexyloxy group,
  • R 9 denotes a methyl or ethyl group
  • a pyrrolidino or piperidino group which is substituted by two RgO-CO or RgO-CO-C x _ 2 -alkyl groups wherein R 6 is as hereinbefore defined, a piperazino group which is substituted in the 4 position by the group R x0 and is additionally substituted at a cyclic carbon atom by an R 6 0-CO or R 6 0-CO-C x . 2 -alkyl group, while R 6 is as hereinbefore defined and
  • R 10 denotes a hydrogen atom, a methyl, ethyl, acetyl or methylsulfonyl group
  • R 6 0-CO-C x . 4 -alkyl bis- (R 6 0-CO) -C x . 4 -alkyl or (R 7 0-PO-OR 8 ) -C x _ 2 -alkyl group wherein R 6 to R 8 are as hereinbefore defined,
  • a morpholino group which is substituted in the 2 and 6 positions in each case by a methoxy or ethoxy group, a 2 , 2-dimethoxyethyl-NR 5 , 2 , 2-diethoxyethyl-NR 5 , 1, 3-dioxolan- 2 -yl-methyl-NR S or 1, 3-dioxan-2-yl-methyl-NR S group wherein R 5 is as hereinbefore defined,
  • R xl denotes a 2-oxo-tetrahydrofuran-3-yl, 2-oxo-tetrahy- drofuran-4-yl , 2-oxo-tetrahydropyran-3-yl, 2-oxo-tetrahy- dropyran-4-yl, 2-oxo-tetrahydropyran-5-yl, 2-oxo-tetrahy- drothiophen-3-yl, 2-oxo-tetrahydrothiophen-4-yl, 2-oxo- tetrahydrothiopyran-3-yl, 2-oxo-tetrahydrothiopyran-4-yl or 2-oxo-tetrahydrothiopyran-5-yl group optionally substituted by one or two methyl groups ,
  • R g CO-0- (R e CR f ) -O-CO or (R 7 0-PO-OR 8 ) group wherein R e to R g and R 7 and R 8 are as hereinbefore defined,
  • F denotes an -0-C x , 4 -alkylene group, while the alkylene moiety is linked to the group G, or an oxygen atom, which may not be linked to a nitrogen atom of the group G, and
  • G denotes an R 6 0-C0-alkylene-NR 5 group wherein the alkylene moiety, which is straight-chained and contains 1 to 4 carbon atoms, may additionally be substituted by one or two C x.2 -alkyl groups or by an R 6 0-CO or R 6 0-CO-C x _ 2 -alkyl group, while R s and R 6 are as hereinbefore defined,
  • a pyrrolidino or piperidino group which is substituted by two RgO-CO or R 6 0-CO-C x - 2 -alkyl groups wherein R 6 is as hereinbefore defined, a piperazino group which is substituted in the 4 position by the group R 10 and additionally at a cyclic carbon atom by an R g O-CO or R 6 0-CO-C x . 2 -alkyl group, while R 6 and R xo are as hereinbefore defined,
  • a 2-oxo-morpholinyl group which is substituted in the 4 position by a methyl, ethyl or R 6 0-CO-C x . 2 -alkyl group, while R 6 is as hereinbefore defined and the abovementioned 2-oxo-morpholinyl groups in are each case linked to a carbon atom of the group F,
  • a morpholino group which is substituted in the 2 and 6 positions in each case by a methoxy or ethoxy group, a 2, 2-dimethoxyethyl-NR 5 , 2 , 2-diethoxyethyl-NR s , 1, 3-dioxolan- 2 -yl-methyl-NR 5 or 1, 3 -dioxan-2-yl-methyl-NR 5 - group or
  • F and G together denote a hydrogen atom
  • At least one of the groups E, G or F together with G contains an R 6 0-CO, (R 7 0-PO-OR 8 ) or (R 7 0-PO-R 9 ) group or
  • D together with E contains an R g CO-0- (R e CR f ) -O-CO or (R 7 0-PO-OR 8 ) group or
  • E or G contains an optionally substituted 2-oxo-morpholinyl group ,
  • E contains an optionally substituted 2-oxo-tetrahydrofuran- 3-yl, 2-oxo-tetrahydrofuran-4-yl, 2-oxo-tetrahydropyran-3 -yl , 2-oxo-tetrahydropyran-4-yl, 2-oxo-tetrahydropyran-5-yl, 2-oxo- thiomorpholino, 2-oxo-tetrahydrothiophen-3-yl , 2-oxo-tetra- hydrothiophen-4-yl, 2-oxo-tetrahydrothiopyran-3-yl , 2-oxo-te- trahydrothiopyran-4-yl or 2-oxo-tetrahydrothiopyran-5-yl group ,
  • aryl moieties mentioned in the definition of the abovementioned groups denote a phenyl group which may be mono- or disubstituted by R 13 , wherein the substituents may be identical or different and
  • R x3 denotes a fluorine, chlorine, bromine or iodine atom, a C x . 2 -alkyl, trifluoromethyl or C x . 2 -alkoxy group or
  • R a denotes a hydrogen atom
  • R b denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups R x to R 3 , while
  • R x and R 2 which may be identical or different, each denote a hydrogen, fluorine, chlorine or bromine atom or a methyl group and
  • R 3 denotes a hydrogen atom
  • R c and R d in each case denote a hydrogen atom
  • X denotes a methine group substituted by a cyano group, or a nitrogen atom
  • A denotes an imino group
  • C denotes a 1,2-vinylene or an ethynylene group
  • D denotes a C x . 4 -alkylene group
  • R 4 denotes a hydrogen atom
  • D is bound to a nitrogen atom of the group E, it may also denote a carbonyl group
  • E denotes an R s O-CO-alkylene-NR s or (R 7 0-PO-OR 8 ) -alkylene-NR 5 group wherein in each case the alkylene moiety, which is straight-chained and contains 1 to 2 carbon atoms, may additionally be substituted by a methyl group or by an R 6 0-CO or RgO-CO-methyl group, while
  • R s denotes a hydrogen atom
  • an ethyl group optionally substituted by one or two methyl groups, which is terminally substituted by a hydroxy, C x . 2 -alkylcarbonylsulphenyl or C x . 2 -alkylcarbonyloxy group,
  • R 6 denotes a hydrogen atom
  • a phenyl group optionally substituted by one or two methyl groups, a phenylmethyl group which may be substituted in the phenyl moiety by one or two methyl groups, a 5-indanyl group or an R g CO-0- (R e CR f ) group, while
  • R e denotes a hydrogen atom or a methyl group
  • R f denotes a hydrogen atom
  • R g denotes a C x . 4 -alkyl or C x . 2 -alkoxy group
  • R 7 and R 8 which may be identical or different, in each case denote a hydrogen atom, a methyl, ethyl or phenyl group ,
  • R xo denotes a hydrogen atom, a methyl, ethyl, acetyl or methylsulfonyl group
  • R 6 0-CO-C x _ 4 -alkyl bis- (R 6 0-CO) -C x . 4 -alkyl or (R 7 0-PO-OR 8 ) -C x _ 2 -alkyl group wherein R 6 to R 8 are as hereinbefore defined,
  • R xl denotes a 2-oxo-tetrahydrofuran-3-yl or 2-oxo-tetrahy- drofuran-4-yl group
  • R g CO-0- (R e CR f ) -O-CO group wherein R e to R g are as hereinbefore defined, F denotes an -0-C x . 4 -alkylene group, while the alkylene moiety is linked to the group G, or an oxygen atom, which may not be linked to a nitrogen atom of the group G, and
  • G denotes an R s O-CO-alkylene-NR s group wherein the alkylene moiety, which is straight-chained and contains 1 or 2 carbon atoms, may additionally be substituted by a methyl group or by an RgO-CO or R 6 0-CO-methyl group, while R 5 and R 6 are as hereinbefore defined,
  • F and G together denote a hydrogen atom
  • D together with E contains an R g CO-0- (R e CR f ) -O-CO group or
  • E contains an optionally substituted 2 -oxo-morpholinyl group , a morpholino group substituted in the 2 position or in the 2 and 6 positions in each case by a methoxy or ethoxy group,
  • the compounds of general formula I may be prepared, for example, by the following processes:
  • R a to R d , A, F, G and X are as hereinbefore defined, with a compound of general formula
  • Z x denotes a leaving group such as a halogen atom, e.g. a chlorine or bromine atom, or a hydroxy group.
  • the reaction is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/te- trahydrofuran or dioxane optionally in the presence of an inorganic or organic base and optionally in the presence of a dehydrating agent expediently at temperatures between -50 and 150 °C, preferably at temperatures between -20 and 80°C.
  • a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/te- trahydrofuran or dioxane
  • a dehydrating agent expediently at temperatures between -50 and 150 °C, preferably at temperatures between -20 and 80°C.
  • the reaction is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane, conveniently in the presence of a tertiary organic base such as triethylamine, pyridine or 2-dimethylaminopyridine, in the presence of N-ethyl-diisopropylamine (H ⁇ nig's base) , whilst these organic bases may simultaneously serve as solvent, or in the presence of an inorganic base such as sodium carbonate, potassium carbonate or sodium hydroxide solution expediently at temperatures between -50 and 150 °C, preferably at temperatures between -20 and 80°C.
  • solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene
  • the reaction is preferably carried out in the presence of a dehydrating agent, e.g. in the presence of isobutyl chloroformate, thionyl chloride, trimethylchlorosilane, phosphorus trichloride, phosphorus pentoxide, hexamethyldisi- lazane, N, N' -dicyclohexylcarbodiimide, N,N' -dicyclohexylcar- bodiimide/N-hydroxysuccinimide or 1-hydroxy-benzotriazole and optionally also in the presence of 4-dimethylamino-pyridine, N,N' -carbonyldiimidazole or triphenylphosphine/carbon tetra- chloride, conveniently in a solvent such as methylene chloride, tetrahydrofuran, dioxane, toluene, chlorobenzene,
  • a dehydrating agent e.g. in the presence of isobutyl
  • R a to R d , A to D, F, G and X are as hereinbefore defined and Z2 denotes a leaving group such as a halogen atom, a substituted hydroxy or sulphonyloxy group such as a chlorine or bromine atom, a methanesulphonyloxy or p-toluenesulphonyloxy group or a hydroxy group, with a compound of general formula
  • Y denotes one of the groups mentioned for E hereinbefore, which is linked to the group D via a nitrogen atom.
  • reaction is conveniently carried out in a solvent such as isopropanol, butanol, tetrahydrofuran, dioxan, toluene, chlorobenzene, dimethylformamide, dimethylsulphoxide, methylene chloride, ethyleneglycol monomethylether, ethyleneglycol di- ethylether or sulpholane, optionally in the presence of an inorganic or tertiary organic base, e.g. sodium carbonate or potassium hydroxide, a tertiary organic base, e.g.
  • a solvent such as isopropanol, butanol, tetrahydrofuran, dioxan, toluene, chlorobenzene, dimethylformamide, dimethylsulphoxide, methylene chloride, ethyleneglycol monomethylether, ethyleneglycol di- ethylether or sulpholane, optionally in the presence of an inorganic or tertiary organic base
  • Z 2 in a compound of general formula IV denotes a hydroxy group
  • the reaction is preferably carried out in the presence of a dehydrating agent, e.g. in the presence of isobutyl chlo- roformate, thionylchloride, trimethylchlorosilane, phosphorus trichloride, phosphorus pentoxide, hexamethyldisilazane, N,N' -dicyclohexylcarbodiimide, N,N' -dicyclohexylcarbodiimi- de/N-hydroxysuccinimide or 1-hydroxy-benzotriazole and optionally also in the presence of 4-dimethylamino-pyridine, N,N' -carbonyldiimidazole or triphenylphosphine/carbon tetra- chloride, conveniently in a solvent such as methylene chloride, tetrahydrofuran, dioxane, toluene, chlor
  • R a to R d A to C, F, G and X are as hereinbefore defined,
  • R e to R g are as hereinbefore defined and
  • Z 3 denotes a leaving group such as a halogen atom, e.g. a chlorine, bromine or iodine atom.
  • reaction is appropriately carried out in a solvent such as tetrahydrofuran, dioxane, toluene, chlorobenzene, dimethylformamide, dimethylsulphoxide, methylene chloride, acetonitrile, N-methyl-pyrrolidinone, ethylenglycol diethylether or sulpholane, optionanally in the presence of an inorganic base, e.g. sodium carbonate or potassium hydroxide, or a tertiary organic base, e.g.
  • a solvent such as tetrahydrofuran, dioxane, toluene, chlorobenzene, dimethylformamide, dimethylsulphoxide, methylene chloride, acetonitrile, N-methyl-pyrrolidinone, ethylenglycol diethylether or sulpholane, optionanally in the presence of an inorganic base, e.g. sodium carbonate or potassium hydroxide, or
  • a compound of general formula I which contains a hydroxy, amino, alkylamino or imino group
  • this may be converted by acylation or sulphonyla- tion into a corresponding acyloxy, acylamino, N-alkyl-acyl- amino, acyl-imino, sulphonyloxy, sulphonylamino, N-alkyl-sulphonylamino or sulphonyl-imino compound
  • a sulphonyloxy compound thus obtained may further be converted into a corresponding sulphenyl compound by reacting with an alkali metal salt of a thio compound, or
  • the subsequent acylation or sulphonylation is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane with a corresponding acyl or sulphonyl derivative optionally in the presence of a tertiary organic base or in the presence of an inorganic base or in the presence of a dehydrating agent, e.g.
  • the subsequent alkylation is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxan with an alkylating agent such as a corresponding halide or sulphonic acid ester, e.g. with methyl iodide, ethyl bromide, dimethylsulphate or benzyl chloride, optionally in the presence of a tertiary organic base or in the presence of an inorganic base, expediently at temperatures between 0 and 150°C, preferably at temperatures between 0 and 100°C.
  • solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxan
  • the subsequent reductive alkylation is carried out with a corresponding carbonyl compound such as formaldehyde, acetal- dehyde, propionaldehyde, acetone or butyraldehyde in the presence of a complex metal hydride such as sodium borohydride, lithium borohydride, sodium triacetoxyborohydride or sodium cyanoborohydride expediently at a pH of 6-7 and at ambient temperature or in the presence of a hydrogenation catalyst, e.g. with hydrogen in the presence of palladium/charcoal, at a hydrogen pressure of 1 to 5 bar.
  • the methylation may also be carried out in the presence of formic acid as reducing agent at elevated temperatures, e.g. at temperatures between 60 and 120°C.
  • the subsequent intramolecular cyclisation is optionally carried out in a solvent such as acetonitrile, methylene chloride, tetrahydrofuran, dioxan or toluene in the presence of an axis such as hydrochloric acid or p-toluenesulphonic acid at temperatures between -10 and 120°C.
  • a solvent such as acetonitrile, methylene chloride, tetrahydrofuran, dioxan or toluene
  • an axis such as hydrochloric acid or p-toluenesulphonic acid at temperatures between -10 and 120°C.
  • the subsequent esterification is carried out by reacting a corresponding carboxylic acid, phosphonic acid, phosphinic acid or the salts thereof with a corresponding alkyl halide, optionally in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, dimethylsulphoxide, sul- pholane, acetonitrile, N-methyl-pyrrolidinone, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane, optionally in the presence of an inorganic or tertiary organic base, conveniently at temperatures between 0 and 150 °C, preferably at temperatures between 0 and 80 °C.
  • a solvent or mixture of solvents such as methylene chloride, dimethylformamide, dimethylsulphoxide, sul- pholane, acetonitrile, N-methyl-pyrrolidinone, benzene, to
  • compounds of general formula I wherein E or G denotes a piperazino or homopiperazino group each substituted in position 4 by an R 6 0-CO-C x _ 4 -alkyl group wherein R s is as hereinbefore defined may also be prepared, for example, by reacting a corresponding compound containing a piperazino or homopiperazino group each unsubstituted in position 4 with a compound of general formula
  • Rg is as hereinbefore defined and
  • Z 4 denotes a leaving group such as a chlorine or bromine atom or an alkyl or arylsulfonyloxy group, or
  • R 6 is as hereinbefore defined, or
  • R a to R d , A, F, G and X are as hereinbefore defined and alkyl denotes a lower alkyl group, with a compound of general formula
  • D and E are as hereinbefore defined according to known methods .
  • any reactive groups present such as hydroxy, carboxy, phosphono, 0-alkyl -phosphono, amino, alkylamino or imino groups may be protected during the reaction by conventional protecting groups which are cleaved again after the reaction.
  • a protecting group for a hydroxy group may be a trimethylsilyl, acetyl, benzoyl, methyl, ethyl, tert. -butyl, trityl, benzyl or tetrahydropyranyl group
  • protecting groups for a carboxy group may be the trimethyl- silyl, methyl, ethyl, tert. -butyl, benzyl or tetrahydropyranyl group
  • protecting groups for a phosphono group may be an alkyl group such as the methyl, ethyl, isopropyl or n-butyl group, the phenyl or benzyl group and
  • protecting groups for an amino, alkylamino or imino group may be a formyl, acetyl, trifluoroacetyl, ethoxycarbonyl , tert . -butoxycarbonyl , benzyloxycarbonyl , benzyl, methoxybenzyl or 2 , 4-dimethoxybenzyl group and for the amino group additionally a phthalyl group.
  • Any protecting group used is optionally subsequently cleaved for example by hydrolysis in an aqueous solvent, e.g. in water, isopropanol/water, acetic acid/water, tetrahydrofuran/water or dioxane/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulphuric acid or in the presence of an alkali metal base such as sodium hydroxide or potassium hydroxide or aprotically, e.g. in the presence of io- dotrimethylsilane, an temperatures between 0 and 120°C, preferably at temperatures between 10 and 100°C.
  • an aqueous solvent e.g. in water, isopropanol/water, acetic acid/water, tetrahydrofuran/water or dioxane/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulphuric acid or in the presence of an al
  • a benzyl, methoxybenzyl or benzyloxycarbonyl group is cleaved, for example, hydrogenolytically, e.g. with hydrogen in the presence of a catalyst such as palladium/charcoal in a suitable solvent such as methanol, ethanol, ethyl acetate or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid at temperatures between 0 and 100°C, but preferably at temperatures between 20 and 60°C, and at a hydrogen pressure of 1 to 7 bar, but preferably 3 to 5 bar.
  • a 2 , 4-dimethoxybenzyl group is preferably cleaved in trifluoroacetic acid in the presence of anisol .
  • a tert-butyl or ter .butyloxycarbonyl group is preferably cleaved by treating with an acid such as trifluoroacetic acid or hydrochloric acid or by treating with iodotrimethylsilane optionally using a solvent such as methylene chloride, dioxane, methanol or diethylether .
  • a trifluoroacetyl group is preferably cleaved by treating with an acid such as hydrochloric acid, optionally in the presence of a solvent such as acetic acid at temperatures between 50 and 120°C or by treating with sodium hydroxide solution optionally in the presence of a solvent such as tetrahydrofuran at temperatures between 0 and 50 °C.
  • a phthalyl group is preferably cleaved in the presence of hy- drazine or a primary amine such as methylamine, ethylamine or n-butylamine in a solvent such as methanol, ethanol, isopro- panol, toluene/water or dioxane at temperatures between 20 and 50°C.
  • a single alkyl group may be cleaved from an O, O ' -dialkylphos- phono group with sodium iodide, for example, in a solvent such as acetone, methylethylketone, acetonitrile or dimethylformamide at temperatures between 40 and 150°C, but preferably at temperatures between 60 and 100°C.
  • a solvent such as acetone, methylethylketone, acetonitrile or dimethylformamide
  • Both alkyl groups may be cleaved from an O, 0 ' -dialkyl-phosphono group with iodotrimethylsilane, bromotrimethylsilane or chlorotrimethylsilane/sodium iodide, for example, in a solvent such as methyl chloride, chloroform or acetonitrile at temperatures between 0°C and the boiling temperature of the reaction mixture, but preferably at temperatures between 20 and 60°C.
  • a solvent such as methyl chloride, chloroform or acetonitrile
  • the compounds of general formula I obtained may be resolved into their enantiomers and/or diastereomers, as mentioned hereinbefore.
  • cis/trans mixtures may be resolved into their cis and trans isomers, and compounds with at least one optically active carbon atom may be separated into their enantiomers.
  • the cis/trans mixtures may be resolved by chromatography into the cis and trans isomers thereof, the compounds of general formula I obtained which occur as race- mates may be separated by methods known per se (cf . allinger
  • the enantiomers are preferably separated by column separation on chiral phases or by recrystallisation from an optically active solvent or by reacting with an optically active substance which forms salts or derivatives such as e.g. esters or amides with the racemic compound, particularly acids and the activated derivatives or alcohols thereof, and separating the diastereomeric mixture of salts or derivatives thus obtained, e.g. on the basis of their differences in solubility, whilst the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents.
  • Optically active acids in common use are e.g.
  • An optically active alcohol may be for example (+) or (-) -menthol and an optically active acyl group in amides, for example, may be a (+) -or ( - ) -menthyloxycarbonyl .
  • the compounds of formula I may be converted into the salts thereof, and particularly for pharmaceutical use into the physiologically acceptable salts with inorganic or organic acids .
  • Acids which may be used for this purpose include for example hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or aleic acid.
  • the new compounds of formula I thus obtained contain a carboxy or hydroxyphosphoryl group, they may subsequently, if desired, be converted into the salts thereof with inorganic or organic bases, particularly for pharmaceutical use into the physiologically acceptable salts thereof.
  • Suitable bases for this purpose include for example sodium hydroxide, potassium hydroxide, arginine, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine .
  • a starting compound of general formula II is obtained by reacting a corresponding fluoronitro compound with a corresponding alkoxide and subsequently reducing the nitro compound thus obtained or
  • a starting compound of general formula IV is obtained by reacting a corresponding fluoronitro compound with a corresponding alkoxide, subsequently reducing the nitro compound thus obtained and then acylating with a corresponding compound.
  • the compounds of general formula I according to the invention and the physiologically acceptable salts thereof have valuable pharmacological properties, particularly an inhibiting effect on signal transduction mediated by the Epidermal Growth Factor receptor (EGF-R) , whilst this may be achieved for example by inhibiting ligand bonding, receptor dimerisation or tyrosinekinase itself. It is also possible to block the transmission of signals to components located further down.
  • EGF-R Epidermal Growth Factor receptor
  • EGF-R-mediated signal transmission can be demonstrated e.g. with cells which express human EGF-R and whose survival and proliferation depend on stimulation by EGF or TGF-alpha.
  • a cell line of murine origin dependent on in- terleukin-3 (IL-3) which was genetically modified to express functional human EGF-R was used here.
  • the proliferation of these cells known as F/L-HERc can therefore be stimulated either by murine IL-3 or by EGF (cf . von R ⁇ den, T. et al . in EMBO J. 1, 2749-2756 (1988) and Pierce, J. H. et al . in Science 212, 628-631 (1988)).
  • the starting material used for the F/L-HERc cells was the cell line FDC-Pi, the production of which has been described by Dexter, T. M. et al . in J. Exp . Med. 1 ? . . 1036-1047 (1980) .
  • other growth-factor-dependent cells may also be used (cf. for example Pierce, J. H. et al . in Science 239, 628-631 (1988), Shibuya, H. et al . in Cell 2H, 57-67 (1992) and alexander, W. S. et al . in EMBO J. IH, 3683- 3691 (1991)).
  • F/L-HERc cells were cultivated in RPMI/1640 medium (BioWhittaker) , supplemented with 10 % foetal calf serum (FCS, Boehringer Mannheim) , 2 mM glutamine (BioWhittaker) , standard antibiotics and 20 ng/ml of human EGF (Promega) , at 37°C and 5% CO2.
  • FCS foetal calf serum
  • FCS 2 mM glutamine
  • standard antibiotics 20 ng/ml of human EGF (Promega)
  • 1.5 x 10 4 cells per well were cultivated in triplicate in 96-well plates in the above medium (200 ⁇ l) , the cell proliferation being stimulated with either EGF (20 ng/ml) or murine IL-3.
  • the IL-3 used was obtained from culture supernatants of the cell line X63/0 mIL-3 (cf. Karasuyama, H. et al . in Eur. J. Immunol. 18., 97-104 (1988) ) .
  • the compounds according to the invention were dissolved in 100% dimethylsulphoxide (DMSO) and added to the cultures in various dilutions, the maximum DMSO concentration being 1%. The cultures were incubated for 48 hours at 37°C.
  • DMSO dimethylsulphoxide
  • the relative cell number was measured in O.D. units using the Cell Titer 96TM AQ u ⁇ ous Non- Radioactive Cell Proliferation Assay (Promega) .
  • the relative cell number was calculated as a percentage of the control (F/LHERc cells without inhibitor) and the concentration of active substance which inhibits the proliferation of the cells by 50% (IC50) was derived therefrom. The following results were obtained:
  • the compounds of general formula I according to the invention thus inhibit the signal transduction by tyrosine kinases, as demonstrated by the example of the human EGF receptor, and are therefore useful for treating pathophysiological processes caused by hyperfunction of tyrosinekinases .
  • tyrosine kinases e.g. benign or malignant tumours, particularly tumours of epithelial and neuroepithelial origin, metastasisation and the abnormal proliferation of vascular endothelial cells (neoangio- genesis) .
  • the compounds according to the invention are also useful for preventing and treating diseases of the airways and lungs which are accompanied by increased or altered production of mucus caused by stimulation by tyrosine kinases, e.g. in inflammatory diseases of the airways such as chronic bronchitis, chronic obstructive bronchitis, asthma, bronchiec- tasias, allergic or non-allergic rhinitis or sinusitis, cystic fibrosis, ⁇ l-antitrypsin deficiency, or coughs, pulmonary emphysema, pulmonary fibrosis and hyperreactive airways.
  • inflammatory diseases of the airways such as chronic bronchitis, chronic obstructive bronchitis, asthma, bronchiec- tasias, allergic or non-allergic rhinitis or sinusitis, cystic fibrosis, ⁇ l-antitrypsin deficiency, or coughs, pulmonary emphysema,
  • the compounds are also suitable for treating diseases of the gastrointestinal tract and bile duct and gall bladder which are associated with disrupted activity of the tyrosine kinases, such as may be found e.g. in chronic inflammatory changes such as cholecystitis, CrohnA disease, ulcerative colitis, and ulcers in the gastrointestinal tract or such as may occur in diseases of the gastrointestinal tract which are associated with increased secretions, such as MenetrieAs disease, secreting adenomas and protein loss syndrome,
  • nasal polyps and polyps of the gastrointestinal tract of varying origins such as villous or ade- nomatous polyps of the large bowel, but also polyps in familial polyposis coli, intestinal polyps in Gardner ⁇ " s syndrome, polyps throughout the entire gastrointestinal tract in Koz- Jeghers syndrome, in inflammatory Pseudopolyps, in juvenile polyps, in colitis cystica profunda and in pneumatosis cys- toides intestinales .
  • kidney diseases particularly in cystic changes such as cystic kidneys
  • renal cysts which may be of idiopathic origin or which occur in syndromes such as tuberous sclerosis, in von Hippel-Lindau syndrome, in nephronophthisis and spongy kidney and other diseases caused by abnormal function of tyrosine kinases, such as e.g. epidermal hyperproliferation (psoriasis), inflammatory processes, diseases of the immune system, hyperproliferation of haematopoietic cells, etc.
  • psoriasis epidermal hyperproliferation
  • haematopoietic cells etc.
  • the compounds according to the invention may be used on their own or in conjunction with other pharmacologically active compounds, for example in tumour therapy, in monotherapy or in conjunction with other anti-tumour therapeutic agents, for example in combination with topoisomerase inhibitors (e.g. etoposide), mitosis inhibitors (e.g. vinblastin) , compounds which interact with nucleic acids (e.g. cis-platin, cyclophosphamide, adriamycin) , hormone antagonists (e.g. tamoxifen) , inhibitors of metabolic processes (e.g. 5-FU etc.), cytokines (e.g. interferons), antibodies, etc.
  • topoisomerase inhibitors e.g. etoposide
  • mitosis inhibitors e.g. vinblastin
  • nucleic acids e.g. cis-platin, cyclophosphamide, adriamycin
  • hormone antagonists e.g
  • these compounds may be used on their own or in conjunction with other therapeutic agents for the airways, such as substances with a secre- tolytic, broncholytic and/or antiinflammatory activity.
  • these compounds may also be administered on their own or in conjunction with substances having an effect on motility or secretion or with antiinflammatories . These combinations may be administered either simultaneously or sequentially.
  • These compounds may be administered either on their own or in conjunction with other active substances by intravenous, subcutaneous, intramuscular, intrarectal, intraperitoneal or intranasal route, by inhalation or transdermally or orally, whilst aerosol formulations are particularly suitable for inhalation.
  • the compounds according to the invention are generally used for warm-blooded vertebrates, particularly humans, in doses of 0.01-100 mg/kg of body weight, preferably 0.1-15 mg/kg.
  • they are formulated with one or more conventional inert carriers and/or diluents, e.g.
  • the organic phase is washed with water and saturated sodium chloride solution, dried over magnesium sulphate and concentrated by evaporation.
  • the yellowish, resin-like crude product is recrystallised from 7 ml of ethanol.
  • the yellow crystals are washed with some cold ethanol and dried in the desiccator.
  • Partially precipitated product is dissolved by the addition of more methylene chloride and methanol.
  • the aqueous phase is separated off and extracted with methylene chloride/methanol (9:1) .
  • the combined extracts are washed with water, dried over magnesium sulphate and concentrated by evaporation.
  • the crude product is heated to boiling with 25 ml of tert. butylmethylether, cooled with stirring and suction filtered.
  • the oily brown crude product is taken up in 25 ml of tetrahydrofuran and added dropwise, while cooling with a ice bath, to a solution of 3.15 g of 4-[(3- bromophenyl) amino] -6-amino-quinazoline and 2.30 ml of H ⁇ nig base in 25 ml of tetrahydrofuran.
  • the reaction mixture is stirred for 30 minutes while cooling with ice and then stirred for another 1.5 hours at ambient temperature.
  • 25 ml of water and 50 ml of ethyl acetate are added.
  • the organic phase is separated off, washed with saturated sodium chloride solution, dried over magnesium sulphate and concentrated by evaporation.
  • the residue is boiled in 30 ml of ethyl acetate to purify it further and filtered while hot.
  • the yellow crystalline product is washed with hot ethyl acetate and dried.
  • a solution of 17.90 g 3- (tert-butyloxycarbonylamino) propyl bromide in 50 ml of acetonitrile is added dropwise to a mixture of 11.55 g of sarcosine ethylester hydrochloride and 28.8 ml of Hunig base in 200 ml of acetonitrile within 30 minutes while cooling with an ice bath.
  • the reaction mixture is allowed to come up to ambient temperature overnight in the ice bath.
  • the solvent is distilled off using the rotary evaporator, the residue is taken up in tert-butyl-methylether and washed with ice water.
  • the organic phase is dried over magnesium sulphate and concentrated by evaporation.
  • the crude product is chromatographed on a silica gel column with methylene chloride/methanol/concentrated aqueous ammonia solution (100:2:0.1) .
  • 0.08 ml of a 37% formaldehyde solution is added to a suspension of 487 mg of 4 -[ (3 -bromophenyl) amino] -6-nitro-7- [3 - (pipe- razin-l-yl)propyloxy] -quinazoline in 3 ml of dioxane.
  • the suspension is briefly heated in an oil bath until a clear solution is obtained.
  • 0.16 ml of diethylphosphite are pipetted in with stirring at ambient temperature.
  • the reaction mixture is then stirred for a further half hour at ambient temperature, then heated to 90-100°C in an oil bath. After another three hours the reaction is complete.
  • the brown crude product is reacted without any further purification.
  • R f value 0.55 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/trifluoroacetic acid
  • the precipitate formed is suction filtered and washed with water.
  • the crude product is purified by chromatography on a silica gel column with methylene chloride/methanol (20:1) as eluant .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to bicyclic heterocycles of general formula (I), wherein Ra to Rd, A to G and X are defined as in claim 1, the tautomers, the stereoisomers and the salts thereof, particularly the physiologically acceptable salts thereof particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly an inhibiting effect on signal transduction mediated by tyrosine kinases, their use for treating diseases, particularly tumoral diseases, diseases of the lungs and respiratory tract, and the preparation thereof.

Description

4-AMINO-QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES
The present invention relates to bicyclic heterocycles of general formula
Figure imgf000003_0001
the tautomers, the stereoisomers and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, their use for treating diseases, particularly tumoral diseases, diseases of the lungs and respiratory tract and the preparation thereof.
In the above general formula I
Ra denotes a hydrogen atom or a Ci-4-alkyl group,
Rb denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups R-_ to R3, whilst
R-_ and R2, which may be identical or different, in each case denote a hydrogen, fluorine, chlorine, bromine or iodine atom, a Cj.,4-alkyl, hydroxy, C-^-alkoxy, C3_6-cycloalkyl, C4.6-cycloalkoxy, C2.5-alkenyl or C2.5-alkynyl group,
an aryl, aryloxy, arylmethyl or arylmethoxy group,
a C3.5-alkenyloxy or C3_s-alkynyloxy group, wherein the unsaturated part may not be linked to the oxygen atom,
a CA4-alkylsulphenyl, C1_4-alkylsulphinyl, C-__4-al- kylsulphonyl, C1.4-alkylsulphonyloxy, trifluoromethyl- sulphenyl, trifluoromethylsulphinyl or trifluoromethyl- sulphonyl group,
a methyl or methoxy group substituted by 1 to 3 fluorine atoms,
an ethyl or ethoxy group substituted by 1 to 5 fluorine atoms,
a cyano or nitro group or an amino group optionally substituted by one or two C1.4-alkyl groups, while the substituents may be identical or different, or
Rx together with R2, if they are bound to adjacent carbon atoms, denote a -CH=CH-CH=CH, -CH=CH-NH or -CH=N-NH group and
R3 denotes a hydrogen, fluorine, chlorine or bromine atom,
a CA.J-alkyl, trifluoromethyl or C^-alkoxy group,
Rc and Rd, which may be identical or different, in each case denote a hydrogen, fluorine or chlorine atom, a methoxy group or a methyl group optionally substituted by a methoxy, dime- thylamino, diethylamino, pyrrolidino, piperidino or morpholino group , X denotes a methine group substituted by a cyano group or a nitrogen atom,
A denotes an oxygen atom or an imino group optionally substituted by a C-^-alkyl group,
B denotes a carbonyl or sulphonyl group,
C denotes a 1, 3-allenylene, 1,1- or 1,2-vinylene group which may be substituted in each case by one or two methyl groups or by a trifluoromethyl group,
an ethynylene group or
a 1, 3-butadien-l, 4-ylene group optionally substituted by 1 to 4 methyl groups or by a trifluoromethyl group,
D denotes an alkylene, -CO-alkylene or -S02-alkylene group wherein the alkylene moiety in each case contains 1 to 8 carbon atoms and additionally 1 to 4 hydrogen atoms in the alkylene moiety may be replaced by fluorine atoms, whilst the linking of the -CO-alkylene and -S02-alkylene group to the adjacent group C in each case must take place via the carbonyl or sulphonyl group,
a -CO-O-alkylene, -CO-NR4-alkylene or -S02-NR4-alkylene group wherein the alkylene moiety in each case contains 1 to 8 carbon atoms, whilst the linking to the adjacent group C in each case must take place via the carbonyl or sulphonyl group wherein
R4 denotes a hydrogen atom or a C-__4-alkyl group,
or, if D is bound to a carbon atom of the group E, it may also denote a bond or, if D is bound to a nitrogen atom of the group E, it may also denote a carbonyl or sulphonyl group,
E denotes an R60-CO-alkylene-NRs, (R70-PO-OR8) -alkylene-NR5 or (R70-PO-R9) -alkylene-NR5-group wherein in each case the alkylene moiety, which is straight-chained and contains 1 to δ carbon atoms, may additionally be substituted by one or two C^-alkyl groups or by an RsO-CO or
Figure imgf000006_0001
group, wherein
R5 denotes a hydrogen atom,
a C1.4-alkyl group, which may be substituted by an R60-CO, (R70-PO-OR8) or (R70-PO-R9) group,
an ethyl or propyl group optionally substituted by one or two methyl or ethyl groups, which may be terminally substituted in each case by a CAg-alkylcarbonylsulphenyl, C3.7-cycloalkylcarbonylsulphenyl, C3_7-cycloalkyl-C1.3-alkyl- carbonylsulphenyl, arylcarbonylsulphenyl or aryl-C1_3-al- kylcarbonylsulphenyl group,
an ethyl or propyl group optionally substituted by one or two methyl or ethyl groups which may be terminally substituted in each case by a
Figure imgf000006_0002
C3.7-cyc- loalkylcarbonyloxy, C3_7-cycloalkyl-C^-alkylcarbonyloxy, arylcarbonyloxy or aryl-C-^^-alkylcarbonyloxy group,
an ethyl or propyl group optionally substituted by one or two methyl or ethyl groups, each of which may be terminally substituted by a hydroxy, C-^-alkoxy, amino, C^-alkylamino or di- (Ci-4-alkyl) -amino group or by a 4- to 7-membered al- kyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups a methylene group in the 4 position may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, imino or N- (C1.4-alkyl) -imino group,
a C3_7-cycloalkyl or C3_7-cycloalkyl-C1_3-alkyl group, Rg, R7 and R8, which may be identical or different, in each case denote a hydrogen atom,
a CAg-alkyl group, which may be substituted by a hydroxy, C-^-alkoxy, amino, C^-alkylamino or di- (C^-alkyl) -amino group or by a 4- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, imino or N- (C^-alkyl) -imino group,
a C4_7-cycloalkyl group optionally substituted by 1 or 2 methyl groups,
a C3.5-alkenyl or C3.s-alkynyl group, wherein the unsaturated part may not be linked to the oxygen atom,
a
Figure imgf000007_0001
or RgCO-0- (ReCRf) -group, whilst
Re and Rf, which may be identical or different, in each case denote a hydrogen atom or a CA4-alkyl group and
Rg denotes a C-^-alkyl, C3.7-cycloalkyl, C^-alkoxy or C5_7-cycloalkoxy group,
and R9 denotes a C^-alkyl, aryl or aryl-C^-alkyl group,
a 4- to 7-membered alkyleneimino group which may be substituted by an R60-CO, (R70-PO-OR8) , (R70-PO-R9) , R60-CO-C1.4-alkyl , bis- (RgO-CO) -C^-alkyl, (R70-PO-OR8) -C-^-alkyl or (R70-PO-R9) -C^-alkyl group wherein R6 to R9 are as hereinbefore defined,
a 4- to 7-membered alkyleneimino group which may be substituted by two R6OCO or
Figure imgf000007_0002
groups or by an RgOCO-group and an
Figure imgf000008_0001
group wherein R6 is as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by the group R10 and is additionally substituted at a cyclic carbon atom by an RsO-CO, (R70-P0-OR8) , (R70-PO-R9) ,
Figure imgf000008_0002
or (R70-P0-R9) -Ci-4-alkyl group wherein R6 to R9 are as hereinbefore defined and
R10 denotes a hydrogen atom, a G^.,-alkyl, formyl, C1.4-alkylcarbonyl or C1.4-alkylsulphonyl group,
a piperazino or homopiperazino group which is substituted in the 4 position by the group R10 and additionally at cyclic carbon atoms by two R60-CO or R60-CO-Cx.4-alkyl groups or by an RgO-CO-group and an R60-CO-C1.4-alkyl group wherein R6 and R10 are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in each case in the 4 position by an R60-CO-C1.4-alkyl, bis- (RgO-CO) -C1_4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) - C._-4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by an R60-CO-C1.4-alkyl, bis- (R60-CO) -C^-alkyl , (R70-PO-OR8) -C-._4-alkyl or (R70-PO-R9) -C1.4-alkyl group and is additionally substituted at cyclic carbon atoms by one or two RgO-CO or RgO-CO-C1.4-alkyl groups or by an R60-CO-group and an R60-CO-C1.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a morpholino or homomorpholino group which is substituted in each case by an R60-CO, (R70-PO-OR8) , (R70-PO-R9) ,
Figure imgf000008_0003
kyl, bis- (RsO-CO) -C1_„-alkyl, (R70-P0-0R8) -C^-alkyl or (R70-PO-R9) -C1.4-alkyl group wherein R6 to R9 are as hereinbefore defined, a morpholino or homomorpholino group which is substituted by two RgO-CO or
Figure imgf000009_0001
groups or by an R60-CO-group and an RgO-CO-C1.4-alkyl group wherein Rs is as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group R10, whilst the above- mentioned 5- to 7-membered rings are additionally substituted in each case at a carbon atom by an R60-CO, (R70-PO-OR8) , (R70- PO-R9) , R60-CO-C1.4-alkyl, bis- (RsO-CO) -C^-alkyl , (R70-PO-OR8) - C-L.-j-alkyl or (R70-PO-R9) -C-^-alkyl group wherein Rs to R10 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group R10, while the abovementioned 5- to 7-membered rings are in each case additionally substituted at carbon atoms by two R60-CO or
Figure imgf000009_0002
groups or by an R60-CO-group and an RgO-CO-C1_4-alkyl group wherein R6 and R10 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an
Figure imgf000009_0003
bis- (RsO-CO) - C^-alkyl, (R70-PO-OR8) -C1.4-alkyl or (R70-PO-R9) -C1.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an
Figure imgf000009_0004
, bis- (R60-CO) - C-^-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -C^-alkyl group, while the abovementioned 5- to 7-membered rings are in each case additionally substituted at carbon atoms by one or two RgO-CO or
Figure imgf000009_0005
groups or by an R60-CO-group and an RgO-CO-C1_4-alkyl group wherein Rs to R9 are as hereinbefore defined,
a 2-oxo-morpholino group which may be substituted by 1 to 4 C-^-alkyl groups, a 2-oxo-thiomor holino group which may be substituted by 1 to 4 Cj.-j-alkyl groups,
morpholino or thiomorpholino group which is substituted in thLee 22 ppoossition by a Cx.4-alkoxy group,
a morpholino or thiomorpholino group which is substituted in the 2 and 6 position by a C^-alkoxy group,
a C1.4-alkyl-NR5-group wherein the C^-alkyl moiety, which is straight-chained and may additionally be substituted by one or two methyl groups, is in each case terminally substituted by a di- (C.__4-alkoxy) -methyl or tri- (C1_4-alkoxy) -methyl group, whilst Rs is as hereinbefore defined,
a C1.4-alkyl-NR5-group wherein the C1.4-alkyl moiety, which is straight-chained and may additionally be substituted by one or two methyl groups, is in each case terminally substituted by a 1, 3-dioxolan-2-yl or 1, 3-dioxan-2-yl group optionally substituted by one or two methyl groups, while Rs is as hereinbefore defined,
an Rι:LNRs-group wherein R5 is as hereinbefore defined and
RX1 denotes a 2-oxo-tetrahydrofuran-3 -yl , 2-oxo-tetrahy- drofuran-4-yl, 2-oxo-tetrahydropyran-3 -yl , 2-oxo-tetrahy- dropyran-4-yl, 2-oxo-tetrahydropyran-5-yl , 2-oxo-tetrahy- drothiophen-3-yl, 2-oxo-tetrahydrothiophen-4-yl, 2-oxo- tetrahydrothiopyran-3-yl, 2-oxo-tetrahydrothiopyran-4-yl or 2-oxo-tetrahydrothiopyran-5-yl group optionally substituted by one or two methyl groups,
an amino group or an amino group optionally substituted by 1 or 2 C^,,-alkyl groups wherein the alkyl groups may be identical or different and each alkyl moiety may be substituted from position 2 by a hydroxy, C1.4-alkoxy, amino, C1_4-alkylamino or di- (C^-alkyl) -amino group or by a 4- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulphur atom, or by a sulphi- nyl, sulphonyl, imino or N- (C-__4-alkyl) -imino group,
a 4- to 7-membered alkyleneimino group optionally substituted by 1 to 4 methyl groups,
a 6- to 7-membered alkyleneimino group optionally substituted by 1 or 2 methyl groups wherein in each case a methylene group in the 4 position is replaced by an oxygen or sulphur atom, by an imino group substituted by the group R10, by a sulphinyl or sulphonyl group, whilst R10 is as hereinbefore defined,
an imidazolyl group optionally substituted by 1 to 3 methyl groups ,
a C5.7-cycloalkyl group wherein a methylene group is replaced by an oxygen or sulphur atom, by an imino group substituted by the group R10, by a sulphinyl or sulphonyl group, wherein R10 is as hereinbefore defined,
or D together with E denotes a hydrogen, fluorine or chlorine atom,
a C1.4-alkyl group optionally substituted by 1 to 5 fluorine atoms,
a C3.6-cycloalkyl group,
an aryl, heteroaryl, C1_4-alkylcarbonyl, arylcarbonyl , carboxy, C1_4-alkoxycarbonyl, RgCO-0- (ReCRf) -O-CO, (R70-PO-OR8) or (R70-PO- R9) -group wherein Re to Rg and R7 to R9 are as hereinbefore defined,
an aminocarbonyl , C^-alkylaminocarbonyl or di- (C1.4-alkyl) - aminocarbonyl group or a carbonyl group, which is substituted by a 4- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7- membered alkyleneimino groups, a methylene group in the 4 position may be replaced by an oxygen or sulphur atom, by an imino group substituted by the group R10, by a sulphinyl or sulphonyl group, wherein R10 is as hereinbefore defined,
F denotes a
Figure imgf000012_0001
group, whilst the alkylene moiety is linked to the group G, or an oxygen atom, whilst the latter may not be linked to a nitrogen atom of the group G, and
G denotes an RsO-CO-alkylene-NRs, (R70-PO-OR8) -alkylene-NR5 or (R70-PO-R9) -alkylene-NRs-group wherein in each case the alkylene moiety, which is straight -chained and contains 1 to 6 carbon atoms, may additionally be substituted by one or two C^-alkyl groups or by an RsO-CO or
Figure imgf000012_0002
group, wherein R5 to R9 are as hereinbefore defined,
a 4- to 7-membered alkyleneimino group which is substituted by an RgO-CO, (R70-PO-OR8) , (R70-PO-R9) ,
Figure imgf000012_0003
, bis- (RgO-CO) -C-^-alkyl, (R70-PO-OR8) -C-..4-alkyl or (R70-PO-R9) - Ci-4-alkyl group wherein Rs to R9 are as hereinbefore defined,
a 4- to 7-membered alkyleneimino group which is substituted by two RgO-CO or RgO-CO-C1.4-alkyl groups or by an R60-CO-group and an
Figure imgf000012_0004
group wherein Rs is as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by the group R10 and is additionally substituted at a cyclic carbon atom by an RεO-CO, (R70-PO-OR8) , (R70-P0-R9) , R60-CO-C1_4-alkyl, bis- (RsO-CO) -C^-alkyl, (R70-P0-0Rg) -C-.4-alkyl or (R70-PO-R9) -C1.4-alkyl group wherein R6 to R10 are as hereinbefore defined, O 00/51991
- 11 -
a piperazino or homopiperazino group which is substituted in the 4 position by the group R10 and is additionally substituted at cyclic carbon atoms by two RβO-CO or RgO-CO-C1_4-alkyl groups or by an RsO-CO-group and an
Figure imgf000013_0001
group wherein R6 and R10 are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in each case in the 4 position by an
Figure imgf000013_0002
bis- (RgO-CO) -Cx.4-alkyl, (R70-PO-OR8) -C-^-alkyl or (R70-PO-R9) - Ci.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by an R60-CO-C1.4-alkyl, bis- (R60-CO) -C-_.4-alkyl, (R70-PO-ORs) -C1.4-alkyl or (R70-PO-R9) -C1.4-alkyl group and is additionally substituted at cyclic carbon atoms by one or two RgO-CO or R60-CO-C1.4-alkyl groups or by an R60-CO-group and an
Figure imgf000013_0003
group wherein Rs to R9 are as hereinbefore defined,
a morpholino or homomorpholino group which is substituted in each case by an RsO-CO, (R70-PO-OR8) , (R70-PO-R9) , R60-CO- C^-alkyl, bis- (RsO-CO) -C^-alkyl, (R70-PO-OR8) -C^-alkyl or (R70-PO-R9) -0^4-alkyl group wherein Rs to R9 are as hereinbefore defined,
a morpholino or homomorpholino group which is substituted by two RgO-CO or RgO-CO-C1_4-alkyl groups or by an R60-C0-group and an
Figure imgf000013_0004
group wherein R6 is as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group R10, whilst the abovementioned 5- to 7-membered rings are in each case additionally substituted at a carbon atom by an R60-C0, (R70-PO-OR3) , (R70-P0-R9) ,
Figure imgf000013_0005
, bis- (R60-C0) - C^-alkyl, (R70-PO-OR8) -C^-alkyl or (R70-PO-R9) -C1.4-alkyl group wherein R6 to R10 are as hereinbefore defined, O 00/51991
- 12 -
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group R10, while the abovementioned 5- to 7-membered rings are in each case additionally substituted at carbon atoms by two R60-C0 or R60-CO-Cx.4-alkyl groups or by an R60-CO-group and an R60-CO-C1_4-alkyl group wherein Rs and R10 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an R60-CO-C1.4-alkyl, bis- (R60-CO) - Ci-4-alkyl, (R70-PO-OR8) -C^-alkyl or (R70-PO-R9) -C^-alkyl group wherein R6 to R9 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an R60-CO-C.__4-alkyl, bis- (R60-CO) - 0^4-alkyl, (R70-PO-OR8) -C1_4-alkyl or (R70-PO-R9) -C-_.4-alkyl group, while the abovementioned 5- to 7-membered rings are in each case additionally substituted at carbon atoms by one or two RgO-CO or RgO-CO-Ci-4-al yl groups or by an Rs0-C0-group and an
Figure imgf000014_0001
group wherein R6 to R9 are as hereinbefore defined,
a 2-oxo-morpholino group which may be substituted by 1 or 2 methyl groups,
a 2-oxo-morpholinyl group which is substituted in the 4 position by a hydrogen atom, by a C^-alkyl, R60-CO-C1_4-alkyl , (R70-PO-OR8) -C-..4-alkyl or (R70-PO-R9) -C-^-alkyl group, while R6 to R9 are as hereinbefore defined and the abovementioned 2-oxo- morpholinyl groups are in each case linked to a carbon atom of the group F,
a morpholino or thiomorpholino group which is substituted in the 2 position by a C-^-alkoxy group,
a morpholino or thiomorpholino group which is substituted in the 2 and 6 position by a C1.4-alkoxy group, a Ci-4-alkyl-NRS-group wherein the C-__4-alkyl moiety, which is straight-chained and may additionally be substituted by one or two methyl groups, is in each case terminally substituted by a di- (C^-alkoxy) -methyl or tri- (C1.4-alkoxy) -methyl group, whilst R5 is as hereinbefore defined,
a C1,4-alkyl-NRS-group wherein the C-^-alkyl moiety, which is straight-chained and may additionally be substituted by one or two methyl groups, is terminally substituted in each case by a 1, 3-dioxolan-2-yl or 1, 3-dioxan-2-yl-group optionally substituted by one or two methyl groups, while R5 is as hereinbefore defined,
an RhNRs-group wherein Rs is as hereinbefore defined and Rh denotes a 2-oxo-tetrahydrofuran-3-yl , 2-oxo-tetrahydrofuran- 4-yl, 2-oxo-tetrahydropyran-3-yl, 2-oxo-tetrahydropyran-4-yl or 2-oxo-tetrahydropyran-5-yl group optionally substituted by one or two methyl groups,
an amino group or an amino group optionally substituted by 1 or 2 Cx.4-alkyl groups wherein the alkyl groups may be identical or different and each alkyl moiety may be substituted from position 2 by a hydroxy, C-^-alkoxy, amino, C^-alkylamino or di- (Ci.4-alkyl) -amino group or by a 4- to 7-membered alkyleneimino group, wherein in the abovementioned 6 - to 7-membered alkyleneimino groups a methylene group in the 4 position may be replaced in each case by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, imino or N- (C1.4-alkyl) -imino group,
a 4- to 7-membered alkyleneimino group optionally substituted by 1 to 4 methyl groups,
a 6- to 7-membered alkyleneimino group optionally substituted by 1 or 2 methyl groups wherein in each case a methylene group in the 4 position is replaced by an oxygen or sulphur atom, by an imino group substituted by the group R10, a by a sulphinyl or sulphonyl group, wherein R10 is as hereinbefore defined, an imidazolyl group optionally substituted by 1 to 3 methyl groups ,
a Cs„7-cycloalkyl group wherein a methylene group is replaced by an oxygen or sulphur atom, by an imino group substituted by the group R10, by a sulphinyl or sulphonyl group, while R10 is as hereinbefore defined, or
F and G together denote a hydrogen, fluorine or chlorine atom,
a
Figure imgf000016_0001
group optionally substituted from position 2 by a hydroxy or C1_4-alkoxy group,
a C^-alkoxy group which is substituted by an R60-CO, (R70-P0- OR8) or (R70-PO-R9) -group, while Rs to R9 are as hereinbefore defined,
a C3_7-cycloalkoxy or C3.7-cycloalkyl-C1.4-alkoxy group, an amino group optionally substituted by 1 or 2 Cx.4-alkyl groups,
a 5- to 7-membered alkyleneimino group, wherein in the above- mentioned 6- to 7-membered alkyleneimino groups a methylene group in the 4 position may be replaced in each case by an oxygen or sulphur atom, by an imino group substituted by the group R10, or by a sulphinyl or sulphonyl group, wherein R10 is as hereinbefore defined,
with the proviso that at least one of the groups E, G or F together with G contains an R60-CO, (R70-PO-OR8) or (R70-PO-R9) - group or
D together with E contains an RgCO-0- (ReCRf) -O-CO, (R70-PO-OR8) or (R70-PO-R9) -group or
E or G contains an optionally substituted 2-oxo-morpholinyl group, a morpholino or thiomorpholino group substituted in the 2 position or in the 2 and 6 positions by a C^-alkoxy group,
a di- (C1.4-alkoxy) -methyl or tri- (C1.4-alkoxy) -methyl group or
an optionally substituted 1, 3-dioxolan-2-yl, 1, 3-dioxan-2-yl, 2-oxo-tetrahydrofuran-3-yl, 2-oxo-tetrahydrofuran-4-yl, 2-oxo- tetrahydropyran-3 -yl , 2-oxo-tetrahydropyran-4-yl or 2-oxo-te- trahydropyran-5-yl group or
E contains an optionally substituted 2-oxo-thiomorpholino group or an optionally substituted 2-oxo-tetrahydrothio- phen-3-yl, 2-oxo-tetrahydrothiophen-4-yl, 2-oxo-tetrahy- drothiopyran-3 -yl , 2-oxo-tetrahydrothiopyran-4-yl or 2-oxo-tetrahydrothiopyran-5-yl group.
By the aryl moieties mentioned in the definitions of the abovementioned groups is meant a phenyl group which in each case may be monosubstituted by R12, mono-, di- or trisubsti- tuted by R13 or monosubstituted by R12 and additionally mono- or disubstituted by R13, whilst the substituents may be identical or different and
R12 denotes a cyano, carboxy, C1.4-alkoxycarbonyl , aminocarbonyl, C1_4-alkylaminocarbonyl, di- (C^-alkyl) -aminocarbonyl , C^-alkylsulphenyl, C1.4-alkylsulphinyl , C1_4-alkylsulphonyl , hydroxy, C-^-alkylsulphonyloxy, trifluoromethyloxy, nitro, amino, C-^-alkylamino, di- (C^-alkyl) -amino, Cx.4-alkyl- carbonylamino, N- (C-^-alkyl) -Cx.4-alkylcarbonylamino, C^-alkylsulphonylamino, N- (C1.4-alkyl) -Cx_4-alkylsulphonyl- amino, aminosulphonyl , C1.4-alkylaminosulphonyl or di- (C1.4-alkyl) -aminosulphonyl group or a carbonyl group, which is substituted by a 5- to 7-membered alkyleneimino group, wherein in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, imino or N- (C1.4-alkyl) -imino-group, and
R13 denotes a fluorine, chlorine, bromine or iodine atom, a Cx_4-alkyl, trifluoromethyl or Cx_4-alkoxy group or
two groups Rx3, if they are bound to adjacent carbon atoms, together denote a C3.5 -alkylene, methylenedioxy or
1, 3-butadien-l, 4-ylene group.
Moreover, the heteroaryl groups mentioned in the definitions of the abovementioned groups also include a 5-membered heteroaromatic group which contains an imino group, an oxygen or sulphur atom or an imino group, an oxygen or sulphur atom and one or two nitrogen atoms, or
a 6-membered heteroaromatic group, which contains one, two or three nitrogen atoms,
whilst the abovementioned 5-membered heteroaromatic groups may be substituted in each case by 1 or 2 methyl or ethyl groups and the abovementioned 6-membered heteroaromatic groups may be substituted in each case by 1 or 2 methyl or ethyl groups or by a fluorine, chlorine, bromine or iodine atom, or by a tri- fluoromethyl , hydroxy, methoxy or ethoxy group.
Preferred compounds of the above general formula I are those wherein
Ra denotes a hydrogen atom or a C-^-alkyl group,
Rb denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups Rx to R3, wherein
Rx and R2, which may be identical or different, each denote a hydrogen, fluorine, chlorine, bromine or iodine atom, a G^-alkyl, hydroxy, C1.4-alkoxy, C3.6-cycloalkyl, C4.g-cycloalkoxy, C2.5-alkenyl or C2.5-alkynyl group,
a C3_5-alkenyloxy or C3.5-alkynyloxy group, while the unsaturated moiety may not be linked to the oxygen atom,
a Ci-4-alkylsulphenyl, Cx.4-alkylsulphinyl, C^-alkyl- sulphonyl, C-^-alkylsulphonyloxy, trifluoromethylsulphenyl, trifluoromethylsulphinyl or trifluoromethylsulphonyl group,
a methyl or methoxy group substituted by 1 to 3 fluorine atoms,
an ethyl or ethoxy group substituted by 1 to 5 fluorine atoms,
a cyano or nitro group or an amino group optionally substituted by one or two Cx_4-alkyl groups, wherein the substituents may be identical or different, and
R3 denotes a hydrogen, fluorine, chlorine or bromine atom,
a C-^-alkyl, trifluoromethyl- or C1.4-alkoxy group, Rc and Rd, which may be identical or different, each denote a hydrogen, fluorine or chlorine atom, a methoxy group or a methyl group optionally substituted by a methoxy, dimethylamino, diethylamino, pyrrolidino, piperidino or morpholino group,
X denotes a methine group substituted by a cyano group or a nitrogen atom,
A denotes an oxygen atom or an imino group optionally substituted by a C-__4-alkyl group,
B denotes a carbonyl or sulphonyl group, C denotes a 1, 3-allenylene, 1,1- or 1,2-vinylene group, which may be substituted in each case by one or two methyl groups or by a trifluoromethyl group,
an ethynylene group or
a 1, 3-butadien-l, 4-ylene group optionally substituted by 1 to 4 methyl groups or by a trifluoromethyl group,
D denotes an alkylene, -CO-alkylene or -S02-alkylene group wherein the alkylene moiety contains 1 to 8 carbon atoms in each case and additionally 1 to 4 hydrogen atoms in the alkylene moiety may be replaced by fluorine atoms, while the linking of the -CO-alkylene or -S02-alkylene group to the adjacent group C must take place via the carbonyl or sulphonyl group,
a -CO-O-alkylene, -CO-NR4-alkylene or -S02-NR4-alkylene group wherein the alkylene moiety contains 1 to 8 carbon atoms in each case, while the linking to the adjacent group C must take place via the carbonyl or sulphonyl group wherein
R4 denotes a hydrogen atom or a C1.i-alkyl group,
or, if D is bound to a carbon atom of the group E, it may also denote a bond
or, if D is bound to a nitrogen atom of the group E, it may also denote a carbonyl or sulphonyl group,
E denotes an RsO-CO-alkylene-NR5, (R70-PO-OR8) -alkylene-NR5 or (R70-PO-R9) -alkylene-NR5 group wherein in each case the alkylene moiety, which is straight -chained and contains 1 to 6 carbon atoms, may additionally be substituted by one or two C^-alkyl groups or by an R60-CO or R60-CO-Cx.2-alkyl group, while
R5 denotes a hydrogen atom, a Cx.4-alkyl group which may be substituted by a hydroxy, Ci-4-alkoxy, carboxy, RsO-CO, (R70-PO-OR8) , (R70-PO-R9) , ami- no, C-_.4-alkylaiT.in0 or di- (Cx.4-alkyl) -amino group or by a 4- to 7-membered alkyleneimino group, while in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group may be replaced in the 4 position by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, imino or N- (C___4-alkyl) -imino group,
a C3.7-cycloalkyl or C3_7-cycloalkyl-C1_3-alkyl group,
R6, R7 and R8, which may be identical or different, in each case denote a hydrogen atom,
a C-_.β-alkyl group which may be substituted by a hydroxy, C1.4-alkoxy, amino, C1.4-alkylamino or di- (C1.4-alkyl) -amino group or by a 4- to 7-membered alkyleneimino group, while in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, imino or N- (Cx_4-alkyl) -imino group,
a C4_7-cycloalkyl group optionally substituted by 1 or 2 methyl groups,
a C3.5-alkenyl or C3.5-alkynyl group, while the unsaturated moiety may not be linked to the oxygen atom,
a C3.7-cycloalkyl-C1.4-alkyl, aryl, aryl-C-__4-alkyl or RgCO-0- (ReCRf) group, wherein
Re and Rf, which may be identical or different, in each case denote a hydrogen atom or a Cx.4-alkyl group and
Rg denotes a C-__4 -alkyl, C3_7-cycloalkyl , C1.4-alkoxy or Cs_7-cycloalkoxy group, and R9 denotes a Cx_4-alkyl, aryl or aryl-Cx_4-alkyl group,
a 4- to 7-membered alkyleneimino group, which is substituted by an R60-C0, (R70-PO-OR8) , (R70-PO-R9) , R60-CO-C1.4-alkyl, (R70-PO-OR8) -Cx_4-alkyl or (R70-PO-R9) -Cx„4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by the group R10 and additionally at a cyclic carbon atom by an RgO-CO, (R70-PO-OR8) , (R70-PO-R9) , R60-CO- Cx_4-alkyl, (R70-PO-OR8) -Cx_4-alkyl or (R70-PO-R9) -Cx_4-alkyl group wherein Rs to R9 are as hereinbefore defined and
R10 denotes a hydrogen atom, a Cx_4-alkyl, formyl, Cx_4-al- kylcarbonyl or C___4-alkylsulphonyl group,
a piperazino or homopiperazino group which is substituted in each case in the 4 position by an R60-CO-C1.4-alkyl, (R70-P0- OR8) -C-__4-alkyl or (R70-PO-R9) -Cx.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group R10, while the above- mentioned 5- to 7-membered rings in each case are additionally substituted at a carbon atom by an RsO-CO, (R70-PO-OR8) , (R70- PO-R9) , R60-CO-C-_4-alkyl, (R70-PO-OR8) -C-.4-alkyl or (R70-P0-R9) - C1.4-alkyl group wherein R6 to R10 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an R60-CO-Cx_4-alkyl , (R70-PO-OR8) - C-__4-alkyl or (R70-PO-R9) -Cx_4-alkyl group wherein R6 to R9 are as hereinbefore defined,
an amino group or an amino group optionally substituted by 1 or 2 Cx-4-alkyl groups, wherein the alkyl groups may be identical or different and each alkyl moiety may be substituted from position 2 onwards by a hydroxy, Cx.4-alkoxy, amino, Cx.4-alkylamino or di- (Cx_4-alkyl) -amino group or by a 4- to 7- membered alkyleneimino group, while in the abovementioned 6- to 7-membered alkyleneimino groups, in each case a methylene group may be replaced in the 4 position by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, imino or N- (Cx_4-alkyl) - imino group,
a 4- to 7-membered alkyleneimino group optionally substituted by 1 to 4 methyl groups,
a 6- to 7-membered alkyleneimino group optionally substituted by 1 or 2 methyl groups, wherein in each case a methylene group in the 4 position is replaced by an oxygen or sulphur atom, by an imino group substituted by the group Rxo, by a sulphinyl or sulphonyl group, while Rx0 is as hereinbefore defined,
an imidazolyl group optionally substituted by 1 to 3 methyl groups,
a Cs.7-cycloalkyl group, wherein a methylene group is replaced by an oxygen or sulphur atom, by an imino group substituted by the group R10, or by a sulphinyl or sulphonyl group, while Rx0 is as hereinbefore defined,
or D together with E denotes a hydrogen, fluorine or chlorine atom,
a Cx_4-alkyl group optionally substituted by 1 to 5 fluorine atoms ,
a C3.s-cycloalkyl group,
an aryl, heteroaryl, Cx.4-alkylcarbonyl , arylcarbonyl , carboxy, Cx.4-alkoxycarbonyl, RgCO-0- (ReCRf) -O-CO, (R70-PO-OR8) or (R70-PO- - 22 -
R9) group wherein Re to Rg and R7 to R9 are as hereinbefore defined,
an aminocarbonyl, Cx.4-alkylaminocarbonyl or di- (Cx_4-alkyl) - aminocarbonyl group or
a carbonyl group which is substituted by a 4- to 7-membered alkyleneimino group, while in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulphur atom, by an imino group substituted by the group Rxo or by a sulphinyl or sulphonyl group, while R10 is as hereinbefore defined,
F denotes a Cx-.s- lkylene group, an -0-Cx_s-alkylene group, wherein the alkylene moiety is linked to the group G, or an oxygen atom, which may not be linked to a nitrogen atom of the group G, and
G denotes an R60-CO-alkylene-NRS, (R70-PO-OR8) -alkylene-NRs or (R70-PO-R9) -alkylene-NR5 group wherein in each case the alkylene moiety, which is straight-chained and contains 1 to 6 carbon atoms, may additionally be substituted by one or two Cx_2-alkyl groups or by an R60-CO or R60-CO-Cx_2-alkyl group, wherein R5 to R9 are as hereinbefore defined,
a 4- to 7-membered alkyleneimino group, which is substituted by an R60-CO, (R70-PO-OR8) , (R70-PO-R9) , RsO-CO-Cx.4-alkyl , (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by the group Rxo and additionally at a cyclic carbon atom by an R60-CO, (R70-PO-OR8) , (R70-PO-R9) , R60-CO- Cx_4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx.4-alkyl group wherein R6 to Rxo are as hereinbefore defined, a piperazino or homopiperazino group, which is substituted in each case in the 4 position by an R60-CO-Cx_4- lkyl, (R70-PO- OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group Rx0, while the abovementioned 5- to 7-membered rings in each case are additionally substituted at a carbon atom by an R60-CO, (R70-PO-OR8) , (R70- P0-R9) , R60-CO-Cx.4-alkyl, (R70-P0-0R8) -Cx.4-alkyl or (R70-PO-R9) - Cx.4-alkyl group wherein R6 to R10 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an R60-CO-Cx.4-alkyl , (R70-PO-OR8) - Cx.4-alkyl or (R70-PO-R9) -Cx.4-alkyl group wherein Rs to R9 are as hereinbefore defined,
an amino group or an amino group optionally substituted by 1 or 2 Cx.4-alkyl groups wherein the alkyl groups may be identical or different and each alkyl moiety may be substituted from position 2 by a hydroxy, Cx.4-alkoxy, amino, Cx.4-alkylamino or di- (Cx_4-alkyl) -amino group or by a 4- to 7-membered alkyleneimino group, while in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, imino or N- (Cx.4-alkyl) -imino group,
a 4- to 7-membered alkyleneimino group optionally substituted by 1 to 4 methyl groups,
a 6- to 7-membered alkyleneimino group optionally substituted by 1 or 2 methyl groups wherein in each case a methylene group in the 4 position is replaced by an oxygen or sulphur atom, by an imino group substituted by the group R10, by a sulphinyl or sulphonyl group, while Rxo is as hereinbefore defined, an imidazolyl group optionally substituted by 1 to 3 methyl groups ,
a C5.7-cycloalkyl group wherein a methylene group is replaced by an oxygen or sulphur atom, by an imino group substituted by the group Rx0, by a sulphinyl or sulphonyl group, while Rxo is as hereinbefore defined, or
F and G together denote a hydrogen, fluorine or chlorine atom,
a Cx.6-alkoxy group optionally substituted from position 2 onwards by a hydroxy or Cx.4-alkoxy group,
a Cx.6-alkoxy group which is substituted by an R60-CO, (R70-PO- OR8) or (R70-PO-R9) group, while R6 to R9 are as hereinbefore defined,
a C4.7-cycloalkoxy or C3.7-cycloalkoxy-C1.4-alkoxy group,
an amino group optionally substituted by 1 or 2 Cx.4-alkyl groups ,
a 5- to 7-membered alkyleneimino group, while in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulphur atom, by an imino group substituted by the group Rx0, or by a sulphinyl or sulphonyl group, while Rxo is as hereinbefore defined,
with the proviso that at least one of the groups E, G or F together with G contains an RsO-CO, (R70-PO-OR8) or (R70-PO-R9) group or
D together with E contains an RgCO-0- (ReCRf) -O-CO, (R70-PO-OR8) or (R70-PO-R9) group, and also the compounds of the abovementioned general formula I wherein Ra to Rd, A to G and X are as hereinbefore defined, but additionally
the 4- to 7-membered alkyleneimino groups mentioned above in the definition of groups E and G, the piperazino and homopiperazino groups substituted by R10 are each additionally substituted at a cyclic carbon atom by a bis- (R60-CO) -Cx.4-alkyl group and the piperazino, homopiperazino, pyrrolidinyl, piperidinyl and hexahydroazepinyl group mentioned above in the definition of the groups E and G are each substituted at the nitrogen atom by a bis- (R60-CO) -Cx.4-alkyl group,
Rx and R2, which may be identical or different, denote aryl, - aryloxy, arylmethyl or arylmethoxy groups or
Rx together with R2, if they are bound to adjacent carbon atoms, denote an -CH=CH-CH=CH, -CH=CH-NH or -CH=N-NH group,
E denotes a 2-oxo-morpholino group which may be substituted by 1 or 2 methyl groups ,
G denotes a 2-oxo-morpholino group which may be substituted by 1 or 2 methyl groups, or
a 2-oxo-morpholinyl group which is substituted in the 4 position by a hydrogen atom, by a Cx.4-alkyl, R60-CO-Cx_4-alkyl , (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx.4-alkyl group, while R6 to R9 are as hereinbefore defined and the abovementioned 2-oxo- morpholinyl groups in each case are linked to a carbon atom of the group F, and/or
F and G together may denote a C3.7-cycloalkyl-Cx.4-alkoxy group, with the proviso that
at least one of the groups E, G or F together with G contains an RgO-CO, (R70-PO-OR8) or (R70-PO-R9) group or D together with E contains an RgCO-0- (ReCRf) -O-CO, (R70-PO-OR8) or (R70-PO-R9) group or
E or G contains an optionally substituted 2-oxo-morpholinyl group,
the compounds of the abovementioned general formula I wherein Ra to Rd, A to G and X are as hereinbefore defined, but additionally
R5 denotes an ethyl or propyl group optionally substituted by one or two methyl groups, which is terminally substituted in each case by a Cx.6-alkylcarbonylsulphenyl , C3.7-cycloalkylcarbo- nylsulphenyl, C3.7-cycloalkyl-Cx.3-alkylcarbonylsulphenyl, aryl- carbonylsulphenyl or aryl-Cx.3-alkylcarbonylsulphenyl group,
E denotes a morpholino or homomorpholino group, which is substituted in each case by an R60-CO, (R70-PO-OR8) , (R70-PO-R9) , RgO-CO-Cx.4-alkyl, bis- (RgO-CO) -C._4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -C-.-4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a 2-oxo-morpholino group substituted by 1 to 4 Cx.,-alkyl groups with the proviso that a 2-oxo-morpholino group substituted by 1 or 2 methyl groups is excluded,
a 2-oxo-thiomorpholino group which may be substituted by 1 to 4 Cx.2-alkyl groups,
a morpholino group which is substituted in the 2 position by a Cx_4-alkoxy group,
a morpholino group which is substituted in the 2- and 6 -positions in each case by a Cx.4-alkoxy group, a Cx_4-alkyl-NR5 group wherein the Cx_4-alkyl moiety, which is straight-chained and may additionally be substituted by one or two methyl groups, is terminally substituted in each case by a di- (Cx.4-alkoxy) -methyl or tri- (Cx_4-alkoxy) -methyl group, while R5 is as hereinbefore defined,
a Cx_4-alkyl-NR5 group wherein the Cx.4-alkyl moiety, which is straight-chained and may additionally be substituted by one or two methyl groups, is terminally substituted in each case by a 1, 3-dioxolan-2-yl or 1, 3-dioxan-2-yl group optionally substituted by one or two methyl groups, while R5 is as hereinbefore defined, or
an R1XNR5 group wherein R5 is as hereinbefore defined and
R1X denotes a 2-oxo-tetrahydrofuran-3-yl , 2-oxo-tetrahy- drofuran-4-yl , 2-oxo-tetrahydropyran-3-yl, 2-oxo-tetrahy- dropyran-4-yl , 2-oxo-tetrahydropyran-5-yl, 2-oxo-tetrahy- drothiophen-3-yl, 2-oxo-tetrahydrothiophen-4-yl, 2-oxo- tetrahydrothiopyran-3-yl, 2-oxo-tetrahydrothiopyran-4-yl or 2-oxo-tetrahydrothiopyran-5-yl group optionally substituted by one or two methyl groups,
and/or G denotes a morpholino or homomorpholino group which is substituted in each case by an R60-CO, (R70-PO-OR8) , (R70-PO-R9) , R60-CO-Cx.4-alkyl, bis- (R60-CO) -Cx.4-alkyl, (R70-PO-OR8) -C1_4-alkyl or (R70-PO-R9) -Cx.4-alkyl group wherein R6 to R3 are as hereinbefore defined,
a morpholino group which is substituted in the 2 position by a Cx_4-alkoxy group,
a morpholino group which is substituted in the 2 and 6 positions in each case by a Cx.4-alkoxy group,
a Cx.4-alkyl-NR5 group wherein the Cx-4-alkyl moiety, which is straight-chained and may additionally be substituted by one or O 00/51991
- 28 -
two methyl groups, is terminally substituted in each case by a di- (Cx.4-alkoxy) -methyl or tri- (Cx.4-alkoxy) -methyl group, while Rs is as hereinbefore defined,
a Cx_4-alkyl-NR5 group wherein the Cx.4-alkyl moiety, which is straight-chained and may additionally be substituted by one or two methyl groups, is terminally substituted in each case by a 1, 3-dioxolan-2-yl or 1, 3-dioxan-2-yl group optionally substituted by one or two methyl groups, while Rs is as hereinbefore defined, or
a RhNRs group wherein Rs is as hereinbefore defined and
Rh denotes a 2-oxo-tetrahydrofuran-3-yl, 2-oxo-tetrahy- drofuran-4-yl, 2-oxo-tetrahydropyran-3-yl , 2-oxo-tetrahy- dropyran-4-yl or 2-oxo-tetrahydropyran-5-yl group optionally substituted by one or two methyl groups,
with the proviso that
at least one of the groups E, G or F together with G contains an RgO-CO, (R70-PO-OR8) or (R70-PO-R9) group or
D together with E contains an RgCO-0- (ReCRf) -O-CO, (R70-PO-ORa) or (R70-PO-R9) group or
E or G contains an optionally substituted 2-oxo-morpholinyl group,
a morpholino group in each case substituted in the 2 position or in the 2 and 6 positions by a Cx.4-alkoxy group,
a di (Cx_4-alkoxy) -methyl or tri- (Cx_4-alkoxy) -methyl group or
an optionally substituted 1, 3-dioxolan-2-yl , 1 , 3 -dioxan-2-yl , 2-oxo-tetrahydrofuran-3-yl , 2-oxo-tetrahydrofuran-4-yl , 2-oxo- tetrahydropyran-3-yl , 2-oxo-tetrahydropyran-4-yl or 2-oxo-te- trahydropyran-5-yl group or
E contains an optionally substituted 2-oxo-thiomorpholino group or an optionally substituted 2-oxo-tetrahydrothiophen- 3-yl, 2-oxo-tetrahydrothiophen-4-yl, 2-oxo-tetrahydrothio- pyran-3-yl, 2-oxo-tetrahydrothiopyran-4-yl or 2-oxo-tetrahy- drothiopyran-5-yl group,
and the compounds of the abovementioned general formula I wherein Ra to Rd, A to G and X are as hereinbefore defined, but additionally
R5 denotes an ethyl or propyl group substituted by a methyl group and a ethyl group or by two ethyl groups, which is terminally substituted in each case by a Cx.s-alkylcarbonylsul- phenyl , C3.7-cycloalkylcarbonylsulphenyl, C3.7-cycloalkyl- Cx.3-alkylcarbonylsulphenyl , arylcarbonylsulphenyl or aryl- Cx.3-alkylcarbonylsulphenyl group,
an ethyl or propyl group optionally substituted by one or two methyl or ethyl groups, which is terminally substituted in each case by a Cx_6-alkylcarbonyloxy, C3.7-cycloalkylcarbonyloxy, C3.7-cycloalkyl-Cx.3-alkylcarbonyloxy, arylcarbonyloxy or aryl-Cx_3-alkylcarbonyloxy group ,
E denotes a 4- to 7-membered alkyleneimino group which is substituted by two RgOCO or R6OCO-Cx_4-alkyl groups or by an R6OCO group and an R6OCO-Cx.4-alkyl group wherein R6 is as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by the group Rx0 and is additionally substituted at cyclic carbon atoms by two R60-CO or R60-CO-Cx.4-alkyl groups or by an R60-CO group and an RsO-CO-Cx.4-alkyl group wherein R6 and R10 are as hereinbefore defined, - 30 -
a piperazino or homopiperazino group which is substituted in the 4 position by an RsO-CO-Cx.4-alkyl , Bis- (R60-CO) -Cx.4-alkyl , (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx.4-alkyl group and is additionally substituted at cyclic carbon atoms by one or two RgO-CO or R60-CO-Cx.4-alkyl groups or by an RsO-CO group and an R60-CO-Cx.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a morpholino or homomorpholino group which is substituted by two RgO-CO or RsO-CO-Cx.4-alkyl groups or by an RsO-CO group and an RsO-CO-Cx_4-alkyl group wherein R6 is as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group Rx0, while the abovementioned 5- to 7-membered rings are additionally substituted in each case at carbon atoms by two R60-CO or RgO-CO-Cx.4-alkyl groups or by an R60-CO group and an R60-CO-Cx_4-alkyl group wherein R6 and Rx0 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an R60-CO-Cx_4-alkyl , bis- (R60-CO) - Cx.4-alkyl, (R70-PO-OR3) -Cx.4-alkyl or (R70-PO-R9) -Cx_4-alkyl group, while the abovementioned 5- to 7-membered rings in each case are additionally substituted at carbon atoms by one or two RgO- CO or R60-CO-Cx.4-alkyl groups or by an R60-CO group and an R60- CO-Cx_4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a thiomorpholino group which is substituted in the 2 position by a Cx_4-alkoxy group, or
a thiomorpholino group which is substituted in the 2 and 6 positions in each case by a Cx_4-alkoxy group, and/or
G denotes a 4- to 7-membered alkyleneimino group which is substituted by two RgO-CO or R60-CO-Cx_4-alkyl groups or by an RgO-CO group and an R50-CO-C,_4-alkyl group wherein R6 is as hereinbefore defined, a piperazino or homopiperazino group which is substituted in the 4 position by the group Rxo and is additionally substituted at cyclic carbon atoms by two R60-CO or RsO-CO-Cx_4-alkyl groups or by an R60-CO group and an RsO-CO-Cx.4-alkyl group wherein Rs and R10 are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by an
Figure imgf000033_0001
bis- (RsO-CO) -Cx.4-alkyl , (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx.4-alkyl group and additionally at cyclic carbon atoms by one or two R60-CO or RgO-CO-Cx.4-alkyl groups or by an R60-CO group and an RsO-CO- Cx_4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a morpholino or homomorpholino group which is substituted by two RsO-CO or RsO-CO-Cx.4-alkyl groups or by an R60-C0 group and an RgO-CO-Cx.4-alkyl group wherein Rs is as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group Rx0, while the abovementioned 5- to 7-membered rings in each case are additionally substituted at carbon atoms by two RsO-CO or R60-CO-Cx„4-alkyl groups or by an R60-CO group and an RgO-CO-Cx.4-alkyl group wherein R6 and R10 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an R60-CO-Cx.4-alkyl , bis- (RsO-CO) - Cx.4-alkyl, (R70-PO-OR8) -Cx_4-alkyl or (R70-PO-R9) -Cx.4-alkyl group, while the abovementioned 5- to 7-membered rings in each case are additionally substituted at carbon atoms by one or two RgO- CO or RgO-CO-Cx_4-alkyl groups or by an RsO-CO group and an R60- CO-Cx_4-alkyl group wherein Rs to R9 are as hereinbefore defined,
a thiomorpholino group which is substituted in the 2 position by a Cx_4-alkoxy group, or a thiomorpholino group which is substituted in the 2 and 6 positions in each case by a C-__4-alkoxy group,
with the proviso that
at least one of the groups E, G or F together with G contains an RgO-CO, (R70-PO-OR8) or (R70-PO-R9) group or
D together with E contains an RgC0-0- (ReCRf) -O-CO, (R70-PO-OR8) or (R70-PO-R9) group or
E or G contains an optionally substituted 2-oxo-morpholinyl group ,
a morpholino or thiomorpholino group substituted in the 2 position or in the 2 and 6 positions in each case by a Cx_4-alkoxy group,
a di (Cx.4-alkoxy) -methyl or tri- (Cx_4-alkoxy) -methyl group or
an optionally substituted 1, 3-dioxolan-2-yl, 1, 3 -dioxan-2-yl , 2-oxo-tetrahydrofuran-3-yl , 2-oxo-tetrahydrofuran-4-yl , 2-oxo- tetrahydropyran-3-yl, 2-oxo-tetrahydropyran-4-yl or 2-oxo- tetrahydropyran-5-yl group or
E contains an optionally substituted 2-oxo-thiomorpholino group or an optionally substituted 2-oxo-tetrahydrothio- phen-3-yl, 2-oxo-tetrahydrothiophen-4-yl , 2-oxo-tetrahy- drothiopyran-3-yl , 2-oxo-tetrahydrothiopyran-4-yl or 2-oxo-tetrahydrothiopyran-5-yl group,
while the abovementioned aryl and heteroaryl moieties are as hereinbefore defined,
the tautomers, the stereoisomers and the salts thereof. Particularly preferred compounds of the above general formula I are those wherein
Ra denotes a hydrogen atom,
Rb denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups Rx to R3, wherein
Rx and R2, which may be identical or different, each denote a hydrogen, fluorine, chlorine, bromine or iodine atom,
a methyl, ethyl, hydroxy, methoxy, ethoxy, amino, cyano, vinyl or ethynyl group,
an aryl, aryloxy, arylmethyl or arylmethoxy group,
a methyl or methoxy group substituted by 1 to 3 fluorine atoms or
Rx together with R2, if they are bound to adjacent carbon atoms, denote a -CH=CH-CH=CH, -CH=CH-NH or -CH=N-NH group and
R3 denotes a hydrogen, fluorine, chlorine or bromine atom,
Rc and Rd in each case denote a hydrogen atom,
X denotes a methine group substituted by a cyano group or a nitrogen atom,
A denotes an imino group optionally substituted by a methyl or ethyl group,
B denotes a carbonyl group, C denotes a 1,1- or 1,2-vinylene group which is substituted in each case by one or two methyl groups or may be substituted by a trifluoromethyl group,
an ethynylene group or
a 1, 3-butadien-l, 4-ylene group optionally substituted by a methyl or trifluoromethyl group,
D denotes an alkylene or -CO-alkylene group wherein the alkylene moiety in each case contains 1 to 4 carbon atoms, while the linking of the -CO-alkylene group to the adjacent group C in each case must take place via the carbonyl group,
a -CO-O-alkylene or -CO-NR4-alkylene- group wherein the alkylene moiety in each case contains 1 to 4 carbon atoms, while the linking to the adjacent group C in each case must take place via the carbonyl group wherein
R4 denotes a hydrogen atom or a methyl or ethyl group,
or, if D is bound to a carbon atom of the group E, it may also denote a bond
or, if D is bound to a nitrogen atom of the group E, it may also denote a carbonyl or sulphonyl group,
E denotes an R60-CO-alkylene-NR5, (R70-PO-OR8) -alkylene-NRs or (R70-PO-R9) -alkylene-NR5 group wherein in each case the alkylene moiety, which is straight -chained and contains 1 to 4 carbon atoms, may additionally be substituted by one or two Cx.2-alkyl groups or by an R60-CO or R60-CO-Cx.2-alkyl group, wherein
R5 denotes a hydrogen atom,
a Cx.4-alkyl group which may be substituted by an R60-CO group , an ethyl or propyl group optionally substituted by one or two methyl or ethyl groups which is terminally substituted in each case by a hydroxy, Cx.4-alkoxy, di- (Cx_4-alkyl) amino, Cx.g-alkylcarbonylsulphenyl , C3.6-cyclo- alkylcarbonylsulphenyl, C3.6-cycloalkyl-Cx_3-alkylcarbonyl- sulphenyl, arylcarbonylsulphenyl or aryl-Cx.3-alkylcarbo- nylsulphenyl group,
an ethyl or propyl group optionally substituted by one or two methyl or ethyl groups which is terminally substituted in each case by a Cx.s-alkylcarbonyloxy, C3.g-cycloalkyl- carbonyloxy, C3.6-cycloalkyl-Cx.3-alkylcarbonyloxy, aryl- carbonyloxy or aryl -Cx_3-alkylcarbonyloxy group,
a C3_6-cycloalkyl or C3.g-cycloalkyl-Cx.3-alkyl group,
R6, R7 and R8, which may be identical or different, in each case denote a hydrogen atom,
a Cx.8-alkyl group which may be substituted by a hydroxy, Cx_4-alkoxy, or di- (Cx_4-alkyl) -amino group or by a 4- to 7-membered alkyleneimino group, while in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen atom or by an N- (Cx.2-alkyl) -imino group,
a C4_s-cycloalkyl group,
a C3_5-alkenyl or C3_5-alkynyl group, while the unsaturated moiety may not be linked to the oxygen atom,
a C3-.g-cycloalkyl-Cx_4-alkyl, aryl, aryl-Cx.4-alkyl or RgCO-0- (RβCRf) group, while
Re and Rf, which may be identical or different, in each case denote a hydrogen atom or a Cx.4-alkyl group and Rg denotes a Cx.4-alkyl, C3.6-cycloalkyl, Cx.4-alkoxy or C5.g-cycloalkoxy group,
and Rg denotes a Cx.4-alkyl group,
a 4- to 7-membered alkyleneimino group which is substituted by an RgO-CO, R60-CO-Cx.4-alkyl or bis- (R60-CO) -Cx.4-alkyl group wherein R6 is as hereinbefore defined,
a 4- to 7-membered alkyleneimino group which is substituted by two RgO-CO or RgO-CO-Cx.4-alkyl groups wherein Rs is as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by the group R10 and additionally at a cyclic carbon atom by an RsO-CO, R60-CO-Cx.4-alkyl or bis- (R60-CO) - Cx.4-alkyl group wherein Rs is as hereinbefore defined and
R10 denotes a hydrogen atom, a methyl, ethyl, acetyl or methylsulfonyl group,
a piperazino or homopiperazino group which is substituted in the 4 position by the group R10 and is additionally substituted at cyclic carbon atoms by two R60-CO or R60-CO-Cx.4-alkyl groups wherein R6 and Rx0 are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in each case in the 4 position by an R60-CO-Cx.4-alkyl, bis- (RgO-CO) -Cx.4-alkyl, (R70-PO-OR8) -C..4-alkyl or (R70-PO-R9) - Cx.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by an R60-CO-Cx.4-alkyl or bis- (R60-CO) -Cx.4-alkyl group and is additionally substituted at cyclic carbon atoms by one or two R60-CO or R60-CO-Cx.4-alkyl groups wherein R6 is as hereinbefore defined, a morpholino or homomorpholino group which is substituted in each case by an R60-CO, RsO-CO-Cx.4-alkyl or bis- (R60-CO) - Cx.4-alkyl group wherein R6 is as hereinbefore defined,
a morpholino or homomorpholino group which is substituted by two RgO-CO or RgO-CO-Cx.4-alkyl groups wherein R6 is as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group Rx0, while the above- mentioned 5- to 7-membered rings in each case are additionally substituted at a carbon atom by an RsO-CO, RgO-CO-Cx.4-alkyl or bis- (RgO-CO) -Cx.4-alkyl group wherein R6 and R10 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group Rx0, while the above- mentioned 5- to 7-membered rings in each case are additionally substituted at carbon atoms by two RsO-CO or R60-CO-Cx.4-alkyl groups wherein R6 and Rxo are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an RgO-CO-Cx.4-alkyl, bis- (R60-CO) - Cx.4-alkyl, (R70-PO-OR8) -C-_4-alkyl or (R70-PO-R9) -Cx.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an RgO-CO-Cx.4-alkyl or bis- (RgO-CO) -Cx_4-alkyl group, while the abovementioned 5- to 7-membered rings in each case are additionally substituted at carbon atoms by one or two RsO-CO or RgO-CO-Cx.4-alkyl groups wherein Rs is as hereinbefore defined,
a 2-oxo-morpholino group which may be substituted by 1 to 4 Cx_2-alkyl groups, a 2-oxo-thiomorpholino group which may be substituted by 1 to 4 Cx.2-alkyl groups,
a morpholino group which is substituted in the 2 position by a Cx_4-alkoxy group,
a morpholino group which is substituted in the 2 and 6 positions in each case by a Cx.4-alkoxy group,
a Cx_4-alkyl-NR5 group wherein the Cx.4-alkyl moiety, which is straight-chained, is terminally substituted by a di- (Cx_4-alk- oxy) -methyl group, while Rs is as hereinbefore defined,
a Cx_4-alkyl-NR5 group wherein the Cx.4-alkyl moiety, which is straight-chained, is terminally substituted by a 1, 3-dioxolan- 2-yl or 1, 3 -dioxan-2-yl group, while R5 is as hereinbefore defined,
a R1XNR5 group wherein R5 is as hereinbefore defined and
Rxx denotes a 2-oxo-tetrahydrofuran-3-yl , 2-oxo-tetrahy- drofuran-4-yl, 2-oxo-tetrahydropyran-3-yl , 2-oxo-tetrahy- dropyran-4-yl, 2-oxo-tetrahydropyran-5-yl , 2-oxo-tetrahy- drothiophen-3-yl, 2-oxo-tetrahydrothiophen-4 -yl , 2-oxo- tetrahydrothiopyran-3-yl, 2-oxo-tetrahydrothiopyran-4-yl or 2-oxo-tetrahydrothiopyran-5-yl group optionally substituted by one or two methyl groups,
or D together with E denotes a hydrogen atom,
a methyl, trifluoromethyl , aryl, RgCO-0- (ReCRf) -O-CO or (R70-PO-OR8) group wherein Re to Rg and R7 and R8 are as hereinbefore defined,
F denotes an -0-Cx,4-alkylene group, while the alkylene moiety is linked to the group G, or an oxygen atom, while this may not be linked to a nitrogen atom of the group G, and G denotes an RsO-CO-alkylene-NR5, (R70-PO-OR8) -alkylene-NRs or (R70-PO-R9) -alkylene-NR5 group wherein in each case the alkylene moiety, which is straight-chained and contains 1 to 4 carbon atoms, may additionally be substituted by one or two Cx.2-alkyl groups or by an RsO-CO or R60-CO-Cx_2-alkyl group, while R5 to R9 are as hereinbefore defined,
a 4- to 7-membered alkyleneimino group which is substituted by an RgO-CO, RgO-CO-Cx.4-alkyl or bis- (R60-CO) -Cx.4-alkyl group wherein R6 is as hereinbefore defined,
a 4- to 7-membered alkyleneimino group which is substituted by two RgO-CO or R60-CO-Cx.4-alkyl groups wherein R6 is as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by the group Rxo and is additionally substituted at a cyclic carbon atom by an R60-CO, RsO-CO-Cx_4-alkyl or bis- (RgO-CO) -Cx_4-alkyl group wherein R6 and Rxo are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by the group R10 and is additionally substituted at cyclic carbon atoms by two RgO-CO or R60-CO-Cx_4-alkyl groups wherein R6 and R10 are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in each case in the 4 position by an R60-CO-Cx.4-alkyl , bis- (RgO-CO) -Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) - Cx.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by an R60-CO-Cx.4-alkyl or bis- (R60-CO) -Cx.4-alkyl group and additionally at cyclic carbon atoms by one or two RgO-CO or RgO-CO-Cx_4-alkyl groups wherein Rs is as hereinbefore defined, a morpholino or homomorpholino group which is substituted in each case by an R60-CO, R60-CO-Cx.4-alkyl or bis- (RgO-CO) -C1_4-alkyl group wherein Rβ is as hereinbefore defined,
a morpholino or homomorpholino group which is substituted by two RgO-CO or RgO-CO-Cx_4-alkyl groups wherein R6 is as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group Rxo, while the above- mentioned 5- to 7-membered rings in each case are additionally substituted at a carbon atom by an R60-CO, R60-CO-Cx_4-alkyl or bis- (RgO-CO) -Cx_4-alkyl group wherein R6 and Rxo are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group R10, while the above- mentioned 5- to 7-membered rings in each case are additionally substituted at carbon atoms by two R60-CO or R60-CO-Cx.4-alkyl groups wherein Rs and Rxo are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an RgO-CO-Cx.4-alkyl, bis- (R60-C0) - Cx.4-alkyl, (R70-P0-0R8) -Cx_4-alkyl or (R70-PO-R9) -Cx.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an R60-CO-Cx.4-alkyl or bis- (RgO-CO) -Cx_4-alkyl group, while the abovementioned 5- to 7-membered rings in each case are additionally substituted at carbon atoms by one or two R60-CO or RsO-CO-Cx.4-alkyl groups wherein R6 is as hereinbefore defined,
a 2-oxo-morpholino group which may be substituted by 1 or 2 methyl groups , a 2-oxo-morpholinyl group which is substituted in the 4 position by a Cx.4-alkyl or R60-CO-Cx.4-alkyl group, while Rs is as hereinbefore defined and the abovementioned 2-oxo-morpholinyl groups in each case are linked to a carbon atom of the group F,
a morpholino group which is substituted in the 2 position by a Cx.4-alkoxy group,
a morpholino group which is substituted in the 2 and 6 positions in each case by a Cx_4-alkoxy group,
a Cx.4-alkyl-NR5 group wherein the Cx.4-alkyl moiety, which is straight-chained, is terminally substituted by a di- (Cx.4-alkoxy) -methyl group, while Rs is as hereinbefore defined,
a Cx_4-alkyl-NRS group wherein the Cx.4-alkyl moiety, which is straight -chained, is terminally substituted by a 1, 3-dioxolan- 2-yl or 1 , 3 -dioxan-2-yl group, while R5 is as hereinbefore defined,
an RhNR5 group wherein R5 is as hereinbefore defined and Rh denotes a substituted 2-oxo-tetrahydrofuran-3-yl, 2-oxo- tetrahydrofuran-4-yl, 2-oxo-tetrahydropyran-3-yl, 2-oxo- tetrahydropyran-4-yl or 2-oxo-tetrahydropyran-5-yl group optionally by one or two methyl groups, or
F and G together denote a hydrogen atom,
a Cx.4-alkoxy group optionally substituted from position 2 onwards by a hydroxy or Cx_4-alkoxy group,
a Cx.4-alkoxy group which is substituted by an R60-CO group, where R6 is as hereinbefore defined, or
a C4_7-cycloalkoxy or C3.7-cycloalkyl-Cx.4-alkoxy group with the proviso that at least one of the groups E, G or F together with G contains an R60-CO, (R70-PO-OR8) or (R70-PO-R9) group or
D together with E contains an RgCO-0- (ReCRf) -O-CO or (R70-P0-0R8) group or
E or G contains an optionally substituted 2-oxo-morpholinyl group,
a morpholino group substituted in the 2 position or in the 2 and 6 positions in each case by a Cx.4-alkoxy group,
a di- (Cx_4-alkoxy) -methyl group or
an optionally substituted 1, 3-dioxolan-2-yl , 1, 3 -dioxan-2-yl , 2-oxo-tetrahydrofuran-3-yl, 2-oxo-tetrahydrofuran-4-yl , 2-oxo- tetrahydropyran-3-yl, 2-oxo-tetrahydropyran-4-yl or 2-oxo- tetrahydropyran-5-yl group or
E contains an optionally substituted 2-oxo-thiomorpholino group or an optionally substituted 2-oxo-tetrahydrothio- phen-3-yl, 2-oxo-tetrahydrothiophen-4-yl, 2-oxo-tetrahydro- thiopyran-3-yl, 2-oxo-tetrahydrothiopyran-4-yl or 2-oxo- tetrahydrothiopyran-5-yl group,
while the aryl moieties mentioned in the definition of the abovementioned groups denote a phenyl group which may in each case be monosubstituted by R12, mono- or disubstituted by RX3 or monosubstituted by Rx2 and additionally mono or disubstituted by RX3, while the substituents may be identical or different and
Rx2 denotes a cyano, Cx.2-alkoxycarbonyl , aminocarbonyl, Cx.2-alkylaminocarbonyl, di- (Cx_2-alkyl) -aminocarbonyl, Cx.2-alkylsulphenyl, Cx.2-alkylsulphinyl, Cx.2-alkylsulphonyl , hydroxy, nitro, amino, Cx.2-alkylamino or di- (Cx_2-alkyl) -amino group and
Rx3 denotes a fluorine, chlorine, bromine or iodine atom, a Cx.2-alkyl, trifluoromethyl or Cx.2-alkoxy group or
two groups R13, if they are bound to adjacent carbon atoms, together denote a C3.5-alkylene, methylenedioxy or 1, 3-butadien-l, 4-ylene group,
the tautomers, the stereoisomers and the salts thereof.
Most particularly preferred compounds of the above general formula I are those wherein
Ra denotes a hydrogen atom,
Rb denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups Rx to R3, wherein
Rx and R2, which may be identical or different, each denote a hydrogen, fluorine, chlorine or bromine atom, or a methyl, trifluoromethyl , methoxy, ethynyl or cyano group,
R3 denotes a hydrogen atom,
Rc and Rd in each case denote a hydrogen atom,
X denotes a methine group substituted by a cyano group, or a nitrogen atom,
A denotes an imino group,
B denotes a carbonyl group,
C denotes a 1,1- or 1,2-vinylene group, an ethynylene group or
a 1, 3-butadien-l, 4-ylene group,
D denotes a Cx.4-alkylene group,
a -CO-NR4-alkylene group wherein the alkylene moiety contains 2 to 4 carbon atoms, while the linking to the adjacent group C in each case must take place via the carbonyl group and wherein
R4 denotes a hydrogen atom,
or, if D is bound to a carbon atom of the group E, it may also denote a bond
or, if D is bound to a nitrogen atom of the group E, it may also denote a carbonyl group,
E denotes an R60-CO-alkylene-NR5, (R70-PO-OR8) -alkylene-NR5 or (R70-PO-R9) -alkylene-NR5 group wherein in each case the alkylene moiety, which is straight -chained and contains 1 to 4 carbon atoms, may additionally be substituted by one or two Cx_2-alkyl groups or by an R60-CO or RgO-CO-Cx.2-alkyl group, while
R5 denotes a hydrogen atom,
a Cx.4-alkyl group which may be substituted by an R60-CO group ,
an ethyl group optionally substituted by one or two methyl or ethyl groups which is terminally substituted by a Cx.4-alkylcarbonylsulphenyl, arylcarbonylsulphenyl or arylmethylcarbonylsulphenyl group , an ethyl group optionally substituted by one or two methyl or ethyl groups which is terminally substituted by a hydroxy, Cx_4-alkylcarbonyloxy, arylcarbonyloxy or arylmethyl- carbonyloxy group,
a 2 , 2-dimethoxyethyl or 2 , 2-diethoxyethyl group,
a C3.6-cycloalkyl or C3.6-cycloalkyl-methyl group,
Rs, R7 and R8, which may be identical or different, in each case denote a hydrogen atom,
a Cx_8-alkyl group,
a cyclopentyl, cyclopentylmethyl , cyclohexyl or cyclohexyl- methyl group,
an aryl, arylmethyl or RgCO-0- (ReCRf) group, while
Re denotes a hydrogen atom or a Cx_4-alkyl group,
Rf denotes a hydrogen atom and
Rg denotes a Cx.4-alkyl, cyclopentyl, cyclohexyl, Cx.4-alk- oxy, cyclopentyloxy or cyclohexyloxy group,
and R9 denotes a methyl or ethyl group,
a pyrrolidino or piperidino group which is substituted by an RgO-CO or R60-CO-Cx.2-alkyl group wherein R6 is as hereinbefore defined,
a pyrrolidino or piperidino group which is substituted by two RgO-CO or RgO-CO-Cx_2-alkyl groups wherein R6 is as hereinbefore defined, a piperazino group which is substituted in the 4 position by the group Rx0 and is additionally substituted at a cyclic carbon atom by an R60-CO or R60-CO-Cx.2-alkyl group, while R6 is as hereinbefore defined and
R10 denotes a hydrogen atom, a methyl, ethyl, acetyl or methylsulfonyl group,
a piperazino or homopiperazino group which is substituted in the 4 position by an R60-CO-Cx.4-alkyl, bis- (R60-CO) -Cx.4-alkyl or (R70-PO-OR8) -Cx_2-alkyl group wherein R6 to R8 are as hereinbefore defined,
a piperazino group which is substituted in the 4 position by an RgO-CO-Cx_2-alkyl group and is additionally substituted at a cyclic carbon atom by an R60-CO or R60-CO-Cx.2-alkyl group wherein R6 is as hereinbefore defined,
a morpholino group which is substituted by an R60-C0 or R60-C0- Cx.2-alkyl group, while R6 is as hereinbefore defined,
a piperidinyl group substituted in the 1 position by an R60-CO- Cx_4-alkyl, bis- (R60-CO) -Cx.4-alkyl or (R70-PO-OR8) -Cx.2-alkyl group wherein Rs to R8 are as hereinbefore defined,
a 2-oxo-morpholino group which may be substituted by 1 to 2 Cx.2-alkyl groups,
a 2-oxo-thiomorpholino group which may be substituted by 1 to 2 Cx_2-alkyl groups,
a morpholino group which is substituted in the 2 position by a methoxy or ethoxy group,
a morpholino group which is substituted in the 2 and 6 positions in each case by a methoxy or ethoxy group, a 2 , 2-dimethoxyethyl-NR5, 2 , 2-diethoxyethyl-NR5, 1, 3-dioxolan- 2 -yl-methyl-NRS or 1, 3-dioxan-2-yl-methyl-NRS group wherein R5 is as hereinbefore defined,
a N-methyl-RxlN or N-ethyl-RxlN group wherein
Rxl denotes a 2-oxo-tetrahydrofuran-3-yl, 2-oxo-tetrahy- drofuran-4-yl , 2-oxo-tetrahydropyran-3-yl, 2-oxo-tetrahy- dropyran-4-yl, 2-oxo-tetrahydropyran-5-yl, 2-oxo-tetrahy- drothiophen-3-yl, 2-oxo-tetrahydrothiophen-4-yl, 2-oxo- tetrahydrothiopyran-3-yl, 2-oxo-tetrahydrothiopyran-4-yl or 2-oxo-tetrahydrothiopyran-5-yl group optionally substituted by one or two methyl groups ,
or D together with E denotes a hydrogen atom,
a methyl, trifluoromethyl , aryl, RgCO-0- (ReCRf) -O-CO or (R70-PO-OR8) group wherein Re to Rg and R7 and R8 are as hereinbefore defined,
F denotes an -0-Cx,4-alkylene group, while the alkylene moiety is linked to the group G, or an oxygen atom, which may not be linked to a nitrogen atom of the group G, and
G denotes an R60-C0-alkylene-NR5 group wherein the alkylene moiety, which is straight-chained and contains 1 to 4 carbon atoms, may additionally be substituted by one or two Cx.2-alkyl groups or by an R60-CO or R60-CO-Cx_2-alkyl group, while Rs and R6 are as hereinbefore defined,
a pyrrolidino or piperidino group which is substituted by an RgO-CO or R60-CO-Cx_2-alkyl group wherein R6 is as hereinbefore defined,
a pyrrolidino or piperidino group which is substituted by two RgO-CO or R60-CO-Cx-2-alkyl groups wherein R6 is as hereinbefore defined, a piperazino group which is substituted in the 4 position by the group R10 and additionally at a cyclic carbon atom by an RgO-CO or R60-CO-Cx.2-alkyl group, while R6 and Rxo are as hereinbefore defined,
a piperazino group which is substituted in the 4 position by an RsO-C0-Cx.4-alkyl, bis- (R60-CO) -Cx.4-alkyl or (R70-PO-OR8) - Cx_2-alkyl group wherein R6 to R8 are as hereinbefore defined,
a piperazino group which is substituted in the 4 position by an R60-CO-Cx_2-alkyl group and additionally at a cyclic carbon atom by an RsO-CO or R60-CO-Cx..2-alkyl group wherein Rs is as hereinbefore defined,
a morpholino group which is substituted by an R60-CO or R60-CO- Cx.2-alkyl group, while R6 is as hereinbefore defined,
a piperidinyl group substituted in the 1 position by an RgO-CO-Cx.4-alkyl, bis- (R60-C0) -Cx.4-alkyl or (R70-PO-OR8) -Cx_2-alkyl group wherein R6 to R8 are as hereinbefore defined,
a 2-oxo-morpholino group which may be substituted by 1 or 2 methyl groups ,
a 2-oxo-morpholinyl group which is substituted in the 4 position by a methyl, ethyl or R60-CO-Cx.2-alkyl group, while R6 is as hereinbefore defined and the abovementioned 2-oxo-morpholinyl groups in are each case linked to a carbon atom of the group F,
a morpholino group which is substituted in the 2 position by a methoxy or ethoxy group,
a morpholino group which is substituted in the 2 and 6 positions in each case by a methoxy or ethoxy group, a 2, 2-dimethoxyethyl-NR5, 2 , 2-diethoxyethyl-NRs, 1, 3-dioxolan- 2 -yl-methyl-NR5 or 1, 3 -dioxan-2-yl-methyl-NR5- group or
F and G together denote a hydrogen atom,
a methoxy or ethoxy group,
a Cx.3-alkoxy group which is substituted by an R60-CO group, while Rs is as hereinbefore defined,
a C4.6-cycloalkoxy or C3_6-cycloalkyl-Cx.3-alkoxy group
with the proviso that at least one of the groups E, G or F together with G contains an R60-CO, (R70-PO-OR8) or (R70-PO-R9) group or
D together with E contains an RgCO-0- (ReCRf) -O-CO or (R70-PO-OR8) group or
E or G contains an optionally substituted 2-oxo-morpholinyl group ,
a morpholino group substituted in the 2 position or in the 2 and 6 positions in each case by a methoxy or ethoxy group,
a dimethoxymethyl or diethoxymethyl group or
an optionally substituted 1, 3-dioxolan-2-yl or 1,3-dioxan- 2-yl- group or
E contains an optionally substituted 2-oxo-tetrahydrofuran- 3-yl, 2-oxo-tetrahydrofuran-4-yl, 2-oxo-tetrahydropyran-3 -yl , 2-oxo-tetrahydropyran-4-yl, 2-oxo-tetrahydropyran-5-yl, 2-oxo- thiomorpholino, 2-oxo-tetrahydrothiophen-3-yl , 2-oxo-tetra- hydrothiophen-4-yl, 2-oxo-tetrahydrothiopyran-3-yl , 2-oxo-te- trahydrothiopyran-4-yl or 2-oxo-tetrahydrothiopyran-5-yl group ,
while the aryl moieties mentioned in the definition of the abovementioned groups denote a phenyl group which may be mono- or disubstituted by R13, wherein the substituents may be identical or different and
Rx3 denotes a fluorine, chlorine, bromine or iodine atom, a Cx.2-alkyl, trifluoromethyl or Cx.2-alkoxy group or
two groups R13, if they are bound to adjacent carbon atoms, together denote a C3.4-alkylene, methylenedioxy or 1, 3-butadien-l, 4-ylene group,
the tautomers, the stereoisomers and the salts thereof.
However, the most preferred compounds of the above general formula I are those wherein
Ra denotes a hydrogen atom,
Rb denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups Rx to R3, while
Rx and R2, which may be identical or different, each denote a hydrogen, fluorine, chlorine or bromine atom or a methyl group and
R3 denotes a hydrogen atom,
Rc and Rd in each case denote a hydrogen atom,
X denotes a methine group substituted by a cyano group, or a nitrogen atom, A denotes an imino group,
B denotes a carbonyl group,
C denotes a 1,2-vinylene or an ethynylene group,
D denotes a Cx.4-alkylene group,
a -CO-NR4-alkylene group wherein the alkylene moiety contains 2 or 3 carbon atoms, while the linking to the adjacent group C must take place via the carbonyl group, wherein
R4 denotes a hydrogen atom,
or, if D is bound to a nitrogen atom of the group E, it may also denote a carbonyl group,
E denotes an RsO-CO-alkylene-NRs or (R70-PO-OR8) -alkylene-NR5 group wherein in each case the alkylene moiety, which is straight-chained and contains 1 to 2 carbon atoms, may additionally be substituted by a methyl group or by an R60-CO or RgO-CO-methyl group, while
Rs denotes a hydrogen atom,
a Cx_2-alkyl group which may be substituted by an R60-CO group ,
an ethyl group optionally substituted by one or two methyl groups, which is terminally substituted by a hydroxy, Cx.2-alkylcarbonylsulphenyl or Cx.2-alkylcarbonyloxy group,
a 2 , 2-dimethoxyethyl or 2 , 2-diethoxyethyl group,
R6 denotes a hydrogen atom,
a Cx.8-alkyl group, a cyclopentyl, cyclopentylmethyl, cyclohexyl or cyclohexylmethyl group,
a phenyl group optionally substituted by one or two methyl groups, a phenylmethyl group which may be substituted in the phenyl moiety by one or two methyl groups, a 5-indanyl group or an RgCO-0- (ReCRf) group, while
Re denotes a hydrogen atom or a methyl group,
Rf denotes a hydrogen atom and
Rg denotes a Cx.4-alkyl or Cx.2-alkoxy group,
R7 and R8, which may be identical or different, in each case denote a hydrogen atom, a methyl, ethyl or phenyl group ,
a pyrrolidino or piperidino group which is substituted by an RgO-CO or RgO-CO-methyl group, wherein R6 is as hereinbefore defined,
a pyrrolidino or piperidino group which is substituted by two RgO-CO or RgO-CO-methyl groups wherein R6 is as hereinbefore defined,
a piperazino group which is substituted in the 4 position by the group Rxo and additionally at a cyclic carbon atom by an RgO-CO group, wherein R6 is as hereinbefore defined and
Rxo denotes a hydrogen atom, a methyl, ethyl, acetyl or methylsulfonyl group,
a piperazino or homopiperazino group which is substituted in the 4 position by an R60-CO-Cx_4-alkyl , bis- (R60-CO) -Cx.4-alkyl or (R70-PO-OR8) -Cx_2-alkyl group wherein R6 to R8 are as hereinbefore defined,
a piperazino group which is substituted in the 4 position by an RgO-CO-methyl group and additionally at a cyclic carbon atom by an RsO-CO group wherein Rs is as hereinbefore defined,
a morpholino group which is substituted by an R60-CO- group, while R6 is as hereinbefore defined,
a 2-oxo-morpholino group which may be substituted by 1 or 2 Cx_2-alkyl groups ,
a 2-oxo-thiomorpholino group which may be substituted by 1 or 2 Cx.2-alkyl groups,
a morpholino group which is substituted in the 2 position by a methoxy or ethoxy group,
a morpholino group which is substituted in the 2 and 6 positions in each case by a methoxy or ethoxy group,
a 2, 2-dimethoxyethyl-NR5, 2 , 2-diethoxyethyl-NR5 or 1,3-di- oxolan-2 -yl-methyl -NR5- group wherein Rs is as hereinbefore defined,
an N-methyl-RlxN or N-ethyl-RXXN group wherein
Rxl denotes a 2-oxo-tetrahydrofuran-3-yl or 2-oxo-tetrahy- drofuran-4-yl group,
or D together with E denotes a hydrogen atom,
a methyl group or an RgCO-0- (ReCRf) -O-CO group wherein Re to Rg are as hereinbefore defined, F denotes an -0-Cx.4-alkylene group, while the alkylene moiety is linked to the group G, or an oxygen atom, which may not be linked to a nitrogen atom of the group G, and
G denotes an RsO-CO-alkylene-NRs group wherein the alkylene moiety, which is straight-chained and contains 1 or 2 carbon atoms, may additionally be substituted by a methyl group or by an RgO-CO or R60-CO-methyl group, while R5 and R6 are as hereinbefore defined,
a pyrrolidino or piperidino group which is substituted by an RgO-CO or RgO-CO-methyl group wherein R6 is as hereinbefore defined,
a pyrrolidino or piperidino group which is substituted by two RgO-CO or RgO-CO-methyl groups wherein R6 is as hereinbefore defined,
a piperazino group which is substituted in the 4 position by an RgO-CO-Cx_4-alkyl, bis- (R60-CO) -Cx.4-alkyl or (R70-PO-OR8) - Cx.2-alkyl group wherein R6 to R8 are as hereinbefore defined,
a piperidinyl group substituted in the 1 position by an R60-CO- Cx.2-alkyl group wherein R6 is as hereinbefore defined, or
F and G together denote a hydrogen atom,
a methoxy or ethoxy group,
a C4.g-cycloalkoxy or C3.6-cycloalkyl -Cx.3-alkoxy group ,
with the proviso that at least one of the groups E or G contains an R60-CO or (R70-P0-0R8) group or
D together with E contains an RgCO-0- (ReCRf ) -O-CO group or
E contains an optionally substituted 2 -oxo-morpholinyl group , a morpholino group substituted in the 2 position or in the 2 and 6 positions in each case by a methoxy or ethoxy group,
a dimethoxymethyl or dietho ymethyl group or
a 1, 3-dioxolan-2-yl , 2-oxo-tetrahydrofuran-3-yl or 2-oxo- tetrahydrofuran-4-yl group or
an optionally substituted 2-oxo-thiomorpholino group,
particularly the compounds characterised in claims 5 to 17,
the tautomers, the stereoisomers and the salts thereof.
The compounds of general formula I may be prepared, for example, by the following processes:
a) reacting a compound of general formula
Figure imgf000057_0001
wherein
Ra to Rd, A, F, G and X are as hereinbefore defined, with a compound of general formula
Zx - B - C - D - E , (III)
wherein
B to E are as hereinbefore defined and Zx denotes a leaving group such as a halogen atom, e.g. a chlorine or bromine atom, or a hydroxy group.
The reaction is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/te- trahydrofuran or dioxane optionally in the presence of an inorganic or organic base and optionally in the presence of a dehydrating agent expediently at temperatures between -50 and 150 °C, preferably at temperatures between -20 and 80°C.
With a compound of general formula III, wherein Zx denotes a leaving group, the reaction is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane, conveniently in the presence of a tertiary organic base such as triethylamine, pyridine or 2-dimethylaminopyridine, in the presence of N-ethyl-diisopropylamine (Hύnig's base) , whilst these organic bases may simultaneously serve as solvent, or in the presence of an inorganic base such as sodium carbonate, potassium carbonate or sodium hydroxide solution expediently at temperatures between -50 and 150 °C, preferably at temperatures between -20 and 80°C.
With a compound of general formula III, wherein Zx denotes a hydroxy group, the reaction is preferably carried out in the presence of a dehydrating agent, e.g. in the presence of isobutyl chloroformate, thionyl chloride, trimethylchlorosilane, phosphorus trichloride, phosphorus pentoxide, hexamethyldisi- lazane, N, N' -dicyclohexylcarbodiimide, N,N' -dicyclohexylcar- bodiimide/N-hydroxysuccinimide or 1-hydroxy-benzotriazole and optionally also in the presence of 4-dimethylamino-pyridine, N,N' -carbonyldiimidazole or triphenylphosphine/carbon tetra- chloride, conveniently in a solvent such as methylene chloride, tetrahydrofuran, dioxane, toluene, chlorobenzene, dime- thylsulphoxide , ethyleneglycol diethylether or sulpholane and optionally in the presence of a reaction accelerator such as 4-dimethylaminopyridine at temperatures between -50 and 150 °C, but preferably at temperatures between -20 and 80°C.
b) In order to prepare compounds of general formula I, wherein the group E is linked to the group D via a nitrogen atom:
reacting a compound of general formula
Figure imgf000059_0001
wherein
Ra to Rd, A to D, F, G and X are as hereinbefore defined and Z2 denotes a leaving group such as a halogen atom, a substituted hydroxy or sulphonyloxy group such as a chlorine or bromine atom, a methanesulphonyloxy or p-toluenesulphonyloxy group or a hydroxy group, with a compound of general formula
H - Y (V)
wherein
Y denotes one of the groups mentioned for E hereinbefore, which is linked to the group D via a nitrogen atom.
The reaction is conveniently carried out in a solvent such as isopropanol, butanol, tetrahydrofuran, dioxan, toluene, chlorobenzene, dimethylformamide, dimethylsulphoxide, methylene chloride, ethyleneglycol monomethylether, ethyleneglycol di- ethylether or sulpholane, optionally in the presence of an inorganic or tertiary organic base, e.g. sodium carbonate or potassium hydroxide, a tertiary organic base, e.g. triethyl- amine, or in the presence of N-ethyl-diisopropylamine (Hϋnig's base), whilst these organic bases may simultaneously serve as solvent, and optionally in the presence of a reaction accelerator such as an alkali metal halide at temperatures between -20 and 150 °C, but preferably at temperatures between -10 and 100°C. The reaction may, however, also be carried out without a solvent or in an excess of the compound of general formula V used.
If Z2 in a compound of general formula IV denotes a hydroxy group, the reaction is preferably carried out in the presence of a dehydrating agent, e.g. in the presence of isobutyl chlo- roformate, thionylchloride, trimethylchlorosilane, phosphorus trichloride, phosphorus pentoxide, hexamethyldisilazane, N,N' -dicyclohexylcarbodiimide, N,N' -dicyclohexylcarbodiimi- de/N-hydroxysuccinimide or 1-hydroxy-benzotriazole and optionally also in the presence of 4-dimethylamino-pyridine, N,N' -carbonyldiimidazole or triphenylphosphine/carbon tetra- chloride, conveniently in a solvent such as methylene chloride, tetrahydrofuran, dioxane, toluene, chlorobenzene, di- methylsulphoxide, ethyleneglycol diethylether or sulpholane and optionally in the presence of a reaction accelerator such as 4-dimethylaminopyridine at temperatures between -50 and 150°C, but preferably at temperatures between -20 and 80°C.
c) In order to prepare compounds of general formula I wherein D together with E denotes a RgCO-0- (ReCRf) -O-CO- group:
reacting a compound of general formula
Figure imgf000061_0001
wherein
Ra to Rd, A to C, F, G and X are as hereinbefore defined,
with a compound of general formula
R CO-O- (ReCRf) -Z3 , (VII)
wherein
Re to Rg are as hereinbefore defined and
Z3 denotes a leaving group such as a halogen atom, e.g. a chlorine, bromine or iodine atom.
The reaction is appropriately carried out in a solvent such as tetrahydrofuran, dioxane, toluene, chlorobenzene, dimethylformamide, dimethylsulphoxide, methylene chloride, acetonitrile, N-methyl-pyrrolidinone, ethylenglycol diethylether or sulpholane, optionanally in the presence of an inorganic base, e.g. sodium carbonate or potassium hydroxide, or a tertiary organic base, e.g. triethylamine, N-ethyl-diisopropylamine (Hύnig's base), 1 , 8-diazabicyclo [5 , 4 , 0] undec-7-ene or N,N'-di- cyclohexyl-morpholmocarboxamidme, whilst these organic bases may simultaneously serve as solvents, and optionally in the presence of a reaction accelerator such as an alkali metal halide at temperatures between -20 and 150°C, but preferably at temperatures between -10 and 100°C. However, the reaction may also be carried out without a solvent or in an excess of the compound of general formula VII used.
If according to the invention a compound of general formula I is obtained which contains a hydroxy, amino, alkylamino or imino group, this may be converted by acylation or sulphonyla- tion into a corresponding acyloxy, acylamino, N-alkyl-acyl- amino, acyl-imino, sulphonyloxy, sulphonylamino, N-alkyl-sulphonylamino or sulphonyl-imino compound, whilst a sulphonyloxy compound thus obtained may further be converted into a corresponding sulphenyl compound by reacting with an alkali metal salt of a thio compound, or
if a compound of general formula I is obtained which contains an amino, alkylamino or imino group, this may be converted by alkylation or reductive alkylation into a corresponding alkyl compound of general formula I or
if a compound of general formula I is obtained wherein E denotes a bis- [2, 2-di- (Cx.4-alkoxy) ethyl] amino group, this may be converted by intramolecular cyclisation into a corresponding morpholino compound of general formula I, or
if a compound of general formula I is obtained wherein E or G denotes an optionally substituted N- (2 -hydroxyethyl) -glycine or N- (2 -hydroxyethyl) -glycine ester group, this may be converted by intramolecular cyclisation into a corresponding 2-oxo-morpholino compound, or
if a compound of general formula I is obtained which contains a carboxy or hydroxyphosphoryl group, this may be converted by alkylation into a corresponding ester of general formula I.
The subsequent acylation or sulphonylation is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane with a corresponding acyl or sulphonyl derivative optionally in the presence of a tertiary organic base or in the presence of an inorganic base or in the presence of a dehydrating agent, e.g. in the presence of isobutyl chloroformate, thionyl chloride, trimethyl chlorosilane, sulphuric acid, methanesul- phonic acid, p-toluenesulphonic acid, phosphorus trichloride, phosphorus pentoxide, N,N' -dicyclohexylcarbodiimide, N,N'-di- cyclohexylcarbodiimide/N-hydroxysuccinimide or 1-hydroxy-benzotriazole and optionally additionally in the presence of 4-dimethylamino-pyridine, N,N' -carbonyldiimidazole or tri- phenylphosphine/carbon tetrachloride, expediently at temperatures between 0 and 150°C, preferably at temperatures between 0 and 80°C.
The subsequent alkylation is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxan with an alkylating agent such as a corresponding halide or sulphonic acid ester, e.g. with methyl iodide, ethyl bromide, dimethylsulphate or benzyl chloride, optionally in the presence of a tertiary organic base or in the presence of an inorganic base, expediently at temperatures between 0 and 150°C, preferably at temperatures between 0 and 100°C.
The subsequent reductive alkylation is carried out with a corresponding carbonyl compound such as formaldehyde, acetal- dehyde, propionaldehyde, acetone or butyraldehyde in the presence of a complex metal hydride such as sodium borohydride, lithium borohydride, sodium triacetoxyborohydride or sodium cyanoborohydride expediently at a pH of 6-7 and at ambient temperature or in the presence of a hydrogenation catalyst, e.g. with hydrogen in the presence of palladium/charcoal, at a hydrogen pressure of 1 to 5 bar. The methylation may also be carried out in the presence of formic acid as reducing agent at elevated temperatures, e.g. at temperatures between 60 and 120°C.
The subsequent intramolecular cyclisation is optionally carried out in a solvent such as acetonitrile, methylene chloride, tetrahydrofuran, dioxan or toluene in the presence of an axis such as hydrochloric acid or p-toluenesulphonic acid at temperatures between -10 and 120°C.
The subsequent esterification is carried out by reacting a corresponding carboxylic acid, phosphonic acid, phosphinic acid or the salts thereof with a corresponding alkyl halide, optionally in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, dimethylsulphoxide, sul- pholane, acetonitrile, N-methyl-pyrrolidinone, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane, optionally in the presence of an inorganic or tertiary organic base, conveniently at temperatures between 0 and 150 °C, preferably at temperatures between 0 and 80 °C.
Moreover, compounds of general formula I wherein E or G denotes a piperazino or homopiperazino group each substituted in position 4 by an R60-CO-Cx_4-alkyl group wherein Rs is as hereinbefore defined may also be prepared, for example, by reacting a corresponding compound containing a piperazino or homopiperazino group each unsubstituted in position 4 with a compound of general formula
RgO-CO-Cx.4-alkyl-Z4 , (VIII)
wherein
Rg is as hereinbefore defined and
Z4 denotes a leaving group such as a chlorine or bromine atom or an alkyl or arylsulfonyloxy group, or
compounds of general formula I wherein E or G denotes a piperazino or homopiperazino group each substituted in position 4 by an R60-CO-CH2CH2-group wherein R6 is as hereinbefore defined may also be prepared, for example, by reacting a corresponding compound containing a piperazino or homopiperazino group each unsubstituted in position 4 with a compound of general formula
RsO-CO-CH=CH2 , (IX) wherein
R6 is as hereinbefore defined, or
compounds of general formula I wherein C denotes a 1,2-vinylene group may also be prepared, for example, by reacting a compound of general formula
Figure imgf000065_0001
wherein
Ra to Rd, A, F, G and X are as hereinbefore defined and alkyl denotes a lower alkyl group, with a compound of general formula
OCH-D-E (XI)
wherein
D and E are as hereinbefore defined according to known methods .
In the reactions described above, any reactive groups present such as hydroxy, carboxy, phosphono, 0-alkyl -phosphono, amino, alkylamino or imino groups may be protected during the reaction by conventional protecting groups which are cleaved again after the reaction.
For example, a protecting group for a hydroxy group may be a trimethylsilyl, acetyl, benzoyl, methyl, ethyl, tert. -butyl, trityl, benzyl or tetrahydropyranyl group, protecting groups for a carboxy group may be the trimethyl- silyl, methyl, ethyl, tert. -butyl, benzyl or tetrahydropyranyl group ,
protecting groups for a phosphono group may be an alkyl group such as the methyl, ethyl, isopropyl or n-butyl group, the phenyl or benzyl group and
protecting groups for an amino, alkylamino or imino group may be a formyl, acetyl, trifluoroacetyl, ethoxycarbonyl , tert . -butoxycarbonyl , benzyloxycarbonyl , benzyl, methoxybenzyl or 2 , 4-dimethoxybenzyl group and for the amino group additionally a phthalyl group.
Any protecting group used is optionally subsequently cleaved for example by hydrolysis in an aqueous solvent, e.g. in water, isopropanol/water, acetic acid/water, tetrahydrofuran/water or dioxane/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulphuric acid or in the presence of an alkali metal base such as sodium hydroxide or potassium hydroxide or aprotically, e.g. in the presence of io- dotrimethylsilane, an temperatures between 0 and 120°C, preferably at temperatures between 10 and 100°C.
However, a benzyl, methoxybenzyl or benzyloxycarbonyl group is cleaved, for example, hydrogenolytically, e.g. with hydrogen in the presence of a catalyst such as palladium/charcoal in a suitable solvent such as methanol, ethanol, ethyl acetate or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid at temperatures between 0 and 100°C, but preferably at temperatures between 20 and 60°C, and at a hydrogen pressure of 1 to 7 bar, but preferably 3 to 5 bar. A 2 , 4-dimethoxybenzyl group, however, is preferably cleaved in trifluoroacetic acid in the presence of anisol .
A tert-butyl or ter .butyloxycarbonyl group is preferably cleaved by treating with an acid such as trifluoroacetic acid or hydrochloric acid or by treating with iodotrimethylsilane optionally using a solvent such as methylene chloride, dioxane, methanol or diethylether .
A trifluoroacetyl group is preferably cleaved by treating with an acid such as hydrochloric acid, optionally in the presence of a solvent such as acetic acid at temperatures between 50 and 120°C or by treating with sodium hydroxide solution optionally in the presence of a solvent such as tetrahydrofuran at temperatures between 0 and 50 °C.
A phthalyl group is preferably cleaved in the presence of hy- drazine or a primary amine such as methylamine, ethylamine or n-butylamine in a solvent such as methanol, ethanol, isopro- panol, toluene/water or dioxane at temperatures between 20 and 50°C.
A single alkyl group may be cleaved from an O, O ' -dialkylphos- phono group with sodium iodide, for example, in a solvent such as acetone, methylethylketone, acetonitrile or dimethylformamide at temperatures between 40 and 150°C, but preferably at temperatures between 60 and 100°C.
Both alkyl groups may be cleaved from an O, 0 ' -dialkyl-phosphono group with iodotrimethylsilane, bromotrimethylsilane or chlorotrimethylsilane/sodium iodide, for example, in a solvent such as methyl chloride, chloroform or acetonitrile at temperatures between 0°C and the boiling temperature of the reaction mixture, but preferably at temperatures between 20 and 60°C.
Moreover, the compounds of general formula I obtained may be resolved into their enantiomers and/or diastereomers, as mentioned hereinbefore. Thus, for example, cis/trans mixtures may be resolved into their cis and trans isomers, and compounds with at least one optically active carbon atom may be separated into their enantiomers. Thus, for example, the cis/trans mixtures may be resolved by chromatography into the cis and trans isomers thereof, the compounds of general formula I obtained which occur as race- mates may be separated by methods known per se (cf . allinger
N. L. and Eliel E. L. in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) into their optical antipodes and compounds of general formula I with at least 2 asymmetric carbon atoms may be resolved into their diastereomers on the basis of their physical-chemical differences using methods known per se, e.g. by chromatography and/or fractional crystallisation, and, if these compounds are obtained in racemic form, they may subsequently be resolved into the enantiomers as mentioned above.
The enantiomers are preferably separated by column separation on chiral phases or by recrystallisation from an optically active solvent or by reacting with an optically active substance which forms salts or derivatives such as e.g. esters or amides with the racemic compound, particularly acids and the activated derivatives or alcohols thereof, and separating the diastereomeric mixture of salts or derivatives thus obtained, e.g. on the basis of their differences in solubility, whilst the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents. Optically active acids in common use are e.g. the D- and L-forms of tartaric acid or dibenzoyltartaric acid, di-o-tolyltartaric acid, malic acid, mandelic acid, camphorsulphonic acid, gluta- mic acid, aspartic acid or quinic acid. An optically active alcohol may be for example (+) or (-) -menthol and an optically active acyl group in amides, for example, may be a (+) -or ( - ) -menthyloxycarbonyl .
Furthermore, the compounds of formula I may be converted into the salts thereof, and particularly for pharmaceutical use into the physiologically acceptable salts with inorganic or organic acids . Acids which may be used for this purpose include for example hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or aleic acid.
Moreover, if the new compounds of formula I thus obtained contain a carboxy or hydroxyphosphoryl group, they may subsequently, if desired, be converted into the salts thereof with inorganic or organic bases, particularly for pharmaceutical use into the physiologically acceptable salts thereof. Suitable bases for this purpose include for example sodium hydroxide, potassium hydroxide, arginine, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine .
The compounds of general formulae II to XI used as starting materials are known from the literature in some cases or may be obtained by methods known from the literature (cf . Examples I to XVIII) .
For example, a starting compound of general formula II is obtained by reacting a corresponding fluoronitro compound with a corresponding alkoxide and subsequently reducing the nitro compound thus obtained or
a starting compound of general formula IV is obtained by reacting a corresponding fluoronitro compound with a corresponding alkoxide, subsequently reducing the nitro compound thus obtained and then acylating with a corresponding compound.
As already mentioned hereinbefore, the compounds of general formula I according to the invention and the physiologically acceptable salts thereof have valuable pharmacological properties, particularly an inhibiting effect on signal transduction mediated by the Epidermal Growth Factor receptor (EGF-R) , whilst this may be achieved for example by inhibiting ligand bonding, receptor dimerisation or tyrosinekinase itself. It is also possible to block the transmission of signals to components located further down. The biological properties of the new compounds were investigated as follows:
The inhibition of the EGF-R-mediated signal transmission can be demonstrated e.g. with cells which express human EGF-R and whose survival and proliferation depend on stimulation by EGF or TGF-alpha. A cell line of murine origin dependent on in- terleukin-3 (IL-3) which was genetically modified to express functional human EGF-R was used here. The proliferation of these cells known as F/L-HERc can therefore be stimulated either by murine IL-3 or by EGF (cf . von Rύden, T. et al . in EMBO J. 1, 2749-2756 (1988) and Pierce, J. H. et al . in Science 212, 628-631 (1988)).
The starting material used for the F/L-HERc cells was the cell line FDC-Pi, the production of which has been described by Dexter, T. M. et al . in J. Exp . Med. 1 ? .. 1036-1047 (1980) . alternatively, however, other growth-factor-dependent cells may also be used (cf. for example Pierce, J. H. et al . in Science 239, 628-631 (1988), Shibuya, H. et al . in Cell 2H, 57-67 (1992) and alexander, W. S. et al . in EMBO J. IH, 3683- 3691 (1991)). For expressing the human EGF-R cDNA (cf. Ullrich, A. et al . in Nature 309, 418-425 (1984)) recombinant retroviruses were used as described by von Ruden, T. et al . , EMBO J. 1, 2749-2756 (1988) , except that the retroviral vector LXSN (cf. Miller, A. D. et al . in BioTechniques X, 980-990 (1989) ) was used for the expression of the EGF-R cDNA and the line GP+E86 (cf. Markowitz, D. et al . in J. Virol. £2, 1120- 1124 (1988)) was used as the packaging cell.
The test was performed as follows:
F/L-HERc cells were cultivated in RPMI/1640 medium (BioWhittaker) , supplemented with 10 % foetal calf serum (FCS, Boehringer Mannheim) , 2 mM glutamine (BioWhittaker) , standard antibiotics and 20 ng/ml of human EGF (Promega) , at 37°C and 5% CO2. In order to investigate the inhibitory activity of the compounds according to the invention, 1.5 x 104 cells per well were cultivated in triplicate in 96-well plates in the above medium (200 μl) , the cell proliferation being stimulated with either EGF (20 ng/ml) or murine IL-3. The IL-3 used was obtained from culture supernatants of the cell line X63/0 mIL-3 (cf. Karasuyama, H. et al . in Eur. J. Immunol. 18., 97-104 (1988) ) . The compounds according to the invention were dissolved in 100% dimethylsulphoxide (DMSO) and added to the cultures in various dilutions, the maximum DMSO concentration being 1%. The cultures were incubated for 48 hours at 37°C.
In order to determine the inhibitory activity of the compounds according to the invention the relative cell number was measured in O.D. units using the Cell Titer 96™ AQuθous Non- Radioactive Cell Proliferation Assay (Promega) . The relative cell number was calculated as a percentage of the control (F/LHERc cells without inhibitor) and the concentration of active substance which inhibits the proliferation of the cells by 50% (IC50) was derived therefrom. The following results were obtained:
Figure imgf000071_0001
Figure imgf000072_0001
The compounds of general formula I according to the invention thus inhibit the signal transduction by tyrosine kinases, as demonstrated by the example of the human EGF receptor, and are therefore useful for treating pathophysiological processes caused by hyperfunction of tyrosinekinases . These are e.g. benign or malignant tumours, particularly tumours of epithelial and neuroepithelial origin, metastasisation and the abnormal proliferation of vascular endothelial cells (neoangio- genesis) .
The compounds according to the invention are also useful for preventing and treating diseases of the airways and lungs which are accompanied by increased or altered production of mucus caused by stimulation by tyrosine kinases, e.g. in inflammatory diseases of the airways such as chronic bronchitis, chronic obstructive bronchitis, asthma, bronchiec- tasias, allergic or non-allergic rhinitis or sinusitis, cystic fibrosis, αl-antitrypsin deficiency, or coughs, pulmonary emphysema, pulmonary fibrosis and hyperreactive airways.
The compounds are also suitable for treating diseases of the gastrointestinal tract and bile duct and gall bladder which are associated with disrupted activity of the tyrosine kinases, such as may be found e.g. in chronic inflammatory changes such as cholecystitis, CrohnA disease, ulcerative colitis, and ulcers in the gastrointestinal tract or such as may occur in diseases of the gastrointestinal tract which are associated with increased secretions, such as MenetrieAs disease, secreting adenomas and protein loss syndrome,
and also for treating nasal polyps and polyps of the gastrointestinal tract of varying origins, such as villous or ade- nomatous polyps of the large bowel, but also polyps in familial polyposis coli, intestinal polyps in Gardner~"s syndrome, polyps throughout the entire gastrointestinal tract in Peutz- Jeghers syndrome, in inflammatory Pseudopolyps, in juvenile polyps, in colitis cystica profunda and in pneumatosis cys- toides intestinales .
In addition, the compounds of general formula I and the physiologically acceptable salts thereof may be used to treat kidney diseases, particularly in cystic changes such as cystic kidneys, for treating renal cysts which may be of idiopathic origin or which occur in syndromes such as tuberous sclerosis, in von Hippel-Lindau syndrome, in nephronophthisis and spongy kidney and other diseases caused by abnormal function of tyrosine kinases, such as e.g. epidermal hyperproliferation (psoriasis), inflammatory processes, diseases of the immune system, hyperproliferation of haematopoietic cells, etc.
By reason of their biological properties the compounds according to the invention may be used on their own or in conjunction with other pharmacologically active compounds, for example in tumour therapy, in monotherapy or in conjunction with other anti-tumour therapeutic agents, for example in combination with topoisomerase inhibitors (e.g. etoposide), mitosis inhibitors (e.g. vinblastin) , compounds which interact with nucleic acids (e.g. cis-platin, cyclophosphamide, adriamycin) , hormone antagonists (e.g. tamoxifen) , inhibitors of metabolic processes (e.g. 5-FU etc.), cytokines (e.g. interferons), antibodies, etc. For treating respiratory tract diseases, these compounds may be used on their own or in conjunction with other therapeutic agents for the airways, such as substances with a secre- tolytic, broncholytic and/or antiinflammatory activity. For treating diseases in the region of the gastrointestinal tract, these compounds may also be administered on their own or in conjunction with substances having an effect on motility or secretion or with antiinflammatories . These combinations may be administered either simultaneously or sequentially.
These compounds may be administered either on their own or in conjunction with other active substances by intravenous, subcutaneous, intramuscular, intrarectal, intraperitoneal or intranasal route, by inhalation or transdermally or orally, whilst aerosol formulations are particularly suitable for inhalation.
For pharmaceutical use the compounds according to the invention are generally used for warm-blooded vertebrates, particularly humans, in doses of 0.01-100 mg/kg of body weight, preferably 0.1-15 mg/kg. For administration they are formulated with one or more conventional inert carriers and/or diluents, e.g. with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol , water/sorbitol , water/polyethyleneglycol, propyleneglycol, stearylalcohol, car- boxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof in conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions, solutions, sprays or suppositories.
The following Examples are intended to illustrate the present invention without restricting it: Preparation of the starting compounds:
Example I
6-amino-4- [ (3-bromophenyl) amino] -7- (3-{4- [ (ethoxycarbonyl) me- hyl ] -piperazin-l-yl}propyloxy) -qui nazoline
180 mg of iron powder are added to 465 mg of 4- [ (3-bromophenyl) amino] -7- (3- {4- [ (ethoxycarbonyl) methyl] -piperazin-1-yl } - propyloxy) -6-nitro-quinazoline in 20 ml of ethanol. The reaction mixture is heated to boiling and combined with 0.6 ml of glacial acetic acid, then a further 2 ml of water are pipetted in. The reaction solution turns dark and is heated for about another half hour until the reaction is complete. The solvent is distilled off using the rotary evaporator, the residue is taken up in methylene chloride and made alkaline with 3 ml of 4N sodium hydroxide solution. The organic phase is separated off and the aqueous phase extracted with methylene chloride. The combined extracts are dried over magnesium sulphate and concentrated by evaporation. The crude product is stirred with a little diethyl ether, suction filtered and washed again. The light grey crystals obtained are dried in the desiccator. Yield: 350 mg (79 % of theory), Melting poin : 183-189°C Mass spectrum (ESI+) : m/z = 543, 545 [M+H] +
The following compounds are obtained analogously to Example I :
(1) 6 -amino-4- [ (3-bromophenyl) amino] -7- (3-{4- [ (isopropyloxy- carbonyl) methyl] -piperazin-1-yl }propyloxy) -quinazoline (the reaction is carried out in dioxane instead of ethanol) Melting point: 188-193°C
Mass spectrum (ESI"): m/z = 557, 559 [M+H] +
(2) 6 -amino-4- [ (3 -bromophenyl) amino] -7- (3-{4- [ (cyclohexyloxy- carbonyl) methyl] -piperazin-1-yl }propyloxy) -quinazoline (the reaction is carried out in dioxane instead of ethanol) Melting point: 166-169°C Mass spectrum (ESI+) : m/z = 597, 599 [M+H] +
(3) 6-amino-4- [ (3-bromophenyl) amino] -7- (3- {4- [2- (ethoxycarbonyl) ethyl] -piperazin-l-yl}propyloxy) -quinazoline
Melting point: 120-123°C
Mass spectrum (ESI+) : m/z = 557, 559 [M+H] +
(4) 6-amino-4- [ (3-bromophenyl) amino] -7- (3- {4- [3- (ethoxycarbonyl) propyl] -piperazin-l-yl}propyloxy) -quinazoline
Melting point: 119-122°C
Mass spectrum (ESI+) : m/z = 571, 573 [M+H] +
(5) 6-amino-4- [ (3-bromophenyl) amino] -7- (2- {4- [ (ethoxycarbonyl) methyl] -piperazin-l-yl}ethoxy) -quinazoline
Melting point : 147-161°C
Mass spectrum (ESI+) : m/z = 529, 531 [M+H] +
(6) 6-amino-4- [ (3-bromophenyl) amino] -7- ( {l- [ (ethoxycarbonyl) - methyl] -piperidin-4-yl }oxy) -quinazoline
Melting point: 202°C
Mass spectrum (ESI+) : m/z = 500, 502 [M+H] +
(7) 6-amino-4- [ (3-bromophenyl) amino] -7- ( {l- [ (ethoxycarbonyl) - methyl] -piperidin-4-yl }methoxy) -quinazoline
Melting point: 155°C
Mass spectrum (ESI+) : m/z = 514, 516 [M+H] +
(8) 6-amino-4- [ (3-bromophenyl) amino] -7- (2- {l- [ (ethoxycarbonyl) methyl] -piperidin-4-yl} ethoxy) -quinazoline
Melting point: 143 °C
Mass spectrum (ESI") : m/z = 528, 530 [M+H] +
(9) 6-amino-4- [ (3-bromophenyl) amino] -7- (3- {l- [ (ethoxycarbonyl) methyl] -piperidin-4-yl}propyloxy) -quinazoline Melting point: 181°C
Mass spectrum (ESI+) : m/z = 542, 544 [M+H] + (10) 6 -amino-4- [ (3-bromophenyl) amino] -7- (3- {4- [ (diethoxyphos- phoryl) methyl] -piperazin-l-yl}propyloxy) -quinazoline Melting point: 201-205°C
Mass spectrum (ESI+) : m/z = 607, 609 [M+H] +
(11) 6-amino-4- [ (3-bromophenyl) amino] -7- (3- {4- [ (butyloxycarbo- nyl) methyl] -piperazin-l-yl}propyloxy) -quinazoline
Melting point: 158-160°C
Mass spectrum (ESI+) : m/z = 571, 573 [M+H] +
(12) 6-amino-4- [ (3-bromophenyl) amino] -7- (3- {N- [ (ethoxycarbonyl) methyl] -N-methylamino}propyloxy) -quinazoline
Rf value: 0.49 (silica gel, methylene chloride/methanol/concen- trated aqueous ammonia solution = 90:10:0.1) Mass spectrum (ESI+) : m/z = 488, 490 [M+H] +
(13) 6-amino-4- [ (3-bromophenyl) amino] -7- (2- {N- [ (ethoxycarbonyl) methyl] -N-methylamino} ethoxy) -quinazoline
Rf value: 0.50 (silica gel, methylene chloride/methanol/concen- trated aqueous ammonia solution = 90:10:0.1)
(14) 6-amino-4- [ (3 -chloro-4-fluorophenyl) amino] -7-cyclopropyl- methoxy-quinazoline
Melting point: 209°C
Rf value: 0.68 (silica gel, ethyl acetate)
(15) 6-amino-4- [ (3-bromophenyl) amino] -7- (4- {N- [ (ethoxycarbonyl) methyl] -N-methylamino}butyloxy) -quinazoline
Rf value: 0.44 (silica gel, methylene chloride/methanol/concen- trated aqueous ammonia solution = 90:10:0.1)
(16) 6-amino-4- [ (3-chloro-4-fluorophenyl) amino] -7-cyclohexyl - methoxy-quinazoline
Melting point: 234°C
Mass spectrum (ESI+) : m/z = 401, 403 [M+H] + (17) 6-amino-4- [ (3-chloro-4-fluorophenyl) amino] -7-cyclohexyl - oxy-quinazoline
Melting point: 176°C
Mass spectrum (ESI+) : m/z = 387, 389 [M+H] +
(18) 6-amino-4- [ (3 -chloro-4-fluorophenyl) amino] -7-cyclobutyl- oxy-quinazoline
Melting point: 238-239°C
Mass spectrum (ESI+) : m/z = 359, 361 [M+H] +
(19) 6-amino-4- [ (3-chloro-4-fluorophenyl) amino] -7-cyclobutyl- methoxy-quinazoline
Melting point : 214-215°C
Mass spectrum (ESI+) : m/z = 373, 375 [M+H] +
(20) 6-amino-4- [ (3-chloro-4-fluorophenyl) amino] -7-cyclopentyl- methoxy-quinazoline
Melting point: 218-219°C
Mass spectrum (ESI+) : m/z = 387, 389 [M+H] +
(21) 6-amino-4- [ (3 -chloro-4 -fluorophenyl) amino] -7- (2-cyclopro- pylethoxy) -quinazoline
Melting point: 188-190°C
Mass spectrum (ESI+) : m/z = 373, 375 [M+H] +
(22) 6-amino-4- [ (3-chloro-4-fluorophenyl) amino] -7-cyclopentyl- oxy-quinazoline
Melting point: 204°C
Mass spectrum (ESI+) : m/z = 373, 375 [M+H] +
(23) 6-amino-4- [ (3 -chlorophenyl) amino] -7-methoxy-quinazoline Melting point: 208-209°C
Mass spectrum (ESI+) : m/z = 301, 303 [M+H] + (24 ) (R) -6 -amino-4 - [ ( 1-phenylethyl ) amino] - 7-methoxy-quinazo- line
Rf value: 0.42 (silica gel, methylene chloride/methanol/con- centrated aqueous ammonia solution = 9:1:0.1) Mass spectrum (ESI+) : m/z = 295 [M+H] +
(25) 6-Amino-4- [ (R) - (1-phenyl-ethyl) amino] -7- {2- [2- (meth- oxycarbonyl) -piperidin-1-yl] -ethoxy} -quinazoline
Rf value: 0.50 (silica gel, methylene chloride/methanol/con- centrated aqueous ammonia = 90:10:1) Mass spectrum (ESI"): m/z = 448 [M-H] "
(26) 6-Amino-4- [ (R) - (1-phenyl-ethyl) amino] -7- {2- [ (J?) -2- (meth- oxycarbonyl) -pyrrolidin-1-yl] -ethoxy} -quinazoline
Rf value: 0.20 (silica gel, methylene chloride/methanol = 95:5)
Mass spectrum (ESI"): m/z = 434 [M-H]"
(27) 6-Amino-4- [ (R) - (1-phenyl-ethyl) amino] -7- {2- [ (S) -2- (meth- oxycarbonyl) -pyrrolidin-1-yl] -ethoxy} -quinazoline
Rf value: 0.20 (silica gel, methylene chloride/methanol = 95:5)
Mass spectrum (ESI"): m/z = 434 [M-H]"
(28) 6-Amino-4- [ (R) - (1-phenyl-ethyl) amino] -7- {3- [ (R) -2- (meth- oxycarbonyl) -pyrrolidin-1-yl] -propyloxy} -quinazoline
Rf value: 0.40 (silica gel, methylene chloride/methanol = 9:1)
Mass spectrum (ESI"): m/z = 448 [M-H]"
(29) 6-Amino-4- [ (R) - (1-phenyl-ethyl) amino] -7- {4- [2- (methoxy- carbonyl) -piperidin-1-yl] -butyloxy} -quinazoline
Rf value: 0.20 (silica gel, methylene chloride/methanol = 95:5)
Mass spectrum (ESI"): m/z = 476 [M-H]"
(30) 6-Amino-4- [ (J?) - ( 1-phenyl-ethyl) amino] -7-cyclobutyloxy- quinazoline
Rf value: 0.28 (silica gel, ethyl acetate)
Mass spectrum (ESI+) : m/z = 335 [M+H] + (31) 6-Amino-4- [ (R) - (1-phenyl-ethyl) amino] -7-cyclopentyloxy- quinazoline
Rf value: 0.20 (silica gel, ethyl acetate)
Mass spectrum (ESI+) : m/z = 349 [M+H] +
(32) 6-Amino-4- [ (R) - (1-phenyl-ethyl) amino] -7-cyclopropyl- methoxy-quinazoline
Melting point: 183 °C
Mass spectrum (ESI+) : m/z = 335 [M+H] +
(33 ) 6-Amino-4-benzylamino-7-cyclopropylmethoxy-quinazoline Melting point: 190°C
Mass spectrum (ESI+) : m/z = 321 [M+H] +
(34) 6-Amino-4- [ (R) - (1-phenyl -ethyl) amino] -7- (2- {N- [ (methoxy- carbonyl) methyl] -N-methylamino} -ethoxy] -quinazoline
Rf value: 0.16 (silica gel, methylene chloride/methanol = 95:5)
Mass spectrum (El) : m/z = 409 [M] +
Example II
4- [ ( 3 -bromophenyl ) amino] - 7- ( 3 - { 4 - [ (ethoxycarbonyl ) methyl] - piperazin-l.-yl }propyloxy) -6-ni tro-gui naznli ne
292 mg of ethyl bromoacetate are added to 780 mg of 4-[(3- bromophenyl) amino] -7- [3- (piperazin-1-yl) propyloxy] -6-nitro- quinazoline and 0.55 ml of triethylamine in 7 ml of acetonitrile. The reaction mixture is stirred for one hour at ambient temperature, then for about 1.5 hours at 65°C and then for a further 2 days at ambient temperature. As the reaction is incomplete, 2 drops of ethyl bromoacetate are added twice more. The reaction solution is concentrated by evaporation and the residue is partitioned between copious amounts of ethyl acetate and dilute potassium carbonate solution. The organic phase is washed with water and saturated sodium chloride solution, dried over magnesium sulphate and concentrated by evaporation. The yellowish, resin-like crude product is recrystallised from 7 ml of ethanol. The yellow crystals are washed with some cold ethanol and dried in the desiccator.
Yield: 640 mg (70 % of theory),
Melting point: 75°C
Mass spectrum (ESI+) : m/z = 573, 575 [M+H] +
The following compounds are obtained analogously to Example II:
(1) 4- [ (3-bromophenyl) amino] -7- (3- {4- [ (isopropyloxycarbonyl) - methyl] -piperazin-1-yl }propyloxy) -6-nitro-quinazoline Melting point: 7l-74°C
Mass spectrum (ESI+) : m/z = 587, 589 [M+H] +
(2) 4- [ (3-bromophenyl) amino] -7- (3- {4- [ (cyclohexyloxycarbonyl) methyl] -piperazin-l-yl}propyloxy) -6-nitro-quinazoline Melting point: 80-100°C
Mass spectrum (ESI+) : m/z = 627, 629 [M+H] +
(3) 4- [ (3-bromophenyl) amino] -7- (3-{4- [2- (ethoxycarbonyl) ethyl] -piperazin-l-yl}propyloxy) -6-nitro-quinazoline
(reaction is carried out with ethyl acrylate in ethanol) Melting point: 153-156°C Mass spectrum (ESI+) : m/z = 587, 589 [M+H]*
(4) 4- [ (3-bromophenyl) amino] -7- (3-{4- [3- (ethoxycarbonyl) propyl] -piperazin-l-yl}propyloxy) -6-nitro-quinazoline Melting point: 50-58°C
Mass spectrum (ESI*) : m/z = 601, 603 [M+H]*
(5) 4- [ (3-bromophenyl) amino] -7- (2- {4- [ (ethoxycarbonyl) methyl] piperazin-1-yl} ethoxy) -6-nitro-quinazoline
Melting point: 103-120°C
Mass spectrum (ESI*) : m/z = 559, 561 [M+H]* (6) 4- [ (3-bromophenyl) amino] -7- ( {l- [ (ethoxycarbonyl) methyl] - piperidin-4 -yl } oxy) - 6-nitro-quinazoline
Melting point: 151°C
Mass spectrum (ESI*) : m/z = 530, 532 [M+H]*
( 7 ) 4 - [ ( 3 -bromophenyl ) amino] - 7- ( { 1- [ (ethoxycarbonyl ) ethyl] - piperidin-4 -yl}methoxy) -6-nitro-quinazoline
Melting point: 189°C
Mass spectrum (ESI*) : m/z = 544, 546 [M+H]*
(8 ) 4 - [ (3 -bromophenyl ) amino] -7- (2 - {1- [ (ethoxycarbonyl ) methyl] - piperidin-4 -yl}ethoxy) -6-nitro-quinazoline
Melting point: 185-187°C
Mass spectrum (ESI*): m/z = 558, 560 [M+H]*
(9) 4- [ (3-bromophenyl) amino] -7- (3-{l- [ (ethoxycarbonyl) methyl] - piperidin-4 -yl}propyloxy) -6-nitro-quinazoline
Melting point: 101°C
Mass spectrum (ESI*) : m/z = 572, 574 [M+H]*
(10) 4- [ (3-bromophenyl) amino] -7- (3- {4- [ (butyloxycarbonyl) methyl] -piperazin-l-yl}propyloxy) -6-nitro-quinazoline Melting point: 70-75°C
Mass spectrum (ESI*) : m/z = 601, 603 [M+H]*
Exampl TXT
4- [ (3-bromophenyl) amino] -6 -nitro- 7- [3- (piperazin-1-yl) propyl - oxy] -qui nazo] j.ne
15 ml of trifluoroacetic acid are added dropwise to a suspension of 7.05 g of 4- [ (3-bromophenyl) mino] -6 -nitro-7- {3- [4- ( tert-butyloxycarbonyl) -piperazin-1-yl] propyloxy} -quinazoline in 80 ml of methylene chloride at ambient temperature with stirring. While gas is given off, a dark solution is rapidly formed which is stirred for approximately a further 1.5 hours at ambient temperature. The reaction solution is concentrated by evaporation using the rotary evaporator. The resin-like residue is taken up in methylene chloride, combined with ice water and carefully made alkaline with 4N sodium hydroxide solution. Partially precipitated product is dissolved by the addition of more methylene chloride and methanol. The aqueous phase is separated off and extracted with methylene chloride/methanol (9:1) . The combined extracts are washed with water, dried over magnesium sulphate and concentrated by evaporation. The crude product is heated to boiling with 25 ml of tert. butylmethylether, cooled with stirring and suction filtered. The yellow crystals thus obtained are washed with diethylether and dried. Yield: 5.16 g (88 % of theory), Melting point: 179-182°C Mass spectrum (ESI*): m/z = 487, 489 [M+H]*
The following compounds are obtained analogously to Example III:
(1) 4- [ (3-bromophenyl) amino] -6-nitro-7- [2- (piperazin-1-yl) ethoxy] -quinazoline
Melting point: 133-136°C
Mass spectrum (ESI*): m/z = 473, 475 [M+H]*
(2) 4- [ (3-bromophenyl) amino] -6-nitro-7- [ (piperidin-4-yl) oxy] - quinazoline
Melting point: 131°C
Mass spectrum (ESI*): m/z = 444, 446 [M+H]*
(3) 4- [ (3-bromophenyl) amino] -6-nitro-7- [ (piperidin-4 -yl) methoxy] -quinazoline
Melting point: 145°C
Mass spectrum (ESI*): m/z = 458, 460 [M+H]*
(4) 4- [ (3-bromophenyl) amino] -6-nitro-7- [2- (piperidin-4-yl) ethoxy] -quinazoline
Melting point: 228°C
Mass spectrum (ESI*): m/z = 472, 474 [M+H]* (5) 4- [ (3-bromophenyl) amino] -6-nitro-7- [3- (piperidin-4-yl) pro- pyloxy] -quinazoline
Melting point: 194°C
Mass spectrum (ESI*): m/z = 486, 488 [M+H]*
(6) 4- [ (3-Chloro-4-fluoro-phenyl) amino] -6- { [4- (piperazin- 1-yl) -l-oxo-2-buten-l-yl] amino} -7-cyclopropylmethoxy-quinazo- line
Rf value: 0.60 (reversed phase TLC-plate (E. Merck), acetoni- trile/water/trifluoro-acetic acid = 50:50:1) Mass spectrum (ESI*): m/z = 511, 513 [M+H]*
Example IV
4- [ (3-bromophenyl) amino] -6-nitro-7- {3- [4- (tert-butyloxycarbonyl -pipe-raAn-T -yl 1 propyl oxy} - innazol i πe
1.08 g sodium hydride are added to a solution of 6.35 g of 3- [4- (tert-butyloxycarbonyl) -piperazin-1-yl] -propan-1-ol in 100 ml of tetrahydrofuran under a nitrogen atmosphere . The suspension is stirred for about 10 minutes at ambient temperature, then 4.72 g of 4- [ (3-bromophenyl) amino] -7-fluoro-6-nitro- quinazoline in 20 ml of tetrahydrofuran are added thereto. The reaction mixture turns dark reddish-brown, while giving off gas, and is gently refluxed for about 25 minutes. Since only a partial reaction has taken place, a further 0.52 g of sodium hydride are added. The reaction mixture is heated for a further 40 minutes until the reaction has ended. The cooled reaction solution is poured onto about 250 ml of ice-water and neutralised with a little citric acid. The partially precipitated product is extracted with ethyl acetate. The combined extracts are washed with a little water, followed by saturated sodium chloride solution, dried over magnesium sulphate and concentrated by evaporation. 11.30 g of crude product is obtained as a dark resin which is heated to boiling with 25 ml of methanol with stirring, whereupon the product crystallises out. The suspension is cooled with ice-water and suction fil- tered. The brownish-yellow crystals obtained are washed again with 10 ml of cold methanol and dried in the desiccator.
Yield: 7.08 g (92 % of theory),
Melting point : 152-156°C
Mass spectrum (ESI*) : m/z = 587, 589 [M+H] *
The following compounds are obtained analogously to Example IV:
(1) 4- [ (3-bromophenyl) amino] -6-nitro-7- {2- [4- (tert-butyloxycarbonyl) -piperazin-1-yl] ethoxy} -quinazoline
Melting point: 219-222°C
Mass spectrum (ESI*): m/z = 573, 575 [M+H]*
(2) 4- [ (3-bromophenyl) amino] -6-nitro-7- { [1- (tert-butyloxycar- bonyl) -piperidin-4 -yl] oxy} -quinazoline
Melting point: 190 °C
Mass spectrum (ESI"): m/z = 542, 544 [M-H]"
(3) 4- [ (3-bromophenyl) amino] -6-nitro-7-{ [1- (ter -butyloxycarbonyl) -piperidin-4 -yl] methoxy} -quinazoline
Melting point: 240°C
Mass spectrum (ESI*) : m/z = 558, 560 [M+H]*
(4) 4- [ (3-bromophenyl) amino] -6-nitro-7- {2- [1- (tert-butyloxy- carbonyl) -piperidin-4 -yl] ethoxy} -quinazoline
Melting point: 208°C
Mass spectrum (ESI*): m/z = 572, 574 [M+H]*
(5) 4- [ (3-bromophenyl) amino] -6 -nitro-7- {3- [1- (tert-butyloxycarbonyl) -piperidin-4 -yl] propyloxy} -quinazoline
Melting point: 203 °C
Mass spectrum (ESI") : m/z = 584, 586 [M-H]" (6) 4- [ (3-bromophenyl) amino] -7- [3- (tert-butyldimethylsilyl- oxy) -propyloxy] -6-nitro-quinazoline
Rf value: 0.84 (silica gel, petroleum ether/ethyl acetate =
1:1) Mass spectrum (ESI*): m/z = 533, 535 [M+H]*
(7) 4- [ (3-bromophenyl) amino] -7- [2- (tert-butyldimethylsilyl- oxy) -ethoxy] -6-nitro-quinazoline
Melting point: 206-208°C
Mass spectrum (ESI*): m/z = 519, 521 [M+H]*
(8) 4- [ (3-chloro-4-fluorophenyl) amino] -7-cyclopropylmethoxy-6- nitro-quinazoline (carried out in dimethylformamide with potassium tert-butoxide as base)
Melting point : 211-213°C
Mass spectrum (ESI*): m/z = 389, 391 [M+H]*
(9) 4- [ (3-bromophenyl) amino] -7- [4- (tert-butyldimethylsilyl- oxy) -butyloxy] -6-nitro-quinazoline
Rf value: 0.73 (silica gel, petroleum ether/ethyl acetate =
1:1) Mass spectrum (ESI"): m/z = 545, 547 [M-H]"
(10) 4- [ (3 -chloro-4 -fluorophenyl) amino] -7-cyclohexylmethoxy- 6-nitro-quinazoline (carried out in dimethylformamide with potassium-tert . butoxide as base)
Melting point: 258°C
Mass spectrum (ESI*): m/z = 431, 433 [M+H]*
(11) 4- [ (3 -chloro-4 -fluorophenyl) amino] -7-cyclohexyloxy-6- nitro-quinazoline (carried out in dimethylformamide with potassium-tert-butoxide as base)
Melting point: 196°C
Mass spectrum (ESI*): m/z = 417, 419 [M+H]* (12) 4- [ (3 -chloro-4 -fluorophenyl) amino] -7-cyclobutyloxy-6- nitro-quinazoline (carried out in dimethylformamide with potassium tert-butoxide as base)
Melting point: 230-231°C
Mass spectrum (ESI*): m/z = 389, 391 [M+H]*
(13) 4- [ (3-chloro-4-fluorophenyl) amino] -7-cyclobutylmethoxy- 6-nitro-quinazoline (carried out in dimethylformamide with potassium tert-butoxide as base)
Melting point: 223-225°C
Mass spectrum (ESI*): m/z = 403, 405 [M+H]*
(14) 4- [ (3-chloro-4-fluorophenyl) amino] -7-cyclopentylmethoxy- 6-nitro-quinazoline (carried out in dimethylformamide with potassium-tert . butoxide as base)
Melting point: 220-224°C
Mass spectrum (ESI*): m/z = 417, 419 [M+H]*
(15) 4- [ (3 -chloro-4 -fluorophenyl) amino] -7- (2-cyclopropyleth- oxy) -6-nitro-quinazoline (carried out in dimethylformamide with potassium tert-butoxide as base)
Melting point: 200-202°C
Mass spectrum (ESI*): m/z = 403, 405 [M+H]*
(16) 4- [ (3 -chloro-4 -fluorophenyl) amino] -7-cyclopentyloxy- 6-nitro-quinazoline (carried out in dimethylformamide with potassium tert-butoxide as base)
Melting point: 224°C
Mass spectrum (ESI*): m/z = 403, 405 [M+H]*
(17) 4- [ (3 -chlorophenyl) amino] -7-methoxy-6-nitro-quinazoline (carried out with sodium methoxide in tetrahydrofuran)
Melting point: 199-201°C
Mass spectrum (ESI*): m/z = 331, 333 [M+H]* (18) (R) -4- [ (1-phenylethyl) amino] -7-methoxy-6-nitro-quinazo- line (carried out with sodium methoxide in tetrahydrofuran) Rf value: 0.17 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI*): m/z = 325 [M+H]*
(19) 4- [ (R) - (1-Phenyl-ethyl) amino] -7- [2- (tetrahydro-pyran-
2-yloxy) -ethoxy] -6-nitro-quinazoline
Rf value: 0.11 (silica gel, cyclohexane/ethyl acetate = 1:1)
Mass spectrum (El) : m/z = 438 [M] *
(20) 4- [ (R) - (1-Phenyl-ethyl) amino] -7- [3- (tetrahydro-pyran-
2-yloxy) -propyloxy] -6-nitro-quinazoline
Rf value: 0.19 (silica gel, cyclohexane/ethyl acetate = 1:1)
Mass spectrum (El) : m/z = 452 [M] *
(21) 4- [ (R) - (1-Phenyl-ethyl) amino] -7- [4- (tetrahydro-pyran-
2-yloxy) -butyloxy] -6-nitro-quinazoline
Rf value: 0.18 (silica gel, cyclohexane/ethyl acetate = 1:1)
Mass spectrum (ESI"): m/z = 465 [M-H]"
(22) 4- [ (R) - (1-Phenyl-ethyl) amino] -7-cyclobutyloxy-6-nitro- quinazoline (reaction is carried out with potassium tert.bu- tylate in N,N-dimethyl -formamide)
Rf value: 0.54 (silica gel, ethyl acetate) Mass spectrum (ESI") : m/z = 363 [M-H] "
(23 ) 4- [ (R) - (1-Phenyl-ethyl) amino] -7-cyclopentyloxy-6-nitro- quinazoline (reaction is carried out with potassium tert.bu- tylate in N,N-dimethyl-formamide)
Rf value: 0.24 (silica gel, petroleum ether/ethyl acetate =
1:1)
Mass spectrum (ESI*): m/z = 379 [M+H]*
(24) 4- [ (R) - (1-Phenyl-ethyl) amino] -7-cyclopropylmethoxy-6-nitro-quinazoline (reaction is carried out with potassium tert. butylate in N,N-dimethyl-formamide) Melting point: 155°C
Mass spectrum (ESI*): m/z = 365 [M+H]*
(25) 4-Benzylamino-7-cyclopropylmethoxy- 6-nitro-quinazoline (reaction is carried out with potassium tert .butylate in
N, N-dimethyl-formamide)
Melting point: 168°C
Mass spectrum (ESI*): m/z = 351 [M+H]*
Example V
4- [ (3-bromophenyl) amino] -6- [ (4-bromo-l-oxo-2-buten-l-yl) ami- no3 -quinazoline
1.74 ml of oxalylchloride and one drop of dimethylformamide are added to a solution of 1.65 g of 4-bromo-2-butenoic acid in 15 ml of methylene chloride at ambient temperature. The reaction mixture is stirred for about one hour at ambient temperature until the development of gas has ceased. The acid chloride formed is largely freed from the solvent in vacuo using the rotary evaporator. The oily brown crude product is taken up in 25 ml of tetrahydrofuran and added dropwise, while cooling with a ice bath, to a solution of 3.15 g of 4-[(3- bromophenyl) amino] -6-amino-quinazoline and 2.30 ml of Hϋnig base in 25 ml of tetrahydrofuran. The reaction mixture is stirred for 30 minutes while cooling with ice and then stirred for another 1.5 hours at ambient temperature. For working up, 25 ml of water and 50 ml of ethyl acetate are added. The organic phase is separated off, washed with saturated sodium chloride solution, dried over magnesium sulphate and concentrated by evaporation. The residue is boiled in 30 ml of ethyl acetate to purify it further and filtered while hot. The yellow crystalline product is washed with hot ethyl acetate and dried.
Yield: 3.00 g (65 % of theory), Rf value: 0.33 (silica gel, methylene chloride/methanol/concen- trated aqueous ammonia solution = 9:1:0.1) Mass spectrum (ESI*): m/z = 463 [M+H]* The following compound is obtained analogously to Example V:
(1) 4- [ (3-bromophenyl) amino] -6- [ (4-bromo-l-oxo-2-buten-l-yl) - amino] -7-methoxy-quinazoline
Rf value: 0.38 (reversed phase ready-made TLC plates (E.Merck), acetonitrile/water, trifluoroacetic acid = 50:50:1)
Examp] e VI
3-{N- [ (ethoxycarbonyl) methyl] -N-methylamino}propylamine-hydro- chlori e
20 ml of trifluoroacetic acid are added dropwise to a solution of 6.10 g of N- [3- (tert. butyloxycarbonylamino) -propyl] -sarco- sine ethyl ester in 40 ml of methylene chloride whilst cooling with an ice bath. The reaction mixture is then stirred for about another three hours at 0°C until the evaluation of gas has ended. For working up, the solvent is largely distilled off in vacuo in the rotary evaporator. The residue is taken up in ethereal hydrochloric acid solution and again evaporated to dryness .
Yield: 4.72 g (86 % of theory),
Rf value: 0.80 (silica gel, acetonitrile/water/trifluoroacetic acid = 50:50:1) Mass spectrum (El) : m/z = 174 [M] *
The following compound is obtained analogously to Example VI :
(1) 2-{N- [ (ethoxycarbonyl) methyl] -N-methylamino}ethylamine-di- hydrochloride
Rf value: 0.74 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/trifluoroacetic acid =
50:50:1) Mass spectrum (ESI*): m/z = 161 [M+H]* Example VII
N- [3- (tert-butyloxycarbonylamino) -propyl] -sarcosine ethyl ester
A solution of 17.90 g 3- (tert-butyloxycarbonylamino) propyl bromide in 50 ml of acetonitrile is added dropwise to a mixture of 11.55 g of sarcosine ethylester hydrochloride and 28.8 ml of Hunig base in 200 ml of acetonitrile within 30 minutes while cooling with an ice bath. The reaction mixture is allowed to come up to ambient temperature overnight in the ice bath. Then the solvent is distilled off using the rotary evaporator, the residue is taken up in tert-butyl-methylether and washed with ice water. The organic phase is dried over magnesium sulphate and concentrated by evaporation. The crude product is chromatographed on a silica gel column with methylene chloride/methanol/concentrated aqueous ammonia solution (100:2:0.1) .
Yield: 20.62 g (30 % of theory),
Rf value: 0.50 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution = 20:1:0.1) Mass spectrum (ESI*): m/z = 275 [M+H]*
The following compound is obtained analogously to Example VII:
(1) N- [2- (tert .butyloxycarbonylamino) -ethyl] -sarcosine ethylester Rf value: 0.45 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution = 90:10:0.5) Mass spectrum (ESI*): m/z = 261 [M+H]*
Fxam l^ VTTT
4- [ (3 -bromophenyl ) amino] -7- (3 - {4 - [ (diethoxyphosphoryl) methyl] - piperazin-1-yl }propyl oxy) -6-ni o-gn na ol i ne
0.08 ml of a 37% formaldehyde solution is added to a suspension of 487 mg of 4 -[ (3 -bromophenyl) amino] -6-nitro-7- [3 - (pipe- razin-l-yl)propyloxy] -quinazoline in 3 ml of dioxane. The suspension is briefly heated in an oil bath until a clear solution is obtained. Then 0.16 ml of diethylphosphite are pipetted in with stirring at ambient temperature. The reaction mixture is then stirred for a further half hour at ambient temperature, then heated to 90-100°C in an oil bath. After another three hours the reaction is complete. The reaction solution is concentrated by evaporation, the residue is stirred with ice-water, filtered off and dried in the desiccator. The crude product is purified by chromatography over a silica gel column with methylene chloride/ethanol (9:1) . Yield: 540 mg (85 % of theory) , Melting point: 140-143°C Mass spectrum (ESI*): m/z = 637, 639 [M+H]*
Example IX
6-amino-4- [ (3-bromophenyl) amino] -7-{3- [4- (carboxymethyl) - piperazin-l-yl]prQpyloxy} -quinazoline
2.0 ml of 1.0 N sodium hydroxide solution are added to a solution of 440 mg of 6-amino-4- [ (3-bromophenyl) amino] -7- (3 - {4- [ (butyloxycarbonyl) methyl] -piperazin-l-yl}propyloxy) -quinazoline in 25 ml of tetrahydrofuran and 5 ml of methanol. The dark solution formed is stirred overnight at ambient temperature. The reaction mixture is neutralised with 2.0 ml of 1.0 N hydrochloric acid and freed from solvent in the rotary evaporator. The brown, resin-like residue is taken up in methylene chloride/methanol (9:1) and suction filtered. The filtrate is concentrated by evaporation, moistened with toluene and dried in the desiccator.
The brown crude product is reacted without any further purification.
Yield: 460 mg (116 % of theory) Rf value: 0.50 (Reversed phase ready-made TLC plate (E. merck), acetonitrile/water/trifluoroacetic acid
= 90:10:1) Mass spectrum (ESI"): m/z = 513, 515 [M-H]" The following compound is obtained analogously to Example IX:
(1) 4- [ (3-chloro-4-fluorophenyl) amino] -6- { [ (2-carboxy-vinyl) - carbonyl] amino} -7-cyclopropylmethoxy-quinazoline
Rf value: 0.55 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/trifluoroacetic acid
= 50:50:1) Mass spectrum (ESI*): m/z = 457, 459 [M+H]*
Example X
4- [ (3 -Bromophenyl) amino] -7- (3-{N- [ (ethoxycarbonyl) ethyl] -N- methyl mino} ropyloxy) -6-nitro-guinazol.in
A mixture of 1.40 g 4- [ (3-bromophenyl) amino] -7- [3- (methylsul- phonyloxy) -propyloxy] -6-nitro-quinazoline and 5.60 g sarcosine ethylester is stirred for 2.5 hours at 110°C. The reaction mixture is stirred with 100 ml of ice-water. The yellow supernatant emulsion is decanted and the orange-yellow mucilaginous precipitate is dissolved in methylene chloride, dried over sodium sulphate and concentrated by evaporation. The brownish- orange crude product is purified by chromatography over a silica gel column with methylene chloride/methanol (96:4) . Yield: 763 mg (52 % of theory)
Rf value: 0.65 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI*): m/z = 518, 520 [M+H]*
The following compounds are obtained analogously to Example X:
(1) 4- [ (3-bromophenyl) amino] -7- (2- {N- [ (ethoxycarbonyl) methyl] - N-methylamino} ethoxy) -6-nitro-quinazoline
R£ value: 0.71 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI*) : m/z = 504, 506 [M+H]*
(2) 4- [ (3-bromophenyl) amino] -7- (4- {N- [ (ethoxycarbonyl) methyl] - N-methylamino }butyloxy) -6-nitro-quinazoline
Rf value: 0.55 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (El) : m/z = 531, 533 [M] *
(3) 4- [ (R) - (1-Phenyl -ethyl) amino] -7- {2- [2- (methoxycarbonyl) - piperidin-1-yl] -ethoxy} -6-nitro-quinazoline (reaction is carried out in acetonitrile in the presence of diisopropylethylamine and sodium iodide)
Rf value: 0.21 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI") : m/z = 478 [M-H]"
(4) 4- [ (j ) - (1 -Phenyl -ethyl) amino] -7- {2- [ (R) -2- (methoxycarbonyl) -pyrrolidin-1-yl] -ethoxy} -6-nitro-quinazoline (reaction is carried out in acetonitrile in the presence of diisopropylethylamine and sodium iodide)
Rf value: 0.25 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI") : m/z = 464 [M-H] "
(5) 4- [ (R) - (1-Phenyl -ethyl) amino] -7- {2- [ ( S) - 2 - (methoxycarbo- nyl) -pyrrolidin-1-yl] -ethoxy} -6-nitro-quinazoline (reaction is carried out in acetonitrile in the presence of diisopropylethylamine and sodium iodide)
Rf value: 0.30 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI") : m/z = 464 [M-H] "
(6) 4- [ (R) - (1-Phenyl -ethyl) amino] -7- {3- [ (R) -2- (methoxycarbo- nyl) -pyrrolidin-1-yl] -propyloxy} -6-nitro-quinazoline (reaction is carried out in acetonitrile in the presence of diisopropylethylamine, potassium carbonate, and sodium iodide) Rf value: 0.23 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI") : m/z = 478 [M-H]"
(7) 4- [ (R) - (1-Phenyl -ethyl) amino] -7- {4- [2- (methoxycarbonyl) - piperidin-1-yl] -butyloxy} -6-nitro-quinazoline (reaction is carried out in acetonitrile in the presence of potassium carbonate and sodium iodide)
Rf value: 0.25 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI") : m/z = 506 [M-H]" - 94 -
Mass spectrum (ESI*): m/z = 483, 485 [M+H]*
(2) 4- [ (3-bromophenyl) amino] -7- [4- (methylsulphonyloxy) -butyl- oxy] -6-nitro-quinazoline
Rf value: 0.73 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI"): m/z = 509, 511 [M-H]"
(3) 4- [ (3-bromophenyl) amino] -6- [ (4- {N- [ (tert-butyloxycarbo- nyDmethyl] -N- [2- (methylsulphonyloxy) ethyl] amino} -l-oxo-2-bu- ten-l-yl) amino] -7-methoxy-quinazoline
Rf value: 0.65 (silica gel, methylene chloride/methanol = 9:1)
(4) 4- [ (3-chloro-4-fluorophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N- [2- (methylsulphonyloxy) ethyl] mino} -l-oxo-2-bu- ten-l-yl) amino] -7-cyclopropylmethoxy-quinazoline
Rf value: 0.68 (silica gel, ethyl acetate)
(5) 4- [ (R) - (1-Phenyl-ethyl) amino] -7- [2- (methylsulfonyloxy) - ethoxy] -6-nitro-quinazoline
Rf value: 0.45 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI") : m/z = 431 [M-H] "
(6) 4- [ (R) - (1-Phenyl-ethyl) amino] -7- [3- (methylsulfonyloxy) - propyloxy] -6-nitro-quinazoline
Rf value: 0.40 (silica gel, methylene chloride/methanol = 95:5)
Mass spectrum (ESI") : m/z = 445 [M-H] "
(7) 4- [ (R) - (1-Phenyl-ethyl) amino] -7- [4- (methylsulfonyloxy) -butyloxy] -6-nitro-quinazoline
Rf value: 0.45 (silica gel, methylene chloride/methanol = 95:5]
-rampl P> YTT
4- [ (3 -Bromophenyl) amino] -7- (3-hydroxy-propyloxy) -6-nitro- ■jιιinaτ:r.l IΠP
5.60 g tetrabutylammonium fluoride-trihydrate are added to 2.50 g of 4- [ (3-bromophenyl) amino] -7- [3- (tert . butyldimethyl- - 93 -
(8) 4- [ (R) - (1-Phenyl-ethyl) amino] -7- (2-{N- [ (methoxycarbonyl) - methyl] -N-methylamino} -ethoxy] -6-nitro-quinazoline (reaction is carried out in acetonitrile in the presence of diisopropylethylamine and sodium iodide)
Rf value: 0.35 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI"): m/z = 438 [M-H]"
Example XI
4- [ (3 -Bromophenyl) amino] -7- [3- (methylsulphonyloxy) -propyloxy] -
6-ni t-o-qr-i na ol ine ,
1.10 ml of triethylamine are added to 1.28 g of 4- [(3 -bromophenyl) amino] -7- (3-hydroxy-propyloxy) -6-nitro-quinazoline in 55 ml of methylene chloride. Then, whilst cooling with an ice bath, a solution of 0.47 ml of methanesulphonic acid chloride in 5 ml of methylene chloride is added dropwise. The reaction mixture is stirred for about one hour at ambient temperature. Since some starting material can still be detected, another 20 drops of triethylamine and 10 drops of methanesulphonic acid chloride are added, whilst cooling with an ice bath. The mixture is stirred for a further 30 minutes at ambient temperature, whereupon a clear, reddish-orange solution is formed. For work-up, this is diluted with methylene chloride and added to 100 ml of water. The organic phase is washed with 3 % sodium hydrogen carbonate solution and water, dried over sodium sulphate and concentrated by evaporation. A brownish-yellow resin remains, which is further reacted as the crude product. Yield: 1.4 g (92 % of theory) Rf value: 0.70 (silica gel, methylene chloride/methanol = 9:1)
The following compounds are obtained analogously to Example XI:
(1) 4- [ (3 -bromophenyl) amino] -7- [2- (methylsulphonyloxy) -ethoxy] -6-nitro-quinazoline Rf value: 0.73 (silica gel, methylene chloride/methanol = 9:1) O 00/51
- 95 -
silyloxy) -propyloxy] -6-nitro-quinazoline in 25 ml of tetrahydrofuran. The reaction mixture is stirred for about 2 hours at ambient temperature. After the cleavage is complete, the reaction mixture is combined with 150 ml of a 2 % ammonium chloride solution and cooled in the ice bath. A yellow precipitate is formed which is suction filtered and washed with water. The precipitate, while still damp, is dissolved in methylene chloride/methanol (6:4), dried over sodium sulphate and concentrated by evaporation. The yellow residue is stirred with a little petroleum ether and suction filtered, washed with petroleum ether and dried in vacuo .
Yield: 1.29 g (66 % of theory)
Rf value: 0.63 (silica gel, methylene chloride/methanol = 9:1)
Mass spectrum (ESI"): m/z = 417, 419 [M-H]"
The following compounds are obtained analogously to Example XII:
(1) 4- [ (3-bromophenyl) amino] -7- (2-hydroxy-ethoxy) -6-nitro- quinazoline
Rf value: 0.66 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI*): m/z = 405, 407 [M+H]*
(2) 4- [ (3-bromophenyl) amino] -7- (4-hydroxy-butyloxy) -6-nitro- quinazoline
Rf value: 0.62 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI"): m/z = 431, 433 [M-H]"
Example XXIX
4- f ( -chlorophenyl) amino! -7-flur.rn-6-m' ro-quina ol ine A solution of 2.76 ml of 3-chloroaniline in 7 ml of dioxan is added dropwise to 5.0 g of 4-chloro-7-fluoro-6-nitro-quinazo- line in 40 ml of methylene chloride at 15°C within 15 minutes. The reaction mixture is stirred for a further 15 minutes at this temperature before being poured onto 100 ml of n-hexane for working up. The mixture is stirred for about one hour while cooling with an ice bath, then the precipitate formed is filtered off. The hydrochloride thus obtained is suspended in
30 ml of methanol, made alkaline with triethylamine while cooling with an ice bath and combined with 100 ml of water.
The precipitate formed is suction filtered and washed with water. The crude product is purified by chromatography on a silica gel column with methylene chloride/methanol (20:1) as eluant .
Yield: 3.50 g (50 % of theory),
Melting point: 223-225°C
Mass spectrum (ESI*): m/z = 319, 321 [M+H]*
The following compounds are obtained analogously to Example XIII:
(1) (R) -4- [ (1-phenylethyl) amino] -7-fluoro-6-nitro-quinazoline
Melting point: 204-206°C
Mass spectrum (ESI*): m/z = 313 [M+H]*
(2) 4 -Benzylamino-7-fluoro-6-nitro-quinazoline Melting point: 223-225°C
Mass spectrum (ESI*): m/z = 299 [M+H]*
Example XXV
4- [ (3-chloro-4-fluorophenyl) amino] -6- [ (3 -ethoxycarbonyl-1-oxo-
2-propen-l-yl) a inol -7-eyc opropylmethoxy-quinazQ.line
A solution of 3.00 g of ethyl 3 -chlorocarbonyl-acrylate in 50 ml of tetrahydrofuran is added dropwise to 5.00 g of 6-amino- 4- [ (3-chloro-4-fluorophenyl) amino] -7-cyclopropylmethoxy-qui- nazoline and 3.5 ml of diisopropylethylamine in 150 ml of tetrahydrofuran while cooling with an ice bath. The reaction mixture is stirred for a further hour while cooling with an ice bath and then stirred overnight at ambient temperature. Next, the solvent is largely distilled off in the rotary evaporator and the residue is partitioned between water and ethyl acetate . The organic phase is washed with saturated O 00/51991
- 97 -
sodium chloride solution, dried over magnesium sulphate and concentrated by evaporation. The brown, oily crude product is stirred with diethylether, the precipitate formed is suction filtered and washed with a little diethylether.
Yield: 3.20 g (47 % of theory),
Rf value : 0 . 80 (silica gel , ethyl acetate)
Mass spectrum (ESI*) : m/z = 485 , 487 [M+H] *
Exatnpl XV
4- [ (R) - (1-Phenyl -ethyl) amino] -7- (2-hydroxy-ethoxy) -6-nitro- quinazol ri
To a stirred solution of 7.70 g 4- [ (R) - (1-phenyl-ethyl) amino] -
7- [2- (tetrahydro-pyran-2-yloxy) -ethoxy] -6-nitro-quinazoline in 120 ml of methanol are added 2 ml of concentrated hydrochloric acid. The reaction mixture is stirred for 1.5 hours at 50°C. After cooling, the mixture is neutralized with solid sodium bicarbonate and concentrated in vacuo . The solid residue is dissolved in ethyl acetate, washed with concentrated aqueous sodium bicarbonate solution, dried over magnesium sulfate, and concentrated. The residue is triturated with 30 ml of diethyl ether, filtered off with suction, and dried.
Yield: 4,34 g (88 % of theory),
Melting point : 187-192°C
Mass spectrum (ESI*): m/z = 355 [M+H]*
The following compounds are obtained analogously to Example XV:
(1) 4- [ (R) - (1-Phenyl-ethyl) amino] -7- (3-hydroxy-propyloxy) -
6-nitro-quinazoline
Melting point: 178-183°C
Mass spectrum (ESI*): m/z = 369 [M+H]* O 00/51991
- 98 -
(2) 4- l (R) - (1-Phenyl-ethyl) amino] -7- (4-hydroxy-butyloxy) -
6-nitro-quinazoline
Melting point : 143-146°C
Mass spectrum (ESI*): m/z = 383 [M+H]*
Example XVI
4- [ (3 -Chloro-4-fluoro-phenyl) amino] -6- ( {4- [4- (tert .butyloxycarbonyl) -piperazin-1-yl] -l-oxo-2-buten-l-yl}amino) -7-cyclo- propylme hoxy-qπina ol i e
4.7 ml of oxalyl dichloride are added to a solution of 4.51 g 4-bromo-but-2-enoic acid in 100 ml of methylene chloride at room temperature. After addition of one drop of N, N-dimethyl- formamide, the reaction mixture is stirred for approximately 45 minutes until the gas evolution has ceased. The solvent is distilled off in vacuo to give the crude acid chloride.
In the meantime, a mixture of 7.00 g 6-amino-4- [ (3-chloro- 4 -fluoro-phenyl) amino] -7-cyclopropylmethoxy-quinazoline and 10.2 ml diisopropylethylamine in 250 ml tetrahydrofuran is cooled to 0°C in an ice/water bath. The crude 4-bromo-but- 2-enoic acid chloride is dissolved in 20 ml of methylene chloride and added dropwise to this mixture within 5 minutes . After stirring for 45 minutes at 0°C and one hour at room temperature, 18.17 g of piperazine-1-carboxylic acid tert.butyl ester suspended in 5 ml of N, N-dimethyl-formamide are added. After stirring for 48 hours at room temperature, the solvent is distilled off in vacuo and the residue is partitioned between 100 ml of water and 200 ml of ethyl acetate. The aqueous layer is extracted with ethyl acetate, the combined organic layers are washed with concentrated aqueous sodium chloride solution, dried over magnesium sulfate, and concentrated in vacuo . The crude product is purified by column chromatography on silica gel with ethyl acetate/methanol (15:1 to 9:1) .
Yield: 5.2 g (44 % of theory), Rf value: 0.42 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI"): m/z = 609, 611 [M-H]"
The following compound is obtained analogously to Example XVI :
(1) 4- [ (3 -Chloro-4 -fluoro-phenyl) amino] -6- ({4- [2- (ethoxycarbonyl) -4- (tert .butyloxycarbonyl) -piperazin-1-yl] -l-oxo-2-buten- 1-yl } amino) -7-cyclopropylmethoxy-quinazoline (The starting material 1- (tert . butyloxycarbonyl ) -3 - (ethoxycarbonyl) -pipera- zine was obtained by treatment of piperazine-2-carboxylic acid ethyl ester with tert. butyl carbonic anhydride in ethanol.) Rf value: 0.26 (silica gel, ethyl acetate/cyclohexane = 7:3) Mass spectrum (ESI*): m/z = 683, 685 [M+H]*
FiXr?TT.p1 . XVTI
Rthyl [4- M , 1 -Dimethyl -2 -oxo-ethyl ) -piperazi n-1 -yl 1 -arpf.afp A solution of 10.0 g 2-bromo-2-methyl-propionaldehyde in 20 ml of ethanol is added dropwise to a mixture of 25.0 g N-[ (ethoxycarbonyl) methyl] -piperazine in 80 ml of ethanol at room temperature. The resulting mixture is stirred for 72 hours, concentrated in vacuo, and submitted directly to column chromatography on silica gel with methylene chloride/methanol (95:5 to 80:20) to give the title compound as a yellow oil. Yield: 10.0 g (62 % of theory),
Rf value: 0.60 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI") : m/z = 241 [M-K] "
Figure imgf000101_0001
4- [ (3-Chloro-4-fluoro-phenyl) amino] -6- { [2- (diethoxyphospho- •ryl ) -1 -oxo-ethyl 1 ami no} -7-cyclopropylmethoxy-gιιi naτ:ol i ΠP 137 mg (diethoxyphosphoryl) -acetic acid and 225 mg benzo- triazol-l-yl-N,N,N' , N ' -tetramethyluronium tetrafluoroborate are added subsequently to a solution of 200 mg 6-amino-4- [ (3 - chloro-4 -fluoro-phenyl) amino] -7-eyelopropylmethoxy-quinazoline and 0.11 ml triethylamine in 1 ml of anhydrous N, -dime hy1- formamide . The reaction mixture is stirred for one hour at O 00/51991
- 100 -
room temperature, quenched with 10 ml of water, and extracted with ethyl acetate/methanol (10:1). The combined extracts are washed with water and brine, dried over magnesium sulfate, and concentrated in vacuo . The crude product is recrystallized from diethyl ether.
Yield: 190 mg (64 % of theory) ,
Melting point: 185-187°C
Mass spectrum (ESI*): m/z = 537, 539 [M+H]*
Preparation of the end products:
Example 1
4- [ (3 -Bromophenyl) amino] -7- (3- {4- [ (ethoxycarbonyl) methyl] - piperazin-l-yl}propyloxy) -6- , (vinylcarbonyl) am-inol -qninazol ine 440 mg of 6-amino-4- [ (3-bromophenyl) amino] -7- (3- {4- [ (ethoxycarbonyl) methyl] -piperazin-l-yl}propyloxy) -quinazoline are suspended in 20 ml of methylene chloride at ambient temperature and combined with 0.24 ml of triethylamine under a nitrogen atmosphere. The reaction mixture is cooled to -10°C with an ice/sodium chloride bath, then a solution of 84 mg of acrylic acid chloride in 5 ml of methylene chloride is added drop- wise within about 10 minutes. After another 10 minutes the reaction is complete. The reaction solution is washed with a little dilute potassium carbonate solution and water, dried and concentrated by evaporation. 526 mg of crude product are obtained as a brown resin which is purified by chromatography on a silica gel column with methylene chloride/ethanol (95:5). Yield: 300 mg (62 % of theory) , Melting point: 110-113°C Mass spectrum (ESI*): m/z = 597, 599 [M+H]*
The following compounds are obtained analogously to Example 1 :
(1) 4- [ (3-bromophenyl) amino] -7- (3-{4- [ (isopropyloxycarbonyl) methyl] -piperazin-l-yl}propyloxy) -6- [ (vinylcarbonyl) ami- no] -quinazoline
Melting point: 95-100°C
Mass spectrum (ESI*): m/z = 611, 613 [M+H]*
(2) 4- [ (3-bromophenyl) amino] -7- (3- {4- [ (cyclohexyloxycarbonyl) - methyl] -piperazin-l-yl}propyloxy) -6- [ (vinylcarbonyl) amino] - quinazoline
Melting point: 96-104°C
Mass spectrum (ESI*): m/z = 651, 653 [M+H]* (3) 4- [ (3-bromophenyl) amino] -7-(3-{4-[2- (ethoxycarbonyl) - ethyl] -piperazin-l-yl}propyloxy) -6- [ (vinylcarbonyl) amino] - quinazoline
Melting point: 97-102°C
Mass spectrum (ESI*): m/z = 611, 613 [M+H]*
(4) 4- [ (3-bromophenyl) amino] -7- (3- {4- [3- (ethoxycarbonyl) propyl] -piperazin-l-yl}propyloxy) -6- [ (vinylcarbonyl) amino] -quinazoline
Melting point: 107-111°C
Mass spectrum (ESI*): m/z = 625, 627 [M+H]*
(5) 4- [ (3-bromophenyl) amino] -7- (2- {4- [ (ethoxycarbonyl) methyl] - piperazin-l-yl}ethoxy) -6- [ (vinylcarbonyl) amino] -quinazoline Melting point: 75-79°C
Mass spectrum (ESI*) : m/z = 583, 585 [M+H]*
(6) 4- [ (3-bromophenyl) amino] -7- ({l- [ (ethoxycarbonyl) methyl] - piperidin-4 -yl}oxy) -6- [ (vinylcarbonyl) amino] -quinazoline Melting point: 95°C
Mass spectrum (ESI*): m/z = 554, 556 [M+H]*
(7) 4- [ (3-bromophenyl) amino] -7- ( {l- [ (ethoxycarbonyl) methyl] - piperidin-4 -yl}methoxy) -6- [ (vinylcarbonyl) amino] -quinazoline Melting point: 141°C
Mass spectrum (ESI*): m/z = 568, 570 [M+H]*
(8) 4- [ (3-bromophenyl) amino] -7- (2- (l- [ (ethoxycarbonyl) methyl] - piperidin-4 -yl} ethoxy) -6- [ (vinylcarbonyl) amino] -quinazoline Melting point: 156°C
Mass spectrum (ESI*): m/z = 582, 584 [M+H]*
(9) 4 - [ (3 -bromophenyl ) amino] -7- (3 - {1- [ (ethoxycarbonyl) methyl] - piperidin-4 -yl}propyloxy) -6- [ (vinylcarbonyl) amino] -quinazoline Melting point: 124 °C
Mass spectrum (ESI*): m/z = 596, 598 [M+H]* (10) 4- [ (3-bromophenyl) amino] -7- (3- {4- [ (diethoxyphosphoryl) - methyl] -piperazin-1-yl}propyloxy) -6- [ (vinylcarbonyl) amino] - quinazoline
Melting point: 80-85°C
Mass spectrum (ESI*): m/z = 661, 663 [M+H]*
(11) 4- [ (3-bromophenyl) amino] -7- (3- {4- [ (diethoxyphosphoryl) - methyl] -piperazin-l-yl}propyloxy) -6- [ (l-oxo-2-butyn-l-yl) ami- no] -quinazoline (the reaction is carried out with 2-butyne- carboxylic acid and isobutyl chloroformate in tetrahydrofuran) Melting point: 137-139°C
Mass spectrum (ESI*): m/z = 673, 675 [M+H]*
(12) 4- [ (3-bromophenyl) amino] -7- (3-{4- [ (butyloxycarbonyl) methyl] -piperazin-l-yl}propyloxy) -6- [ (vinylcarbonyl) ami- no] -quinazoline
Rf value: 0.53 (silica gel, methylene chloride/methanol/concen- trated aqueous ammonia solution = 90:10:1) Mass spectrum (ESI*): m/z = 625, 627 [M+H]*
(13) 4- [ (3-bromophenyl) amino] -7- (3- {N- [ (ethoxycarbonyl) methyl] -N-methylaminoJpropyloxy) -6- [ (vinylcarbonyl) amino] - quinazoline
Rf value: 0.68 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI*): m/z = 542, 544 [M+H]*
(14) 4- [ (3-bromophenyl) amino] -7- (2- {N- [ (ethoxycarbonyl) methyl] N-methylamino}ethoxy) -6- [ (vinylcarbonyl) amino] -quinazoline
Rf value: 0.71 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI*): m/z = 528, 530 [M+H]*
(15) 4- [ (3-bromophenyl) amino] -7- (4- {N- [ (ethoxycarbonyl) methyl] -N-methylaminoJbutyloxy) -6- [ (vinylcarbonyl) amino] - quinazoline
R£ value: 0.67 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (El): m/z = 555, 557 [M] * (16) 4- [ (22) - (1-Phenyl-ethyl) amino] -7- {2- [2- (methoxycarbonyl) - piperidin-1-yl] -ethoxy} -6- [ (vinylcarbonyl) amino] -quinazoline Rf value: 0.70 (silica gel, methylene chloride/methanol/ concentrated aqueous ammonia = 90:10:1) Mass spectrum (ESI"): m/z = 502 [M-H]"
(17) 4- [ (R) - (1-Phenyl-ethyl) amino] -7- (2- [ (R) -2- (methoxycarbonyl) -pyrrolidin-1-yl] -ethoxy} -6- [ (vinylcarbonyl) amino] -quinazoline
Rf value: 0.30 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI"): m/z = 488 [M-H]"
(18) 4- [ (R) - (1-Phenyl-ethyl) amino] -7- {2- [ (5) -2- (methoxycarbonyl) -pyrrolidin-1-yl] -ethoxy} -6- [ (vinylcarbonyl) amino] -quinazoline
R£ value: 0.32 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI"): m/z = 488 [M-H]"
(19) 4- [ (R) - (1-Phenyl -ethyl) amino] -7- {3- [ (R) -2 - (methoxycarbonyl) -pyrrolidin-1-yl] -propyloxy} -6- [ (vinylcarbonyl) amino] - quinazoline
Rf value: 0.30 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI"): m/z = 502 [M-H]"
(20) 4- [ (R) - (1-Phenyl-ethyl) amino] -7- {4- [2- (methoxycarbonyl) - piperidin-1-yl] -butyloxy} -6- [ (vinylcarbonyl) amino] -quinazoline Rf value: 0.27 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI*): m/z = 532 [M+H]*
(21) 4- [ (R) - (1-Phenyl -ethyl) amino] -7- (2- {N- [ (methoxycarbonyl) - methyl] -N-methylamino} -ethoxy) -6- [ (vinylcarbonyl) amino] -quinazoline
Rf value: 0.30 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI*): m/z = 464 [M+H]* Example 2
4- [ (3 -Bromophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) methyl] -
N-methylamino} -l-oxo-2-buten-l-yl) mino] -quinazol ine
13.94 ml of Hύnig base are pipetted into a suspension of 9.37 g of sarcosine ethylester hydrochloride in 25 ml of tetrahydrofuran while cooling with an ice bath. Then a solution of 2.00 g of 4- [ (3-bromophenyl) amino] -6- [ (4-bromo-l-oxo-2-buten- 1-yl) amino] -quinazoline in 10 ml of dimethylformamide is added dropwise within 15 minutes. The reaction mixture is allowed to come up to ambient temperature overnight in an ice bath. For working up, 25 ml of saturated sodium hydrogen carbonate solution and 50 ml of ethyl acetate are added. The organic phase is separated off and the aqueous phase is extracted with ethyl acetate. The combined organic phases are washed with saturated sodium chloride solution, dried over magnesium sulphate and concentrated by evaporation. The dark-brown oily residue is stirred with 50 ml of water, the precipitate formed is suction filtered and washed with water. The crude product is purified by chromatography on a silica gel column with methylene chloride/methanol (50:1 to 20:1). Yield: 1.00 g (46 %of theory), Melting point: 182-183°C Mass spectrum (ESI"): m/z = 496, 498 [M-H]"
The following compounds are obtained analogously to Example 2 :
(1) 4- [ (3-bromophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-me hoxy-quinazoline
Melting point: 121-125°C
Mass spectrum (El): m/z = 527, 529 [M] *
(2) 4- [ (3-bromophenyl) amino] -6- [ (4- {N,N-bis [ (ethoxycarbonyl) methyl] -amino} -l-oxo-2-buten-l-yl) amino] -quinazoline Melting point: 150-154°C
Mass spectrum (El): m/z = 541, 543 [M] * O 00/51991
- 106 -
(3) 4- [ (3-bromophenyl) amino] -6- ({4- [2- (methoxycarbonyl) -pyr- rolidin-1-yl] -l-oxo-2-buten-l-yl}amino) -7-methoxy-quinazoline Rf value: 0.43 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI*): m/z = 539, 541 [M+H]*
(4) 4- [ (3-bromophenyl) amino] -6- [ (4- (N- [ (diethoxyphosphoryl) methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy-quinazoline
Rf value: 0.38 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI"): m/z = 590, 592 [M-H]"
(5) 4- [ (3-bromophenyl) amino] -6- [ (4- {4- [ (ethoxycarbonyl) methyl] -piperazin-1-yl} -l-oxo-2-buten-l-yl) amino] quinazoline
Rf value: 0.37 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI*): m/z = 553, 555 [M+H]*
(6) 4- [ (3-bromophenyl) amino] -6- [ (4- (N- [1, 2-bis (methoxycarbonyl) -ethyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy-quinazoline (reaction took place in acetonitrile under reflux)
Rf value: 0.50 (silica gel, ethyl acetate/methanol = 15:1) Mass spectrum (El): m/z = 585, 587 [M] *
Example 3
4- [ (3 -Bromophenyl) amino] -6- { [4- (3- {N- [ (ethoxycarbonyl) methyl] - N-methylamino}propylamino) -1, 4-dioxo-2-buten-l-yl] amino} - quinazoline
106 mg of benzotriazol-1-yl-N-tetramethyl-uronium-tetrafluo- roborate and 68 mg of 1-hydroxybenzotriazole are added to a solution of 200 mg of 4- [ (3 -bromophenyl) amino] -6- {[ (2-carboxy- vinyl) carbonyl] amino} -quinazoline in 2.5 ml of dimethyl-formamide . The solution is stirred for 20 minutes at ambient temperature, then 0.5 ml of Hϋnig's base and 148 mg of 3-{N- [ (ethoxycarbonyl) methyl] -N-methylamino}propylamine, dissolved in 0.5 ml of dimethylformamide, are added. The reaction mixture is stirred for a further two hours at ambient temperature before being poured onto 50 ml of water for working up. The aqueous phase is extracted with ethyl acetate, the combined organic phases are washed with saturated sodium chloride solution, dried over magnesium sulphate and concentrated by evaporation. The crude product is purified by chromatography on a silica gel column with methylene chlori- de/ethanol (20:1 to 9:1). Yield: 106 mg (39 % of theory) , Melting point: 278-279°C Mass spectrum (ESI*): m/z = 569, 571 [M+H]*
The following compounds are obtained analogously to Example 3 :
(1) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- { [4- (3- {N- [ (ethoxycarbonyl) methyl] -N-methylamino}propylamino) -1, 4-dioxo-2-buten- 1-yl] amino} -7-cyclopropylmethoxy-quinazoline
Melting point : 155-158°C
Mass spectrum (El): m/z = 612, 614 [M] *
(2) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6-{ [4- (2-{N- [ (ethoxycarbonyl) methyl] -N-methylaminoJethylamino) -1, 4-dioxo-2-buten- 1-yl] amino} -7-cyclopropylmethoxy-quinazoline
Rf value: 0.56 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI*): m/z = 599, 601 [M+H]*
(3) 4- [ (3 -Chloro-4-fluoro-phenyl) amino] -6-[(4-{4-[ (ethoxycarbonyl) methyl] -piperazin-1-yl} -1, 4-dioxo-2-buten-l-yl) amino] - 7-eyelopropylmethoxy-quinazoline
Melting point: 199°C
Mass spectrum (ESI"): m/z = 609, 611 [M-H]"
(4) ( S) -4- [ (3-Chloro-4-fluoro-phenyl) amino] -6- ( {4- [2- (methoxycarbonyl) -pyrrolidin-1-yl] -1, 4-dioxo-2-buten-l-yl}amino) -
7-eyelopropylmethoxy-quinazoline
Rf value: 0.57 (silica gel, ethyl acetate/methanol = 95:5) Mass spectrum (ESI"): m/z = 566, 568 [M-H]"
Example 4
4- [ (3 -Bromophenyl) amino] -6- ( {4- [ (tert-butylcarbonyloxy) meth- oxyl -1. r4-dioxo-2-bu n-l -yl } ami no) gπinazol ine
207 mg of potassium carbonate and 0.144 ml of chloromethyl pivalate are added to 200 mg of 4- [ (3-bromophenyl) amino] -6- {[ (2 -carboxy-vinyl) carbonyl] amino} -quinazoline in 2 ml of dimethylsulphoxide . Then a further 30 mg of sodium iodide are added and the reaction mixture is stirred for 48 hours at ambient temperature. For working up, the reaction mixture is diluted with 20 ml of water and extracted with ethyl acetate. The combined extracts are washed with saturated sodium chloride solution, dried over magnesium sulphate and concentrated by evaporation. The crude product mixture is purified by chromatography on a silica gel column with methylene chloride/methanol (20:1). Yield: 10 mg (4 % of theory),
Rf value: 0.42 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (El) : m/z = 526 [M] *
The following compounds are obtained analogously to Example 4 :
(1) 4- [ (3-bromophenyl) amino] -6- ( {4- [1- (ethyloxycarbonyloxy) - ethoxy] -1, 4-dioxo-2-buten-l-yl }amino) quinazoline (the reaction is carried out in dimethylformamide)
Rf value: 0.43 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI*): m/z = 529, 531 [M+H]*
(2) 4- [ (3-Chloro-4-fluoro-phenyl)amino] -6-{ [4- (4-{ [ (tert .bu- tylcarbonyloxy) methoxycarbonyl] methyl} -piperazin-1-yl) -1-oxo- 2-buten-l-yl] amino} -7-cyclopropylmethoxy-quinazoline (by reaction of the compound of Example 9(1) with chloromethyl pivalate in N,N-dimethyl-formamide in the presence of triethylamine)
Rf value: 0.50 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI"): m/z = 681, 683 [M-H]"
Example 5
4- [ (3-methylphenyl) amino] -6- [(4-{N- [ (ethoxycarbonyl) methyl] -N- methylamino}-l-oxo-2-buten-l -yl) a inol -7-methoxy-qπ nazol ine 0.86 ml of oxalylchloride and- one drop of dimethylformamide are added to a solution of 842 mg of 4-bromo-2-butenoic acid in 15 ml of methylene chloride at ambient temperature. The reaction mixture is stirred for about a further hour at ambient temperature until the evaluation of gas has ended. The acid chloride formed is largely freed from solvent in the rotary evaporator in vacuo . Then the crude product is taken up in 10 ml of methylene chloride and, while cooling with an ice bath, added dropwise within five minutes to a mixture of 1.0 g of 6- amino-4- [ (3-methylphenyl) amino] -7-methoxy-quinazoline and 2.0 ml of Hϋnig's base in 50 ml of tetrahydrofuran. The reaction mixture is stirred for two hours whilst cooling with an ice bath and for a further two hours at ambient temperature. 6.7 ml of Hϋnig base, 5.48 g of sarcosine ethylester hydrochloride and 3 ml of dimethylformamide are then added and the resulting mixture is stirred overnight at ambient temperature. For working up, the reaction mixture is concentrated by evaporation in the rotary evaporator in vacuo and the residue from the flask is partitioned between 75 ml of ethyl acetate and 75 ml of water. The organic phase is washed with water and saturated sodium chloride solution, dried over magnesium sulphate and concentrated by evaporation. The crude product is purified by chromatography on a silica gel column with methylene chloride/methanol (20 : 1) . Yield: 326 mg (20 % of theory) Melting point: 122-124°C Mass spectrum (ESI*): m/z = 464 [M+H]*
The following compounds are obtained analogously to Example 5: (1) 4- [ (3 -chlorophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy-quinazoline
Melting point: 118-120°C
Mass spectrum (ESI*) : m/z = 484 [M+H]*
(2) (R) -4- [ (1-phenylethyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy-quinazoline
Rf value: 0.49 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI*) : m/z = 478 [M+H] *
(3) 4- [ (3-bromophenyl) amino] -6- [ (4- {N- [ (methoxycarbonyl) methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy-quinazoline
Melting point: 197-199°C
Mass spectrum (El) : m/z = 513, 515 [M] *
(4) 4- [ (3-bromophenyl) amino] -6- [ (4- {N- [ (butyloxycarbonyl) methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy- quinazoline
Melting point: 120-123 °C
Mass spectrum (El) : m/z = 555, 557 [M] *
(5) 4- [ (3-bromophenyl) amino] -6- [ (4- {N- [ (cyclohexyloxycarbo- nyl)methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy-quinazoline
(The sarcosine eyelohexylester used was obtained by treating sarcosine in cyclohexanol with gaseous hydrochloric acid) Melting point : 124-125°C Mass spectrum (ESI*): m/z = 582, 584 [M+H]*
(6) 4- [ (3-bromophenyl) amino] -6- [ (4- {4- [ (ethoxycarbonyl) methyl] -piperazin-1-yl} -l-oxo-2-buten-l-yl) amino] -7-methoxy-quinazoline
Melting point: 147-150°C
Mass spectrum (ESI*): m/z = 583, 585 [M+H]* - Ill
(7) 4- [ (3-bromophenyl) amino] -6-[(4-{4-[ (isopropyloxycarbonyl) - methyl] -piperazin-1-yl} -l-oxo-2-buten-l-yl) amino] -7-methoxy- quinazoline
(The isopropyl piperazin-1-yl-acetate used was obtained from N-benzylpiperazine by reacting with isopropyl bromoacetate and subsequently cleaving the benzyl group by hydrogenolysis.) Melting point: 125-127°C Mass spectrum (ESI*): m/z = 597, 599 [M+H]*
(8) 4- [ (3 -bromophenyl) amino] -6- ( {4- [N- (2 , 2-dimethoxyethyl) -N- methylamino] -l-oxo-2-buten-l-yl}amino) -7-methoxy-quinazoline Melting point: 135-137°C
Mass spectrum (ESI*): m/z = 530, 532 [M+H]*
(9) 4- [ (3-bromophenyl) amino] -6- ( {4- [N- (1, 3-dioxolan-2-yl- methyl) -N-methylamino] -l-oxo-2-buten-l-yl}amino) -7-methoxy- quinazoline
Melting point: 120-123°C
Mass spectrum (ESI*): m/z = 528, 530 [M+H]*
(10) 4- [ (3-bromophenyl) amino] -6- { [4- (2-ethoxy-morpholin-4-yl) - l-oxo-2-buten-l-yl] amino} -7-methoxy-quinazoline
Melting point : 118-120°C
Mass spectrum (ESI*): m/z = 542, 544 [M+H]*
(11) 4- [ (3-bromophenyl) amino] -6- { [4- (2-oxo-morpholin-4-yl) -1- oxo-2-buten-l-yl] amino} -7-methoxy-quinazoline
Rf value: 0.43 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (El): m/z = 511, 513 [M] *
(12) 4- [ (3-bromophenyl) amino] -3-cyano-6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -quinoline Melting point: 156°C
Mass spectrum (ESI*): m/z = 522, 524 [M+H]* (13) 4- [ (3-bromophenyl) amino] -6- ( (4- [N, N-bis (2 , 2-diethoxy- ethyl) amino] -l-oxo-2-buten-l-yl} amino) -7-methoxy-quinazoline Rf value: 0.43 (aluminium oxide, cyclohexane/ethyl acetate =
1:1)
Mass spectrum (ESI*): m/z = 660, 662 [M+H]*
(14) 4- [ (3-bromophenyl) amino] -6- [ (4- {4- [bis (methoxycarbonyl) methyl] -piperazin-1-yl} -l-oxo-2-buten-l-yl) amino] -quinazoline
(The N-bis (methoxycarbonyl) methyl-piperazine used is obtained by reacting N- tert-butyloxycarbonyl-piperazine with dimethyl bromomalonate and subsequently cleaving the BOC protecting group . )
Rf value: 0.45 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI*): m/z = 597, 599 [M+H]*
(15) 4- [ (3-bromophenyl) amino] -6-[(4-{4-[l, 2 -bis (methoxycarbonyl) ethyl] -piperazin-1-yl } -l-oxo-2-buten-l-yl) amino] -quinazoline
(The N- [1, 2 -bis (methoxycarbonyl) ethyl] -piperazine used is obtained by reacting N-benzylpiperazine with dimethyl ma- leinate and subsequently cleaving the benzyl protecting group by hydrogenolysis . ) Rf value: 0.51 (silica gel, ethyl acetate/methanol = 9:1)
(16) 4- [ (3-bromophenyl) amino] -6- [ (4- {N- [ (tert . butyloxycarbonyl) methyl] -N- (2-hydroxyethyl) amino} -l-oxo-2-buten-l-yl) ami- no] -7-methoxy-quinazoline
Rf value: 0.45 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI"): m/z = 584, 586 [M-H]"
(17) 4- [ (3-chlorone-4-fluorophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7- cyclopropylmethoxy-quinazoline
Melting point: 113-118°C Mass spectrum (El): m/z = 541, 543 [M] *
(18) 4- [ (3 -chlorone-4-fluorophenyl) amino] -6- [ (4- {4- [ (ethoxycarbonyl) methyl] -piperazin-1-yl} -l-oxo-2-buten-l-yl) amino] -7- cycloprσpylmethoxy-quinazoline
Melting point: 115-117°C
Mass spectrum (El): m/z = 596, 598 [M] *
(19) 4- [ (3-bromophenyl) amino] -6-[(4-{4-[l, 3 -bis (methoxycarbonyl) prop-2-yl] -piperazin-1-yl} -l-oxo-2-buten-l-yl) amino] -quinazoline
Rf value: 0.62 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI*): m/z = 625, 627 [M+H]*
(20) 4- [ (3-chloro-4-fluorophenyl) mino] -6- [ (4- {N- [1, l-bis- (methoxycarbonyl) -methyl] -N-methylamino} -l-oxo-2-buten-l-yl) - amino] -7-cyclopropylmethoxy-quinazoline
Melting point: 120-125°C
Mass spectrum (El): m/z = 585, 587 [M] *
(21) 4- [ (3-bromophenyl) amino] -6- [ (4-{4- [ (diethoxyphosphoryl) - methyl] -piperazin-1-yl} -l-oxo-2-buten-l-yl) amino] -quinazoline
(The N- [ (diethoxyphosphoryl) methyl] -piperazine used is obtained by reacting N-benzylpiperazine with formaldehyde and diethyl phosphorate and subsequently cleaving the benzyl pror.ec- ting group by hydrogenolysis.)
Rf value: 0.18 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI*): m/z = 617, 619 [M+H]*
(22) 4- [ (3-chloro-4-fluorophenyl) amino] -6- [ (4- {N- [2- (ethoxycarbonyl) -ethyl] -N- [ (ethoxycarbonyl) methyl] amino} -l-oxo-2-bu- ten-l-yl) amino] -7-cyclopropylmethoxy-quinazoline
Rf value: 0.62 (aluminium oxide, cyclohexane/ethyl acetate
= 1:1) Mass spectrum (El): m/z = 627, 629 [M] * (23) 4- [ (3 -chloro-4-fluorophenyl) amino] -6- [ (4- {4- [ (tert-butyl- oxycarbonyl) methyl] -piperazin-1-yl} -l-oxo-2-buten-l-yl) amino] - 7-cyclopropylmethoxy-quinazoline
Rf value: 0.42 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI*): m/z = 625, 627 [M+H]*
(24) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- [ (4- {N, N-bis [2- (ethoxycarbonyl) -ethyl] -amino} -l-oxo-2-buten-l-yl) amino] -7-cyclo- propylmethoxy-quinazoline
Rf value: 0.37 (aluminium oxide, cyclohexane/ethyl acetate
= 1:1) Mass spectrum (ESI*): m/z = 642, 644 [M+H]*
(25) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- { [4- (2-oxo-morpho- lin-4-yl) -l-oxo-2-buten-l-yl] amino} -7-cyclopropylmethoxy-quinazoline
Melting point: 230-232°C
Mass spectrum (El): m/z = 525, 527 [M] *
(26) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N- (2 -hydroxyethyl) amino} -l-oxo-2-buten-l- yl) amino] -7-cyclopropylmethoxy-quinazoline
Rf value: 0.25 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (El): m/z = 571, 573 [M] *
(27) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- [ (4- {4- [ (ethoxycarbonyl) methyl] -piperazin-1-yl} -l-oxo-2-buten-l-yl) amino] -7-cyc- lohexylmethoxy-quinazoline
Melting point: 110-114°C
Mass spectrum (El): m/z = 638, 640 [M] *
(28) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- [ (4- {4- [ (ethoxycarbonyl) methyl] -piperazin-1-yl } -l-oxo-2-buten-l-yl) amino] -7-cyc- lohexyloxy-quinazoline
Melting point: 117°C
Mass spectrum (El): m/z = 624, 626 [M] * (29) 4- [ (3-chloro-4-fluorophenyl) amino] -6- [ (4- {4- [ (ethoxycarbonyl) methyl] -piperazin-1-yl} -l-oxo-2-buten-l-yl) amino] -7-cyc- lobutyloxy-quinazoline
Melting point: 194-195°C
Mass spectrum (El): m/z = 596, 598 [M] *
(30) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- [ (4- {4- [ (ethoxycarbonyl) methyl] -piperazin-1-yl} -l-oxo-2-buten-l-yl) amino] -7-cyc- lobutylmethoxy-quinazoline
Rf value: 0.53 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (El): m/z = 610, 612 [M] *
(31) 4- [ (3-chloro-4-fluorophenyl) amino] -6- [ (4- {4- [ (ethoxycarbonyl) methyl] -piperazin-1-yl} -l-oxo-2-buten-l-yl) amino] -7-cyc- lopentylmethoxy-quinazoline
Rf value: 0.53 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (El): m/z = 624, 626 [M] *
(32) 4- [ (3 -chloro-4-fluorophenyl) amino] -6- [ (4- {4- [ (ethoxycarbonyl) methyl] -piperazin-1-yl} -l-oxo-2-buten-l-yl) amino] -
7- (2 -cyclopropylethoxy) -quinazoline
Rf value: 0.53 (silica gel, methylene chloride/methanol = 9:1)
Mass spectrum (El): m/z = 610, 612 [M] *
(33) 4- [ (3-chloro-4-fluorophenyl) amino] -6- [ (4- {4- [ (ethoxycarbonyl) methyl] -piperazin-1-yl} -l-oxo-2-buten-l-yl) amino] -7-cyc- lopentyloxy-quinazoline
Rf value: 0.35 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (El): m/z = 610, 612 [M] *
(34) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- [ (4-{N- [ (ethoxycarbonyl) methyl] -N- (2 -hydroxy-2 -methyl -propyl) amino} -l-oxo-2-bu- ten-l-yl) amino] -7-cyclopropylmethoxy-quinazoline
Rf value: 0.42 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI*): m/z = 600, 602 [M+H]* (35) 4- [ (3-chloro-4-fluorophenyl) amino] -6- ( {4- [2- (methoxycarbonyl) -piperidin-1-yl] -l-oxo-2-buten-l-yl}amino) -7-cyclopro- pylmethoxy-quinazoline
Rf value: 0.42 (silica gel, ethyl acetate) Mass spectrum (ESI*): m/z = 568, 570 [M+H]*
(36) ( S) -4- [ (3 -chloro-4 -fluorophenyl) amino] -6- ({4- [2- (methoxycarbonyl) -pyrrolidin-1-yl] -l-oxo-2-buten-l-yl}amino) -7-cyclo- propylmethoxy-quinazoline Melting point: 135-138°C Mass spectrum (El) : m/z = 553, 555 [M] *
(37) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- [ (4- {N, N-bis [ (methoxycarbonyl) methyl] mino} -l-oxo-2-buten-l-yl) amino] -7-cyclo- propylmethoxy-quinazoline Melting point: 122 °C Mass spectrum (ESI*): m/z = 586, 588 [M+H]*
(38) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- { [4- (5, 5 -dimethyl - 2-oxo-morpholin-4-yl) -l-oxo-2-buten-l-yl] amino} - 7-cyclo-propylmethoxy-quinazoline
Rf value: 0.39 (silica gel, ethyl acetate) Mass spectrum (ESI*): m/z = 554, 556 [M+H]*
(39) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- { [4- ( 5 -methyl -2-oxo- morpholin-4-yl) -l-oxo-2-buten-l-yl] amino} -7-cyclopropylmethoxy-quinazoline
Rf value: 0.15 (silica gel, ethyl acetate/cyclohexane = 4:1) Mass spectrum (ESI*): m/z = 540, 542 [M+H]*
(40) (R) -4- [ (3 -chloro-4 -fluorophenyl) amino] -6- ( {4- [2- (methoxycarbonyl) -pyrrolidin-1-yl] -l-oxo-2-buten-l-yl }amino) -7-cyclo- propylmethoxy-quinazoline Melting point: 133 °C Mass spectrum (ESI*) : m/z = 554, 556 [M+H]* (41) cis-4- [ (3-chloro-4-fluorophenyl) amino] -6- ( {4- [2, 5-bis-
(ethoxycarbonyl) -pyrrolidin-1-yl] -l-oxo-2-buten-l-yl}amino) -
7-cyclopropylmethoxy-quinazoline
Melting point : 117-120°C
Mass spectrum (ESI*): m/z = 640, 642 [M+H]*
(42) cis-4- [ (3 -Chloro-4 -fluoro-phenyl) amino] -6- ( {4- [2, 6-bis-
(methoxycarbonyl) -piperidin-1-yl] -l-oxo-2-buten-l-yl}amino) - 7-cyclopropylmethoxy-quinazoline
Rf value: 0.20 (silica gel, cyclohexane/ethyl acetate = 2:3) Mass spectrum (El): m/z = 625, 627 [M] *
(43) trans- 4 - [ (3 -Chloro-4 -fluoro-phenyl) amino] -6- ({4- [2, 6-bis-
(methoxycarbonyl) -piperidin-1-yl] -l-oxo-2-buten-l-yl}amino) - 7-cyclopropylmethoxy-quinazoline
Rf value: 0.28 (silica gel, cyclohexane/ethyl acetate = 2:3) Mass spectrum (El): m/z = 625, 627 [M] *
(44) cis-4- [ (3 -Chloro-4 -fluoro-phenyl) amino] -6- ( {4- [2, 5-bis-
(methoxycarbonyl) -pyrrolidin-1-yl] -l-oxo-2-buten-l-yl}amino) -
7-eyelopropylmethoxy-quinazoline
Melting point: 125°C
Mass spectrum (ESI"): m/z = 610, 612 [M-H]"
(45) trans-4- [ (3 -Chloro-4-fluoro-phenyl) amino] -6- ( {4- [2, 5-bis-
(methoxycarbonyl) -pyrrolidin-1-yl] -l-oxo-2-buten-l-yl}amino) -
7-cyclopropylmethoxy-quinazoline
Melting point: 165°C
Mass spectrum (El): m/z = 611, 613 [M] *
(46) 4- [ (3 -Chloro-4 -fluoro-phenyl) amino] -6- [ (4- {4- [ (ethoxycarbonyl) methyl] -piperazin-1-yl} -4-methyl-l-oxo-2-buten-l-yl) - amino] -7-cyclopropylmethoxy-quinazoline
Rf value: 0.45 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI"): m/z = 609, 611 [M-H]" (47) 4- [ (3 -Chloro-4 -fluoro-phenyl) amino] -6- [ (4- {4- [1,2-bis- (methoxycarbonyl) -ethyl] -piperazin-1-yl} -l-oxo-2-buten-l-yl) - amino] -7-cyclobutyloxy-quinazoline (The starting material 2- (piperazin-1-yl) -succinic acid dimethyl ester is prepared by reaction of N-benzyl-piperazine with maleic acid dimethyl ester followed by hydrogenolytic cleavage of the benzyl protecting group.)
Rf value: 0.39 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (El) : m/z = 654, 656 [M] *
(48) 4- [ (3-Chloro-4-fluoro-phenyl) amino] -6- [ (4- {N- [1- (methoxycarbonyl) -ethyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -
7-cyclopropylmethoxy-quinazoline
Rf value: 0.41 (silica gel, ethyl acetate)
Mass spectrum (ESI"): m/z = 540, 542 [M-H]"
(49) (S) -4- [ (3-Chloro-4-fluoro-phenyl) amino] -6- ({4- [2- (benzyloxycarbonyl) -pyrrolidin-1-yl] -l-oxo-2-buten-l-yl }amino) -
7-cyclopropylmethoxy-quinazoline
Rf value: 0.20 (silica gel, cyclohexane/ethyl acetate = 2:3)
Mass spectrum (ESI"): m/z = 628, 630 [M-H]"
(50) 4- [ (R) - (1-Phenyl-ethyl) amino] -6- [ (4- {4- [ (ethoxycarbonyl) - methyl] -piperazin-1-yl} -l-oxo-2-buten-l-yl) amino] -7-cyclobutyloxy-quinazoline
Rf value: 0.25 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (El): m/z = 572 [M] *
(51) 4- [ (R) - (1-Phenyl-ethyl) amino] -6- [ (4- {4- [ (ethoxycarbonyl) - methyl] -piperazin-l-yl } -l-oxo-2-buten-l-yl) amino] -7-cyclopentyloxy-quinazoline
Rf value: 0.27 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI"): m/z = 585 [M-H]" (52) 4- [ (R) - (1-Phenyl-ethyl) amino] -6- [ (4- {4- [ (ethoxycarbonyl) - methyl] -piperazin-1-yl} -l-oxo-2-buten-l-yl) amino] -7-cyclopro- pylmethoxy-quinazoline
Rf value: 0.20 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI"): m/z = 571 [M-H]"
(53) 4- [ (3-Chloro-4-fluoro-phenyl) amino] -6- [ (4- {2- [ (ethoxycarbonyl) methyl] -piperidin-l-yl}-l-oxo-2-buten-l-yl) amino] -
7-eyelopropylmethoxy-quinazoline
Rf value: 0.28 (silica gel, ethyl acetate)
Mass spectrum (ESI"): m/z = 594, 596 [M-H]"
(54) 4- [ (3 -Chloro-4 -fluoro-phenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N- [1- (ethoxycarbonyl) -ethyl] amino} -l-oxo-2-bu- ten-l-yl) amino] -7-cyclopropylmethoxy-quinazoline
Rf value: 0.56 (silica gel, ethyl acetate) Mass spectrum (El): m/z = 627, 629 [M] *
(55) ( S) -4-Benzylamino-6- ({4- [2- (methoxycarbonyl) -pyrrolidin-
1-yl] -l-oxo-2-buten-l-yl}amino) -7-cyclopropylmethoxy-quina- zoline
Rf value: 0.48 (silica gel, ethyl acetate/methanol = 9:1)
Mass spectrum (ESI"): m/z = 514 [M-H]"
(56) 4-Benzylamino-6- [ (4- {4- [ (ethoxycarbonyl) methyl] -pipe- razin-1-yl} -l-oxo-2-buten-l-yl) amino] -7-cyclopropylmethoxy- quinazoline
Rf value: 0.20 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI"): m/z = 557 [M-H]"
(57) (R) -4- [ (3-Chloro-4-fluoro-phenyl) amino] -6- [ (4-{N- [1- (ethoxycarbonyl) -ethyl] -N- (2-hydroxyethyl) amino} -l-oxo-2-buten- 1-yl) amino] -7-cyclopropylmethoxy-quinazoline
Rf value: 0.24 (silica gel, ethyl acetate) Mass spectrum (ESI"): m/z = 584, 586 [M-H]" (58) 4- [ (3-Chloro-4-fluoro-phenyl) amino] -6- [ (4- {4- [ (ethoxycarbonyl) methyl] -homopiperazin-1-yl} -l-oxo-2-buten-l-yl) amino] - 7-cyclopropylmethoxy-quinazoline (The starting material N-
[ (ethoxycarbonyl) methyl] -homopiperazine was prepared by reaction of N-benzyl-homopiperazine with ethyl bromo-acetate and subsequent hydrogenolytic removal of the benzyl group.) Rf value: 0.18 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI"): m/z = 609, 611 [M-H]"
(59) 4- [ (3-chloro-4-fluorophenyl) amino] -6- [ (4- [N- (2-oxo-tetra- hydrofuran-3-yl) -N-methyl-amino] -l-oxo-2-buten-l-yl) amino] -
7-cyclopropylmethoxy-quinazoline
(The starting material 3-methylamino-2-oxo-tetrahydrofuran is prepared by reaction of 3 -bromo-2-oxo-tetrahydrofuran with N-methyl-benzylamin followed by hydrogenolytic cleavage of the benzyl group) melting point: 109°C
Mass spectrum (ESI-): m/z = 538, 540 (M-H) "
(60) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- [ (4- [N- (2-oxo-tetra- hydrofuran-4-yl) -N-methyl-amino] -l-oxo-2-buten-l-yl) amino] -
7-cyclopropylmethoxy-quinazoline
(The starting material 4 -methylamino-2-oxo-tetrahydrofuran is prepared by reaction of (5H) -furan-2-on with N-methyl-benzylamin followed by hydrogenolytic cleavage of the benzyl group) Rf-value: 0.56 (silica gel, ethylacetate/methanol = 9:1)
Mass spectrum (ESI-): m/z = 538, 540 (M-H) "
Exa pl 6
4- [ (3 -Bromophenyl) amino] -7- {3- [4- (carboxymethyl) -piperazin-1- yll propyloxy} -6- \ (vinylcarbonyl aminol -guinazol ne
0.43 ml of triethylamine and 0.15 ml of chlorotrimethylsilane are added to a suspension of 440 mg of 6 -amino-4 -[ (3-bromophenyl) amino] -7- {3- [4- (carboxymethyl) -piperazin-1-yl] propyloxy} - quinazoline in 15 ml of methylene chloride at ambient temperature. The reaction mixture is refluxed gently for about 30 minutes and then stirred overnight at ambient temperature. The cloudy solution is cooled with a mixture of ice and sodium chloride and combined with a solution of 82 mg of acrylic acid chloride in 5 ml of methylene chloride. The reaction mixture is stirred for about one hour at ambient temperature, then at intervals of an hour two drops of acrylic acid chloride are added twice until the reaction is almost complete. The reaction mixture is stirred with 20 ml of ice water and a little methanol. The aqueous phase is extracted several times with methylene chloride/methanol (9:1). The combined extracts are washed with a little water, dried over magnesium sulphate and concentrated by evaporation. The crude product obtained is stirred with acetone, suction filtered, washed again with diethylether and dried at 60 °C in vacuo .
Yield: 105 mg (24 % of theory)
Melting point: 140°C (decomposition)
Mass spectrum (ESI"): m/z = 567, 569 [M-H]"
Example 7
4- [ (3-bromophenyl) amino] -6- { [4- (2 , 6-diethoxy-morpholin-4-yl) - l-oxo-2-buten-l-yll amino} -7-methoxy-quinazoline
1 ml of ice-cooled concentrated hydrochloric acid is added to 340 mg of 4- [ (3-bromophenyl) amino] -6- ( {4- [N, N-bis (2 , 2-dieth- oxyethyl) amino] -l-oxo-2-buten-l-yl }amino) -7-methoxy-quinazoline while cooling with an ice bath. The mixture is left to stand for 3 hours before 1.5 ml of concentrated ammonia solution is added dropwise while cooling with an ice bath for working up. The precpitate formed is suction filtered and washed with water. The crude product is purified by chromatography on a silica gel column with methylene chloride/methanol (20:1) .
Yield: 50 mg (17 % of theory) Melting point: 133-138°C Mass spectrum (El): m/z = 585, 587 [M] * Exampl 8
4- [ (3 -Bromophenyl) amino] -6- [ (4- {N- [ (tert-butyloxycarbonyl) methyl] -N- [2- (acetylsulphanyl) ethyl] amino} -l-oxo-2-buten-l-yl) - aminol -7-me hoxy-qni nazol inp
34 mg of potassium thioacetate are added to 150 mg of 4-[(3- bromophenyl) amino] -6- [(4-{N- [ (tert-butyloxycarbonyl) methyl] -N- [2- (methylsulphonyloxy) ethyl] amino} -l-oxo-2-buten-l-yl) amino] - 7-methoxy-quinazoline in 1 ml of dimethylformamide at ambient temperature. The reaction mixture is stirred overnight at ambient temperature and then combined with water for working up. The aqueous phase is separated off and extracted with ethyl acetate, the combined organic phases are dried over magnesium sulphate and freed from solvent in the rotary evaporator. Yield: 20 mg (14 % of theory) ,
Rf value: 0.62 (silica gel, ethyl acetate/methanol = 15:1) Mass spectrum (El): m/z = 643, 645 [M] *
The following compound is obtained analogously to Example 8 :
(1) 4- [ (3 -chloro-4-fluorophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N- [2- (acetylsulphanyl) ethyl] amino} -l-oxo-2-buten- 1-yl) amino] -7-cyclopropylmethoxy-quinazoline R£ value: 0.64 (silica gel, ethyl acetate) Mass spectrum (El): m/z = 629, 631 [M] *
F.xa pl e 9
4- [ (3-bromophenyl) amino] -6- ( {4- [N- (carboxymethyl) -N- (2-hy- droxyethyl) amino] -l-oxo-2-buten-l-yl }amino) -7-methoxy- quinazoline
1 ml of trifluoroacetic acid is added dropwise within two minutes to a solution of 330 mg of 4- [ (3-bromophenyl) amino] -6- [(4-{N- [ (tert-butyloxycarbonyl) methyl] -N- (2 -hydroxyethyl) ami- no} -l-oxo-2-buten-l-yl) amino] -7-methoxy-quinazoline in 4 ml of methylene chloride while cooling with an ice bath. The reaction mixture is stirred for half an hour while cooling with an ice bath and then for a further 24 hours at ambient temperature. For working up, the mixture is evaporated to dryness in the rotary evaporator. The crude product is stirred with ethyl acetate, the solid precipitate is filtered off, washed with ethyl acetate and dried in vacuo at 50 °C.
Yield: 169 mg (57 % of theory) ,
Rf value: 0.50 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/trifluoroacetic acid = 50:50:1)
Mass spectrum (ESI"): m/z = 528, 530 [M-H]"
The following compounds are obtained analogously to Example 9 :
(1) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- ({4- [4- (carboxymethyl) -piperazin-1-yl] -l-oxo-2-buten-l-yl}amino) -7-cyclopropyl- methoxy-quinazoline
Rf value: 0.43 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/trifluoroacetic acid = 1:1:1) Mass spectrum (ESI") : m/z = 567, 569 [M-H]"
(2) 4- [ (3-bromophenyl) amino] -6- [ (4- {4- [ (phosphono) methyl] -pi- perazin-1-yl} -l-oxo-2-buten-l-yl) amino] -quinazoline (The substance is obtained by treating the compound obtained in Example 5 (21) with trimethylbromosilane in dimethylformamide)
Rf value: 0.58 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/trifluoroacetic acid = 1:1:1) Mass spectrum (ESI") : m/z = 559, 561 [M-H]"
Exampl 0
4- [ (3 -chloro-4 -fluorophenyl) amino] -6- { [4- (2, 2 -dimethyl -6 -oxo- morpholin-4-yl) -1-oxo-2-buten-l-yl] amino} -7-cyclopropylmeth- oxy-qn nazol ine
15 mg of p-toluenesulphonic acid monohydrate are added to 150 mg of 4- [ (3-chloro-4-fluorophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N- (2-hydroxy-2-methyl-propyl) amino} -1-oxo- 2-buten-l-yl) amino] -7-cyclopropylmethoxy-quinazoline in 2.5 ml of acetonitrile. The solution formed is stirred first for O 00/51991
- 124 -
three hours at ambient temperature, then refluxed for a further two hours until the reaction is complete. For working up, the reaction mixture is combined with 30 ml of ethyl acetate. The organic phase is separated off, washed with saturated sodium hydrogen carbonate solution and saturated sodium chloride solution, dried over magnesium sulphate and concentrated by evaporation. The oily yellow residue is stirred with diethylether, whereupon a light yellow solid crystallises out, which is filtered off and dried. Yield: 85 mg (61 % of theory) , Melting point: 140-142°C Mass spectrum (ESI*): m/z = 554, 556 [M+H]*
The following compound is obtained analogously to Example 10 :
(1) (R) -4- [ (3 -Chloro-4 -fluoro-phenyl) amino] -6- { [4- (3 -methyl -
2-oxo-morpholin-4-yl) -l-oxo-2-buten-l-yl] amino} -7-eyelopropylmethoxy-quinazoline Melting point: 192°C Mass spectrum (ESI"): m/z = 538, 540 [M-H]"
Example 11
4- [ (3 -chloro- -fluorophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) - methyl] -N- [2- (methylcarbonyloxy) ethyl] amino} -l-oxo-2-buten-
1-yl) mino] A-cyclopropylmethoxy-quinazoline
47 μl of acetic anhydride and catalytic amounts of 4-dimethylaminopyridine are added to 250 mg of 4- [ (3 -chloro-4-fluorophenyl) amino] -6- [(4-{N- [ (ethoxycarbonyl) methyl] -N- (2-hydroxy- ethyl) amino} -1-oxo-2-buten-l-yl) amino] -7-cyclopropylmethoxy- quinazoline in 2 ml of methylene chloride. The reaction mixture is stirred overnight at ambient temperature and then evaporated to dryness . The crude product is purified by chromatography on a silica gel column with methylene chloride, followed by methylene chloride/methanol (9:1) as eluant . Yield: 150 mg (56 % of theory) , Melting point: 90-92°C Mass spectrum (ESI*): m/z = 614, 616 [M+H]*
Example 12
4- [ (3 -Chloro-4 -fluoro-phenyl) amino] -6- [ (4- {4- [ (benzyloxycarbonyl) methyl] -piperazin-1-yl} -l-oxo-2-buten-l-yl) amino] -7-cyclo- propylmethoxy-quinazoline
500 mg of 4- [ (3-chloro-4-fluoro-phenyl) amino] -6- { [4- (pipera- zin-l-yl) -l-oxo-2-buten-l-yl] amino} -7-cyclopropylmethoxy-quinazoline are dissolved in 5 ml of acetonitrile, and 0.35 ml of triethylamine followed by 0.17 ml of benzyl bromo-acetate are added dropwise at room temperature. The reaction mixture is stirred for approximately 45 minutes at room temperature and then concentrated in vacuo . The solid residue is triturated with water and filtered off . The crude product is purified by column chromatography on silica gel with methylene chloride/methanol (20:1) followed by recrystallization from ethyl acetate .
Yield: 380 mg (59 % of theory) , Melting point: 174°C Mass spectrum (ESI"): m/z = 657, 659 [M-H]"
The following compounds are obtained analogously to Example 12:
(1) 4- [ (3 -Chloro-4 -fluoro-phenyl) amino] -6- [ (4- {4- [ (phenyloxy- carbonyl) methyl] -piperazin-1-yl } -1-oxo-2-buten-l-yl) amino] -
7 -cyclopropylmethoxy-quinazoline
Rf value: 0.50 (silica gel, methylene chloride/methanol = 9:1)
Mass spectrum (ESI*) : m/z = 645, 647 [M+H]*
(2) 4- [ (3-Chloro-4-fluoro-phenyl) amino] -6- [ (4- {4- [ (indan-5-yl- oxycarbonyl) methyl] -piperazin-1-yl } -l-oxo-2-buten-l-yl) amino] -
7-cyclopropylmethoxy-quinazoline (reaction is carried out in N, N-dimethyl- formamide)
Rf value: 0.52 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI*) : m/z = 685, 687 [M+H]* (3) 4- [ (3-Chloro-4-fluoro-phenyl) amino] -6- [ (4- {4- [ (cyclohexyl- methoxycarbonyl) methyl] -piperazin-l-yl} -l-oxo-2-buten-1-yl) - amino] -7-cyclopropylmethoxy-quinazoline (reaction is carried out in tetrahydrofuran)
Rf value: 0.52 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI*): m/z = 665, 667 [M+H] "
(4) 4- [ (3-Chloro-4-fluoro-phenyl) amino] -6- [ (4- {4- [ (octyloxy- carbonyl) methyl] -piperazin-l-yl} -l-oxo-2-buten-l-yl) amino] - 7-cyclopropylmethoxy-quinazoline (reaction is carried out in tetrahydrofuran)
Rf value: 0.50 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI*): m/z = 681, 683 [M+H]*
(5) 4- [ (3 -Chloro-4-fluoro-phenyl) amino] -6- [ (4- {4- [ (hexyloxy- carbonyl) methyl] -piperazin-l-yl } -l-oxo-2-buten-l-yl) amino] - 7-cyclopropylmethoxy-quinazoline
Rf value: 0.52 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI*): m/z = 653, 655 [M+H]*
(6) 4- [ (3 -Chloro-4 -fluoro-phenyl) amino] -6- [ (4- {2- (ethoxycarbonyl) -4- [ (ethoxycarbonyl) methyl] -piperazin-l-yl } -l-oxo-2-buten- 1-yl) amino] -7-cyclopropylmethoxy-quinazoline (reaction is carried out in tetrahydrofuran)
Rf value: 0.60 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (El): m/z = 668, 670 [M] *
(7) 4- [ (3-Chloro-4-fluoro-phenyl) amino] -6- [ (4- {4- [3- (ethoxycarbonyl) -propyl] -piperazin-l-yl} -l-oxo-2-buten-l-yl) amino] - 7-cyclopropylmethoxy-quinazoline (reaction is carried out with ethyl 4-bromobutyrate in tetrahydrofuran)
Rf value: 0.42 (silica gel, methylene chloride/methanol/con- centrated aqueous ammonia = 90:10:1)
Mass spectrum (ESI"): m/z = 623, 625 [M-H]" O 00/51991
- 127 -
Example 13
4- [ (3 -Chloro-4 -fluoro-phenyl) amino] -6- ( {4- [2- (ethoxycarbonyl) - piperazin-l-yl] -l-oxo-2-buten-l-yl}amino) -7-cyclopropyl- me hoxy-qπi.nazol ine
5 ml of trifluoro-acetic acid are added dropwise to a mixture of 4.00 g 4- [ (3 -chloro-4-fluoro-phenyl) amino] -6- ({4- [2- (ethoxycarbonyl) -4- ( tert-butyloxycarbonyl) -piperazin-l-yl] -1-oxo-
2 -buten-1-yl}amino) -7-cyclopropylmethoxy-quinazoline in 15 ml of methylene chloride cooled to 0°C in an ice/water bath. The resulting mixture is stirred for one hour at 0°C and then allowed to warm to room temperature over night . The solvent is distilled off in vacuo and the residue is partitioned between
150 ml of methylene chloride/methanol (9:1) and 100 ml of IN aqueous sodium hydroxide. The aqueous layer is extracted with methylene chloride/methanol (9:1), the combined organic extracts are dried over magnesium sulfate, and concentrated in vacuo to give the title compound.
Yield: 3.08 g (90 % of theory),
Rf value: 0.40 (reversed phase TLC-plate (E. Merck), acetonitrile/water/trifluoro-acetic acid = 50:50:1) Mass spectrum (ESI*): m/z = 583, 585 [M+H]*
Example.14
4- [ (3-Chloro-4-fluoro-phenyl) amino] -6- ( {4- [2- (ethoxycarbonyl) - 4-methyl-piperazin-l-yl] -l-oxo-2-buten-l-yl}amino) -7-cyclo- propyl methoxy-quinazolin
A mixture of 500 mg 4- [ (3-chloro-4-fluoro-phenyl) amino] - 6- ( {4- [2- (ethoxycarbonyl) -piperazin-l-yl] -l-oxo-2-buten- l-yl}amino) -7-cyclopropylmethoxy-quinazoline, 50 μl glacial acetic acid, and 80 μl of an aqueous formaldehyde solution (37 weight %) in 5 ml methanol is treated with 270 mg sodium triacetoxyborohydride at room temperature. After 6 hours, insoluble salts are removed by filtration and the filtrate is concentrated in vacuo . The residue is made alkaline with 0. IN O 00/51991
- 128 -
aqueous sodium hydroxide solution and extracted with ethyl acetate. The combined extracts are dried over magnesium sulfate and concentrated in vacuo . The crude product is purified by column chromatography on silica gel with ethyl acetate/methanol (90:10 to 85:15). Yield: 350 mg (68 % of theory) ,
Rf : 0.27 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI*) : m/z = 597, 597 [M+H]*
Example 15
4- [ (3 -Chloro-4 -fluoro-phenyl) amino] -6- ({4- [2- (ethoxycarbonyl) - 4- (methylsulfonyl) -piperazin-l-yl] -l-oxo-2-buten-l-yl}amino) -
7-cyclopropylmethoxy-quina oline
A stirred mixture of 500 mg 4- [ (3-chloro-4-fluoro-phenyl) - amino] -6- ({4- [2- (ethoxycarbonyl) -piperazin-l-yl] -1-oxo-
2-buten-1-yl}amino) -7-cyclopropylmethoxy-quinazoline and
0.20 ml triethylamine in 5 ml of methylene chloride is cooled in an ice/water bath, and 80 μl of methanesulfonyl chloride are added dropwise. The reaction mixture is stirred for one hour at 0°C and another two hours at room temperature. Aqueous work-up followed by column chromatography on silica gel with methylene chloride/methanol (97:2) gives the title compound as a slightly yellow solid.
Yield: 395 mg (70 % of theory),
Melting point: 170-173 °C
Mass spectrum (ESI*): m/z = 661, 663 [M+H]*
Exampl e 16
4- [ (3 -Chloro-4 -fluoro-phenyl) amino] -6- [ (4-{4- [2- (ethoxycarbonyl) -ethyl] -piperazin-l-yl} -1-oxo-2-buten-1-yl) amino] -
7-cyclopropylmethoxy-quinazoline
A mixture of 200 mg of 4- [ (3 -chloro-4-fluoro-phenyl) amino] - 6- { [4- (piperazin-l-yl) -l-oxo-2-buten-l-yl] amino} -7-cyclo- propylmethoxy-quinazoline and 0.11 ml of ethyl acrylate in 2 ml of ethanol is heated under reflux for one hour. The sol- vent is evaporated in vacuo and the crude product is purified by column chromatography on silica gel with methylene chloride/methanol (95:5 to 90:10) followed by recrystallization from diethyl ether.
Yield: 164 mg (69 % of theory) , Melting point: 183-185°C Mass spectrum (ESI"): m/z = 609, 611 [M-H]"
Example 17
4- [ (3 -Chloro-4 -fluoro-phenyl) amino] -6- [ (4 , 4 -dimethyl-
4- {4- [ (ethoxycarbonyl) methyl] -piperazin-l-yl} -l-oxo~2-buten-
1-yl) mino] A-cyclopropylmethoxy-quinazQline
A mixture of 150 mg 4- [ (3-chloro-4-fluoro-phenyl) amino] - 6-{ [2- (diethoxyphosphoryl) -1-oxo-ethyl] amino} -7-cyclopropyl- methoxy-quinazoline and 12 mg dry lithium chloride in 2 ml of anhydrous tetrahydrofuran is stirred for 15 minutes at room temperature under an argon atmosphere. The mixture is cooled to 0°C and 43 μl of 1 , 8-diazabicyclo [5.4.0] undec-7-ene are added. After 30 minutes at 0°C, 84 mg of [4- (1, 1-dimethyl- 2-oxo-ethyl) -piperazin-l-yl] -acetic acid ethyl ester are added and the resulting mixture is allowed to warm to room temperature over night . The reaction mixture is diluted with ethyl acetate/methanol (15:1) and washed with water. The organic layer is directly submitted to column chromatography on silica gel with ethyl acetate/methanol (95:5 to 90:10). Yield: 36 mg (21 % of theory) , Melting point : 165-167°C Mass spectrum (ESI*): m/z = 625, 627 [M+H]*
Exampl 1
4- [ (3 -Chloro-4 -fluoro-phenyl) amino] -6- ( {4- [2- (ethoxycarbonyl) - 4- (methylcarbonyl) -piperazin-l-yl] -l-oxo-2-buten-l-yl}amino) -
7-cycl opropylmethoxy-quina ol inp
0.12 ml of acetic acid anhydride are added dropwise to a mixture of 500 mg of 4- [ (3-chloro-4-fluoro-phenyl) amino] - 6- ( {4- [2- (ethoxycarbonyl) - piperazin-l-yl] -l-oxo-2-buten- 1-yl} amino) -7-cyclopropylmethoxy-quinazoline and 0.18 ml of triethylamine in 5 ml of methylene chloride at 0°C. The reaction mixture is stirred for one hour at 0°C followed by one hour at room temperature, washed with water, concentrated sodium chloride solution, dried over magnesium sulfate, and concentrated in vacuo . The crude product is purified by column chromatography on silica gel with ethyl acetate/methanol (98:2 to 95:5) .
Yield: 291 mg (54 % of theory),
Melting point: 152-156°C
Mass spectrum (ESI*): m/z = 625, 627 [M+H]*
The following compounds may also be obtained analogously to the preceding Examples and other methods known from the literature :
(1) 4- [ (3-bromophenyl) amino] -7- (3-{4- [ (butyloxycarbonyl) methyl] -piperazin-l-yl }propyloxy) -6- [ (vinylcarbonyl) amino] - quinazoline
(2) 4- [ (3-bromophenyl) amino] -7- (3- {4- [ (diethoxyphosphoryl) - methyl] -piperazin-l-yl Jpropyloxy) -6- [ (vinylcarbonyl) amino] - quinazoline
(3) 4- [ (3-bromophenyl) amino] -7- (2- {N- [ (ethoxycarbonyl) methyl] ■ N-methylamino} ethoxy) -6- [ (vinylcarbonyl) amino] -quinazoline
(4) 4- [ (3-bromophenyl) amino] -7- (3- {N- [ (ethoxycarbonyl) methyl] • N-methylamino}propyloxy) - [ (vinylcarbonyl) amino] -quinazoline
(5) 4- [ (3-bromophenyl) amino] -7- (4- {N- [ (ethoxycarbonyl) methyl] N-methylamino}butyloxy) -6- [ (vinylcarbonyl) amino] -quinazoline
(6) 4- [ (3-bromophenyl) amino] -7-{3- [4- (carboxymethyl) -piperazin-l-yl] propyloxy} -6- [ (vinylcarbonyl) amino] -quinazoline O 00/51991
- 131 -
(7) 4- [ (3-bromophenyl) amino] -7- (3- {4- [ (diethoxyphosphoryl) methyl] -piperazin-l-yl }propyloxy) -6- [ (l-oxo-2-butyn-l-yl) amino] - quinazoline
(8) 4- [ (3-bromophenyl) amino] -6- [(4-{N- [ (methoxycarbonyl) methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy- quinazoline
(9) 4- [ (3-bromophenyl) amino] -6- [ (4-{N- [ (propyloxycarbonyl) - methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy- quinazoline
(10) 4- [ (3-bromophenyl) amino] -6- [ (4- {N- [ (isobutyloxycarbonyl) - methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy- quinazoline
(11) 4- [ (3-bromophenyl) amino] -6- [ (4- {N- [ (cyclohexyloxycarbonyl) methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy-quinazoline
(12) 4- [ (3-bromophenyl) amino] -6- [ (4- (N- [ (hexyloxycarbonyl) methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy- quinazoline
(13) 4- [ (3-bromophenyl) amino] -6- [ (4- {N- [ (cyclopropylmethoxycar- bonyl) methyl] -N-methylamino} -l-oxo-2-buten-l-yl) mino] -7-methoxy-quinazoline
(14) 4- [ (3-bromophenyl) amino] -6- [ (4- {N- [ (cyclohexylmethoxycar- bonyl) methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy-quinazoline
(15) 4- [ (3-bromophenyl) amino] -6- [ (4- {N- [ (benzyloxycarbonyl) methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy-quinazoline (16) 4- [ (3-bromophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) - methyl] -N-ethylamino} -1-oxo-2-buten-l-yl) amino] -7-methoxy- quinazoline
(17) 4- [ (3-bromophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) - methyl] -N-butylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy- quinazoline
(18) 4- [ (3-bromophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) - methyl] -N-cyclopropylamino} -l-oxo-2-buten-l-yl) amino] - 7-methoxy-quinazoline
(19) 4- [ (3-bromophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N- (cyclopropylmethyl) amino} -l-oxo-2-buten-l-yl) amino] - 7-methoxy-quinazoline
(20) 4- [ (3-bromophenyl) amino] -6- [ (4-{N- [2- (ethoxycarbonyl) - ethyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy- quinazoline
(21) 4- [ (3-bromophenyl) amino] -6- [ (4- {N- [3- (ethoxycarbonyl) - propyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy- quinazoline
(22) 4- [ (3-bromophenyl) amino] -6- [ (4- {N- [1- (ethoxycarbonyl) - ethyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy- quinazoline
(23) 4- [ (3-bromophenyl) amino] -6- ( {4- [2- (ethoxycarbonyl) -pyr- rolidin-1-yl] -l-oxo-2-buten-l-yl}amino) -7-methoxy-quinazoline
(24) 4- [ (3-bromophenyl) amino] -6- ( {4- [4- (ethoxycarbonyl) -pipe- ridin-1-yl] -l-oxo-2-buten-l-yl }amino) -7-methoxy-quinazoline
(25) 4- [ (3-bromophenyl) amino] -6- [ (4- {4- [ (ethoxycarbonyl) methyl] -piperidin-1-yl } -l-oxo-2-buten-l-yl) amino] -7-methoxy- quinazoline (26) 4- [ (3 -bromophenyl) amino] -6- [ (4-{4- [ (ethoxycarbonyl) methyl] -piperazin-l-yl} -l-oxo-2-buten-l-yl) amino] -7-methoxy- quinazoline
(27) 4- [ (3-bromophenyl) amino] -6- [ (6- {N- [ (ethoxycarbonyl) methyl] -N-methylamino} -l-oxo-2-hexen-l-yl) amino] -7-methoxy- quinazoline
(28) 4- [ (3-bromophenyl) amino] -6- [ (3- {l- [ (ethoxycarbonyl) methyl] -piperidin-4 -yl} -l-oxo-2-propen-l-yl) amino] -7-methoxy- quinazoline
(29) 4- [ (3-bromophenyl) amino] -6- ( {4- [3- (ethoxycarbonyl) -4-me- thyl-piperazin-1-yl] -l-oxo-2-buten-l-yl }amino) -7-methoxy- quinazoline
(30) 4- [ (3-bromophenyl) amino] -6- [ (4- {N- [ (diethoxyphosphoryl) - methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy- quinazoline
(31) 4- [ (3-bromophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N-methylamino} -l-oxo-2-butyn-l-yl) amino] -7-methoxy- quinazoline
(32) 4- [ (3-bromophenyl) amino] -6- [ (4- {N- [2- (ethoxycarbonyl) - ethyl] -N-methylamino} -l-oxo-2-butyn-l-yl) amino] -7-methoxy- quinazoline
(33) 4- [ (3-bromophenyl) amino] -6- [ (4- {N- [3- (ethoxycarbonyl) -propyl] -N-methylamino} -l-oxo-2-butyn-l-yl) amino] -7-methoxy-quinazoline
(34) 4- [ (3-bromophenyl) amino] -6- { [4- (2- {N- [ (ethoxycarbonyl) - methyl] -N-methylamino}ethylamino) -1, 4-dioxo-2-buten-l-yl] - amino} -7-methoxy-quinazoline (35) 4- [ (3-bromophenyl) amino] -6- { [4- (2- {N- [2- (ethoxycarbonyl) ethyl] -N-methylamino} ethylamino) -1, 4-dioxo-2-buten-l-yl] ami- no} -7-methoxy-quinazoline
(36) 4- [ (3-bromophenyl) amino] -6- { [4- (3- {N- [ (ethoxycarbonyl) - methyl] -N-methylamino}propylamino) -1, 4-dioxo-2-buten-l-yl] - amino} -7-methoxy-quinazoline
(37) 4- [ (3-bromophenyl) amino] -6- { [4- (3- {N- [ (methoxycarbonyl) - methyl] -N-methylamino}propylamino) -1, 4-dioxo-2-buten-l-yl] - amino} -7-methoxy-quinazoline
(38) 4- [ (3-bromophenyl) amino] -6- { [4- (3- {N- [ (butyloxycarbonyl) methyl] -N-methylamino}propylamino) -1, 4-dioxo-2-buten-l-yl] - amino} -7-methoxy-quinazoline
(39) 4- [ (3-bromophenyl) amino] -6- { [4- (3- {N- [ (cyclohexyloxycarbonyl) methyl] -N-methylamino}propylamino) -1, 4-dioxo-2-buten- 1-yl] amino} -7-methoxy-quinazoline
(40) 4- [ (3-bromophenyl) amino] -6- [ (4- {3- [2- (ethoxycarbonyl) - pyrrolidin-1-yl] propylamino} -1, 4-dioxo-2-buten-l-yl) amino] - 7-methoxy-quinazoline
(41) 4- [ (3-bromophenyl) amino] -6- [ (4- {3- [2- (methoxycarbonyl) - piperidin-1-yl] propylamino} -1, 4-dioxo-2-buten-l-yl) amino] - 7-methoxy-quinazoline
(42) 4- [ (3-bromophenyl) amino] -6- [ (4- {3- [4- (ethoxycarbonyl) - piperidin-1-yl] propylamino} -1 , 4-dioxo-2-buten-l-yl) amino] - 7-methoxy-quinazoline
(43) 4- [ (3-bromophenyl) amino] -6-[(4-{3-[3- (ethoxycarbonyl) - piperidin-1-yl] propylamino} -1, 4-dioxo-2-buten-l-yl) amino] - 7-methoxy-quinazoline (44) 4- [ (3-bromophenyl) amino] -6-{ [4- (3-{4- [ (ethoxycarbonyl) - methyl] -piperazin-l-yl }propylamino) -1, 4-dioxo-2-buten-l-yl] - amino} -7-methoxy-quinazoline
(45) 4- [ (3-bromophenyl) amino] -6-{ [4- (3- {4- [ (ethoxycarbonyl) - methyl] -piperazin-l-yl }propylamino) -1, 4-dioxo-2-buten-l-yl] - amino} -quinazoline
(46) 4- [ (3-bromophenyl) amino] -6- [ (4- {3- [2- (ethoxycarbonyl) -pyr- rolidin-1-yl] propylamino} -1, 4-dioxo-2-buten-l-yl) amino] -quinazoline
(47) 4- [ (3-bromophenyl) amino] -6- { [4- (N- {l- [ (ethoxycarbonyl) methyl] -2- (ethoxycarbonyl) -ethyl} -N-methylamino) -l-oxo-2-buten- 1-yl] amino} -7-methoxy-quinazoline
(48) 4- [ (3-bromophenyl) amino] -6- [ (4- {N- [1, 2-bis (ethoxycarbonyl) -ethyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy-quinazoline
(49) 4- [ (3-bromophenyl) amino] -6- { [4- (N- { [ (ethoxy) (methyl) -phos- phoryl] methyl} -N-methylamino) -l-oxo-2-buten-l-yl] amino} - 7-methoxy-quinazoline
(50) 4- [ (3-bromophenyl) amino] -7- (3- {N- [ (isobutyloxycarbonyl) methyl] -N-methylamino}propyloxy) -6- [ (vinylcarbonyl) amino] -quinazoline
(51) 4- [ (3-bromophenyl) amino] -7- (3- {N- [ (cyclopentyloxycarbon- yl) methyl] -N-methylamino}propyloxy) -6- [ (vinylcarbonyl) amino] - quinazoline
(52) 4- [ (3-bromophenyl) amino] -7- {3- [2- (ethoxycarbonyl) -pyrro- lidin-1-yl] propyloxy} -6- [ (vinylcarbonyl) amino] -quinazoline
(53 ) 4- [ (3-bromophenyl) amino] -7-{3- [2- (ethoxycarbonyl) -piperi- din-l-yl] propyloxy} -6- [ (vinylcarbonyl) amino] -quinazoline (54) 4- [ (3-bromophenyl) amino] -7- (3- {N- [1- (ethoxycarbonyl) - ethyl] -N-methylamino}propyloxy) -6- [ (vinylcarbonyl) amino] - quinazoline
(55) 4- [ (3-bromophenyl) amino] -7- (3-{4- [ (ethoxycarbonyl) methyl] - piperazin-l-yl }propyloxy) -6- [ (l-oxo-2-buten-l-yl) amino] -quinazoline
(56) 4- [ (3-bromophenyl) amino] -7- (3- {4- [ (ethoxycarbonyl) methyl] - piperazin-l-yl}propyloxy) -6- [ (l-oxo-2, 4-hexadien-l-yl) amino] - quinazoline
(57) 4- [ (3-bromophenyl) amino] -7- (3-{4- [ (ethoxycarbonyl) methyl] - piperazin-l-yl}propyloxy) -6- [ (3-phenyl-l-oxo-2-propen-l-yl) - amino] -quinazoline
(58) 4- [ (3-bromophenyl) amino] -7- (3- {4- [ (ethoxycarbonyl) methyl] - piperazin-l-yl}propyloxy) -6- [ (l-oxo-2 -butyn-1-yl) amino] -quinazoline
(59) 4- [ (3-bromophenyl) amino] -7- (3- {4- [ (ethoxycarbonyl) methyl] - piperazin-l-yl }propyloxy) -6- [ (l-oxo-4 , 4 , 4-trifluor-2-buten- 1-yl) amino] -quinazoline
(60) 4- [ (3-bromophenyl) amino] -7- (3- {N- [ (ethoxycarbonyl) methyl] - N-methylamino}propyloxy) -6- [ (l-oxo-4 , 4 , 4-trifluor-2-buten- l-yl) amino] -quinazoline
(61) 4- [ (3-bromophenyl) amino] -7- (3- {N- [ (ethoxycarbonyl) methyl] • N-methylamino} ropyloxy) - [ (l-oxo-2-buten-l-yl) amino] -quinazoline
(62) 4- [ (3-bromophenyl) amino] -7- (3- {N- [ (ethoxycarbonyl) methyl] N-methylamino}propyloxy) - [ (l-oxo-2-butyn-l-yl) amino] -quinazoline (63) 4- [ (3-bromophenyl) amino] -7- (3-{N- [ (ethoxycarbonyl) methyl] N-methylamino}propyloxy) - [ (l-oxo-2, 4-hexadien-l-yl) amino] - quinazoline
(64) 4- [ (3-bromophenyl) amino] -6- { [2- ( {N- [ (ethoxycarbonyl) methyl] -N-methylamino}methyl) -l-oxo-2-propen-l-yl] amino} -7-methoxy-quinazoline
(65) 4- [ (3-bromophenyl) amino] -6- { [2- ( (N- [ (ethoxycarbonyl) methyl] -N-methylamino}methyl) -l-oxo-2 -propen-1-yl] amino} -quinazoline
(66) 4- [ (3 -chlorophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy-quinazoline
(67) 4- [ (3-chloro-4-fluorophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy-quinazoline
(68) 4- [ (3-methylphenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy- quinazoline
(69) 4- [ (3-trifluoromethylphenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy-quinazoline
(70) 4- [ (3-ethynylphenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) - methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy- quinazoline
(71) 4- [ (3-cyanophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N-methylamino} -l-oxo-2-buten-1-yl) amino] -7-methoxy- quinazoline (72) 4- [ (3-methoxyphenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) - methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy- quinazoline
(73) 4- [ (3 , 4 -difluorophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) - methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy- quinazoline
(74) 4- [ (3 -bromo-4 -fluorophenyl) amino] -6- [ (4- (N- [ (ethoxycarbo- nyDmethyl] -N-methylamino} -l-oxo-2 -buten-1-yl) amino] -7-methoxy-quinazoline
(75) 4- [ (3 -chlorophenyl) amino] -7- (3-{4- [ (ethoxycarbonyl) methyl] -piperazin-l-yl }propyloxy) -6- [ (vinylcarbonyl) amino] - quinazoline
(76) 4- [ (3 -chloro-4 -fluorophenyl) amino] -7- (3- {4- [ (ethoxycarbonyl) methyl] -piperazin-l-yl }propyloxy) -6- [ (vinylcarbonyl) - amino] -quinazoline
(77) 4- [ (3-bromo-4-fluorophenyl) amino] -7- (3- {4- [ (ethoxycarbo- nyDmethyl] -piperazin-l-yl}propyloxy) -6- [ (vinylcarbonyl) ami - no] -quinazoline
(78) 4- [ (3 , 4-difluorophenyl) amino] -7- (3- {4- [ (ethoxycarbonyl) - methyl] -piperazin-l-yl}propyloxy) -6- [ (vinylcarbonyl) amino] - quinazoline
(79) 4- [ (3-cyanophenyl) amino] -7- (3- {4- [ (ethoxycarbonyl) methyl] - piperazin-l-yl }propyloxy) -6- [ (vinylcarbonyl) amino] -quinazoline
(80) 4- [ (3-methoxyphenyl) amino] -7- (3- {4- [ (ethoxycarbonyl) methyl] -piperazin-l-yl}propyloxy) -6- [ (vinylcarbonyl) amino] - quinazoline (81) 4- [ (3-methylphenyl) amino] -7- (3-{4- [ (ethoxycarbonyl) methyl] -piperazin-l-yl}propyloxy) -6- [ (vinylcarbonyl) amino] - quinazoline
(82) 4- [ (3-trifluoromethylphenyl) amino] -7- (3- {4- [ (ethoxycarbonyl) methyl] -piperazin-l-yl }propyloxy) -6- [ (vinylcarbonyl) - amino] -quinazoline
(83) 4- [ (3-ethynylphenyl) amino] -7- (3- {4- [ (ethoxycarbonyl) methyl] -piperazin-l-yl }propyloxy) -6- [ (vinylcarbonyl) amino] - quinazoline
(84) 4- [ (3-bromophenyl) amino] -3-cyano-7- (3- {4- [ (ethoxycarbonyl) methyl] -piperazin-l-yl}propyloxy) -6- [ (vinylcarbonyl) -ami- no] -quinoline
(85) 4- [ (3-bromophenyl) amino] -3 -cyano-7- (2- {4- [ (ethoxycarbonyl) methyl] -piperazin-l-yl} ethoxy) -6- [ (vinylcarbonyl) amino] - quinoline
(86) 4- [ (3-bromophenyl) amino] -3 -cyano-7- (3-{l- [ (ethoxycarbonyl) methyl] -piperidin-4 -yl}propyloxy) -6- [ (vinylcarbonyl) amino] ■ quinoline
(87) 4- [ (3-bromophenyl) amino] -3-cyano-7- (2- {l- [ (ethoxycarbonyl) methyl] -piperidin-4 -yl} ethoxy) -6- [ (vinylcarbonyl) amino] - quinoline
(88) 4- [ (3-bromophenyl) amino] -3-cyano-7- ( {l- [ (ethoxycarbonyl) methyl] -piperidin-4 -yl}methoxy) -6- [ (vinylcarbonyl) amino] - quinoline
(89) 4- [ (3-bromophenyl) amino] -3-cyano-7- (3- {N- [ (ethoxycarbonyl) methyl] -N-methylamino}propyloxy) -6- [ (vinylcarbonyl) amino] quinoline (90) 4- [ (3-bromophenyl) amino] -3-cyano-7- (4- {N- [ (ethoxycarbonyl) methyl] -N-methylamino}butyloxy) -6- [ (vinylcarbonyl) amino] - quinoline
(91) 4- [ (3-bromophenyl) amino] -3-cyano-6- [ (4- (N- [ (ethoxycarbonyl) methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -quinoline
(92) 4- [ (3-bromophenyl) amino] -3-cyano-6- [ (4- (N- [ (ethoxycarbonyl) methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy-quinoline
(93) 4- [ (3-bromophenyl) amino] -3-cyano-6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N-ethylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy- quinoline
(94) 4- [ (3-bromophenyl) amino] -3 -cyano-6- [ (4- {N,N-bis [ (ethoxycarbonyl) methyl] amino} -l-oxo-2-buten-l-yl) amino] -7-methoxy- quinoline
(95) 4- [ (3-bromophenyl) mino] -3-cyano-6- ( {4- [2- (ethoxycarbonyl) -pyrrolidin-1-yl] -l-oxo-2-buten-l-yl}amino) -7-methoxy- quinoline
(96) 4- [ (3-bromophenyl) amino] -3-cyano-6- [ (4- {4- [ (ethoxycarbonyl) methyl] -piperidin-1-yl} -l-oxo-2-buten-l-yl) amino] - 7-methoxy-quinoline
(97) 4- [ (3-bromophenyl) amino] -3-cyano-6- [ (4- {N- [ (diethoxyphosphoryl) methyl] -N-methylamino} -l-oxo-2 -buten-1-yl) amino] - 7-methoxy-quinoline
(98) 4- [ (3-bromophenyl) amino] -3-cyano-6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N-methylamino} -l-oxo-2-butyn-l-yl) amino] -7-methoxy-quinoline (99) 4- [ (3-bromophenyl) amino] -3-cyano-6- { [2- ( {N- [ (ethoxycarbonyl) methyl] -N-methylamino}methyl) -l-oxo-2-propen-l-yl] ami- no} -7-methoxy-quinoline
(100) 4- [ (3-bromophenyl) amino] -3-cyano-6- { [4- (3- {N- [ (ethoxycarbonyl) methyl] -N-methylamino}propylamino) -1, 4-dioxo-2-buten- 1-yl] amino} -7-methoxy-quinoline
(101) 4- [ (3-bromophenyl) amino] -3-cyano-6- { [4- (3- {N,N-bis [ (ethoxycarbonyl) methyl] -amino}propylamino) -1, 4-dioxo-2-buten- 1-yl] amino} -7-methoxy-quinoline
(102) 4- [ (3-bromophenyl) amino] -3-cyano-6- [ (4- {3- [2- (ethoxycarbonyl) -pyrrolidin-1-yl] propylamino} -1, 4-dioxo-2-buten-l-yl) - amino] -7-methoxy-quinoline
(103) 4- [ (3-bromophenyl) amino] -3-cyano-6- { [4- (3- {4- [ (ethoxycarbonyl) methyl] -piperazin-l-yl }propylamino) -1 , 4-dioxo-2-bu- ten-l-yl] amino} -7-methoxy-quinoline
(104) 4- [ (3-bromophenyl) amino] -6- { [4- (2-oxo-morpholin-4-yl) - l-oxo-2 -buten-1-yl] amino} -7-methoxy-quinazoline
(105) 4- [ (3-bromophenyl) amino] -7- [3- (2-oxo-morpholin-4-yl) propyloxy] - 6 - 1 (vinylcarbonyl) amino] -quinazoline
(106) 4- [ (3-bromophenyl) amino] -7- [3- (2-oxo-morpholin-4-yl) propyloxy] -6- [ (l-oxo-2-butyn-l-yl) amino] -quinazoline
(107) 4- [ (3-bromophenyl) amino] -7- [ (4-methyl-2-oxo-morpholin- 6-yl) methyloxy] -6- [ (l-oxo-2-butyn-l-yl) amino] -quinazoline
(108) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] - 7-cyclopropylmethoxy-quinazoline (109) 4- [ (3-chloro-4-fluorophenyl) amino] -6- [ (4- {N, N-bis [ (methoxycarbonyl) methyl] amino} -l-oxo-2-buten-l-yl) amino] -7-cyclo- propylmethoxy-quinazoline
(110) 4- [ (3-chloro-4-fluorophenyl) amino] -6- [ (4- {N- [ (diethoxyphosphoryl) methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] - 7-cyclopropylmethoxy-quinazoline
(111) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- ( {4- [2- (methoxycarbonyl) -pyrrolidin-1-yl] -l-oxo-2-buten-l-yl}amino) -7-cyclopro- pylmethoxy-quinazoline
(112) 4- [ (3-chloro-4-fluorophenyl) amino] -6- ( {4- [2- (methoxycarbonyl) -piperidin-1-yl] -l-oxo-2-buten-l-yl}amino) -7-cyclopro- pylmethoxy-quinazoline
(113) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- [ (4- {4- [ (ethoxycarbonyl) methyl] -piperazin-l-yl} -l-oxo-2 -buten-1-yl) amino] -7-cyc- lopropylmethoxy-quinazoline
(114) 4- [ (3-chloro-4-fluorophenyl) amino] -6- [ (4- {4- [ (diethoxyphosphoryl) methyl] -piperazin-l-yl} -l-oxo-2-buten-l-yl) amino] - 7-cyclopropylmethoxy-quinazoline
(115) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- ( {4- [3- (methoxycarbonyl) -morpholin-4-yl] -l-oxo-2-buten-l-yl}amino) -7-cyclopro- pylmethoxy-quinazoline
(116) 4- [ (3-chloro-4-fluorophenyl) amino] -6- { [4- (2-methoxycarbo- nyl-4-methyl-piperazin-l-yl) -l-oxo-2-buten-l-yl] amino} -7-cy- clopropylmethoxy-quinazoline
(117) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6-{ [4- (2-oxo-morpho- lin-4-yl) -l-oxo-2-buten-l-yl] amino} -7-cyclopropylmethoxy- quinazoline (118) 4- [ (3 -chloro-4-fluorophenyl) amino] -6- { [4- (3-methyl-2-oxo- morpholin-4-yl) -l-oxo-2-buten-l-yl] amino} -7-eyelopropylmethoxy-quinazoline
(119) 4- [ (3-chloro-4-fluorophenyl) amino] -6- { [4- (6-methyl-2-oxo- morpholin-4-yl) -l-oxo-2-buten-l-yl] amino} -7-cyclopropylmethoxy-quinazoline
(120) 4- [ (3-chloro-4-fluorophenyl) amino] -6- { [4- (6, 6-dimethyl- 2-oxo-morpholin-4-yl) -l-oxo-2-buten-l-yl] amino} -7-eyelopropylmethoxy-quinazoline
(121) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- { [4- (2-ethoxy-mor- pholin-4-yl) -l-oxo-2-buten-l-yl] amino} -7-cyclopropylmethoxy- quinazoline
(122) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6-{ [4- (2, 6-diethoxy- morpholin-4-yl) -l-oxo-2-buten-l-yl] amino} -7-cyclopropylmeth- oxy-quinazoline
(123) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- [ (4- [N- (2, 2-dimethoxyethyl) -N-methylamino] -l-oxo-2-buten-l-yl) amino] -7-cyclo- propylmethoxy-quinazoline
(124) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- [ (4- [N- (1, 3-dioxo- lan-2-ylmethyl) -N-methylamino] -l-oxo-2-buten-l-yl) amino] ^--cyclopropylmethoxy-quinazoline
(125) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- [ (4- [N- (2-oxo-tetrahydrofuran-3 -yl) -N-methylamino] -l-oxo-2-buten-l-yl) amino] -
7-cyclopropylmethoxy-quinazoline
(126) 4- [ (3-chloro-4-fluorophenyl) amino] -6- [ (4- [N- (2-oxo-tetra- hydrofuran-4-yl) -N-methylamino] -l-oxo-2 -buten-1-yl) amino] - 7-cyclopropylmethoxy-quinazoline (127) 4- [ (3 -chloro-4-fluorophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N- [2- (acetyl-sulphanyl) ethyl] amino} -l-oxo-2-bu- ten-l-yl) amino] -7-cyclopropylmethoxy-quinazoline
(128) 4- [ (3-chloro-4-fluorophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N- [2- (isobutylcarbonylsulphanyl) ethyl] amino} - l-oxo-2-buten-l-yl) amino] -7-cyclopropylmethoxy-quinazoline
(129) 4- [ (3 -chloro-4-fluorophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N-methylamino} -l-oxo-2-butyn-1-yl) amino] -7-cy- clopropylmethoxy-quinazoline
(130) 4- [ (3-chloro-4-fluorophenyl) amino] -6- [ (4- {N, N-bis [ (methoxycarbonyl) methyl] amino} -l-oxo-2-butyn-l-yl) amino] -7-cyclo- propylmethoxy-quinazoline
(131) 4- [ (3-chloro-4-fluorophenyl) amino] -6- ( {4- [2- (methoxycarbonyl) -pyrrolidin-1-yl] -l-oxo-2-butyn-l-yl}amino) -7-cyclopro- pylmethoxy-quinazoline
(132) 4- [ (3 -chloro-4-fluorophenyl) amino] -6- [ (4- {4- [ (ethoxycarbonyl) methyl] -piperazin-l-yl} -l-oxo-2-butyn-l-yl) amino] -7-cy- clopropylmethoxy-quinazoline
(133) 4- [ (3-chloro-4-fluorophenyl) amino] -6- [ (4- {4- [bis (methoxycarbonyl) methyl] -piperazin-l-yl} -l-oxo-2-buten-l-yl) amino] -
7-cyclopropylmethoxy-quinazoline
(134) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- [ (4- {4- [1, 2-bis-
(methoxycarbonyl) ethyl] -piperazin-l-yl} -l-oxo-2-buten-1-yl) - amino] -7-cyclopropylmethoxy-quinazoline
(135) 4- [ (3-chloro-4-fluorophenyl) amino] -6- { [4- (4- {l- [ (methoxycarbonyl) methyl] -2- (methoxycarbonyl) -ethyl} -piperazin-l-yl) - l-oxo-2-buten-l-yl] amino} -7-cyclopropylmethoxy-quinazoline (136) 4- [ (3-chloro-4-fluorophenyl) amino] -6-{ [4- (3-{N,N-bis-
[ (methoxycarbonyl) methyl] amino}propylamino) -1, 4-dioxo-2-buten- 1-yl] amino} -7-cyclopropylmethoxy-quinazoline
(137) 4- [ (3 -chloro-4-fluorophenyl) amino] -6- { [4- (3- {N- [ (methoxycarbonyl) methyl] -N-methylamino}propylamino) -1, 4-dioxo-2-buten- 1-yl] amino} -7-cyclopropylmethoxy-quinazoline
Example 19
Coated tablets containing 75 mg of active substance
1 tablet core contains : active substance 75.0 mg calcium phosphate 93.0 mg corn starch 35.5 mg polyvinylpyrrolidone 10.0 mg hydroxypropylmethylcellulose 15.0 mg magnesium stearate 1.5 g
230.0 mg
Figure imgf000147_0001
The active substance is mixed with calcium phosphate, corn starch, polyvinylpyrrolidone, hydroxypropylmethylcellulose and half the specified amount of magnesium stearate. Blanks 13 mm in diameter are produced in a tablet-making machine and these are then rubbed through a screen with a mesh size of 1.5 mm using a suitable machine and mixed with the rest of the magnesium stearate. This granulate is compressed in a tablet- making machine to form tablets of the desired shape.
Weight of core: 230 mg die: 9 mm, convex
The tablet cores thus produced are coated with a film consisting essentially of hydroxypropylmethylcellulose. The finished film-coated tablets are polished with beeswax. Weight of coated tablet: 245 mg. Exampl 20
Tablets containing 1QQ mg of .active,, substance
Composition:
1 tablet contains : active substance 100.0 mg lactose 80.0 mg corn starch 34.0 mg polyvinylpyrrolidone 4.0 mg magnesium stearate 2. mg
220.0 mg
Method of Preparation:
The active substance, lactose and starch are mixed together and uniformly moistened with an aqueous solution of the polyvinylpyrrolidone. After the moist composition has been screened (2.0 mm mesh size) and dried in a rack-type drier at 50°C it is screened again (1.5 mm mesh size) and the lubricant is added. The finished mixture is compressed to form tablets.
Weight of tablet: 220 mg
Diameter: 10 mm, biplanar, facetted on both sides and notched on one side.
Example 21
Tablets containing 150 mg of active substance
Composition:
1 tablet contains : active substance 150.0 mg powdered lactose 89.0 mg corn starch 40.0 mg colloidal silica 10.0 mg polyvinylpyrrolidone 10.0 mg magnesium stearate 1.0 mg
300.0 mg Preparation:
The active substance mixed with lactose, corn starch and silica is moistened with a 20% aqueous polyvinylpyrrolidone solution and passed through a screen with a mesh size of 1.5 mm. The granules, dried at 45°C, are passed through the same screen again and mixed with the specified amount of magnesium stearate . Tablets are pressed from the mixture .
Weight of tablet: 300 mg die: 10 mm, flat
Example 22
Hard gelatine capsules containing 150 mg of active substance
1 capsule contains : active substance 150.0 mg corn starch (dried approx . 180.0 mg lactose (powdered) approx . 87.0 mg magnesium stearate 3.0 g approx . 420.0 mg
Prepara ion :
The active substance is mixed with the excipients, passed through a screen with a mesh size of 0.75 mm and homogeneously mixed using a suitable apparatus. The finished mixture is packed into size 1 hard gelatine capsules. Capsule filling: approx. 320 mg Capsule shell: size 1 hard gelatine capsule.
Example 23
Suppositori s containing 150 mg of aetive substance
1 suppository contains: active substance 150.0 mg polyethyleneglycol 1500 550.0 mg polyethyleneglycol 6000 460.0 mg polyoxyethylene sorbitan monostearate 840.0 mg
2,000.0 mg
Preparation:
After the suppository mass has been melted the active substance is homogeneously distributed therein and the melt is poured into chilled moulds .
Exa pl 24
Suspension containing 50 mg of active substance
100 ml of suspension contain: active substance 1.00 g carboxymethylcellulose-Na-salt 0.10 g methyl p-hydroxybenzoate 0.05 g propyl p-hydroxybenzoate 0.01 g glucose 10.00 g glycerol 5.00 g
70% sorbitol solution 20.00 g flavouring 0.30 g dist. water ad 100 ml
Preparation:
The distilled water is heated to 70 °C. The methyl and propyl p-hydroxybenzoates together with the glycerol and sodium salt of carboxymethylcellulose are dissolved therein with stirring. The solution is cooled to ambient temperature and the active substance is added and homogeneously dispersed therein with stirring. After the sugar, the sorbitol solution and the flavouring have been added and dissolved, the suspension is evacuated with stirring to eliminate air.
5 ml of suspension contain 50 mg of active substance. Example 25
Ampoules containing 10 mg aetive si-bstanoe
Composition: active substance 10.0 mg
0.01 N hydrochloric acid q.s. double-distilled water ad 2.0 ml
Preparation :
The active substance is dissolved in the necessary amount of 0.01 N HCI, made isotonic with common salt, filtered sterile and transferred into 2 ml ampoules.
Example 26
Ampoules containing 50 mg of active substance
Composition: active substance 50.0 mg
0.01 N hydrochloric acid q.s. double-distilled water ad 10.0 ml
Prepara ion :
The active substance is dissolved in the necessary amount of 0.01 N HCI, made isotonic with common salt, filtered sterile and transferred into 10 ml ampoules.
Exampl 27
Capsules for powder inhalation containing 5 mg of active snbs anoe
1 capsule contains :
active substance 5.0 mg lactose for inhalation 15.0 g
20.0 mg
Preparation:
The active substance is mixed with lactose for inhalation. The mixture is packed into capsules in a capsule-making machine (weight of the empty capsule approx. 50 mg) .
weight of capsule: 70.0 mg size of capsule = 3
Example 28
Solution for inhalation for hand-held nebul sers containing 2.5 mg active substance
1 spray contains:
active substance 2.500 mg benzalkonium chloride 0.001 mg IN hydrochloric acid q.s. ethanol/water (50/50) ad 15.000 mg
Preparation :
The active substance and benzalkonium chloride are dissolved in ethanol/water (50/50) . The pH of the solution is adjusted with IN hydrochloric acid. The resulting solution is filtered and transferred into suitable containers for use in hand-held nebulisers (cartridges) .
Contents of the container: 4.5 g

Claims

Patent Claims
1. Bicyclic heterocycles of general formula
Figure imgf000153_0001
wherein
Ra denotes a hydrogen atom or a C1_i -alkyl group,
Rb denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups R to
R3, whilst
Rx and R2, which may be identical or different, in each case denote a hydrogen, fluorine, chlorine, bromine or iodine atom,
a C-^-alkyl, hydroxy, C-^-alkoxy, C3_6-cycloalkyl , C4.6-cycloalkoxy, C2_s-alkenyl or C2.5-alkynyl group,
an aryl, aryloxy, arylmethyl or arylmethoxy group,
a C3_5-alkenyloxy or C3_5-alkynyloxy group, wherein the unsaturated moiety may not be linked to the oxygen atom,
a C-^-alkylsulphenyl , C±_Λ -alkylsulphinyl , C1.4-alkyl- sulphonyl , C-^-alkylsulphonyloxy, trifluoromethylsulphenyl, trifluoromethylsulphinyl or trifluoromethylsulphonyl group, a methyl or methoxy group substituted by 1 to 3 fluorine atoms,
an ethyl or ethoxy group substituted by 1 to 5 fluorine atoms,
a cyano or nitro group or an amino group optionally substituted by one or two G^,,-alkyl groups, wherein the substituents may be identical or different, or
Rx together with R2, if they are bound to adjacent carbon atoms, denote a -CH=CH-CH=CH, -CH=CH-NH or -CH=N-NH group and
R3 denotes a hydrogen, fluorine, chlorine or bromine atom,
a C-__4-alkyl, trifluoromethyl or C1.4-alkoxy group,
Rc and Rd, which may be identical or different, in each case denote a hydrogen, fluorine or chlorine atom, a methoxy group, or a methyl group optionally substituted by a methoxy, dimethylamino, diethylamino, pyrrolidino, piperidino or morpholino group,
X denotes a methine group substituted by a cyano group or a nitrogen atom,
A denotes an oxygen atom or an imino group optionally substituted by a Cx.4-alkyl group,
B denotes a carbonyl or sulphonyl group,
C denotes a 1, 3 -allenylene, 1,1 or 1,2-vinylene group which may be substituted in each case by one or two methyl groups or by a trifluoromethyl group, an ethynylene group or
a 1, 3-butadien-l,4-ylene group optionally substituted by 1 to 4 methyl groups or by a trifluoromethyl group,
D denotes an alkylene, -CO-alkylene or -S02-alkylene group wherein the alkylene moiety in each case contains 1 to 8 carbon atoms and additionally 1 to 4 hydrogen atoms in the alkylene moiety may be replaced by fluorine atoms, while the linking of the -CO-alkylene and -S02-alkylene group to the adjacent group C in each case must take place via the carbonyl or sulphonyl group,
a -CO-O-alkylene, -CO-NR4-alkylene or -S02-NR4- lkylene group wherein the alkylene moiety in each case contains 1 to 8 carbon atoms, whilst the linking to the adjacent group C in each case must take place via the carbonyl or sulphonyl group, wherein
R4 denotes a hydrogen atom or a C^-alkyl group,
or, if D is bound to a carbon atom of the group E, it may also denote a bond,
or, if D is bound to a nitrogen atom of the group E, it may also denote a carbonyl or sulphonyl group,
E denotes an R60-CO-alkylene-NRs, (R70-P0-0R8) -alkylene-NRs or (R70-PO-R9) -alkylene-NRs-group wherein in each case the alkylene moiety, which is straight-chained and contains 1 to 6 carbon atoms, may additionally be substituted by one or two C-__2-alkyl groups or by an R60-CO or R60-CO-C^-,-alkyl group, wherein
R5 denotes a hydrogen atom,
a C1.4-alkyl group, which may be substituted by an R60-CO, (R70-PO-OR8) or (R70-PO-R9) group, an ethyl or propyl group optionally substituted by one or two methyl or ethyl groups, which may be terminally substituted in each case by a
Figure imgf000156_0001
C3.7-cycloalkylcarbonylsulphenyl, C3.7-cycloalkyl-Cx_3-alkyl- carbonylsulphenyl, arylcarbonylsulphenyl or aryl-C^-j-al- kylcarbonylsulphenyl group,
an ethyl or propyl group optionally substituted by one or two methyl or ethyl groups which is terminally substituted in each case by a
Figure imgf000156_0002
C3.7-cycloalkyl- carbonyloxy, Cj^-cycloalkyl-C-^^-alkylcarbonyloxy, aryl- carbonyloxy or aryl-C^-alkylcarbonyloxy group,
an ethyl or propyl group optionally substituted by one or two methyl or ethyl groups, each of which may be terminally substituted by a hydroxy, C-__4-alkoxy, amino, C1.4-alkylamino or di- (Cx.4-alkyl) -amino group or by a 4- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups a methylene group in the 4 position may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, imino or N- (C-^-alkyl) -imino group,
a C3.7-cycloalkyl or C3.7-cycloalkyl-C1_3-alkyl group,
R6, R7 and R8, which may be identical or different, in each case denote a hydrogen atom,
a
Figure imgf000156_0003
group, which may be substituted by a hydroxy, C-^-alkoxy, amino, C^-alkylamino or di- (Cx.4-alkyl) -amino group or by a 4- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, imino or N- (C^-alkyl) -imino group, a C4.7-cycloalkyl group optionally substituted by 1 or 2 methyl groups ,
a C3.5-alkenyl or C3.5-alkynyl group, wherein the unsaturated moiety may not be linked to the oxygen atom,
a C3.7-cycloalkyl-C1.4-alkyl, aryl, aryl-Cx_4-alkyl or RgCO-0- (ReCRf) -group, whilst
Re and Rf, which may be identical or different, each denote a hydrogen atom or a Cx_4-alkyl group and
Rg denotes a C^-alkyl, C3.7-cycloalkyl, Cx.4-alkoxy or C5.7-cycloalkoxy group,
and R3 denotes a Cx„4-alkyl, aryl or aryl-Cx.4-alkyl group,
a 4- to 7-membered alkyleneimino group which may be substituted by an R60-CO, (R70-PO-OR8) , (R70-PO-R9) , RgO-CO-C-^-alkyl, bis- (R60-CO) -C-^-alkyl, (R70-PO-OR8) -C^-alkyl or (R70-PO-R9) - C^-alkyl group wherein R6 to R9 are as hereinbefore defined,
a 4- to 7-membered alkyleneimino group which is substituted by two RgOCO or RgOCO-C1.4-alkyl groups or by an R6OCO-group and an RgOCO-Cx_4-alkyl group wherein R6 is as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by the group R10 and additionally at a cyclic carbon atom by an RsO-CO, (R70-PO-ORg) , (R70-PO-R9) , RsO-CO- Cx.4-alkyl, bis- (R60-CO) -C^-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx.4-alkyl group wherein R6 to R9 are as hereinbefore defined and
R10 denotes a hydrogen atom, a C-^-alkyl, formyl , C^-alkylcarbonyl or C1.4-alkylsulphonyl group, a piperazino or homopiperazino group which is substituted in the 4 position by the group R10 and additionally at cyclic carbon atoms by two R60-CO or
Figure imgf000158_0001
groups or by an RgO- CO-group and an RsO-CO-C-^-alkyl group wherein R6 and R10 are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in each case in the 4 position by an RgO-CO-Cx.4-alkyl, bis- (RgO-CO) -Cx..4-alkyl, (R70-PO-OR8) -C1.4-alkyl or (R70-PO-R9) - C^-alkyl group wherein Rs to R9 are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by an
Figure imgf000158_0002
(R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx.4-alkyl group and additionally at cyclic carbon atoms by one or two R60-CO or R60-CO-
Figure imgf000158_0003
group wherein R6 to R9 are as hereinbefore defined,
a morpholino or homomorpholino group which is substituted in each case by an R60-CO, (R70-PO-OR8) , (R70-PO-R9) , R60-CO- C^-alkyl, bis- (R60-CO) -Cx_4-alkyl , (R70-PO-OR8) -C^-alkyl or (R70-PO-R9) -C1.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a morpholino or homomorpholino group which is substituted by two RgO-CO or
Figure imgf000158_0004
groups or by an R60-CO-group and an RgO-CO-Cx.4-alkyl group wherein R6 is as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group R10, while the abovementioned 5- to 7-membered rings are additionally substituted in each case at a carbon atom by an R60-CO, (R70-PO-OR8) , (R70-PO- R9) ,
Figure imgf000158_0005
(R70-PO-OR8) - Cx_4-alkyl or (R70-PO-R9) -C-^-alkyl group wherein R6 to R10 are as hereinbefore defined, a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group R10, while the abovementioned 5- to 7-membered rings are in each case additionally substituted at carbon atoms by two R60-CO or R60-CO-C1_4-alkyl groups or by an RβO-CO-group and an
Figure imgf000159_0001
group wherein R6 and R10 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an
Figure imgf000159_0002
bis- (R60-CO) - C-.-4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-Rs) -C-._4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an RsO-CO-Cx_4-alkyl, bis- (R60-CO) - C-._4-alkyl, (R70-PO-OR8) -C^-alkyl or (R70-PO-R9) -Cx_4-alkyl group, while the abovementioned 5- to 7-membered rings are in each case additionally substituted at carbon atoms by one or two RgO-CO or RgO-CO-Cx_4-alkyl groups or by an R60-CO-group and an R60-CO-C1.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a 2-oxo-morpholino group which may be substituted by 1 to 4 C^--alkyl groups,
a 2-oxo-thiomorpholino group which may be substituted by 1 to 4 C1.2-alkyl groups,
a morpholino or thiomorpholino group which is substituted in the 2 position by a C-_.4-alkoxy group,
a morpholino or thiomorpholino group which is substituted in the 2 and 6 position in each case by a Cx_4-alkoxy group,
a ,4-alkyl -NR5-group wherein the Cx_4-alkyl moiety, which is straight-chained and may additionally be substituted by one or two methyl groups, is in each case terminally substituted by a di- (Cx_4-alkoxy) -methyl or tri- (Cx_4-alkoxy) -methyl group, while R5 is as hereinbefore defined,
a Cx..4-alkyl -NR5 group wherein the C1.4-alkyl moiety, which is straight-chained and may additionally be substituted by one or two methyl groups, is in each case terminally substituted by a 1, 3-dioxolan-2-yl or 1, 3-dioxan-2-yl group optionally substituted by one or two methyl groups, while Rs is as hereinbefore defined,
an RX1NRS group wherein Rs is as hereinbefore defined and
RX1 denotes a 2-oxo-tetrahydrofuran-3-yl, 2-oxo-tetrahydrofuran-4 -yl, 2-oxo-tetrahydropyran-3-yl, 2-oxo-tetrahy- dropyran-4-yl, 2-oxo-tetrahydropyran-5-yl, 2-oxo-tetrahy- drothiophen-3-yl, 2-oxo-tetrahydrothiophen-4-yl, 2-oxo- tetrahydrothiopyran-3-yl, 2-oxo-tetrahydrothiopyran-4-yl or 2-oxo-tetrahydrothiopyran-5-yl group optionally substituted by one or two methyl groups,
an amino group or an amino group optionally substituted by 1 or 2 Cx_4-alkyl groups wherein the alkyl groups may be identical or different and each alkyl moiety may be substituted from position 2 onward by a hydroxy, Cx_4-alkoxy, amino, Cx.4-al- kylamino or di- (Cx.4-alkyl) -amino group or by a 4- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulphur atom, or by a sulphinyl, sulphonyl, imino or N- (Cx_4-alkyl) -imino group,
a 4- to 7-membered alkyleneimino group optionally substituted by 1 to 4 methyl groups,
a 6- to 7-membered alkyleneimino group optionally substituted by 1 or 2 methyl groups wherein in each case a methylene group in the 4 position is replaced by an oxygen or sulphur atom, by an imino group substituted by the group R10, by a sulphinyl or sulphonyl group, whilst Rx0 is as hereinbefore defined,
an imidazolyl group optionally substituted by 1 to 3 methyl groups ,
a Cs_7-cycloalkyl group wherein a methylene group is replaced by an oxygen or sulphur atom, by an imino group substituted by the group R10, by a sulphinyl or sulphonyl group, wherein Rxo is as hereinbefore defined,
or D together with E denotes a hydrogen, fluorine or chlorine atom,
a Cx.4-alkyl group optionally substituted by 1 to 5 fluorine atoms ,
a C3.6-cycloalkyl group,
an aryl, heteroaryl, Cx.4-alkylcarbonyl , arylcarbonyl, carboxy, Cx.4-alkoxycarbonyl, RgCO-0- (ReCRf) -O-CO, (R70-PO-OR8) or (R70-PO- Rg) -group wherein Re to Rg and R7 to R9 are as hereinbefore defined,
an aminocarbonyl, Cx.4-alkylaminocarbonyl or di- (Cx.4-alkyl) - aminocarbonyl group or
a carbonyl group, which is substituted by a 4- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulphur atom, by an imino group substituted by the group R10, by a sulphinyl or sulphonyl group, while Rxo is as hereinbefore defined,
F denotes a Cx_s-alkylene group, an -0-Cx_6-alkylene group, whilst the alkylene moiety is linked to the group G, or an oxygen atom, whilst the latter may not be linked to a nitrogen atom of the group G, and
G denotes an R60-C0-alkylene-NR5, (R70-PO-OR8) -alkylene-NRs or (R70-PO-R9) -alkylene-NR5-group wherein in each case the alkylene moiety, which is straight-chained and contains 1 to 6 carbon atoms, may additionally be substituted by one or two Cx_2-alkyl groups or by an R60-CO or RsO-CO-Cx.2-alkyl group, wherein R5 to R9 are as hereinbefore defined,
a 4- to 7-membered alkyleneimino group which is substituted by an RgO-CO, (R70-PO-OR8) , (R70-PO-R9) , R60-CO-Cx.4-alkyl , bis- (RgO-CO) -Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) - Cx_4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a 4- to 7-membered alkyleneimino group which is substituted by two R60-CO or RgO-CO-Cx_4-alkyl groups or by an R60-CO-group and an RgO-CO-Cx.4-alkyl group wherein R6 is as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by the group Rxo and is additionally substituted at a cyclic carbon atom by an RsO-CO, (R70-PO-OR8) , (R70-PO-R9) , RgO-CO-Cx.4-alkyl, bis- (RsO-CO) -Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx.4-alkyl group wherein R6 to R10 are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by the group Rxo and is additionally substituted at cyclic carbon atoms by two R60-CO or
Figure imgf000162_0001
groups or by an R60-CO-group and an RgO-CO-Cx.4-alkyl group wherein R6 and R10 are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in each case in the 4 position by an R60-CO-Cx.4-alkyl , bis- (RgO-CO) -Cx_4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) - Cx.4-alkyl group wherein R6 to R9 are as hereinbefore defined, a piperazino or homopiperazino group which is substituted in the 4 position by an R60-CO-Cx.4-alkyl, bis- (R60-CO) -Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx.4-alkyl group and is additionally substituted at cyclic carbon atoms by one or two RgO-CO or RgO-CO-Cx_4-alkyl groups or by an R60-CO-group and an RgO-CO-Cx.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a morpholino or homomorpholino group which is substituted in each case by an R60-CO, (R70-PO-OR8) , (R70-PO-R9) , R60-CO- Cx.4-alkyl, bis- (RsO-CO) -Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a morpholino or homomorpholino group which is substituted by two RgO-CO or RgO-CO-Cx.4-alkyl groups or by an R60-CO-group and an R60-CO-Cx.4-alkyl group wherein R6 is as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group Rx0, while the abovementioned 5- to 7-membered rings are in each case additionally substituted at a carbon atom by an RsO-CO, (R70-PO-OR8) , (R70- PO-Rg) , R60-C0-Cx.4-alkyl, bis- (R60-CO) -C-_4-alkyl , (R70-PO-OR8) - C.__4-alkyl or (R70-PO-R9) -Cx_4-alkyl group wherein R6 to Rxo are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group R10, whilst the abovementioned 5- to 7-membered rings are in each case additionally substituted at carbon atoms by two R60-CO or RsO-CO-Cx.4-alkyl groups or by an R60-CO-group and an R60-CO-Cx.4-alkyl group wherein Rs and R10 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an RsO-CO-Cx.4-alkyl, bis- (R60-CO) - Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx_4-alkyl group wherein R6 to R9 are as hereinbefore defined, a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an R60-CO-Cx_4-alkyl, bis- (R60-CO) - Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx.4-alkyl group, while the abovementioned 5- to 7-membered rings are in each case additionally substituted at carbon atoms by one or two RgO-CO or R60-CO-Cx.4-alkyl groups or by an R60-CO-group and an RgO-CO-Cx.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a 2-oxo-morpholino group which may be substituted by 1 or 2 methy1 groups ,
a 2-oxo-morpholinyl group which is substituted in the 4 position by a hydrogen atom, by a Cx..4-alkyl, R60-CO-Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx.4-alkyl group, wherein R6 to R9 are as hereinbefore defined and the abovementioned 2-oxo- morpholinyl groups are each linked to a carbon atom of the group F,
a morpholino or thiomorpholino group which is substituted in the 2 position by a Cx.4-alkoxy group,
a morpholino or thiomorpholino group which is substituted in the 2 and 6 positions by a Cx.4-alkoxy group,
a C1„4-alkyl-NR5-group wherein the Cx.4-alkyl moiety, which is straight-chained and may additionally be substituted by one or two methyl groups, is in each case terminally substituted by a di- (Cx.4-alkoxy) -methyl or tri- (Cx.4-alkoxy) -methyl group, wherein Rs is as hereinbefore defined,
a Cx.4-alkyl-NRS group wherein the Cx.4-alkyl moiety, which is straight-chained and may additionally be substituted by one or two methyl groups, is in each case terminally substituted by a 1, 3-dioxolan-2-yl or 1 , 3-dioxan-2-yl group optionally substituted by one or two methyl groups, wherein R5 is as hereinbefore defined,
a RhNRs-group wherein Rs is as hereinbefore defined and Rh denotes a 2-oxo-tetrahydrofuran-3-yl, 2-oxo-tetrahydrofuran- 4-yl, 2-oxo-tetrahydropyran-3-yl, 2-oxo-tetrahydropyran-4-yl or 2-oxo-tetrahydropyran-5-yl group optionally substituted by one or two methyl groups ,
an amino group or an amino group optionally substituted by 1 or 2 Cx_4-alkyl groups wherein the alkyl groups may be identical or different and each alkyl moiety may be substituted from position 2 onward by a hydroxy, Cx.4-alkoxy, amino, Cx.4-alkylamino or di- (Cx_4-alkyl) -amino group or by a 4- to 7-membered alkyleneimino group, wherein in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, imino or N- (Cx.4-alkyl) -imino group,
a 4- to 7-membered alkyleneimino group optionally substituted by 1 to 4 methyl groups,
a 6- to 7-membered alkyleneimino group optionally substituted by 1 or 2 methyl groups wherein in each case a methylene group in the 4 position is replaced by an oxygen or sulphur atom, by an imino group substituted by the group Rxo, or by a sulphinyl or sulphonyl group, wherein R10 is as hereinbefore defined,
an imidazolyl group optionally substituted by 1 to 3 methyl groups ,
a C5.7-cycloalkyl group wherein a methylene group is replaced by an oxygen or sulphur atom, by an imino group substituted by the group R10, or by a sulphinyl or sulphonyl group, wherein R10 is as hereinbefore defined, or
F and G together denote a hydrogen, fluorine or chlorine atom, a
Figure imgf000166_0001
group optionally substituted from position 2 onwards by a hydroxy or Cx_4-alkoxy group,
a Cx.g-alkoxy group which is substituted by an R60-C0, (R70-PO- OR8) or (R70-PO-R9) -group, while R6 to R9 are as hereinbefore defined,
a C3.7-cycloalkoxy or C3.7-cycloalkyl-Cx.4-alkoxy group, an amino group optionally substituted by 1 or 2 Cx.4-alkyl groups,
a 5- to 7-membered alkyleneimino group, wherein in the above- mentioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulphur atom, by an imino group substituted by the group Rxo, or by a sulphinyl or sulphonyl group, while Rx0 is as hereinbefore defined,
with the proviso that at least one of the groups E, G or F together with G contains an R60-CO, (R70-PO-OR8) or (R70-PO-R9) - group or
D together with E contains an RgC0-0- (ReCRf) -O-CO, (R70-P0-0R8) or (R70-PO-R9) -group or
E or G contains an optionally substituted 2-oxo-morpholinyl group,
a morpholino or thiomorpholino group substituted in the 2 position or in the 2 and 6 position by a Cx.4-alkoxy group,
a di- (Cx.4-alkoxy) -methyl or tri- (Cx.4-alkoxy) -methyl group or
an optionally substituted 1, 3-dioxolan-2-yl , 1, 3-dioxan-2-yl , 2-oxo-tetrahydrofuran-3-yl , 2-oxo-tetrahydrofuran-4-yl , 2-oxo- tetrahydropyran-3 -yl , 2-oxo-tetrahydropyran-4-yl or 2-oxo- tetrahydropyran-5-yl-group or E contains an optionally substituted 2-oxo-thiomorpholino group or an optionally substituted 2-oxo-tetrahydrothio- phen-3-yl, 2-oxo-tetrahydrothiophen-4-yl, 2-oxo-tetrahy- drothiopyran-3-yl, 2-oxo-tetrahydrothiopyran-4-yl or 2 -oxo-tetrahydrothiopyran-5-yl-group,
whilst by the aryl moieties mentioned in the definitions of the abovementioned groups is meant a phenyl group which may in each case be monosubstituted by R12, mono, di or trisubstituted by R13 or monosubstituted by R12 and additionally mono or disubstituted by RX3, wherein the substituents may be identical or different and
RX2 denotes a cyano, carboxy, Cx.4-alkoxycarbonyl , aminocarbonyl, Cx.4-alkylaminocarbonyl, di- (Cx_4-alkyl) -aminocarbonyl , Cx.4-alkylsulphenyl, Cx.4-alkylsulphinyl, Cx.4-alkylsulphonyl, hydroxy, Cx_4-alkylsulphonyloxy, trifluoromethyloxy, nitro, amino, Cx.4-alkylamino, di- (Cx_4-alkyl) -amino, Cx.4-alkyl- carbonylamino, N- (Cx_4-alkyl) -Cx.4-alkylcarbonylamino, Cx.4-alkylsulphonylamino, N- (Cx_4-alkyl) -Cx.4-alkylsulphonyl- amino, aminosulphonyl, Cx_4-alkylaminosulphonyl or di- (Cx.4-alkyl) -aminosulphonyl group or a carbonyl group, which is substituted by a 5- to 7-membered alkyleneimino group, wherein in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, imino or N- (Cx.4-alkyl) -imino-group, and
Rx3 denotes a fluorine, chlorine, bromine or iodine atom, a Cx.4-alkyl, trifluoromethyl or Cx.4-alkoxy group or
two groups R13 , if they are bound to adjacent carbon atoms, together denote a C -alkylene, methylenedioxy or 1, 3-butadien-l, 4-ylene group, and moreover by the heteroaryl groups mentioned in the definitions of the abovementioned groups is meant a 5-membered heteroaromatic group which contains an imino group, an oxygen or sulphur atom or an imino group, an oxygen or sulphur atom and one or two nitrogen atoms, or
a 6-membered heteroaromatic group, which contains one, two or three nitrogen atoms,
whilst the abovementioned 5-membered heteroaromatic groups may be substituted in each case by 1 or 2 methyl or ethyl groups and the abovementioned 6-membered heteroaromatic groups may be substituted in each case by 1 or 2 methyl or ethyl groups or by a fluorine, chlorine, bromine or iodine atom, or by a tri- fluoromethyl , hydroxy, methoxy or ethoxy group,
the tautomers, the stereoisomers and the salts thereof.
2. Bicyclic heterocycles of general formula I according to claim 1, wherein
Ra denotes a hydrogen atom,
Rb denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups Rx to R3, while
Rx and R2, which may be identical or different, each denote a hydrogen, fluorine, chlorine, bromine or iodine atom,
a methyl, ethyl, hydroxy, methoxy, ethoxy, amino, cyano, vinyl or ethynyl group,
an aryl, aryloxy, arylmethyl or arylmethoxy group,
a methyl or methoxy group substituted by 1 to 3 fluorine atoms or Rx together with R2, if they are bound to adjacent carbon atoms, denote a -CH=CH-CH=CH, -CH=CH-NH or -CH=N-NH group and
R3 denotes a hydrogen, fluorine, chlorine or bromine atom,
Rc and Rd in each case denote a hydrogen atom,
X denotes a methine group substituted by a cyano group or a nitrogen atom,
A denotes an imino group optionally substituted by a methyl or ethyl group,
B denotes a carbonyl group,
C denotes a 1,1- or 1,2-vinylene group which is substituted in each case by one or two methyl groups or may be substituted by a trifluoromethyl group,
an ethynylene group or
a 1, 3-butadien-l, 4-ylene group optionally substituted by a methyl or trifluoromethyl group,
D denotes an alkylene or -CO-alkylene group wherein the alkylene moiety in each case contains 1 to 4 carbon atoms, while the linking of the -CO-alkylene group to the adjacent group C in each case must take place via the carbonyl group,
a -CO-O-alkylene or -CO-NR4-alkylene- group wherein the alkylene moiety in each case contains 1 to 4 carbon atoms, while the linking to the adjacent group C in each case must take place via the carbonyl group wherein
R4 denotes a hydrogen atom or a methyl or ethyl group, or, if D is bound to a carbon atom of the group E, it may also denote a bond
or, if D is bound to a nitrogen atom of the group E, it may also denote a carbonyl or sulphonyl group,
E denotes an R60-CO-alkylene-NRs, (R70-PO-OR8) -alkylene-NR5 or (R70-PO-R9) -alkylene-NRs group wherein in each case the alkylene moiety, which is straight-chained and contains 1 to 4 carbon atoms, may additionally be substituted by one or two Cx_2-alkyl groups or by an R60-C0 or R60-CO-Cx.2-alkyl group, while
R5 denotes a hydrogen atom,
a Cx.4-alkyl group which may be substituted by an R60-C0 group,
an ethyl or propyl group optionally substituted by one or two methyl or ethyl groups which is terminally substituted in each case by a hydroxy, Cx.4-alkoxy, di- (Cx_4-alkyl) amino, Cx.s-alkylcarbonylsulphenyl, C3_6-cycloalkylcarbonylsulphe- nyl , C3.g-cycloalkyl-Cx.3-alkylcarbonylsulphenyl , arylcarbo- nylsulphenyl or aryl-Cx.3-alkylcarbonylsulphenyl group,
an ethyl or propyl group optionally substituted by one or two methyl or ethyl groups which is terminally substituted in each case by a Cx_6-alkylcarbonyloxy, C3.G-cycloalkylcar- bonyloxy, C3_6-cycloalkyl-Cx.3-alkylcarbonyloxy, arylcarbo- nyloxy or aryl-Cx_3-alkylcarbonyloxy group,
a C3.s-cycloalkyl or C3.6-cycloalkyl-Cx.3-alkyl group,
Rs, R7 and R8, which may be identical or different, in each case denote a hydrogen atom, a Cx_8-alkyl group which may be substituted by a hydroxy, Cx_4-alkoxy, or di- (Cx_4-alkyl) -amino group or by a 4- to 7-membered alkyleneimino group, while in the abovementioned 6- to 7-membered alkyleneimino groups, in each case a methylene group in the 4 position may be replaced by an oxygen atom or by an N- (Cx.2-alkyl) -imino group,
a C4.6-cycloalkyl group,
a C3.5-alkenyl or C3.5-alkynyl group, while the unsaturated moiety may not be linked to the oxygen atom,
a C3.6-cycloalkyl-Cx.4-alkyl, aryl, aryl -Cx_4-alkyl or RgCO-0- (ReCRf) group, wherein
Re and Rf, which may be identical or different, in each case denote a hydrogen atom or a Cx_4-alkyl group and
Rg denotes a Cx.4-alkyl, C3.6-cycloalkyl , Cx.4-alkoxy or Cs_6-cycloalkoxy group,
and R9 denotes a Cx.4-alkyl group,
a 4- to 7-membered alkyleneimino group which is substituted by an R60-CO, RsO-CO-Cx.4-alkyl or bis- (R60-CO) -Cx.4-alkyl group wherein R6 is as hereinbefore defined,
a 4- to 7-membered alkyleneimino group which is substituted by two RgO-CO or R60-CO-Cx.4-alkyl groups wherein R6 is as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by the group R10 and additionally at a cyclic carbon atom by an R60-CO, R60-CO-Cx.4-alkyl or bis- (R60-CO) - Cx_4-alkyl group wherein R6 is as hereinbefore defined and R10 denotes a hydrogen atom, a methyl, ethyl, acetyl or methylsulfonyl group,
a piperazino or homopiperazino group which is substituted in the 4 position by the group Rxo and is additionally substituted at cyclic carbon atoms by two R60-CO or R60-CO-Cx.4-alkyl groups wherein R6 and R10 are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in each case in the 4 position by an RsO-CO-Cx_4-alkyl, bis- (RgO-CO) -Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) - Cx.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by an RεO-CO-Cx.4-alkyl or bis- (R60-CO) -Cx_4-alkyl group and is additionally substituted at cyclic carbon atoms by one or two R60-CO or R60-CO-Cx.4-alkyl groups wherein R6 is as hereinbefore defined,
a morpholino or homomorpholino group which is substituted in each case by an R60-CO, R60-CO-Cx.4-alkyl or bis- (R60-CO) - Cx.4-alkyl group wherein R6 is as hereinbefore defined,
a morpholino or homomorpholino group which is substituted by two RgO-CO or R60-CO-Cx.4-alkyl groups wherein R6 is as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group Rx0, while the abovementioned 5- to 7-membered rings in each case are additionally substituted at a carbon atom by an R60-CO, R60-CO-Cx_4-alkyl or bis- (RgO-CO) -Cx.4-alkyl group wherein R6 and R10 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group Rxo, while the abovementioned 5- to 7-membered rings in each case are additionally substituted at carbon atoms by two R60-CO or R60-CO-C-__4-alkyl groups wherein R6 and R10 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an R60-CO-Cx.4-alkyl , bis- (RgO-CO) - Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an R60-CO-C1.4-alkyl or bis- (RgO-CO) -Cx.4-alkyl group, while the abovementioned 5- to 7-membered rings in each case are additionally substituted at carbon atoms by one or two RsO-CO or R60-CO-Cx.4-alkyl groups wherein R6 is as hereinbefore defined,
a 2-oxo-morpholino group which may be substituted by 1 to 4 C^-j-alkyl groups,
a 2-oxo-thiomorpholino group which may be substituted by 1 to 4 Cx_2-alkyl groups,
a morpholino group which is substituted in the 2 position by a Cx„4-alkoxy group,
a morpholino group which is substituted in the 2 and 6 positions in each case by a Cx.4-alkoxy group,
a Cx.4-alkyl-NRs group wherein the Cx.4-alkyl moiety, which is straight-chained, is terminally substituted by a di- (Cx.4-alk- oxy) -methyl group, while R5 is as hereinbefore defined,
a Cx.4-alkyl-NRs group wherein the Cx.4-alkyl moiety, which is straight-chained, is terminally substituted by a 1, 3-dioxolan- 2-yl or 1, 3-dioxan-2-yl group, while Rs is as hereinbefore defined,
a RX1NR5 group wherein R5 is as hereinbefore defined and Rxx denotes a 2-oxo-tetrahydrofuran-3 -yl, 2-oxo-tetrahy- drofuran-4-yl, 2-oxo-tetrahydropyran-3-yl, 2-oxo-tetrahy- dropyran-4-yl, 2-oxo-tetrahydropyran-5-yl, 2-oxo-tetrahy- drothiophen-3-yl, 2-oxo-tetrahydrothiophen-4-yl , 2-oxo- tetrahydrothiopyran-3-yl, 2-oxo-tetrahydrothiopyran-4-yl or 2-oxo-tetrahydrothiopyran-5-yl group optionally substituted by one or two methyl groups,
or D together with E denotes a hydrogen atom,
a methyl, trifluoromethyl, aryl, RgCO-0- (ReCRf) -O-CO or (R70-PO-OR8) group wherein Re to Rg and R7 and R8 are as hereinbefore defined,
F denotes an -0-Cx_4-alkylene group, wherein the alkylene moiety is linked to the group G, or an oxygen atom, while this may not be linked to a nitrogen atom of the group G, and
G denotes an R60-CO-alkylene-NRs, (R70-PO-OR8) -alkylene-NRs or (R70-PO-R9) -alkylene-NRs group wherein in each case the alkylene moiety, which is straight-chained and contains 1 to 4 carbon atoms, may additionally be substituted by one or two Cx_2-alkyl groups or by an R60-CO or RsO-CO-Cx-2-alkyl group, while R5 to R9 are as hereinbefore defined,
a 4- to 7-membered alkyleneimino group which is substituted by an RgO-CO, R60-CO-Cx.4-alkyl or bis- (RsO-CO) -Cx.4-alkyl group wherein R6 is as hereinbefore defined,
a 4- to 7-membered alkyleneimino group which is substituted by two RgO-CO or R60-CO-Cx.4-alkyl groups wherein Rs is as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by the group Rx0 and is additionally substituted at a cyclic carbon atom by an R60-CO, R60-CO-Cx,4-alkyl or bis- (RgO-CO) -Cx.4-alkyl group wherein Rs and R10 are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by the group R10 and is additionally substituted at cyclic carbon atoms by two R60-CO or RgO-CO-Cx.4-alkyl groups wherein Rs and R10 are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in each case in the 4 position by an R60-CO-Cx.4-alkyl, bis- (R50-CO) -Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) - Cx.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by an R60-CO-Cx.4-alkyl or bis- (R60-CO) -Cx.4-alkyl group and additionally at cyclic carbon atoms by one or two R60-CO or RgO-CO-Cx„4-alkyl groups wherein R6 is as hereinbefore defined,
a morpholino or homomorpholino group which is substituted in each case by an RsO-CO, R60-CO-Cx.4-alkyl or bis- (RgO-CO) -Cx.4-alkyl group wherein R6 is as hereinbefore defined,
a morpholino or homomorpholino group which is substituted by two RgO-CO or R60-CO-Cx.4-alkyl groups wherein Rs is as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group R10, while the abovementioned 5- to 7-membered rings in each case are additionally substituted at a carbon atom by an R60-CO, R60-CO-Cx_4-alkyl or bis- (RgO-CO) -Cx_4-alkyl group wherein Rs and Rxo are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group Rxo, while the abovemen- tioned 5- to 7-membered rings in each case are additionally substituted at carbon atoms by two R60-CO or R60-CO-Cx.4-alkyl groups wherein R6 and R10 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an R60-CO-Cx.4-alkyl , bis- (RgO-CO) -Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an RsO-CO-Cx.4-alkyl or bis- (R60-CO) - Cx.4-alkyl group, while the abovementioned 5- to 7-membered rings in each case are additionally substituted at carbon atoms by one or two R60-CO or R60-CO-Cx.4-alkyl groups wherein R6 is as hereinbefore defined,
a 2-oxo-morpholino group which may be substituted by 1 or 2 methyl groups,
a 2-oxo-morpholinyl group which is substituted in the 4 position by a Cx.4-alkyl or RsO-CO-Cx_4-alkyl group, while R6 is as hereinbefore defined and the abovementioned 2-oxo-morpholinyl groups in each case are linked to a carbon atom of the group F,
a morpholino group which is substituted in the 2 position by a Cx_4-alkoxy group,
a morpholino group which is substituted in the 2 and 6 positions in each case by a Cx_4-alkoxy group,
a Cx.4-alkyl-NR5 group wherein the Cx.4-alkyl moiety, which is straight-chained, is terminally substituted by a di- (Cx.4-alkoxy) -methyl group, while Rs is as hereinbefore defined, a Cx_4-alkyl-NRS group wherein the Cx.4-alkyl moiety, which is straight-chained, is terminally substituted by a 1, 3-dioxolan- 2-yl or 1, 3 -dioxan-2 -yl group, while R5 is as hereinbefore defined,
a RhNRs group wherein R5 is as hereinbefore defined and Rh denotes a substituted 2-oxo-tetrahydrofuran-3 -yl, 2-oxo- tetrahydrofuran-4-yl, 2-oxo-tetrahydropyran-3-yl, 2-oxo- tetrahydropyran-4-yl or 2-oxo-tetrahydropyran-5-yl group optionally by one or two methyl groups, or
F and G together denote a hydrogen atom,
a Cx.4-alkoxy group optionally substituted from position 2 onwards by a hydroxy or Cx_4-alkoxy group,
a Cx.4-alkoxy group which is substituted by an R60-CO group, where R6 is as hereinbefore defined, or
a C4.7-cycloalkoxy or C3.7-cycloalkyl-Cx_4-alkoxy group
with the proviso that at least one of the groups E, G or F together with G contains an R60-CO, (R70-PO-OR8) or (R70-PO-R9) group or
D together with E contains an RgCO-0- (RaCRf) -O-CO or (R70-PO-OR8) group or
E or G contains an optionally substituted 2-oxo-morpholinyl group,
a morpholino group substituted in the 2 position or in the 2 and 6 positions in each case by a Cx.4-alkoxy group,
a di- (Cx.4-alkoxy) -methyl group or an optionally substituted 1, 3-dioxolan-2-yl, 1, 3-dioxan-2-yl, 2-oxo-tetrahydrofuran-3-yl, 2-oxo-tetrahydrofuran-4-yl, 2-oxo- tetrahydropyran-3-yl, 2-oxo-tetrahydropyran-4-yl or 2-oxo-te- trahydropyran-5-yl group or
E contains an optionally substituted 2-oxo-thiomorpholino group or an optionally substituted 2-oxo-tetrahydrothio- phen-3-yl, 2-oxo-tetrahydrothiophen-4-yl, 2-oxo-tetrahydro- thiopyran-3-yl, 2-oxo-tetrahydrothiopyran-4-yl or 2-oxo- tetrahydrothiopyran-5-yl group,
while the aryl moieties mentioned in the definition of the abovementioned groups denote a phenyl group which may in each case be monosubstituted by R12, mono- or disubstituted by R13 or monosubstituted by R12 and additionally mono- or disubstituted by R13, wherein the substituents may be identical or different and
R12 denotes a cyano, Cx.2-alkoxycarbonyl, aminocarbonyl, Cx_2-alkylaminocarbonyl , di- (Cx.2-alkyl) -aminocarbonyl, Cx.2-alkylsulphenyl, Cx„2-alkylsulphinyl, Cx.2-alkylsulphonyl , hydroxy, nitro, amino, Cx.2-alkylamino or di- (Cx_2-alkyl) -amino group and
R13 denotes a fluorine, chlorine, bromine or iodine atom, a Cx.2-alkyl, trifluoromethyl or Cx-2-alkoxy group or
two groups Rx3, if they are bound to adjacent carbon atoms, together denote a C3.s-alkylene, methylenedioxy or 1,3-bu- tadien-1, 4-ylene group,
the tautomers, the stereoisomers and the salts thereof.
3. Bicyclic heterocycles of general formula I according to claim 1, wherein
Ra denotes a hydrogen atom, Rb denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups Rx to R3, while
Rx and R2, which may be identical or different, each denote a hydrogen, fluorine, chlorine or bromine atom, or a methyl, trifluoromethyl, methoxy, ethynyl or cyano group,
R3 denotes a hydrogen atom,
Rc and Rd in each case denote a hydrogen atom,
X denotes a methine group substituted by a cyano group, or a nitrogen atom,
A denotes an imino group,
B denotes a carbonyl group,
C denotes a 1,1- or 1,2-vinylene group,
an ethynylene group or
a 1, 3 -butadien-1 , 4-ylene group,
D denotes a Cx.4-alkylene group,
a -CO-NR4-alkylene group wherein the alkylene moiety contains 2 to 4 carbon atoms, while the linking to the adjacent group C in each case must take place via the carbonyl group, wherein
R4 denotes a hydrogen atom,
or, if D is bound to a carbon atom of the group E, it may also denote a bond or, if D is bound to a nitrogen atom of the group E, it may also denote a carbonyl group,
E denotes an RsO-CO-alkylene-NRs, (R70-PO-OR8) -alkylene-NRs or (R70-PO-R9) -alkylene-NRj group wherein in each case the alkylene moiety, which is straight-chained and contains 1 to 4 carbon atoms, may additionally be substituted by one or two Cx.2-alkyl groups or by an R60-CO or R60-CO-Cx_2-alkyl group, while
Rs denotes a hydrogen atom,
a Cx_4-alkyl group which may be substituted by an R60-CO group ,
an ethyl group optionally substituted by one or two methyl or ethyl groups which is terminally substituted by a C-_.4-alkylcarb0nylsulph.enyl, arylcarbonylsulphenyl or aryl- methylcarbonylsulphenyl group,
an ethyl group optionally substituted by one or two methyl or ethyl groups which is terminally substituted by a hydroxy, Cx.4-alkylcarbonyloxy, arylcarbonyloxy or aryl- methylcarbonyloxy group,
a 2 , 2-dimethoxyethyl or 2 , 2 -diethoxyethyl group,
a C3_s-cycloalkyl or C3.6-cycloalkyl-methyl group,
R6, R7 and R8, which may be identical or different, in each case denote a hydrogen atom,
a Cx_8-alkyl group,
a cyclopentyl, cyclopentylmethyl , cyclohexyl or cyclohexyl- methyl group,
an aryl, arylmethyl or R CO-O- (ReCRf) group, while Re denotes a hydrogen atom or a Cx_4-alkyl group,
Rf denotes a hydrogen atom and
Rg denotes a Cx.4-alkyl, cyclopentyl, cyclohexyl, Cx.4-alk- oxy, cyclopentyloxy or cyclohexyloxy group,
and R9 denotes a methyl or ethyl group,
a pyrrolidino or piperidino group which is substituted by an RgO-CO or R60-CO-Cx_2-alkyl group wherein Rs is as hereinbefore defined,
a pyrrolidino or piperidino group which is substituted by two RgO-CO or R60-CO-Cx.2-alkyl groups wherein R6 is as hereinbefore defined,
a piperazino group which is substituted in the 4 position by the group Rxo and is additionally substituted at a cyclic carbon atom by an R60-CO or R60-CO-Cx.2-alkyl group, wherein R6 is as hereinbefore defined and
R10 denotes a hydrogen atom, a methyl, ethyl, acetyl or methylsulfonyl group,
a piperazino or homopiperazino group which is substituted in the 4 position by an R60-CO-Cx.4-alkyl, bis- (ReO-CO) -Cx.4-alkyl or (R70-PO-OR8) -Cx_2-alkyl group wherein R6 to R8 are as hereinbefore defined,
a piperazino group which is substituted in the 4 position by an R60-CO-Cx_2-alkyl group and is additionally substituted at a cyclic carbon atom by an R60-CO or RgO-CO-Cx_2-alkyl group wherein R6 is as hereinbefore defined, a morpholino group which is substituted by an R60-CO or R60-CO- C-_.2-alkyl group, while Rs is as hereinbefore defined,
a piperidinyl group substituted in the 1 position by an RsO-CO- Cx.4-alkyl, bis- (R60-CO) -Cx.4-alkyl or (R70-PO-OR8) -Cx.2-alkyl group wherein Rβ to R8 are as hereinbefore defined,
a 2-oxo-morpholino group which may be substituted by 1 or 2 Cx.2-alkyl groups,
a 2-oxo-thiomorpholino group which may be substituted by 1 or 2 Cx.2-alkyl groups,
a morpholino group which is substituted in the 2 position by a methoxy or ethoxy group,
a morpholino group which is substituted in the 2 and 6 positions in each case by a methoxy or ethoxy group,
a 2, 2-dimethoxyethyl-NRs, 2 , 2-diethoxyethyl-NR5, 1, 3-dioxolan- 2-yl-methyl-NRS or 1 , 3-dioxan-2-yl-methyl-NRs group wherein R5 is as hereinbefore defined,
a N-methyl-RlxN or N-ethyl-RlxN group wherein
Rlx denotes a 2-oxo-tetrahydrofuran-3-yl, 2-oxo-tetrahy- drofuran-4-yl, 2-oxo-tetrahydropyran-3 -yl, 2-oxo-tetrahy- dropyran-4-yl, 2 -oxo-tetrahydropyran-5-yl, 2-oxo-tetrahy- drothiophen-3-yl, 2-oxo-tetrahydrothiophen-4-yl , 2-oxo- tetrahydrothiopyran-3-yl, 2-oxo-tetrahydrothiopyran-4-yl or 2-oxo-tetrahydrothiopyran-5-yl group optionally substituted by one or two methyl groups,
or D together with E denotes a hydrogen atom, a methyl, trifluoromethyl, aryl, RgCO-0- (ReCRf) -O-CO or (R70-PO-OR8) group wherein Re to Rg and R7 and R8 are as hereinbefore defined,
F denotes an -0-Cx.4-alkylene group, while the alkylene moiety is linked to the group G, or an oxygen atom, which may not be linked to a nitrogen atom of the group G, and
G denotes an R60-CO-alkylene-NR5 group wherein the alkylene moiety, which is straight-chained and contains 1 to 4 carbon atoms, may additionally be substituted by one or two Cx.2-alkyl groups or by an R60-CO or R60-C0-Cx.2-alkyl group, while R5 and R6 are as hereinbefore defined,
a pyrrolidino or piperidino group which is substituted by an RgO-CO or RsO-CO-Cx.2-alkyl group wherein Rs is as hereinbefore defined,
a pyrrolidino or piperidino group which is substituted by two RgO-CO or R60-CO-Cx.2-alkyl groups wherein R6 is as hereinbefore defined,
a piperazino group which is substituted in the 4 position by the group Rx0 and additionally at a cyclic carbon atom by an RgO-CO, or RgO-CO-Cx_2-alkyl group, while R6 and Rx0 are as hereinbefore defined,
a piperazino group which is substituted in the 4 position by an R60-CO-Cx.4-alkyl, bis- (RsO-CO) -Cx.4-alkyl or (R70-PO-OR8) - Cx.2-alkyl group wherein R6 to R8 are as hereinbefore defined,
a piperazino group which is substituted in the 4 position by an R60-CO-Cx.2-alkyl group and additionally at a cyclic carbon atom by an R60-CO or R60-CO-Cx_2-alkyl group wherein Rs is as hereinbefore defined, a morpholino group which is substituted by an R60-CO or R60-CO- Cx_2-alkyl group, while R6 is as hereinbefore defined,
a piperidinyl group substituted in the 1 position by an RgO-CO-Cx.4-alkyl, bis- (RsO-CO) -Cx.4-alkyl or (R70-PO-OR8) -Cx.2-alkyl group wherein R6 to R8 are as hereinbefore defined,
a 2-oxo-morpholino group which may be substituted by 1 or 2 methy1 groups,
a 2-oxo-morpholinyl group which is substituted in the 4 position by a methyl, ethyl or R60-CO-Cx.2-alkyl group, while R6 is as hereinbefore defined and the abovementioned 2-oxo-morpholinyl groups are each linked to a carbon atom of the group F,
a morpholino group which is substituted in the 2 position by a methoxy or ethoxy group,
a morpholino group which is substituted in the 2 and 6 positions in each case by a methoxy or ethoxy group,
a 2, 2-dimethoxyethyl-NR5, 2 , 2-diethoxyethyl-NR5, 1, 3 -dioxolan- 2 -yl-methyl-NR5 or 1 , 3-dioxan-2-yl-methyl-NR5- group or
F and G together denote a hydrogen atom,
a methoxy or ethoxy group,
a Cx.3-alkoxy group which is substituted by an R60-CO group, while R6 is as hereinbefore defined,
a C4.s-cycloalkoxy or C3.6-cycloalkyl-Cx_3-alkoxy group with the proviso that at least one of the groups E, G or F together with G contains an RsO-CO, (R70-PO-OR8) or (R70-PO-R9) group or
D together with E contains an RgCO-0- (ReCRf) -O-CO or (R70-PO-OR8) group or
E or G contains an optionally substituted 2-oxo-morpholinyl group,
a morpholino group substituted in the 2 position or in the 2 and 6 positions in each case by a methoxy or ethoxy group,
a dimethoxymethyl or diethoxymethyl group or
an optionally substituted 1, 3-dioxolan-2-yl or 1,3-dioxan- 2-yl- group or
E contains an optionally substituted 2-oxo-tetrahydrofuran- 3-yl, 2-oxo-tetrahydrofuran-4-yl, 2-oxo-tetrahydropyran-3-yl , 2-oxo-tetrahydropyran-4-yl , 2-oxo-tetrahydropyran-5-yl , 2-oxo- thiomorpholino, 2-oxo-tetrahydrothiophen-3-yl, 2-oxo-tetrahy- drothiophen-4-yl , 2-oxo-tetrahydrothiopyran-3-yl , 2-oxo-tetra- hydrothiopyran-4-yl or 2-oxo-tetrahydrothiopyran-5-yl group,
while the aryl moieties mentioned in the definition of the abovementioned groups denote a phenyl group which may be mono- or disubstituted by R13, while the substituents may be identical or different and
R13 denotes a fluorine, chlorine, bromine or iodine atom, a Cx.2-alkyl, trifluoromethyl or Cx,2-alkoxy group or
two groups Rx3, if they are bound to adjacent carbon atoms, together denote a C3.4-alkylene, methylenedioxy or 1,3-bu- tadien-1, 4-ylene group, the tautomers, the stereoisomers and the salts thereof.
4. Bicyclic heterocycles of general formula I according to claim 1, wherein
Ra denotes a hydrogen atom,
Rb denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups Rx to R3, wherein
Rx and R2, which may be identical or different, each denote a hydrogen, fluorine, chlorine or bromine atom or a methyl group and
R3 denotes a hydrogen atom,
Rc and Rd each denote a hydrogen atom,
X denotes a methine group substituted by a cyano group, or a nitrogen atom,
A denotes an imino group,
B denotes a carbonyl group,
C denotes a 1,2-vinylene or an ethynylene group,
D denotes a Cx_4-alkylene group,
a -CO-NR4-alkylene group wherein the alkylene moiety contains 2 or 3 carbon atoms, while the linking to the adjacent group C must take place via the carbonyl group wherein
R4 denotes a hydrogen atom, or, if D is bound to a nitrogen atom of the group E, it may also denote a carbonyl group,
E denotes an RgO-CO-alkylene-NRs or (R70-PO-OR8) -alkylene-NR5 group wherein in each case the alkylene moiety, which is straight-chained and contains 1 to 2 carbon atoms, may additionally be substituted by a methyl group or by an R60-CO or RgO-CO-methyl group, while
R5 denotes a hydrogen atom,
a Cx..2-alkyl group which may be substituted by an R60-C0 group ,
an ethyl group optionally substituted by one or two methyl groups, which is terminally substituted by a hydroxy, Cx.2-alkylcarbonylsulphenyl or Cx.2-alkylcarbonyloxy group,
a 2 , 2-dimethoxyethyl or 2 , 2 -diethoxyethyl group,
R6 denotes a hydrogen atom,
a C-_.8-alkyl group,
a cyclopentyl, cyclopentylmethyl , cyclohexyl or cyclohexylmethyl group,
a phenyl group optionally substituted by one or two methyl groups, a phenylmethyl group which may be substituted in the phenyl moiety by one or two methyl groups, a 5-indanyl group or an RgCO-0- (ReCRf) group, while
Re denotes a hydrogen atom or a methyl group,
Rf denotes a hydrogen atom and
R denotes a Cx.4-alkyl or Cx_2-alkoxy group, R7 and R8, which may be identical or different, each denote a hydrogen atom, a methyl, ethyl or phenyl group,
a pyrrolidino or piperidino group which is substituted by an RgO-CO or RgO-CO-methyl group, wherein R6 is as hereinbefore defined,
a pyrrolidino or piperidino group which is substituted by two RgO-CO or RgO-CO-methyl groups wherein R6 is as hereinbefore defined,
a piperazino group which is substituted in the 4 position by the group R10 and additionally at a cyclic carbon atom by an RgO-CO group, while R6 is as hereinbefore defined and
Rx0 denotes a hydrogen atom, a methyl, ethyl, acetyl or methylsulfonyl group,
a piperazino or homopiperazino group which is substituted in the 4 position by an R60-CO-Cx_4-alkyl, bis- (R60-CO) -Cx.4-alkyl or (R70-PO-OR8) -Cx.2-alkyl group wherein Rs to R8 are as hereinbefore defined,
a piperazino group which is substituted in the 4 position by an RgO-CO-methyl group and additionally at a cyclic carbon atom by an R60-CO group wherein R6 is as hereinbefore defined,
a morpholino group which is substituted by an R60-CO- group, while R6 is as hereinbefore defined,
a 2-oxo-morpholino group which may be substituted by 1 to 2 Cx.2-alkyl groups,
a 2-oxo-thiomorpholino group which may be substituted by 1 to 2 Cx_2-alkyl groups, a morpholino group which is substituted in the 2 position by a methoxy or ethoxy group,
a morpholino group which is substituted in the 2 and 6 positions in each case by a methoxy or ethoxy group,
a 2, 2-dimethoxyethyl-NR5, 2 , 2-diethoxyethyl-NR5 or 1,3-di- oxolan-2 -yl-methyl -NR5- group wherein R5 is as hereinbefore defined,
» an N-methyl-RxxN or N-ethyl-RxlN group wherein
Rxl denotes a 2-oxo-tetrahydrofuran-3 -yl or 2-oxo-tetrahydrofuran-4 -yl group,
or D together with E denotes a hydrogen atom,
a methyl group or an RgCO-0- (ReCRf) -O-CO group wherein Re to Rg are as hereinbefore defined,
F denotes a -0-Cx.4-alkylene group, while the alkylene moiety is linked to the group G, or an oxygen atom, which may not be linked to a nitrogen atom of the group G, and
G denotes an R60-CO-alkylene-NRS group wherein the alkylene moiety, which is straight-chained and contains 1 or 2 carbon atoms, may additionally be substituted by a methyl group or by an RgO-CO or R60-CO-methyl group, while R5 and R6 are as hereinbefore defined,
a pyrrolidino or piperidino group which is substituted by an RgO-CO or RgO-CO-methyl group wherein R6 is as hereinbefore defined,
a pyrrolidino or piperidino group which is substituted by two RgO-CO or RgO-CO-methyl groups wherein R6 is as hereinbefore defined, a piperazino group which is substituted in the 4 position by an RgO-CO-Cx_4-alkyl, bis- (R60-CO) -Cx.4-alkyl or (R70-PO-OR8) - Cx.2-alkyl group wherein R6 to R8 are as hereinbefore defined,
a piperidinyl group substituted in the 1 position by an R60-CO- C-^-alkyl group wherein R6 is as hereinbefore defined, or
F and G together denote a hydrogen atom,
a methoxy or ethoxy group,
a C4.6-cycloalkoxy or C3_6-cycloalkyl-Cx_3-alkoxy group,
with the proviso that at least one of the groups E or G contains an R60-CO or (R70-PO-OR8) group or
D together with E contains an RgCO-0- (ReCRf) -O-CO group or
E contains an optionally substituted 2-oxo-morpholinyl group,
a morpholino group substituted in the 2 position or in the 2 and 6 positions in each case by a methoxy or ethoxy group,
a dimethoxymethyl or diethoxymethyl group or
a 1, 3-dioxolan-2-yl, 2 -oxo-tetrahydrofuran-3-yl or 2-oxo- tetrahydrofuran-4-yl group or
an optionally substituted 2 -oxo-thiomorpholino group,
the tautomers, the stereoisomers and the salts thereof.
5. Bicyclic heterocycles of general formula
Figure imgf000191_0001
wherein
Ra to Rd, A to C and X are defined as in claim 1,
D denotes an alkylene, -CO-alkylene or -S02-alkylene group wherein the alkylene moiety in each case contains 1 to 8 carbon atoms and additionally 1 to 4 hydrogen atoms in the alkylene moiety may be replaced by fluorine atoms, whilst the linking of the -CO-alkylene and -S02-alkylene group to the adjacent group C in each case must take place via the carbonyl or sulphonyl group,
a -CO-O-alkylene, -CO-NR4-alkylene or -S02-NR4-alkylene group wherein the alkylene moiety in each case contains 1 to 8 carbon atoms, whilst the linking to the adjacent group C in each case must take place via the carbonyl or sulphonyl group wherein
R4 denotes a hydrogen atom or a Cx.4-alkyl group,
or, if D is bound to a carbon atom of the group E, it may also denote a bond
or, if D is bound to a nitrogen atom of the group E, it may also denote a carbonyl or sulphonyl group,
E denotes an R60-CO-alkylene-NR5, (R70-PO-OR8) -alkylene-NR5 or (R70-PO-R9) -alkylene-NR5-group wherein in each case the alkylene moiety, which is straight-chained and contains 1 to 6 carbon atoms, may additionally be substituted by one or two Cx.2-alkyl groups or by an RsO-CO or R60-CO-Cx.2-alkyl group, wherein
Rs denotes a hydrogen atom,
a C-__4-alkyl group, which may be substituted by an RgO-CO, (R70-PO-OR8) or (R70-PO-R9) group,
an ethyl or propyl group optionally substituted by one or two methyl or ethyl groups, which may be terminally substituted in each case by a Cx.g-alkylcarbonylsulphenyl, C3.7-cycloalkylcarbonylsulphenyl, C3.7-cycloalkyl-Cx-.3-alkyl- carbonylsulphenyl, arylcarbonylsulphenyl or aryl-Cx_3-alkylcarbonylsulphenyl group,
an ethyl or propyl group optionally substituted by one or two methyl or ethyl groups which may be terminally substituted in each case by a Cx.s-alkylcarbonyloxy, C3.7-cyclo- alkylcarbonyloxy, C3_7-cycloalkyl-C-__3-alkylcarbonyloxy, arylcarbonyloxy or aryl-Cx.3-alkylcarbonyloxy group,
an ethyl or propyl group optionally substituted by one or two methyl or ethyl groups, each of which may be terminally substituted by a hydroxy, Cx.4-alkoxy, amino, Cx.4-alkylamino or di- (Cx_4-alkyl) -amino group or by a 4- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups a methylene group in the 4 position may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, imino or N- (Cx_4-alkyl) -imino group,
a C3.7-cycloalkyl or C3.7-cycloalkyl-Cx.3-alkyl group,
R6, R7 and R8, which may be identical or different, in each case denote a hydrogen atom,
a Cx.8-alkyl group, which may be substituted by a hydroxy, Cx_4-alkoxy, amino, Cx.4-alkylamino or di- (Cx.4-alkyl) -amino group or by a 4- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, imino or N- (Cx.4-alkyl) -imino group,
a C4„7-cycloalkyl group optionally substituted by 1 or 2 methy1 groups ,
a C3.5-alkenyl or C3.s-alkynyl group, wherein the unsaturated part may not be linked to the oxygen atom,
a C3_7-cycloalkyl-C-__4-alkyl, aryl, aryl-Cx.4-alkyl or RgCO-0- (ReCRf) -group, whilst
Re and Rf, which may be identical or different, in each case denote a hydrogen atom or a Cx_4-alkyl group and
Rg denotes a C-__4-alkyl, C3.7-cycloalkyl, Cx.4-alkoxy or C5_7-cycloalkoxy group,
and R9 denotes a Cx_4-alkyl, aryl or aryl-Cx_4-alkyl group,
a 4- to 7-membered alkyleneimino group which may be substituted by an R60-CO, (R70-PO-OR8) , (R70-PO-R9) , R60-CO-Cx.4-alkyl , bis- (RgO-CO) -Cx.4-alkyl, (R70-PO-OR8) -Cx_4-alkyl or (R70-PO-R9) - Cx.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a 4- to 7-membered alkyleneimino group which is substituted by two R6OCO or RgOCO-Cx_4-alkyl groups or by an R6OCO-group and an RgOCO-Cx_4-alkyl group wherein R6 is as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by the group Rxo and is additionally substituted at a cyclic carbon atom by an R60-CO, (R70-PO-OR8) , (R70-PO-R9) , RsO-CO-Cx_4-alkyl, bis- (R60-CO) -Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx.4-alkyl group wherein R6 to R9 are as hereinbefore defined and
Rx0 denotes a hydrogen atom, a Cx.4-alkyl, formyl, C-__4-alkylcarbonyl or C1.4-alkylsulphonyl group,
a piperazino or homopiperazino group which is substituted in the 4 position by the group Rxo and additionally at cyclic carbon atoms by two R60-CO or R60-CO-Cx_4-alkyl groups or by an RgO- CO-group and an RgO-CO-Cx.4-alkyl group wherein R6 and Rx0 are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in each case in the 4 position by an R60-CO-Cx.4-alkyl , bis- (R60-CO) -Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) - Cx.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by an RsO-CO-Cx.4-alkyl, bis- (R60-CO) -Cx.4-alkyl, (R70-PO-OR8) -Cx_4-alkyl or (R70-PO-R9) -Cx.4-alkyl group and is additionally substituted at cyclic carbon atoms by one or two RgO-CO or RgO-CO-Cx_4-alkyl groups or by an R60-CO-group and an R60-CO-Cx.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a morpholino or homomorpholino group which is substituted in each case by an R60-CO, (R70-PO-OR8) , (R70-PO-R9) , RsO-CO- Cx.4-alkyl, bis- (R60-CO) -Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx-.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a morpholino or homomorpholino group which is substituted by two RgO-CO or RgO-CO-Cx.4-alkyl groups or by an R60-CO-group and an R60-CO-Cx.4-alkyl group wherein R6 is as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group Rxo, whilst the abovemen- tioned 5- to 7-membered rings are additionally substituted in each case at a carbon atom by an R60-CO, (R70-PO-OR8) , (R70-PO- R9) , R60-CO-Cx.4-alkyl, bis- (R60-CO) -Cx.4-alkyl, (R70-PO-OR8) - Cx.4-alkyl or (R70-PO-R9) -Cx_4-alkyl group wherein R6 to Rx0 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group Rx0, while the abovementioned 5- to 7-membered rings are in each case additionally substituted at carbon atoms by two R60-CO or R60-CO-Cx.4-alkyl groups or by an R60-CO-group and an R60-CO-Cx_4-alkyl group wherein R6 and Rx0 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an RgO-CO-Cx.4-alkyl, bis- (ReO-CO) - Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx.4-alkyl group wherein R6 to R9 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an R60-CO-Cx.4-alkyl, bis- (R60-CO) - Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx.4-alkyl group, while the abovementioned 5- to 7-membered rings are in each case additionally substituted at carbon atoms by one or two RgO-CO or RgO-CO-Cx.4-alkyl groups or by an R60-CO-group and an RgO-CO-Cx_4-alkyl group wherein Rs to R9 are as hereinbefore defined,
a 2-oxo-morpholino group which may be substituted by 1 to 4 Cx.2-alkyl groups,
a 2 -oxo-thiomorpholino group which may be substituted by 1 to 4 Cj_-2-alkyl groups,
a morpholino or thiomorpholino group which is substituted in the 2 position by a Cx_4-alkoxy group, a morpholino or thiomorpholino group which is substituted in the 2 and 6 positions by a Cx.4-alkoxy group,
a Cx.4-alkyl-NRs-group wherein the Cx.4-alkyl moiety, which is straight-chained and may additionally be substituted by one or two methyl groups, is in each case terminally substituted by a di- (Cx.4-alkoxy) -methyl or tri- (Cx.4-alkoxy) -methyl group, whilst R5 is as hereinbefore defined,
a Cx.4-alkyl-NR5-group wherein the Cx_4-alkyl moiety, which is straight -chained and may additionally be substituted by one or two methyl groups, is in each case terminally substituted by a 1, 3-dioxolan-2-yl or 1 , 3-dioxan-2-yl group optionally substituted by one or two methyl groups, while Rs is as hereinbefore defined,
an RlxNRs-group wherein R5 is as hereinbefore defined and
R1X denotes a 2-oxo-tetrahydrofuran-3 -yl , 2 -oxo-tetrahy- drofuran-4-yl , 2-oxo-tetrahydropyran-3-yl , 2-oxo-tetrahy- dropyran-4-yl, 2-oxo-tetrahydropyran-5-yl , 2-oxo-tetrahy- drothiophen-3-yl , 2-oxo-tetrahydrothiophen-4-yl, 2-oxo- tetrahydrothiopyran-3-yl , 2-oxo-tetrahydrothiopyran-4-yl or 2-oxo-tetrahydrothiopyran-5-yl group optionally substituted by one or two methyl groups,
or D together with E denotes an RgCO-0- (ReCRf) -O-CO, (R70-PO-OR8) or (R70-PO-R9) -group wherein Re to Rg and R7 to R9 are as hereinbefore defined,
F and G together denote a hydrogen atom, a Cx.g-alkoxy group optionally substituted from position 2 onwards by a hydroxy or Cx_4-alkoxy group, a C3.7-cycloalkoxy or C3.7-cycloalkyl-Cx.4-alkoxy group,
whilst by the aryl moieties mentioned in the definitions of the abovementioned groups is meant a phenyl group which in each case may be monosubstituted by Rx2, mono-, di- or trisub- stituted by R13 or monosubstituted by RX2 and additionally mono- or disubstituted by RX3, whilst the substituents may be identical or different and
Rx2 denotes a cyano, carboxy, Cx.4-alkoxycarbonyl , aminocarbonyl, Cx.4-alkylaminocarbonyl, di- (Cx_4-alkyl) -aminocarbonyl, Cx_4-alkylsulphenyl, Cx.4-alkylsulphinyl, Cx.4-alkylsulphonyl, hydroxy, Cx.4-alkylsulphonyloxy, trifluoromethyloxy, nitro, amino, Cx.4-alkylamino, di- (Cx_4-alkyl) -amino, Cx.4-alkyl- carbonylamino, N- (Cx.4-alkyl) -Cx_4-alkylcarbonylamino, Cx.4-alkylsulphonylamino, N- (Cx.4-alkyl) -Cx.4-alkylsulphonyl- amino, aminosulphonyl, Cx.4-alkylaminosulphonyl or di- (Cx.4-alkyl) -aminosulphonyl group or a carbonyl group, which is substituted by a 5- to 7-membered alkyleneimino group, wherein in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, imino or N- (Cx_4-alkyl) -imino-group, and
Rx3 denotes a fluorine, chlorine, bromine or iodine atom, a Cx.4-alkyl, trifluoromethyl or Cx.4-alkoxy group or
two groups Rx3, if they are bound to adjacent carbon atoms, together denote a C -alkylene, methylenedioxy or 1, 3-butadien- 1,4-ylene group,
the tautomers, the stereoisomers and the salts thereof.
6. Bicyclic heterocycles of general formula I according to claim 5, wherein
Ra to Rd, A to C and X are defined as in claim 2,
D denotes an alkylene or -CO-alkylene group wherein the alkylene moiety in each case contains 1 to 4 carbon atoms, while the linking of the -CO-alkylene group to the adjacent group C in each case must take place via the carbonyl group, a -CO-O-alkylene or -CO-NR4-alkylene- group wherein the alkylene moiety in each case contains 1 to 4 carbon atoms, while the linking to the adjacent group C in each case must take place via the carbonyl group wherein
R4 denotes a hydrogen atom or a methyl or ethyl group,
or, if D is bound to a carbon atom of the group E, it may also denote a bond
or, if D is bound to a nitrogen atom of the group E, it may also denote a carbonyl or sulphonyl group,
E denotes an R60-CO-alkylene-NR5, (R70-PO-OR8) -alkylene-NR5 or (R70-P0-R9) -alkylene-NRs group wherein in each case the alkylene moiety, which is straight-chained and contains 1 to 4 carbon atoms, may additionally be substituted by one or two Cx.2-alkyl groups or by an RsO-CO or R60-CO-Cx_2-alkyl group, while
Rs denotes a hydrogen atom,
a Cx.4-alkyl group which may be substituted by an R60-CO group ,
an ethyl or propyl group optionally substituted by one or two methyl or ethyl groups which is terminally substituted in each case by a hydroxy, Cx_„-alkoxy, di- (Cx_4-alkyl) amino, Cx_s-alkylcarbonylsulphenyl, C3_s-cycloalkylcarbonylsul- phenyl, C3.6-cycloalkyl-Cx_3-alkylcarbonylsulphenyl, arylcar- bonylsulphenyl or aryl-Cx.3-alkylcarbonylsulphenyl group,
an ethyl or propyl group optionally substituted by one or two methyl or ethyl groups which is terminally substituted in each case by a Cx_s-alkylcarbonyloxy, C3.6-cycloalkylcar- bonyloxy, C3.6-cycloalkyl-Cx_3-alkylcarbonyloxy, arylcarbo- nyloxy or aryl-Cx_3-alkylcarbonyloxy group, a C3.6-cycloalkyl or C3.g-cycloalkyl-Cx.3-alkyl group,
R6, R7 and R8, which may be identical or different, in each case denote a hydrogen atom,
a Cx.8-alkyl group which may be substituted by a hydroxy, Cx.4-alkoxy, or di- (Cx_4-alkyl) -amino group or by a 4- to 7-membered alkyleneimino group, while in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen atom or by an N- (Cx.2-alkyl) -imino group,
a C4_6-cycloalkyl group,
a C3.5-alkenyl or C3.5-alkynyl group, while the unsaturated moiety may not be linked to the oxygen atom,
a C3_s-cycloalkyl-C1_4-alkyl, aryl, aryl-Cx.4-alkyl or RgCO-0- (ReCRf) group, while
Re and Rf, which may be identical or different, in each case denote a hydrogen atom or a Cx.4-alkyl group and
Rg denotes a Cx_4-alkyl, C3_6-cycloalkyl , Cx.4-alkoxy or C5_s-cycloalkoxy group,
and R9 denotes a Cx_4-alkyl group,
a 4- to 7-membered alkyleneimino group which is substituted by an RgO-CO, R60-CO-Cx„4-alkyl or bis- (R60-CO) -Cx_4-alkyl group wherein Rβ is as hereinbefore defined,
a 4- to 7-membered alkyleneimino group which is substituted by two RgO-CO or R60-CO-Cx.4-alkyl groups wherein R6 is as hereinbefore defined, a piperazino or homopiperazino group which is substituted in the 4 position by the group Rxo and additionally at a cyclic carbon atom by an RgO-CO, R60-CO-C-__4-alkyl or bis- (R60-CO) - C-__4-alkyl group wherein Re is as hereinbefore defined and
R10 denotes a hydrogen atom, a methyl, ethyl, acetyl or methylsulfonyl group,
a piperazino or homopiperazino group which is substituted in the 4 position by the group R10 and is additionally substituted at cyclic carbon atoms by two R60-CO or R60-CO-Cx_4-alkyl groups wherein Rε and Rxo are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in each case in the 4 position by an R60-CO-Cx_4-alkyl, bis- (RgO-CO) -Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) - C-__4- lkyl group wherein R6 to R9 are as hereinbefore defined,
a piperazino or homopiperazino group which is substituted in the 4 position by an R60-CO-Cx.4-alkyl or bis- (R60-CO) -Cx.4-alkyl group and is additionally substituted at cyclic carbon atoms by one or two R60-CO or R60-CO-Cx.4-alkyl groups wherein R6 is as hereinbefore defined,
a morpholino or homomorpholino group which is substituted in each case by an R60-CO, R60-CO-Cx_4-alkyl , or bis- (R60-CO) - Cx_4-alkyl group wherein R6 is as hereinbefore defined,
a morpholino or homomorpholino group which is substituted by two RgO-CO or RgO-CO-Cx.4-alkyl groups wherein R6 is as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group Rx0, while the abovementioned 5- to 7-membered rings in each case are additionally substituted at a carbon atom by an R60-CO, R60-CO-Cx.4-alkyl or bis- (RgO-CO) -Cx.4-alkyl group wherein R6 and Rxo are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group Rxo, while the abovementioned 5- to 7-membered rings in each case are additionally substituted at carbon atoms by two R60-CO or R60-CO-Cx_4-alkyl groups wherein R6 and R10 are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an R60-CO-Cx.4-alkyl , bis- (RsO-CO) - Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx.4-alkyl group wherein R6 to Rg are as hereinbefore defined,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an RsO-CO-Cx„4-alkyl or bis- (RgO-CO) -Cx.4-alkyl group, while the abovementioned 5- to 7-membered rings in each case are additionally substituted at carbon atoms by one or two RsO-CO or RgO-CO-Cx.4-alkyl groups wherein R6 is as hereinbefore defined,
a 2-oxo-morpholino group which may be substituted by 1 to 4 Cx_2-alkyl groups,
a 2 -oxo-thiomorpholino group which may be substituted by 1 to 4 Cx_2-alkyl groups,
a morpholino group which is substituted in the 2 position by a Cx_4-alkoxy group,
a morpholino group which is substituted in the 2 and 6 positions in each case by a Cx,4-alkoxy group,
a Cx_4-alkyl -NRS group wherein the Cx,4-alkyl moiety, which is straight-chained, is terminally substituted by a di- (Cx.4-alk- oxy) -methyl group, while Rs is as hereinbefore defined, a Cx_4-alkyl-NRS group wherein the Cx.4-alkyl moiety, which is straight-chained, is terminally substituted by a 1, 3-dioxolan- 2-yl or 1, 3-dioxan-2-yl group, while R5 is as hereinbefore defined,
a RX1NR5 group wherein R5 is as hereinbefore defined and
Rlx denotes a 2 -oxo-tetrahydrofuran-3 -yl , 2-oxo-tetrahy- drofuran-4-yl, 2-oxo-tetrahydropyran-3-yl , 2-oxo-tetrahy- dropyran-4-yl, 2-oxo-tetrahydropyran-5-yl, 2-oxo-tetrahy- drothiophen-3-yl, 2-oxo-tetrahydrothiophen-4-yl, 2-oxo- tetrahydrothiopyran-3-yl, 2-oxo-tetrahydrothiopyran-4-yl or 2-oxo-tetrahydrothiopyran-5-yl group optionally substituted by one or two methyl groups,
or D together with E denotes an RgCO-0- (ReCRf) -O-CO or (R70-PO-OR8) group wherein Re to Rg and R7 to R9 are as hereinbefore defined,
F and G together denote a hydrogen atom,
a Cx.6-alkoxy group optionally substituted from position 2 by a hydroxy or Cx_4-alkoxy group,
a C4.7-cycloalkoxy or C3.7-cycloalkyl-Cx.4-alkoxy group,
whilst by the aryl moieties mentioned in the definitions of the abovementioned groups is meant a phenyl group which in each case may be monosubstituted by Rx2, mono- or disubstituted by Rx3 or monosubstituted by RX2 and additionally mono- or disubstituted by RX3, whilst the substituents may be identical or different and
Rx2 denotes a cyano, Cx.2-alkoxycarbonyl, aminocarbonyl, Cx.2-alkylaminocarbonyl, di- (Cx_2-alkyl) -aminocarbonyl, Cx,2-al- kylsulphenyl, Cx_2-alkylsulphinyl , Cx.2-alkylsulphonyl , hy- droxy, nitro, amino, Cx.2-alkylamino or di- (Cx_2-alkyl) -amino, and
Rx3 denotes a fluorine, chlorine, bromine or iodine atom, a Cx.2-alkyl, trifluoromethyl or Cx.2-alkoxy group or
two groups RX3, if they are bound to adjacent carbon atoms, together denote a C -alkylene, methylenedioxy or 1, 3-butadien- 1,4-ylene group,
the tautomers, the stereoisomers and the salts thereof.
7. Bicyclic heterocycles of general formula I according to claim 5, wherein
Ra to Rd, A to C and X are defined as in claim 3,
D denotes a Cx_4-alkylene group,
a -CO-NR4-alkylene group wherein the alkylene moiety contains 2 to 4 carbon atoms, while the linking to the adjacent group C in each case must take place via the carbonyl group, wherein
R4 denotes a hydrogen atom,
or, if D is bound to a carbon atom of the group E, it may also denote a bond
or, if D is bound to a nitrogen atom of the group E, it may also denote a carbonyl group,
E denotes an RgO-CO-alkylene-NRj, (R70-PO-OR8) -alkylene-NR5 or (R70-PO-R9) -alkylene-NRs group wherein in each case the alkylene moiety, which is straight -chained and contains 1 to 4 carbon atoms, may additionally be substituted by one or two Cx_2-alkyl groups or by an R60-CO or R60-CO-Cx.2-alkyl group, while R5 denotes a hydrogen atom,
a Cx.4-alkyl group which may be substituted by an R60-CO group,
an ethyl group optionally substituted by one or two methyl or ethyl groups which is terminally substituted by a Cx.4-alkylcarbonylsulphenyl, arylcarbonylsulphenyl or arylmethylcarbonylsulphenyl group,
an ethyl group optionally substituted by one or two methyl or ethyl groups which is terminally substituted by a hydroxy, Cx_4-alkylcarbonyloxy, arylcarbonyloxy or aryl- methylcarbonyloxy group,
a 2 , 2-dimethoxyethyl or 2 , 2-diethoxyethyl group,
a C3.6-cycloalkyl or C3.G-cycloalkyl-methyl group,
R6, R7 and R8, which may be identical or different, in each case denote a hydrogen atom,
a Cx_8-alkyl group,
a cyclopentyl, cyclopentylmethyl , cyclohexyl or cyclohexyl - methyl group,
an aryl, arylmethyl or RgCO-0- (ReCRf) group, wherein
Re denotes a hydrogen atom or a Cx.4-alkyl group,
Rf denotes a hydrogen atom and
Rg denotes a Cx.4-alkyl, cyclopentyl, cyclohexyl, Cx.4-alk- oxy, cyclopentyloxy or cyclohexyloxy group,
and R9 denotes a methyl or ethyl group, a pyrrolidino or piperidino group which is substituted by an RgO-CO or RgO-CO-Cx.2-alkyl group wherein R6 is as hereinbefore defined,
a pyrrolidino or piperidino group which is substituted by two RgO-CO or RgO-CO-Cx_2-alkyl groups wherein R6 is as hereinbefore defined,
a piperazino group which is substituted in the 4 position by the group R10 and is additionally substituted at a cyclic carbon atom by an R60-CO or R60-CO-Cx.2-alkyl group, while R6 is as hereinbefore defined and
Rx0 denotes a hydrogen atom, a methyl, ethyl, acetyl or methylsulfonyl group,
a piperazino or homopiperazino group which is substituted in the 4 position by an R60-CO-Cx.4-alkyl , bis- (ReO-CO) -C-__4-alkyl or (R70-PO-OR8) -Cx.2-alkyl group wherein R6 to R8 are as hereinbefore defined,
a piperazino group which is substituted in the 4 position by an R60-CO-Cx.2-alkyl group and is additionally substituted at a cyclic carbon atom by an RεO-CO or R60-CO-Cx.2-alkyl group wherein R6 is as hereinbefore defined,
a morpholino group which is substituted by an R60-CO or R60-CO- Cx.2-alkyl group, while Rs is as hereinbefore defined,
a piperidinyl group substituted in the 1 position by an R60-CO- Cx_4-alkyl, bis- (R60-CO) -Cx.4-alkyl or (R70-PO-OR8) -Cx.2-alkyl group wherein RG to R8 are as hereinbefore defined,
a 2-oxo-morpholino group which may be substituted by 1 to 2 Cx_2-alkyl groups, a 2 -oxo-thiomorpholino group which may be substituted by 1 to 2 Cx.2-alkyl groups,
a morpholino group which is substituted in the 2 position by a methoxy or ethoxy group,
a morpholino group which is substituted in the 2 and 6 positions in each case by a methoxy or ethoxy group,
a 2, 2-dimethoxyethyl-NRs, 2 , 2-diethoxyethyl-NRs, 1 , 3-dioxolan- 2 -yl-methyl -NRS or 1, 3 -dioxan-2 -yl-methyl-NR5 group wherein Rs is as hereinbefore defined,
a N-methyl-RxlN or N-ethyl-RxlN group wherein
Rxx denotes a 2 -oxo-tetrahydrofuran-3 -yl , 2-oxo-tetrahy- drofuran-4-yl , 2-oxo-tetrahydropyran-3-yl, 2-oxo-tetrahy- dropyran-4-yl, 2-oxo-tetrahydropyran-5-yl , 2-oxo-tetrahy- drothiophen-3-yl, 2-oxo-tetrahydrothiophen-4-yl , 2-oxo- tetrahydrothiopyran-3-yl, 2-oxo-tetrahydrothiopyran-4-yl or 2-oxo-tetrahydrothiopyran-5-yl group optionally substituted by one or two methyl groups,
or D together with E denotes an RgCO-0- (ReCRf) -O-CO or (R70-PO-OR8) group wherein Re to Rg and R7 and R8 are as hereinbefore defined,
F and G together denote a hydrogen atom, a methoxy, ethoxy, C4.6-cycloalkoxy or C3_g-cycloalkyl-Cx.3-alkoxy group,
while the aryl moieties mentioned in the definition of the abovementioned groups denote a phenyl group which may be mono- or disubstituted by Rx3, while the substituents may be identical or different and
RX3 denotes a fluorine, chlorine, bromine or iodine atom, a Cx.2-alkyl, trifluoromethyl or Cx.2-alkoxy group or two groups R13, if they are bound to adjacent carbon atoms, together denote a C3.4-alkylene, methylenedioxy or 1, 3-butadien-l, 4-ylene group,
the tautomers, the stereoisomers and the salts thereof.
8. Bicyclic heterocycles of general formula I according to claim 5, wherein
Ra to Rd, A to C and X are defined as in claim 4,
D denotes a Cx.4-alkylene group,
a -CO-NR4-alkylene group wherein the alkylene moiety contains 2 or 3 carbon atoms, while the linking to the adjacent group C must take place via the carbonyl group wherein
R4 denotes a hydrogen atom,
or, if D is bound to a nitrogen atom of the group E, it may also denote a carbonyl group,
E denotes an R60-CO-alkylene-NR5 or (R70-PO-OR8) -alkylene-NR5 group wherein in each case the alkylene moiety, which is straight-chained and contains 1 to 2 carbon atoms, may additionally be substituted by a methyl group or by an R60-C0 or RgO-CO-methyl group, while
R5 denotes a hydrogen atom,
a Cx.2-alkyl group which may be substituted by an R60-C0 group ,
an ethyl group optionally substituted by one or two methyl groups, which is terminally substituted by a hydroxy, Cx.2-alkylcarbonylsulphenyl or Cx_2-alkylcarbonyloxy group, a 2, 2-dimethoxyethyl or 2 , 2-diethoxyethyl group,
R6 denotes a hydrogen atom,
a C-_.β-alkyl group,
a cyclopentyl, cyclopentylmethyl, cyclohexyl or cyclohexyl- methyl group,
a phenyl group optionally substituted by one or two methyl groups, a phenylmethyl group which may be substituted in the phenyl moiety by one or two methyl groups, a 5-indanyl group or an RgCO-0- (ReCRf) group, while
Re denotes a hydrogen atom or a methyl group,
Rf denotes a hydrogen atom and
Rg denotes a C___4-alkyl or Cx.2-alkoxy group,
R7 and R8, which may be identical or different, in each case denote a hydrogen atom, a methyl, ethyl or phenyl group ,
a pyrrolidino or piperidino group which is substituted by an RgO-CO or RgO-CO-methyl group, wherein R6 is as hereinbefore defined,
a pyrrolidino or piperidino group which is substituted by two RgO-CO or RgO-CO-methyl groups wherein R6 is as hereinbefore defined,
a piperazino group which is substituted in the 4 position by the group R10 and additionally at a cyclic carbon atom by an RgO-CO group, while Rs is as hereinbefore defined and Rx0 denotes a hydrogen atom, a methyl, ethyl, acetyl or methylsulfonyl group,
a piperazino or homopiperazino group which is substituted in the 4 position by an R60-CO-Cx„4-alkyl, bis- (R60-CO) -Cx.4-alkyl or (R70-PO-OR8) -Cx.2-alkyl group wherein R6 to R8 are as hereinbefore defined,
a piperazino group which is substituted in the 4 position by an RgO-CO-methyl group and additionally at a cyclic carbon atom by an R60-CO group wherein R6 is as hereinbefore defined,
a morpholino group which is substituted by an R60-CO- group, wherein R6 is as hereinbefore defined,
a 2-oxo-morpholino group which may be substituted by 1 to 2 Cx.2-alkyl groups,
a 2-oxo-thiomorpholino group which may be substituted by 1 to 2 Cx.2-alkyl groups,
a morpholino group which is substituted in the 2 position by a methoxy or ethoxy group,
a morpholino group which is substituted in the 2 and 6 positions in each case by a methoxy or ethoxy group,
a 2, 2-dimethoxyethyl-NRs, 2 , 2-diethoxyethyl-NR5 or 1,3-dioxo- lan-2-yl-methyl-NR5- group wherein R5 is as hereinbefore defined,
an N-methyl-RxxN or N-ethyl-RxxN group wherein
RX1 denotes a 2 -oxo-tetrahydrofuran-3 -yl or 2-oxo-tetrahy- drofuran-4 -yl group, or D together with E denotes an RgC0-0- (ReCRf) -O-CO group wherein Re to Rσg are as hereinbefore defined,
F and G together denote a hydrogen atom,
a methoxy, ethoxy, C4.6-cycloalkoxy or C3.6-cycloalkyl-Cx.3-alkoxy group,
the tautomers, the stereoisomers and the salts thereof.
9. Bicyclic heterocycles of general formula I according to at least one of claims 5 to 8 , characterised in that Rb denotes one of the optionally substituted 1-phenyl-ethyl groups mentioned in the respective claim 5, 6, 7 or 8,
the tautomers, the stereoisomers and the salts thereof.
10. Bicyclic heterocycles of general formula I according to at least one of claims 5 to 8, characterised in that F and G together denote one of the cycloalkoxy or cycloalkyl -alkoxy groups mentioned in the respective claim 5, 6, 7 or 8 ,
the tautomers, the stereoisomers and the salts thereof.
11. Bicyclic heterocycles of general formula I according to at least one of claims 5 to 8 , characterised in that E denotes one of the optionally substituted 2-oxo-morpholino groups mentioned in the respective claim 5, 6, 7 or 8.
12. Bicyclic heterocycles of general formula
Figure imgf000211_0001
wherein
Ra to Rd, A to C and X are defined as in claim 1,
D together with E denotes a hydrogen atom,
a Cx.4-alkyl group optionally substituted by 1 to 5 fluorine atoms,
a C3.g-cycloalkyl group,
an aryl, heteroaryl, Cx.4-alkylcarbonyl , arylcarbonyl or Cx_4- alkoxycarbonyl group ,
an aminocarbonyl, Cx.4-alkylaminocarbonyl or di- (Cx_4-alkyl A aminocarbonyl group or
a carbonyl group, which is substituted by a 4- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups, a methylene group in the 4 position may be replaced by an oxygen or sulphur atom, by an imino group substituted by the group Rxo, by a sulphinyl or sulphonyl group, wherein R10 is defined as in claim 1,
F denotes a Cx.s-alkylene group, a -0-Cx.6-alkylene group, wherein the alkylene moiety is linked to the group G, or an oxygen atom, whilst the latter may not be linked to a nitrogen atom of the group G, and G denotes an R60-CO-alkylene-NRs, (R70-PO-OR8) -alkylene-NRs or (R70-PO-R9) -alkylene-NR5-group wherein in each case the alkylene moiety, which is straight-chained and contains 1 to 6 carbon atoms, may additionally be substituted by one or two Cx.2-alkyl groups or by an RsO-CO or R60-CO-Cx.2-alkyl group, wherein Rs to R9 are defined as in claim 1,
a 4- to 7-membered alkyleneimino group which is substituted by an RgO-CO, (R70-PO-OR8) , (R70-PO-R9) , R60-CO-Cx.4-alkyl , bis- (RgO-CO) -Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) - Cj_.4-alkyl group wherein R6 to R9 are defined as in claim 1,
a 4- to 7-membered alkyleneimino group which is substituted by two RgO-CO or RgO-CO-Cx_4-alkyl groups or by an R60-CO-group and an RsO-CO-Cx.4-alkyl group wherein R6 is defined as in claim 1,
a piperazino or homopiperazino group which is substituted in the 4 position by the group Rxo and is additionally substituted at a cyclic carbon atom by an RsO-CO, (R70-PO-OR8) , (R70-PO-R9) , RgO-CO-Cx„4-alkyl, bis- (R60-CO) -Cx_4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx.4-alkyl group wherein Rs to Rx0 are defined as in claim 1,
a piperazino or homopiperazino group which is substituted in the 4 position by the group Rx0 and is additionally substituted at cyclic carbon atoms by two R60-CO or R60-CO-Cx.4-alkyl groups or by an R60-CO group and an R60-CO-Cx„4-alkyl group wherein R6 and R10 are defined as in claim 1,
a piperazino or homopiperazino group which is substituted in each case in the 4 position by an RsO-CO-Cx.4-alkyl , bis- (RgO-CO) -Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) - Cx„4-alkyl group wherein R6 to R9 are defined as in claim 1,
a piperazino or homopiperazino group which is substituted in the 4 position by an R60-CO-Cx.4-alkyl , bis- (R60-CO) -Cx,4-alkyl , (R70-PO-OR8) -Cx-4-alkyl or (R70-PO-R9) -Cx.4-alkyl group and is additionally substituted at cyclic carbon atoms by one or two RgO-CO or RgO-CO-Cx_4 -alkyl groups or by an R60-CO-group and an R60-CO-Cx.4-alkyl group wherein R6 to R9 are defined as in claim 1,
a morpholino or homomorpholino group which is substituted in each case by an R60-CO, (R70-PO-OR8) , (R70-PO-R9) , R60-CO- Cx.4-alkyl, bis- (RsO-CO) -Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx_4-alkyl group wherein R6 to R9 are defined as in claim 1,
a morpholino or homomorpholino group which is substituted by two RgO-CO or RgO-CO-Cx_4-alkyl groups or by an R60-CO-group and an R60-CO-Cx.4-alkyl group wherein R6 is defined as in claim 1,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group Rx0, whilst the abovementioned 5- to 7-membered rings are in each case additionally substituted at a carbon atom by an RgO-CO, (R70-PO-OR8) , (R70- PO-Rg) , RgO-CO-Cx.4-alkyl, bis- (R60-CO) -Cx.4-alkyl, (R70-PO-OR8) - Cx_4-alkyl or (R70-PO-R9) -Cx_4-alkyl group wherein R6 to R10 are defined as in claim 1,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group Rxo, while the abovementioned 5- to 7-membered rings are in each case additionally substituted at carbon atoms by two R60-CO or RsO-CO-Cx.4-alkyl groups or by an R60-CO-group and an RgO-CO-Cx.4-alkyl group wherein R6 and Rx0 are defined as in claim 1,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an R60-CO-Cx.4-alkyl , bis- (R60-CO) - Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx.4-alkyl group wherein R6 to R9 are defined as in claim 1,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an RsO-CO-Cx_4-alkyl , bis- (RsO-CO) - Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx.4-alkyl group, while the abovementioned 5- to 7-membered rings are in each case additionally substituted at carbon atoms by one or two RgO-CO or RgO-CO-Cx_4-alkyl groups or by an RsO-CO-group and an R60-CO-Cx.4-alkyl group wherein RG to Rg are defined as in claim 1,
a 2-oxo-morpholino group which may be substituted by 1 or 2 methyl groups ,
a 2-oxo-morpholinyl group which is substituted in the 4 position by a hydrogen atom, by a Cx_4-alkyl, R60-CO-Cx.4-alkyl , (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) -Cx.4-alkyl group, while R6 to R9 are defined as in claim 1 and the abovementioned 2-oxo- morpholinyl groups are in each case linked to a carbon atom of the group F,
a morpholino or thiomorpholino group which is substituted in the 2 position by a Cx_4-alkoxy group,
a morpholino or thiomorpholino group which is substituted in the 2 and 6 position by a Cx.4-alkoxy group,
a Cx_4-alkyl-NRS-group wherein the Cx.4-alkyl moiety, which is straight-chained and may additionally be substituted by one or two methyl groups, is in each case terminally substituted by a di- (Cx_4-alkoxy) -methyl or tri- (Cx.4-alkoxy) -methyl group, whilst R5 is defined as in claim 1,
a Cx.4-alkyl-NR5-group wherein the Cx.4-alkyl moiety, which is straight-chained and may additionally be substituted by one or two methyl groups, is terminally substituted in each case by a 1, 3-dioxolan-2-yl or 1, 3-dioxan-2-yl-group optionally substituted by one or two methyl groups, while Rs is defined as in claim 1, an RhNRs-group wherein R5 is as hereinbefore defined and Rh denotes a 2-oxo-tetrahydrofuran-3 -yl, 2-oxo-tetrahydrofuran- 4-yl, 2-oxo-tetrahydropyran-3-yl, 2-oxo-tetrahydropyran-4-yl or 2-oxo-tetrahydropyran-5-yl group optionally substituted by one or two methyl groups,
whilst by the aryl moieties mentioned in the definitions of the abovementioned groups is meant a phenyl group which in each case may be monosubstituted by Rx2, mono-, di- or tri- substituted by RX3 or monosubstituted by Rx2 and additionally mono- or disubstituted by Rx3, whilst the substituents may be identical or different and
Rx2 denotes a cyano, carboxy, Cx.4-alkoxycarbonyl , aminocarbonyl, Cx.4-alkylaminocarbonyl , di- (Cx_4-alkyl) -aminocarbonyl , Cx.4-alkylsulphenyl, Cx_4-alkylsulphinyl , Cx_4-alkylsulphonyl , hydroxy, C-__4-alkylsulphonyloxy, trifluoromethyloxy, nitro, amino, Cx.4-alkylamino, di- (Cx.4-alkyl) -amino, Cx.4-alkyl- carbonylamino, N- (Cx.4-alkyl) -Cx.4-alkylcarbonylamino, Cx.4-alkylsulphonylamino, N- (Cx.4-alkyl) -Cx_4-alkylsulphonyl- amino, aminosulphonyl, Cx_4-alkylaminosulphonyl or di- (Cx_4-alkyl) -aminosulphonyl group or a carbonyl group, which is substituted by a 5- to 7-membered alkyleneimino group, wherein in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, imino or N- (Cx.4-alkyl) -imino group, and
R13 denotes a fluorine, chlorine, bromine or iodine atom, a Cx.4-alkyl, trifluoromethyl or Cx.4-alkoxy group or
two groups Rx3, if they are bound to adjacent carbon atoms, together denote a C -alkylene, methylenedioxy or 1, 3-butadien-l, 4-ylene group,
and moreover, the heteroaryl groups mentioned in the definitions of the abovementioned groups also include a 5-membered heteroaromatic group which contains an imino group, an oxygen or sulphur atom or an imino group, an oxygen or sulphur atom and one or two nitrogen atoms, or
a 6-membered heteroaromatic group which contains one, two or three nitrogen atoms,
whilst the abovementioned 5-membered heteroaromatic groups may be substituted in each case by 1 or 2 methyl or ethyl groups and the abovementioned 6-membered heteroaromatic groups may be substituted in each case by 1 or 2 methyl or ethyl groups or by a fluorine, chlorine, bromine or iodine atom, or by a tri- fluoromethyl, hydroxy, methoxy or ethoxy group,
the tautomers, the stereoisomers and the salts thereof.
13. Bicyclic heterocycles of general formula I according to claim 12, wherein
Ra to Rd, A to C and X are defined as in claim 2,
D together with E denotes a hydrogen atom,
a methyl, trifluoromethyl or aryl group,
F denotes an -0-Cx.4-alkylene group, wherein the alkylene moiety is linked to the group G, or an oxygen atom, while this may not be linked to a nitrogen atom of the group G, and
G denotes an R60-CO-alkylene-NR5, (R70-PO-OR8) -alkylene-NR5 or (R70-PO-R9) -alkylene-NR5 group wherein in each case the alkylene moiety, which is straight-chained and contains 1 to 4 carbon atoms, may additionally be substituted by one or two Cx_2-alkyl groups or by an R60-CO or R60-CO-Cx.2-alkyl group, while R5 to R9 are defined as in claim 2, a 4- to 7-membered alkyleneimino group which is substituted by an RgO-CO, R60-CO-Cx,4-alkyl or bis- (R60-CO) -Cx.4-alkyl group wherein R6 is defined as in claim 2,
a 4- to 7-membered alkyleneimino group which is substituted by two RgO-CO or RgO-CO-Cx.4-alkyl groups wherein R6 is defined as in claim 2,
a piperazino or homopiperazino group which is substituted in the 4 position by the group Rx0 and is additionally substituted at a cyclic carbon atom by an R60-CO, RG0-CO-Cx_4-alkyl or bis- (RgO-CO) -Cx.4-alkyl group wherein Rs and Rxo are defined as in claim 2,
a piperazino or homopiperazino group which is substituted in the 4 position by the group Rx0 and is additionally substituted at cyclic carbon atoms by two R60-CO or RG0-CO-Cx.4-alkyl groups wherein R6 and Rxo are defined as in claim 2,
a piperazino or homopiperazino group which is substituted in each case in the 4 position by an RgO-CO-Cx.4-alkyl, bis- (RgO-CO) -Cx.4-alkyl, (R70-PO-OR8) -Cx.4-alkyl or (R70-PO-R9) - Cx.4-alkyl group wherein RG to R9 are defined as in claim 2,
a piperazino or homopiperazino group which is substituted in the 4 position by an RgO-CO-Cx.4-alkyl or bis- (R60-CO) -Cx.4-alkyl group and additionally at cyclic carbon atoms by one or two RgO-CO or RG0-CO-Cx.4-alkyl groups wherein RG is defined as in claim 2,
a morpholino or homomorpholino group which is substituted in each case by an RG0-CO, R60-CO-Cx.4-alkyl or bis- (R60-CO) -Cx_4-al- kyl group wherein R6 is defined as in claim 2,
a morpholino or homomorpholino group which is substituted by two RgO-CO or RgO-CO-Cx„4-alkyl groups wherein RG is defined as in claim 2, a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group Rx0, while the abovementioned 5- to 7-membered rings in each case are additionally substituted at a carbon atom by an R60-CO, R60-CO-C1.4-alkyl or bis- (RG0-CO) -Cx.4-alkyl group wherein RG and R10 are defined as in claim 2,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by the group Rxo, while the abovementioned 5- to 7-membered rings in each case are additionally substituted at carbon atoms by two RsO-CO or R60-CO-Cx.4-alkyl groups wherein R6 and Rx0 are defined as in claim 2,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an RgO-CO-Cx.4-alkyl , bis- (R60-CO) - Cx.4-alkyl, (R70-PO-OR8) -Cx_4-alkyl or (R70-PO-R9) -Cx.4-alkyl group wherein R6 to R9 are defined as in claim 2,
a pyrrolidinyl, piperidinyl or hexahydroazepinyl group substituted in the 1 position by an RsO-CO-Cx.4-alkyl or bis- (RgO-CO) -Cx.4-alkyl group, while the abovementioned 5- to 7-membered rings in each case are additionally substituted at carbon atoms by one or two R60-CO or RG0-CO-Cx.4-alkyl groups wherein R6 is defined as in claim 2,
a 2-oxo-morpholino group which may be substituted by 1 or 2 methyl groups ,
a 2-oxo-morpholinyl group which is substituted in the 4 position by a Cx_4-alkyl or RG0-CO-Cx.4-alkyl group, while R6 is defined as in claim 2 and the abovementioned 2-oxo-morpholinyl groups are each are linked to a carbon atom of the group F,
a morpholino group which is substituted in the 2 position by a Cx,4-alkoxy group, a morpholino group which is substituted in the 2 and 6 positions in each case by a Cx_4-alkoxy group,
a Cx_4-alkyl-NR5 group wherein the Cx_4-alkyl moiety, which is straight-chained, is terminally substituted by a di- (Cx.4-alkoxy) -methyl group, while R5 is defined as in claim 2,
a Cx_4-alkyl -NRS group wherein the Cx.4-alkyl moiety, which is straight-chained, is terminally substituted by a 1, 3-dioxolan- 2-yl or 1, 3-dioxan-2-yl group, while Rs is defined as in claim 2,
a RhNRs group wherein R5 is defined as in claim 2 and Rh denotes a substituted 2-oxo-tetrahydrofuran-3-yl , 2-oxo-tetrahydro- furan-4-yl, 2-oxo-tetrahydropyran-3-yl , 2-oxo-tetrahydropyran- 4-yl or 2-oxo-tetrahydropyran-5-yl group optionally by one or two methyl groups,
while the aryl moieties mentioned in the definition of the abovementioned groups denote a phenyl group which may in each case be monosubstituted by RX2, mono- or disubstituted by RX3 or monosubstituted by RX2 and additionally mono or disubstituted by Rx3, while the substituents may be identical or different and
RX2 denotes a cyano, Cx.2-alkoxycarbonyl , aminocarbonyl, Cx.2-alkylaminocarbonyl, di- (Cx.2-alkyl) -aminocarbonyl, Cx.2-alkylsulphenyl, Cx_2-alkylsulphinyl, Cx.2-alkylsulphonyl , hydroxy, nitro, amino, Cx_2-alkylamino or di- (Cx.2-alkyl) -amino group and
R13 denotes a fluorine, chlorine, bromine or iodine atom, a Cx.2-alkyl, trifluoromethyl or Cx.2-alkoxy group or
two groups RX3, if they are bound to adjacent carbon atoms, together denote a C3.5-alkylene, methylenedioxy or 1,3-bu- tadien-1 , 4-ylene group, the tautomers, the stereoisomers and the salts thereof.
14. Bicyclic heterocycles of general formula I according to claim 12, wherein
Ra to Rd, A to C and X are defined as in claim 3,
D together with E denotes a hydrogen atom,
a methyl, trifluoromethyl or aryl group,
F denotes an -0-Cx.4-alkylene group, wherein the alkylene moiety is linked to the group G, or an oxygen atom, while this may not be linked to a nitrogen atom of the group G, and
G denotes an R60-CO-alkylene-NRs group wherein the alkylene moiety, which is straight-chained and contains 1 to 4 carbon atoms, may additionally be substituted by one or two Cx.2-alkyl groups or by an RG0-CO or RsO-CO-Cx_2-alkyl group, while R5 and R6 are defined as in claim 3 ,
a pyrrolidino or piperidino group which is substituted by an RgO-CO or RgO-CO-Cx.2-alkyl group wherein RG is defined as in claim 3 ,
a pyrrolidino or piperidino group which is substituted by two R60-CO or RG0-CO-Cx.2-alkyl groups wherein RG is defined as in claim 3 ,
a piperazino group which is substituted in the 4 position by the group Rx0 and additionally at a cyclic carbon atom by an RgO-CO, or RgO-CO-Cx.2-alkyl group, while R6 and Rx0 are defined as in claim 3, a piperazino group which is substituted in the 4 position by an R60-CO-Cx.4-alkyl, bis- (R60-CO) -Cx.4-alkyl or (R70-PO-OR8) - Cx.2-alkyl group wherein R6 to R8 are defined as in claim 3,
a piperazino group which is substituted in the 4 position by an R60-CO-Cx.2-alkyl group and additionally at a cyclic carbon atom by an R60-CO or RgO-CO-Cx_2-alkyl group wherein Rs is defined as in claim 3,
a morpholino group which is substituted by an R60-CO or R60-CO- Cx.2-alkyl group, while R6 is defined as in claim 3,
a piperidinyl group substituted in the 1 position by an RgO-CO-Cx.4-alkyl, bis- (RsO-CO) -Cx.4-alkyl or
(R7O-P0-OR8) -Cx.2-alkyl group wherein RG to R8 are defined as in claim 3 ,
a 2-oxo-morpholino group which may be substituted by 1 or 2 methyl groups ,
a 2-oxo-morpholinyl group which is substituted in the 4 position by a methyl, ethyl or R60-CO-Cx.2-alkyl group, while RG is defined as in claim 3 and the abovementioned 2-oxo-morpholinyl groups in each case are linked to a carbon atom of the group F,
a morpholino group which is substituted in the 2 position by a methoxy or ethoxy group,
a morpholino group which is substituted in the 2 and 6 positions in each case by a methoxy or ethoxy group,
a 2, 2-dimethoxyethyl-NR5, 2 , 2-diethoxyethyl-NRs, 1, 3-dioxolan- 2-yl-methyl-NRS or 1 , 3-dioxan-2-yl-methyl-NRs group wherein R5 is defined as in claim 3, while the aryl moieties mentioned in the definition of the abovementioned groups denote a phenyl group which may be mono- or disubstituted by R13, while the substituents may be identical or different and
R13 denotes a fluorine, chlorine, bromine or iodine atom, a C-__2-alkyl, trifluoromethyl or Cx.2-alkoxy group or
two groups Rx3, if they are bound to adjacent carbon atoms, together denote a C3.4-alkylene, methylenedioxy or 1,3-bu- tadien-1, 4-ylene group,
the tautomers, the stereoisomers and the salts thereof.
15. Bicyclic heterocycles of general formula I according to claim 12, wherein
Ra to Rd, A to C and X are defined as in claim 4,
D together with E denotes a hydrogen atom or a methyl group,
F denotes an -0-Cx.4-alkylene group, while the alkylene moiety is linked to the group G, or an oxygen atom, which may not be linked to a nitrogen atom of the group G, and
G denotes an RG0-CO-alkylene-NR5 group wherein the alkylene moiety, which is straight-chained and contains 1 or 2 carbon atoms, may additionally be substituted by a methyl group or by an RgO-CO or RG0-CO-methyl group, while R5 and RG are defined as in claim 4,
a pyrrolidino or piperidino group which is substituted by an R60-CO or RgO-CO-methyl group wherein R6 is defined as in claim 4, a pyrrolidino or piperidino group which is substituted by two RgO-CO or RG0-CO-methyl groups wherein R6 is defined as in claim 4,
a piperazino group which is substituted in the 4 position by an R60-CO-Cx.4-alkyl, bis- (RG0-CO) -Cx.4-alkyl or (R70-PO-OR8) - Cx.2-alkyl group wherein R6 to R8 are defined as in claim 4,
a piperidinyl group substituted in the 1 position by an RG0-CO- Cx.2-alkyl group wherein Rs is defined as in claim 4,
the tautomers, the stereoisomers and the salts thereof.
16. Bicyclic heterocycles of general formula I according to at least one of claims 12 to 15, characterised in that Rb denotes one of the optionally substituted 1-phenyl-ethyl groups mentioned in the respective claim 12, 13, 14 or 15,
the tautomers, the stereoisomers and the salts thereof.
17. The following compounds of general formula I according to claim 1 :
(a) 4- [ (3-bromophenyl) amino] -7- (3-{4- [ (ethoxycarbonyl) methyl] - piperazin-l-yl}propyloxy) -6- [ (vinylcarbonyl) amino] -quinazoline,
(b) 4- t (3-bromophenyl) amino] -7- (3-{4- [3- (ethoxycarbonyl) propyl] -piperazin-l-yl}propyloxy) -6- [ (vinylcarbonyl) amino] - quinazoline,
(c) 4- [ (3-bromophenyl) amino] -7- ( {l- [ (ethoxycarbonyl) methyl] - piperidin-4 -yl }oxy) -6- [ (vinylcarbonyl) amino] -quinazoline,
(d) 4- [ (3-bromophenyl) amino] -7- (3- {4- [ (diethoxyphosphoryl) - methyl] -piperazin-l-yl}propyloxy) -6- [ (vinylcarbonyl) amino] - quinazoline, (e) 4- [ (3-bromophenyl) amino] -7- (3-{N- [ (ethoxycarbonyl) methyl] - N-methylamino}propyloxy) -6- [ (vinylcarbonyl) amino] -quinazoline,
(f) 4- [ (3-bromophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N-methylamino} -l-oxo-2 -buten-1-yl) amino] -quinazoline,
(g) 4- [ (3-bromophenyl) amino] -6- [ (4- {N- [ (diethoxyphosphoryl) methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy-quinazoline,
(h) (R) -4- [ (1-phenylethyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N-methylamino} -l-oxo-2-buten-l-yl) amino] -7-methoxy-quinazoline,
(i) 4- [ (3-bromophenyl) amino] -6- ( {4- [N- (2, 2-dimethoxyethyl) - N-methylamino] -l-oxo-2-buten-l-yl }amino) -7-methoxy-quinazoline,
(j ) 4- [ (3-bromophenyl) amino] -6- { [4- (2-ethoxy-morpholin-4-yl) - l-oxo-2-buten-l-yl] amino} -7-methoxy-quinazoline,
(k) 4- [ (3-bromophenyl) amino] -3 -cyano-6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N-methylamino} -l-oxo-2 -buten-1-yl) amino] -quinoline,
(1) 4- [ (3-chloro-4-fluorophenyl) amino] -6- [ (4- {4- [ (ethoxycarbonyl) methyl] -piperazin-l-yl} -l-oxo-2-buten-l-yl) amino] -7-cyclo- propylmethoxy-quinazoline ,
(m) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6-[(4-{N-[2- (ethoxycarbonyl) -ethyl] -N- [ (ethoxycarbonyl) methyl] amino} -l-oxo-2-buten- 1-yl) amino] -7-cyclopropylmethoxy-quinazoline,
(n) 4- [ (3-chloro-4-fluorophenyl) amino] -6- { [4- (2-oxo-morpholin- 4-yl) -l-oxo-2-buten-l-yl] amino} -7-cyclopropylmethoxy-quina- zoline, (o) 4- [ (3 -chloro-4-fluorophenyl) amino] -6- [ (4- {4- [ (ethoxycarbonyl) methyl] -piperazin-l-yl} -l-oxo-2-buten-l-yl) amino] -7-cyclo- butyloxy-quinazoline,
(p) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- [ (4- {4- [ (ethoxycarbonyl) methyl] -piperazin-l-yl} -l-oxo-2-buten-l-yl) amino] -7- (2-cy- clopropylethoxy) -quinazoline,
(q) (S) -4- [ (3 -chloro-4 -fluorophenyl) amino] -6- ( {4- [2- (methoxycarbonyl) -pyrrolidin-1-yl] -l-oxo-2-buten-l-yl}amino) -7-cyclo- propylmethoxy-quinazoline ,
(r) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) methyl] -N- [2- (acetylsulphanyl) ethyl] amino} -l-oxo-2-buten- 1-yl) amino] -7-cyclopropylmethoxy-quinazoline,
(s) 4- [ (3 -chloro-4-fluorophenyl) amino] -6- [ (4- {N- [ (ethoxycarbonyl) -methyl] -N- [2- (methylcarbonyloxy) ethyl] amino} -l-oxo-2 -buten-1-yl) amino] -7-cyclopropylmethoxy-quinazoline,
(t) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- { [4- (5, 5-dimethyl- 2-oxo-morpholin-4-yl) -l-oxo-2-buten-l-yl] amino} -7-cyclo-pro- pylmethoxy-quinazoline and
(u) 4- [ (3 -chloro-4 -fluorophenyl) amino] -6- { [4- (5-methyl-2-oxo- morpholin-4-yl) -l-oxo-2-buten-l-yl] amino} -7-cyclopropylmeth- oxy-quinazoline and the salts thereof.
18. Physiologically acceptable salts of the compounds according to at least one of claims 1 to 17 with inorganic or organic acids or bases.
19. Pharmaceutical compositions containing a compound according to at least one of claims 1 to 17 or a physiologically accep- table salt according to claim 18 optionally together with one or more inert carriers and/or diluents.
20. Use of a compound according to at least one of claims 1 to 18 for preparing a pharmaceutical composition which is suitable for treating benign or malignant tumours, for preventing and treating diseases of the airways and lungs and for treating polyps, diseases of the gastrointestinal tract, the bile duct and gall bladder and also the kidneys and skin.
21. Process for preparing a pharmaceutical composition according to claim 19, characterised in that a compound according to at least one of claims 1 to 18 is incorporated in one or more inert carriers and/or diluents by a non-chemical method.
22. Process for preparing the compounds of general formula I according to claims 1 to 18, characterised in that
a) a compound of general formula
Figure imgf000226_0001
wherein
Ra to Rd, A, F, G and X are defined as in claims 1 to 17, is reacted with a compound of general formula
Zx B C - D - E , (III)
wherein
B to E are defined as in claims 1 to 17 and
Zx denotes a leaving group or a hydroxy group, or b) in order to prepare compounds of general formula I wherein the group E is linked to the group D via a nitrogen atom, a compound of general formula
Figure imgf000227_0001
wherein
Ra to Rd, A to D, F, G and X are defined as in claims 1 to 17 and
Z2 denotes a leaving group or a hydroxy group, is reacted with a compound of general formula
H - Y , (V)
wherein
Y denotes one of the groups mentioned for E in claims 1 to 17, which is linked to the group D via a nitrogen atom, or
c) for preparing compounds of general formula I wherein D together with E denotes an RgC0-0- (ReCR£) -O-CO- group, a compound of general formula
Figure imgf000227_0002
wherein
Ra to Rd, A to C, F, G and X are defined as in claims 1 to 17, is reacted with a compound of general formula
RgCO-0- (ReCRf) -Z3 , (VII)
wherein R Ree ttoo RRgg are defined as in claims 1 to 17 and Z3 denotes a leaving group or
d) for preparing compounds of general formula I wherein E or G denotes a piperazino or homopiperazino group each substituted in position 4 by an R60-CO-Cx.4-alkyl group wherein R6 is defined as in claims 1 to 17, a corresponding compound containing a piperazino or homopiperazino group each unsubstituted in position 4 is reacted with a compound of general formula
RG0-CO-Cx.4-alkyl-Z4 (VIII) ,
wherein
R6 is defined as in claims 1 to 17 and
Z4 denotes a leaving group, or
e) for preparing compounds of general formula I wherein E or G denotes a piperazino or homopiperazino group each substituted in position 4 by an RsO-CO-CH2CH2-group wherein R6 is defined as in claims 1 to 17, a corresponding compound containing a piperazino or homopiperazino group each unsubstituted in position
4 is reacted with a compound of general formula
RsO-CO-CH=CH2, (IX) ,
wherein
Rg is defined as in claims 1 to 17, or
f) for preparing compounds of general formula I wherein C denotes a 1,2-vinylene group, a compound of general formula O 00/
227
Figure imgf000229_0001
wherein
Ra to Rd, A, F, G and X are defined as in claims 1 to 17 and alkyl denotes a lower alkyl group, is reacted with a compound of general formula
OCH-D-E (XI)
wherein
D and E are defined as in claims 1 to 17, and
if desired a compound of general formula I thus obtained which contains a hydroxy, amino, alkylamino or imino group is converted by acylation or sulphonylation into a corresponding acylamino, N-alkyl-acylamino, acyl-imino, sulphonyloxy, sulphonylamino, N-alkyl-sulphonylamino or sulphonyl -imino compound, whilst a sulphonyloxy compound thus obtained may be converted into a corresponding sulphenyl compound by reaction with an alkali metal salt of a thio compound, and/or
a compound of general formula I thus obtained which contains an amino, alkylamino or imino group is converted by alkylation or reductive alkylation into a corresponding alkyl compound of general formula I, and/or
a compound of general formula I thus obtained wherein E denotes a bis- [2 , 2-di- (Cx_4-alkoxy) ethyl] amino group may be converted by intramolecular cyclisation into a corresponding morpholino compound of general formula I, and/or a compound of general formula I thus obtained wherein E or G denotes an optionally substituted N- (2-hydroxyethyl) -glycine or N- (2-hydroxyethyl) -glycine ester group may be converted by intramolecular cyclisation into a corresponding 2-oxo-morpholino compound, and/or
a compound of general formula I thus obtained which contains a carboxy or hydroxyphosphoryl group may be converted by alkylation into a corresponding ester of general formula I, and/or
if necessary any protecting group used during the reactions described above is cleaved again and/or
if desired a compound of general formula I thus obtained is resolved into the stereoisomers thereof and/or
a compound of general formula I thus obtained is converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts thereof.
PCT/EP2000/001496 1999-02-27 2000-02-24 4-AMINO-QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANsSDUCTION MEDIATED BY TYROSINE KINASES Ceased WO2000051991A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
EA200100830A EA200100830A1 (en) 1999-02-27 2000-02-24 DERIVATIVES OF 4-AMINOHINAZOLINE AND QUINOLINE, PROVIDING AN INHIBITING ACTION TO ALARM CONVERSION, MEDIED BY TYROSINKINASE
KR1020017010981A KR20020068261A (en) 1999-02-27 2000-02-24 4-Amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
IL14414300A IL144143A0 (en) 1999-02-27 2000-02-24 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
PL00351619A PL351619A1 (en) 1999-02-27 2000-02-24 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transsduction mediated by tyrosine kinases
CA002361174A CA2361174C (en) 1999-02-27 2000-02-24 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
EEP200100449A EE200100449A (en) 1999-02-27 2000-02-24 4-Aminoquinazoline and Quinoline Derivatives of Inhibitory Effect on Tyrosine Kinase Mediated Signal Transmission
BR0008524-3A BR0008524A (en) 1999-02-27 2000-02-24 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for their preparation
JP2000602218A JP3751201B2 (en) 1999-02-27 2000-02-24 4-Amino-quinazoline derivatives and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
US09/914,323 US6972288B1 (en) 1999-02-27 2000-02-24 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
HU0301132A HUP0301132A3 (en) 1999-02-27 2000-02-24 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases, process for their preparation their use and pharmaceutical compositions containing them
HR20010617A HRP20010617A2 (en) 1999-02-27 2000-02-24 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
EP00910695A EP1157011A1 (en) 1999-02-27 2000-02-24 4-amino- quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
AU32816/00A AU3281600A (en) 1999-02-27 2000-02-24 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transsduction mediated by tyrosine kinases
SK1211-2001A SK12112001A3 (en) 1999-02-27 2000-02-24 4-AMINO-CHINAZOLINE AND CHINOLINE DERIVATIVES, METHODS OF PREPARATION, PHARMACEUTICAL PRODUCTS WITH THEIR CONTENT AND THEIR USE
BG105765A BG105765A (en) 1999-02-27 2001-08-01 4-AMINO-HYANZOLINE AND XINOLINE DERIVATIVES WITH INHIBITORS ON SIGNAL TRANSLATION, THERAPISED BY TYROSINKINASES
NO20014114A NO20014114L (en) 1999-02-27 2001-08-24 4-Amino-quinazoline and quinoline derivatives with inhibitory effect on signal transduction mediated by tyrosine kinases

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
DE1999108567 DE19908567A1 (en) 1999-02-27 1999-02-27 New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors, polyps or respiratory or gastrointestinal diseases
DE19908567.6 1999-02-27
DE1999111366 DE19911366A1 (en) 1999-03-15 1999-03-15 New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors, polyps or respiratory or gastrointestinal diseases
DE19911366.1 1999-03-15
DE19928306.0 1999-06-21
DE1999128306 DE19928306A1 (en) 1999-06-21 1999-06-21 New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors, polyps or respiratory or gastrointestinal diseases
US14932999P 1999-08-17 1999-08-17
US60/149,329 1999-08-17
DE19954816.1 1999-11-13
DE19954816A DE19954816A1 (en) 1999-11-13 1999-11-13 New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors, polyps or respiratory or gastrointestinal diseases

Publications (1)

Publication Number Publication Date
WO2000051991A1 true WO2000051991A1 (en) 2000-09-08

Family

ID=27512681

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/001496 Ceased WO2000051991A1 (en) 1999-02-27 2000-02-24 4-AMINO-QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANsSDUCTION MEDIATED BY TYROSINE KINASES

Country Status (21)

Country Link
US (1) US6972288B1 (en)
EP (2) EP1157011A1 (en)
JP (1) JP3751201B2 (en)
KR (1) KR20020068261A (en)
CN (1) CN1341104A (en)
AU (1) AU3281600A (en)
BG (1) BG105765A (en)
BR (1) BR0008524A (en)
CA (1) CA2361174C (en)
CZ (1) CZ20013079A3 (en)
EE (1) EE200100449A (en)
HR (1) HRP20010617A2 (en)
HU (1) HUP0301132A3 (en)
ID (1) ID29800A (en)
IL (1) IL144143A0 (en)
NO (1) NO20014114L (en)
NZ (1) NZ513802A (en)
PL (1) PL351619A1 (en)
SK (1) SK12112001A3 (en)
TR (1) TR200102505T2 (en)
WO (1) WO2000051991A1 (en)

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018375A1 (en) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Quinazolines, medicaments, which contain these compounds and which are effective as tyrosine kinase inhibitors, their use, and methods for the production thereof
WO2002018373A1 (en) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Quinazoline derivatives, medicaments containing these compounds, their use, and methods for the production thereof
WO2002018376A1 (en) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
US6403580B1 (en) 2000-08-26 2002-06-11 Boehringer Ingelheim Pharma Kg Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
WO2002050043A1 (en) * 2000-12-20 2002-06-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof
WO2002068394A1 (en) * 2001-02-22 2002-09-06 Glaxo Group Limited Quinoline derivative as tyrosine kinase inhibitor
US6653305B2 (en) 2000-08-26 2003-11-25 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
US6706699B2 (en) 2001-06-21 2004-03-16 Ariad Pharmaceuticals, Inc. Quinolines and uses thereof
US6740651B2 (en) 2000-08-26 2004-05-25 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
WO2005026157A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
WO2005037824A3 (en) * 2003-10-17 2005-07-21 Boehringer Ingelheim Int Method for the production of amino crotonyl compounds
JP2005526837A (en) * 2002-04-19 2005-09-08 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for their production
WO2005097803A1 (en) * 2004-04-09 2005-10-20 Chugai Seiyaku Kabushiki Kaisha Novel water-soluble prodrug
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US7049438B2 (en) 2000-06-06 2006-05-23 Astrazeneca Ab Quinazoline derivatives for treatment of tumours
US7115615B2 (en) 2000-08-21 2006-10-03 Astrazeneca Quinazoline derivatives
US7132427B2 (en) 2001-06-21 2006-11-07 Ariad Pharmaceuticals, Inc. Quinazolines and uses thereof
US7148230B2 (en) 2003-07-29 2006-12-12 Astrazeneca Ab Quinazoline derivatives
WO2007029251A3 (en) * 2005-09-06 2007-05-03 T K Signal Ltd Polyalkylene glycol derivatives of 4- (phenylamino)quinazolines useful as irreversible inhibitors of epidermal gr0wth fact0r receptor tyrosine kinase
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
WO2008006287A1 (en) * 2006-07-05 2008-01-17 Tianjin Hemay Bio-Tech Co. Ltd Inreversible protein tyrosine kinases inhibitors and the preparation methods and uses thereof
US7358256B2 (en) 2005-03-28 2008-04-15 Bristol-Myers Squibb Company ATP competitive kinase inhibitors
US7449460B2 (en) 2004-02-20 2008-11-11 Wyeth 3-Quinolinecarbonitrile protein kinase inhibitors
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
US7569577B2 (en) 2003-09-16 2009-08-04 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
US7618975B2 (en) 2003-07-03 2009-11-17 Myriad Pharmaceuticals, Inc. 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US7625908B2 (en) 2003-11-13 2009-12-01 Astrazeneca Ab Quinazoline derivatives
US7632840B2 (en) 2004-02-03 2009-12-15 Astrazeneca Ab Quinazoline compounds for the treatment of hyperproliferative disorders
US7772243B2 (en) 2004-05-06 2010-08-10 Warner-Lambert Company Llc 4-phenylamino-quinazolin-6-yl-amides
US7863281B2 (en) 2002-04-19 2011-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
US7910731B2 (en) 2002-03-30 2011-03-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7989462B2 (en) 2003-07-03 2011-08-02 Myrexis, Inc. 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US7998949B2 (en) 2007-02-06 2011-08-16 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
US8022047B2 (en) 2005-08-22 2011-09-20 Chugai Seiyaku Kabushiki Kaisha Combination anticancer agents
US8048844B1 (en) 1998-08-18 2011-11-01 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US8088782B2 (en) 2008-05-13 2012-01-03 Astrazeneca Ab Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US8399461B2 (en) 2006-11-10 2013-03-19 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for production of same
EP2448409A4 (en) * 2009-07-02 2013-04-10 Newgen Therapeutics Inc Phosphorus containing quinazoline compounds and methods of use
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
US8507502B2 (en) 2008-11-10 2013-08-13 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
EP1303301B1 (en) * 2000-07-14 2014-02-12 The Regents of The University of California Preventing airway mucus production by administration of egf-r antagonists
US8722694B2 (en) 1999-06-21 2014-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US8877764B2 (en) 2006-09-18 2014-11-04 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
US9089571B2 (en) 2005-11-11 2015-07-28 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9545381B2 (en) 2009-07-06 2017-01-17 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
CN106518849A (en) * 2016-10-27 2017-03-22 上海人类基因组研究中心 Quinazoline compound, and preparation method and applications thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9790232B2 (en) 2013-11-01 2017-10-17 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10710968B2 (en) 2016-01-13 2020-07-14 Hadasit Medical Research Services And Development Ltd. Radiolabeled erlotinib analogs and uses thereof
US10766907B2 (en) 2016-09-08 2020-09-08 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2022139304A1 (en) * 2020-12-22 2022-06-30 한미약품 주식회사 Novel quinazoline derivative compound as sos1 inhibitor, and use thereof

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
DE10221018A1 (en) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Use of inhibitors of EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
EP1664030A1 (en) * 2003-09-16 2006-06-07 AstraZeneca AB Quinazoline derivatives
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
WO2005026151A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
DE602004004553T2 (en) * 2003-09-19 2007-10-25 Astrazeneca Ab quinazoline derivatives
US20070037837A1 (en) * 2003-09-19 2007-02-15 Hennequin Laurent Francois A Quinazoline derivatives
BRPI0414735A (en) * 2003-09-25 2006-11-21 Astrazeneca Ab quinazoline derivative, compound, pharmaceutical composition, use of quinazoline derivative, method for producing an antiproliferative effect on a warm-blooded animal, and process for the preparation of a quinazoline derivative
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
DE10345875A1 (en) * 2003-09-30 2005-04-21 Boehringer Ingelheim Pharma Bicyclic heterocycles, pharmaceutical compositions containing them, their use and methods of preparation
US20050096332A1 (en) * 2003-10-30 2005-05-05 Boehringer Ingelheim International Gmbh Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
JP2008501675A (en) * 2004-06-04 2008-01-24 アストラゼネカ アクチボラグ Quinazoline derivatives as ERBB receptor tyrosine kinases
DE602005026865D1 (en) 2004-12-14 2011-04-21 Astrazeneca Ab PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUM-MEANS
WO2006081741A1 (en) * 2005-02-05 2006-08-10 Piaoyang Sun Quinazoline compounds or their medical salts and preparation and medical usage thereof
JP5054544B2 (en) * 2005-02-26 2012-10-24 アストラゼネカ アクチボラグ Quinazoline derivatives as tyrosine kinase inhibitors
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
GB0508717D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
JP2009508917A (en) * 2005-09-20 2009-03-05 アストラゼネカ アクチボラグ Quinazoline derivatives as anticancer agents
DE602006018331D1 (en) * 2005-09-20 2010-12-30 Astrazeneca Ab 4- (1H-INDAZOL-5-YLAMINO) CHINAZOLINE COMPOUNDS AS INHIBITORS OF ERBB RECEPTORT ROSINKINASE FOR THE TREATMENT OF CANCER
KR100832593B1 (en) * 2005-11-08 2008-05-27 한미약품 주식회사 Quinazoline derivatives as an signal trnasduction inhibitor and method for the preparation thereof
ATE443053T1 (en) * 2005-12-02 2009-10-15 Astrazeneca Ab QUINAZOLEIN DERIVATIVES USED AS INHIBITORS OF ERBB TYROSINKINASE
BR112012031340B1 (en) 2010-06-09 2021-09-14 Tianjin Hemay Bio-Tech Co., Ltd CYANOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITION INCLUDING THEM, AND THEIR USE
CN103804308A (en) * 2012-11-06 2014-05-21 天津药物研究院 7-substituted cyclohexyl quinazoline derivatives and preparing method and uses thereof
WO2014177038A1 (en) 2013-04-28 2014-11-06 Sunshine Lake Pharma Co., Ltd. Aminoquinazoline derivatives and their salts and methods of use thereof
CN106565681B (en) * 2016-11-10 2019-07-09 中国医学科学院放射医学研究所 Aniline quinazoline class compound of the group containing nitroimidazole and its preparation method and application
JP2021506974A (en) * 2017-12-18 2021-02-22 スターングリーン、インク． Pyrimidine compounds useful as tyrosine kinase inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0787722A1 (en) * 1996-02-05 1997-08-06 American Cyanamid Company Substituted quinazoline derivatives
WO1999009016A1 (en) * 1997-08-01 1999-02-25 American Cyanamid Company Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors
WO2000018740A1 (en) * 1998-09-29 2000-04-06 American Cyanamid Company Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
BR9707495A (en) 1996-02-13 1999-07-27 Zeneca Ltd Quinazoline derivative process for the preparation of the same pharmaceutical composition and process for the production of an antiangiogenic effect and / or reduction of vascular permeability in a warm-blooded animal
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
UA73073C2 (en) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Substituted 3-cyan chinolines
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
DE19911509A1 (en) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
US6384051B1 (en) * 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
US6403580B1 (en) * 2000-08-26 2002-06-11 Boehringer Ingelheim Pharma Kg Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US6740651B2 (en) * 2000-08-26 2004-05-25 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6653305B2 (en) * 2000-08-26 2003-11-25 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0787722A1 (en) * 1996-02-05 1997-08-06 American Cyanamid Company Substituted quinazoline derivatives
WO1999009016A1 (en) * 1997-08-01 1999-02-25 American Cyanamid Company Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors
WO2000018740A1 (en) * 1998-09-29 2000-04-06 American Cyanamid Company Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ALEXANDER, W. S. ET AL., EMBO J., vol. 10, 1991, pages 3683 - 3691
DEXTER, T. M. ET AL., J. EXP. MED., vol. 152, 1980, pages 1036 - 1047
KARASUYAMA, H., EUR. J. IMMUNOL., vol. 18, 1988, pages 97 - 104
MARKOWITZ, D. ET AL., J. VIROL., vol. 62, 1988, pages 1120 - 1124
MILLER, A. D. ET AL., BIOTECHNIQUES, vol. 7, 1989, pages 980 - 990
PIERCE, J. H. ET AL., SCIENCE, vol. 239, 1988, pages 628 - 631
RIDDEN, T. ET AL., EMBO J., vol. 7, 1988, pages 2749 - 2756
SHIBUYA, H. ET AL., CELL, vol. 70, 1992, pages 57 - 67
ULLRICH, A. ET AL., NATURE, vol. 309, 1984, pages 418 - 425

Cited By (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048844B1 (en) 1998-08-18 2011-11-01 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US8071074B2 (en) 1998-08-18 2011-12-06 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US8722694B2 (en) 1999-06-21 2014-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US7696214B2 (en) 2000-06-06 2010-04-13 Astrazeneca Ab Quinazoline derivatives for the treatment of tumours
US7049438B2 (en) 2000-06-06 2006-05-23 Astrazeneca Ab Quinazoline derivatives for treatment of tumours
EP1303301B1 (en) * 2000-07-14 2014-02-12 The Regents of The University of California Preventing airway mucus production by administration of egf-r antagonists
US7115615B2 (en) 2000-08-21 2006-10-03 Astrazeneca Quinazoline derivatives
US6740651B2 (en) 2000-08-26 2004-05-25 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6653305B2 (en) 2000-08-26 2003-11-25 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
WO2002018373A1 (en) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Quinazoline derivatives, medicaments containing these compounds, their use, and methods for the production thereof
WO2002018376A1 (en) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
US6403580B1 (en) 2000-08-26 2002-06-11 Boehringer Ingelheim Pharma Kg Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
WO2002018375A1 (en) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Quinazolines, medicaments, which contain these compounds and which are effective as tyrosine kinase inhibitors, their use, and methods for the production thereof
EP2112140A1 (en) * 2000-12-20 2009-10-28 Boehringer Ingelheim Pharma GmbH & Co. KG Chinazolin derivatives, medicine containing these compounds, application thereof and method for their production
HRP20030504B1 (en) * 2000-12-20 2011-09-30 Boehringer Ingelheim Pharma Gmbh & Co.Kg. Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof
US8586608B2 (en) 2000-12-20 2013-11-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
USRE43431E1 (en) 2000-12-20 2012-05-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
WO2002050043A1 (en) * 2000-12-20 2002-06-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof
WO2002068394A1 (en) * 2001-02-22 2002-09-06 Glaxo Group Limited Quinoline derivative as tyrosine kinase inhibitor
US7009054B2 (en) 2001-06-21 2006-03-07 Ariad Pharmaceuticals, Inc. Quinolines and uses thereof
US7132427B2 (en) 2001-06-21 2006-11-07 Ariad Pharmaceuticals, Inc. Quinazolines and uses thereof
US6706699B2 (en) 2001-06-21 2004-03-16 Ariad Pharmaceuticals, Inc. Quinolines and uses thereof
US7910731B2 (en) 2002-03-30 2011-03-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US8343982B2 (en) 2002-03-30 2013-01-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocyclic compounds pharmaceutical compositions containing these compounds, their use and process for preparing the same
JP2005526837A (en) * 2002-04-19 2005-09-08 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for their production
US7863281B2 (en) 2002-04-19 2011-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US7618975B2 (en) 2003-07-03 2009-11-17 Myriad Pharmaceuticals, Inc. 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US7989462B2 (en) 2003-07-03 2011-08-02 Myrexis, Inc. 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US7148230B2 (en) 2003-07-29 2006-12-12 Astrazeneca Ab Quinazoline derivatives
US7569577B2 (en) 2003-09-16 2009-08-04 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
WO2005026157A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
EP2508521B1 (en) 2003-10-17 2015-12-30 Boehringer Ingelheim International GmbH Dimaleat of an amino crotonyl compound and method of production thereof
US8426586B2 (en) 2003-10-17 2013-04-23 Boehringer Ingelheim International Gmbh Process for preparing amino crotonyl compounds
AU2004281938B2 (en) * 2003-10-17 2011-04-14 Boehringer Ingelheim International Gmbh Method for the production of amino crotonyl compounds
WO2005037824A3 (en) * 2003-10-17 2005-07-21 Boehringer Ingelheim Int Method for the production of amino crotonyl compounds
EP2508521A3 (en) * 2003-10-17 2013-01-23 Boehringer Ingelheim International GmbH Method for the production of amino crotonyl compounds
KR101180752B1 (en) 2003-10-17 2012-09-10 베링거 인겔하임 인터내셔날 게엠베하 Method for the production of amino crotonyl compounds? ??? 4-[3-???-4-?????????]-6-[4-N,N-??????-1-??-2-??-1-?]???-7-S-?????????-3-???????? ?? ??????? ??? ? ?????? ???? ?? ?, ?? 4-[3-???-4-?????????]-6-[4-N,N-??????-1-??-2-??-1-?]???-7-S-?????????-3-???-???? ??????? ??? ???? ? 4-[3-???-4-?????????]-6-[4-N,N-??????-1-??-2-??-1-?]???
EA016624B1 (en) * 2003-10-17 2012-06-29 Бёрингер Ингельхайм Интернациональ Гмбх Method for the production of amino crotonyl compounds and medicament
US7625908B2 (en) 2003-11-13 2009-12-01 Astrazeneca Ab Quinazoline derivatives
US7632840B2 (en) 2004-02-03 2009-12-15 Astrazeneca Ab Quinazoline compounds for the treatment of hyperproliferative disorders
US7767671B2 (en) 2004-02-20 2010-08-03 Wyeth 3-Quinolinecarbonitrile protein kinase inhibitors
US7449460B2 (en) 2004-02-20 2008-11-11 Wyeth 3-Quinolinecarbonitrile protein kinase inhibitors
RU2413731C2 (en) * 2004-04-09 2011-03-10 Чугаи Сейяку Кабусики Кайся Novel water-soluble prodrugs
WO2005097803A1 (en) * 2004-04-09 2005-10-20 Chugai Seiyaku Kabushiki Kaisha Novel water-soluble prodrug
US7910593B2 (en) 2004-04-09 2011-03-22 Chugai Seiyaku Kabushiki Kaisha Water-soluble prodrugs
US8623883B2 (en) 2004-05-06 2014-01-07 Warner-Lambert Company Llc 4-phenylamino-quinazolin-6-yl-amides
US8466165B2 (en) 2004-05-06 2013-06-18 Warner-Lambert Company Llc 4-phenylamino-quinazolin-6-yl-amides
US7772243B2 (en) 2004-05-06 2010-08-10 Warner-Lambert Company Llc 4-phenylamino-quinazolin-6-yl-amides
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US7358256B2 (en) 2005-03-28 2008-04-15 Bristol-Myers Squibb Company ATP competitive kinase inhibitors
US8022047B2 (en) 2005-08-22 2011-09-20 Chugai Seiyaku Kabushiki Kaisha Combination anticancer agents
WO2007029251A3 (en) * 2005-09-06 2007-05-03 T K Signal Ltd Polyalkylene glycol derivatives of 4- (phenylamino)quinazolines useful as irreversible inhibitors of epidermal gr0wth fact0r receptor tyrosine kinase
US8461166B2 (en) 2005-09-06 2013-06-11 Hadasit Medical Research Services And Development Ltd. Polyalkylene glycol derivatives of inhibitors of epidermal growth factor receptor tyrosine kinase
US9089571B2 (en) 2005-11-11 2015-07-28 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
US9539258B2 (en) 2005-11-11 2017-01-10 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
CN101100466B (en) * 2006-07-05 2013-12-25 天津和美生物技术有限公司 Non-reversible protein tyrosine phosphorus acylase inhibitor and its preparation and application
WO2008006287A1 (en) * 2006-07-05 2008-01-17 Tianjin Hemay Bio-Tech Co. Ltd Inreversible protein tyrosine kinases inhibitors and the preparation methods and uses thereof
US8877764B2 (en) 2006-09-18 2014-11-04 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
US8399461B2 (en) 2006-11-10 2013-03-19 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for production of same
US7998949B2 (en) 2007-02-06 2011-08-16 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
US8772298B2 (en) 2008-02-07 2014-07-08 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
US8088782B2 (en) 2008-05-13 2012-01-03 Astrazeneca Ab Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
US8507502B2 (en) 2008-11-10 2013-08-13 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
US8987284B2 (en) 2009-07-02 2015-03-24 Newgen Therapeutics, Inc. Phosphorus containing quinazoline compounds and methods of use
EP2448409A4 (en) * 2009-07-02 2013-04-10 Newgen Therapeutics Inc Phosphorus containing quinazoline compounds and methods of use
US10004743B2 (en) 2009-07-06 2018-06-26 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
US9545381B2 (en) 2009-07-06 2017-01-17 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
US9877970B2 (en) 2013-02-15 2018-01-30 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9827248B2 (en) 2013-02-15 2017-11-28 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US10966987B2 (en) 2013-02-15 2021-04-06 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US10398703B2 (en) 2013-02-15 2019-09-03 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US11369611B2 (en) 2013-02-20 2022-06-28 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9833453B2 (en) 2013-02-20 2017-12-05 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9861634B2 (en) 2013-02-20 2018-01-09 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US10285991B2 (en) 2013-02-20 2019-05-14 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US10758539B2 (en) 2013-02-20 2020-09-01 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US10975090B2 (en) 2013-11-01 2021-04-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US11713323B2 (en) 2013-11-01 2023-08-01 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9790232B2 (en) 2013-11-01 2017-10-17 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10160765B2 (en) 2013-11-01 2018-12-25 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10618906B2 (en) 2013-11-01 2020-04-14 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
US10710968B2 (en) 2016-01-13 2020-07-14 Hadasit Medical Research Services And Development Ltd. Radiolabeled erlotinib analogs and uses thereof
US10766907B2 (en) 2016-09-08 2020-09-08 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10626121B2 (en) 2016-09-08 2020-04-21 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US11021487B2 (en) 2016-09-08 2021-06-01 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US11104685B2 (en) 2016-09-08 2021-08-31 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN106518849B (en) * 2016-10-27 2019-08-16 上海人类基因组研究中心 Quinazoline compounds and its preparation method and application
CN106518849A (en) * 2016-10-27 2017-03-22 上海人类基因组研究中心 Quinazoline compound, and preparation method and applications thereof
WO2022139304A1 (en) * 2020-12-22 2022-06-30 한미약품 주식회사 Novel quinazoline derivative compound as sos1 inhibitor, and use thereof
CN116648250A (en) * 2020-12-22 2023-08-25 韩美药品株式会社 Novel quinazoline derivatives as SOS1 inhibitors and uses thereof
CN116648250B (en) * 2020-12-22 2025-06-13 韩美药品株式会社 Novel quinazoline derivatives as SOS1 inhibitors and their use

Also Published As

Publication number Publication date
ID29800A (en) 2001-10-11
CZ20013079A3 (en) 2001-11-14
TR200102505T2 (en) 2003-01-21
US6972288B1 (en) 2005-12-06
EP1157011A1 (en) 2001-11-28
CN1341104A (en) 2002-03-20
JP2002538145A (en) 2002-11-12
AU3281600A (en) 2000-09-21
PL351619A1 (en) 2003-05-19
NO20014114L (en) 2001-10-15
HRP20010617A2 (en) 2002-10-31
JP3751201B2 (en) 2006-03-01
EP2298746A1 (en) 2011-03-23
CA2361174C (en) 2009-10-27
KR20020068261A (en) 2002-08-27
BR0008524A (en) 2001-12-18
NZ513802A (en) 2001-09-28
BG105765A (en) 2002-03-29
SK12112001A3 (en) 2001-12-03
IL144143A0 (en) 2002-05-23
EE200100449A (en) 2002-12-16
HUP0301132A2 (en) 2003-12-29
NO20014114D0 (en) 2001-08-24
CA2361174A1 (en) 2000-09-08
HUP0301132A3 (en) 2004-03-29

Similar Documents

Publication Publication Date Title
US6972288B1 (en) 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
EP1163227B1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, and processes for preparing them
US8722694B2 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
JP4901055B2 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and methods for their preparation
US20090203683A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
US20020082270A1 (en) Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
RS60501B1 (en) Ligands that potentiate the bioactivity of gonadotropins
CA2417042A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US20020082420A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-605/01

Country of ref document: YU

Ref document number: 00804215.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000910695

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 144143

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2361174

Country of ref document: CA

Ref document number: 2361174

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/00848/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2001/05983

Country of ref document: ZA

Ref document number: 200105983

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/007480

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 32816/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2000 105765

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12112001

Country of ref document: SK

Ref document number: P20010617A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: PV2001-3079

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2000 602218

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 513802

Country of ref document: NZ

Ref document number: 2001/02505

Country of ref document: TR

Ref document number: 1020017010981

Country of ref document: KR

Ref document number: 200100830

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1200100886

Country of ref document: VN

ENP Entry into the national phase

Ref document number: 20010754

Country of ref document: UZ

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: PV2001-3079

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2000910695

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09914323

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020017010981

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2001-3079

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020017010981

Country of ref document: KR